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ABBREVIATIONS 
 
Amino Acids: singol and 3 letters code 
     
K Lys Lysine 
P Pro Proline 
C Cys Cysteine            
G Gly Glycine             
E Glu Glutamic Acid             
Y Tyr Tyrosine 
 
 
2-Cl-(Trt)-Cl  2-Chlorotrityl chloride resin 
AcOEt  Ethyl acetate 
AhOh   21-Amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid 
Akt   Protein kinase B 
ANS   8-Anilino-1-naphthalenesulfonic acid ammonium salt 
cAMP   Cyclic Adenosine Monophosphate 
CAPITO  Cd Analysis & Plotting TOol 
CARA   Computer Aided Resonance Assignment 
CCRF–CEM  Human drug sensitive cancer cell lines 
CD   Circular Dichroism 
CMC   Critical Micellar Concentration 
CXCL12  natural ligand of CXCR4 
CXCR4  C-X-C chemokine receptor type 4 
D   Diffusion coefficients 
DABCO  1,4-diazabicyclo[2.2.2]octane 
DBU   1,8-diazabicyclo[5.4.0]undec-7-ene 
DCM   Dichloromethane 
DIEA   N,N-diisopropylethylamine 
DLS   Dynamic Light Scattering 
DMF    Dimethylformamide 
DPFGSE  Double Pulsed Field Gradient Selective Echo 
dppp   1,3-bis(diphenylphosphino)propane 
DQFCOSY  Double Quantum Filter Correlation Spectroscopy 
DSS   Dihedral Space Sampling 
ESI   Electro Spray Ionozation 
EtOH   Ethanol 
Et2O   Ethyl ether 
FCS   Fetal Calf Serum 
Fmoc   Fluorenylmethyloxycarbonyl 
HBTU   2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium       
   hexafluorophosphate 
HRMS   High Resolution Mass Spectrometry 
IDP   Intrinsically Disordered Peptide 
IR   Infrared 
IS   Selectivity Index  
LC   Liquid Chromatography  
MD   Molecular Dynamic 
MeOH  Methanol 
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MS   Mass Spectroscopy  
MTS   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NMR   Nuclear Magnetic Resonance 
NMP   N-methyl-2-pyrrolidone 
NOESY  Nuclear Overhauser Enhancement Spectroscopy 
PA   Peptide Amphiphiles 
PBMNC  Peripheral Blood Mononuclear Cells 
PDI   Polydispersity Indices  
PEG   Polyethylene Glycol 
PHA   Polyhydroxyalkanoates 
pip   Piperidine 
PTSA   p-Toluene Sulfonic Acid  
pyr   Pyridine 
QSAR   Quantitative Structure Activity Relationship 
RH   Hydrodynamic Radii 
RMSD   Root Mean Square Deviation 
RMSF   Root Mean Square Fluctuation 
ROESY  Rotating frame Overhauser Enhancement SpectroscopY 
RP-HPLC  Reverse Phase-High Performance Liquid Chromatography 
SAR   Structure Activity Relationship 
SD   Deviation Standard 
THF   Tetrahydrofuran 
TIS   Tri-Isopropyl-Silane 
TFA   Trifluoroacetic Acid 
TOCSY  TOtal Correlation SpectroscopY 
Trt   Trityl 
TSP   TrimethylSilyl-3-Propionic acid sodium salt-d4 
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Abstract 
This PhD thesis work has been covered in the application of an integrated approach 
of different experimental and computational techniques, to get a better understanding 
about the solution structure details and the intermolecular interactions of two 
systems: Akt-heterocyclic ligand (Workpackage 1) and the chemokine, CXCR4 
(Workpackage 2). It is well known that the dysregulation of Akt and CXCR4 proteins, 
normally involved in regulation processes in cell, such as proliferation, is 
overexpressed in different human cancers. For this reason, they are considered as 
valuable targets in the development of potential cancer therapeutic agents. Recent 
efforts in the development and biological evaluation of small molecule inhibitors of 
Akt, a serine/threonine protein kinase, have led to the identification of novel inhibitors 
with various heterocycle scaffolds. Among heterocyclic compounds that attracted a 
lot of attention because of its wide spread biological activities, the pyrrolo[1,2-
a]quinoxaline heterocyclic framework has been identified as interesting scaffolds for 
antiproliferative activity against various human cancer cell lines. Thus, based on 
previous results obtained on the antiproliferative activities of new pyrrolo[1,2-
a]quinoxalines, a novel series of pyrrolo[1,2-a]quinoxaline derivatives 1a-l have been 
designed and synthesized via multistep heterocyclization process. Their cytotoxicities 
were evaluated against five different leukemia cell lines, including Jurkat and U266 
(lymphoid cell lines), and K562, U937, HL60 (myeloid cell lines), as well as normal 
human peripheral blood mononuclear cells. The new series showed promising 
cytotoxic potential against all leukemia cell lines tested, and some compounds 
showed better results than the reference compound A6730. Some compounds, such 
as 1a, 1e, 1g and 1h are promising because of their high activity against leukemia 
and their low activity against normal hematopoietic cells. Structure-activity 
relationships of these new synthetic compounds 1a-l are here also discussed. In 
addition, docking results, conducted on the isolated PH domain, showed that these 
new compounds could be considered as allosteric inhibitors. 
The second workpackage reports on the design and the synthesis of two new 
peptidic sequences containing a few amino acids with disorder propensity. In 
addition, they present a CPC unit: binding motif of the specific ligand of CXCR4 
namely the CXCL12. The peptide structural preferences were analysed by CD and 
NMR techniques that highlighted their flexibility. These results were also confirmed 
by MD simulations that demonstrated the ability of these peptides to assume 
conformational ensembles stabilized by a network of transient and dynamic H-bonds 
and characterized by interactions with water molecules. Afterwards we have explored 
the possibility that these peptides could be used as polar heads connected to alkyl 
chains to generate new molecular buildings (named peptide amphiphiles, PAs) for 
drug delivery vehicles in cells over-expressing the CXCR4 receptor. For these 
reasons, we firstly studied the alkyl chain effect on the conformational rearrangement 
of intrinsically disordered peptides. Solution fluorescence and DLS studies have been 
performed to evaluate critical micellar concentrations and the dimension of 
supramolecular aggregates. Biological tests pointed out that a hydrophobic moiety 
connected to our peptides could improve their activity on CXR4. In fact, these 
molecular buildings show promising activities, even higher than the reference 
molecule (AMD3100). According to these preliminary results, these PA systems 
could be further modified to realize supramolecular peptide-based compounds, able 
to be encapsulated by living cells for biomedical application. 
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Riassunto 
Il processo di ricerca e sviluppo di nuovi farmaci, come è noto, richiede numerose 
fasi. Queste includono, oltre all' identificazione del target biologico, la sintesi, lo 
screening e la successiva costruzione di biblioteche di molecole potenzialmente 
dotate di attività farmacologica. L’intero processo è molto impegnativo dal punto di 
vista dei costi (1-2 miliardi di euro) e dei tempi (12-13 anni) [1]. Pertanto, i metodi 
della chimica computazionale e la dinamica molecolare hanno le potenzialità di 
contribuire allo sviluppo di un farmaco in termini di progettazione, razionalizzazione 
delle relazioni struttura-attività e quindi di riduzione dei costi. In questo ambito, i 
metodi di relazione quantitativa struttura-attività (QSAR), l’analisi di docking 
molecolare e di dinamica molecolare, possono efficacemente contribuire ad una 
razionalizzazione dei risultati ottenuti per via sperimentale. Il principale obiettivo di 
tale approccio multidisciplinare è quello di determinare i dettagli conformazionali 
fondamentali per l’interazione tra la proteina ed il suo ligando, in modo da poter 
avere informazioni utili per la progettazione di nuovi potenziali farmaci. Le molecole 
individuate tramite tale studio necessitano sempre di ulteriori indagini sperimentali in 
vitro ed in vivo per avere un’esaustiva comprensione del meccanismo di azione del 
potenziale farmaco e per affrontare le problematiche che influenzano fortemente la 
farmacocinetica del composto o dei suoi metaboliti (solubilità, permeabilità delle 
molecole e possibili interazioni con altre biomolecole o con altri farmaci). Nell’ ottica 
di definire il meccanismo di azione l’analisi a livello molecolare dei dettagli strutturali 
delle interazioni tra biomolecole permetterebbe l’acquisizione di informazioni utili per 
la loro comprensione e, perciò, per la determinazione delle funzionalizzazioni 
necessarie ad incrementare l’attività del potenziale farmaco. In questo ambito si 
inserisce questo lavoro di tesi, per il quale è stato utilizzato un approccio integrato e 
multidisciplinare di tecniche spettroscopiche (fluorescenza, dicroismo circolare (CD), 
risonanza magnetica nucleare (NMR) and Dynamic Light Scattering, (DLS)) e 
computazionali (molecular docking, molecular dynamics) per migliorare l’interazione 
specifica di molecole di interesse biotecnologico e terapeutico al fine di ottenere 
composti con attività antitumorale e proprietà farmacologiche potenziate rispetto a 
quelle con attività nota. A tal fine sono stati scelti due sistemi proteici per i quali 
esiste un’ampia letteratura e si dispone di banche dati relative a parametri strutturali 
e farmacologici. In particolare in questo lavoro sono state progettate e sintetizzate 
nuove molecole potenzialmente in grado di bloccare l’attività di due proteine 
sovraespresse in diverse patologie: Akt (trattata nella sezione Workpackage 1), e 
CXCR4 (descritta nel Workpackage 2) [2- 4].  
 
Workpackage 1 
Il Workpackage 1 della mia tesi verte sulla progettazione e la sintesi di nuovi 
composti antiproliferativi. Tra questi si è focalizzata l’attenzione su quelle molecole in 
grado di bloccare l’attività di Akt, la cui sovraespressione è stata collegata ad una 
proliferazione non controllata delle cellule cancerogene. In tale contesto un recente 
lavoro evidenzia l'importanza dell’anello pirrolo [1,2-a]quinoxalinico come scaffold 
molecolare ed evidenziano il ruolo fondamentale di opportune sostituzioni in precise 
posizioni per modulare l’attività dell'intera molecola come agente antiproliferativo. 
Infatti, la presenza di un anello fenile ed un gruppo etil estere sulla porzione pirrolica 
di tale scaffolds si sono rivelate importanti per l’attività della molecola, come 
evidenziato dai saggi condotti su diverse linee cellulari tumorali umane [5]. Tali studi 
hanno inoltre mostrato la notevole influenza dei sostituenti 
benzilpiperidinilbenzimidazolone e fluorobenzimidazole sull' attività antiproliferativa. 
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In letteratura è riportato che, da un punto di vista sintetico, la formazione dell’anello 
phenyl-1H-pirrol-diestere costituisce la fase critica dell'intero processo. Per questo si 
è reso necessario confrontare i diversi protocolli sperimentali di sintesi chimica, già 
riportati per molecole analoghe, per valutare gli effetti di diverse condizioni 
(temperatura, solvente e catalizzatore) sulla resa e tempi di reazione. 
L'ottimizzazione delle condizioni di sintesi ha consentito di ottenere fenil-1H-pirrolo-
diesteri, dai quali sono stati sintetizzati gli scaffolds pirrolo[1,2-a]chinossalinici 
diversamente sostituiti, che costituiscono gli intermedi chiave nella sintesi dei 
composti finali 1a-l, le cui strutture sono schematizzate nella Figura 1. 
 
Series D 
 
Figure 1. Struttura chimica dei composti 1a-l. 
 
La struttura dei composti è stata confermata mediante caratterizzazione IR e NMR. 
Test di attività antiproliferativa (MTS) sono stati inoltre condotti su diverse linee 
cellulari cancerogene umane (U937, K562, Jurkat, U266 and HL60) al fine di 
confrontare diverse tipologie di cellule tumorali nelle quali la proteina Akt, 
normalmente coinvolta nella regolazione del processo di proliferazione, è 
sovraespressa. Le molecole 1a, 1e, 1g e 1h hanno mostrato un’elevata attività 
citotossica nei confronti di alcune linee cellulari tumorali (IC50 compresi nell’intervallo 
3-9 M) e una bassa tossicità contro cellule ematopoietiche normali (IC50> 50 M) 
(Tabella 1). Questi composti, mostrando un interessante indice di selettività, 
possono costituire candidati adatti per ulteriori studi farmacologici. Da un punto di 
vista generale della SAR, questi risultati biologici preliminari sottolineano l'importanza 
della presenza di un gruppo benzylpiperidinylfluorobenzimidazole nella posizione C-4 
dello scaffold pirrolo[1,2-a] chinossalinico, ma anche la necessità di una 
funzionalizzazione sull’ anello pirrolico. I dati biologici sembrerebbero indicare che il 
composto 1e é il più promettente. Sarebbe, perciò, interessante valutare in maniera 
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approfondita l’attività biologica di tale molecola per poterne meglio definire il 
meccanismo di azione. 
Tabella 1. Attività in vitro dei composti 1a-l su linee cellulari K562, U937, HL60, Jurkate U266, e 
citotossicità su cellule mononucleari del sangue periferico umano PBMNC + PHA. 
IC50 values (M)a 
Inibitore K562 U937 HL60 Jurkat U266 
Citotossicità su cellule 
mononucleari attive del sangue 
periferico umano (PBMNC) 
PBMNC + PHA 
A6730 
17  0.3 8  0.2 5.5  0.2 3.5  0.2 n.d.b >50 
1a 
4  0.1 >50 >50 41  1.2 >50 >50 
1b 
3  0.1 21  2.2 19  2.8 5  0.2 3.5  0.1 14  1 
1c 
14  0.3 7  0.3 12  2.3 5  0.1 >50 16  2 
1d 
9  0.3 >50 3.5  0.1 4  0.1 10  0.8 41.3  5 
1e 
3  0.1 n.d. 10  0.9 5  0.2 18  1.1 >50 
1f 
7  0.2 7  0.1 5  0.1 2  0.1 5  0.1 8  0.5 
1g 
8  0.2 9  0.4 6  0.1 4  0.1 9  0.8 >50 
1h 
7  0.3 4  0.1 8  0.2 6  0.15 4  0.1 50  4 
1i 
12  0.4 11  0.9 24  3 5  0.1 8  0.5 50  6 
1j 
8.5  0.3 >50 >50 6.5  0.1 >50 >50 
1k 
3  0.1 3  0.1 3  0.1 3.5  0.1 3  0.1 13  1 
1l 
3.5  0.1 8  0.2 7  0.3 
3 
3  0.1 12  1 
aI valori di IC50(M) corrispondonoalla media ± deviazione standard rispetto a tre esperimenti indipendenti. 
bn.d. = nondeterminato. 
 
La possibilità di prevedere la tossicità delle molecole è molto importante nella 
progettazione di nuovi potenziali farmaci. In questo contesto, le molecole sintetizzate 
1a-l sono state analizzate mediante il software “Molinspiration web-enabled” per 
predire dei parametri chimico-fisici importanti per la farmacolgia di tali molecole, 
come la lipofilia (ClogP) e l'assorbimento intestinale (calcolo delle superfici polari 
molecolari, PSA). La superficie polare molecolare (PSA) dei composti della serie 1a-l 
suggerirebbe il loro assorbimento intestinale (PSA < 140 Å2). Inoltre tali molecole non 
sono in grado di attraversare la barriera emato-encefalica (PSA > 60 Å2). Alla luce di 
queste predizioni, i composti 1a-l presenterebbero una buona biodisponibilità per via 
orale con una potenziale bassa tossicità rispetto al sistema nervoso centrale. 
Successivamente, allo scopo razionalizzare i risultati biologici e determinare i dettagli 
strutturali che ne potrebbero essere responsabili nelle molecole, studi di docking 
sono stati condotti utilizzando il server Swiss Dock (http://www.swissdock.ch). La 
proteina considerata per l'analisi iniziale è stata la struttura cristallografica della 
proteina Akt intera depositata nel Protein Data Bank (cod. 3O96 [6]). I risultati di tale 
studio indicano la molecola 1e come la migliore tra quelle sintetizzate, evidenziando 
che la presenza di un anello fenilico nella terza posizione e l’introduzione del piccolo 
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gruppo etil estere sulla seconda posizione dell'anello quinoxalinico potrebbero 
favorire una migliore interazione tra il ligando e la proteina, come mostrato in Figura 
2. 
 
a) b)  
Figura 2. Migliore struttura ottenuta attraverso il docking del il composto 1e rispetto alla Proteina 
intera Akt (cod. 3O96 [6]); a) Dominio PH: in rosso, i residui coinvolti in almeno 10 interazioni e in 
giallo, i residui coinvolti in al massimo 9 interazioni. b) Dominio chinasico: in blu i residui coinvolti in 
almeno 10 interazioni e in ciano, i residui coinvolti in al massimo 9 interazioni. 
 
Succesivamente, gli studi di docking sono stati condotti unicamante sul dominio PH 
estrapolato dalla struttura cristallografica di PKB (codice PDB: 1UNR) [7]. Questa 
analisi è stata effettuata al fine di verificare se la nostra migliore molecola può essere 
considerata come un potenziale inibitore allosterico della proteina Akt o un semplice 
ligando PH-dipendente. I risultati di tale studio hanno mostrato un andamento simile 
a quello ottenuto per la proteina intera. In particolare, essi rivelano che 1e è il miglior 
composto. Infatti, la sovrapposizione della sua migliore struttura ottenuta dal docking 
sul dominio PH di Akt e la struttura cristallina di inositol-(1,3,4,5)-tetrakisfosfato (IP4) 
in complesso con il dominio PH di Akt1 (codice PDB:. 1UNQ [7]) evidenzia la 
presenza del nostro ligando in una tasca distinta dal sito di legame dell’inositolo. In 
conclusione I risultati di docking indicano che le molecole 1a-l, più che essere 
semplici ligandi PH dipendenti, costituiscono degli inibitori allosterici per via della loro 
abilità di interagire con entrambi i domini della proteina Akt, cioè il dominio PH e 
quello chinasico.  
 
Risultati del Workpackage 2 
Il Workpackage 2 è focalizzato su CXCR4, un recettore accoppiato alla proteina G 
che è coinvolto nel signaling di differenti fattori. In un recente lavoro viene descritto il 
comportamento strutturale e l’attività biologica tra CXCR4 e il suo ligando naturale 
CXCL12 [8]. L’ interazione CXCL12-CXCR4 svolge un ruolo fondamentale in malattie 
come HIV, cancro, sindrome WHIM, artrite reumatoide, fibrosi polmonare e il lupus, 
che è per questo indicata come un valido bersaglio terapeutico [9]. Considerato 
l’elevato potere e l’alta specificità che i peptidi possono avere [10], si registra, dai dati 
di letteratura recente, un interesse molto ben documentato nello sviluppo di strumenti 
terapeutici e diagnostici di natura peptidica. In particolare, i peptidi intrinsecamente 
disordinati (IDP) rappresentano attualmente un innovativo e interessante punto di 
partenza, perché il disordine conformazionale, inteso come mancanza di qualunque 
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elemento di struttura secondaria regolare, quale eliche e foglietti beta, consente al 
peptide di subire variazioni conformazionali solo in seguito all’ interazione con i 
sistemi bersaglio. Tale capacità degli IDP conferisce loro una serie di vantaggi 
rispetto ai loro congeneri strutturati, quali maggiori superfici di interazione ed una 
migliore cinetica di legame. Infatti, tali peptidi esplorano dinamicamente un insieme di 
conformazioni assolutamente flessibili, adottando quelle più stabili solo dopo essersi 
legati ai ligandi [11]. Gli IDP possono, perciò, instaurare interazioni con elevata 
specificità / bassa affinità con i loro interattori. Alla luce di ciò, abbiamo disegnato 
due peptidi lineari, PeptideE (YGECPCE-allile) e PeptideK (YGECPCK- allile), con 
un elevato contenuto di residui in grado di favorire strutture disordinate [12], 
considerando come modello la regione N-terminale di CXCL12 e la sequenza CPC, 
dimostrata essere responsabile dell’interazione tra il peptide CXCL12 ed il recettore 
CXCR4[8]. A tali sequenze sono stati aggiunti, alle estremità C-terminali, 
amminoacidi carichi (Glu e Lys, rispettivamente per il PeptideE e PeptideK) allo 
scopo di analizzare l’effetto della carica sulle proprietà di legame del peptide. Il C-
terminale di tali peptidi é stato inoltre modificato da un estere allilico per eventuali 
nuove funzionalizzazioni delle molecole. Gli spettri CD hanno evidenziato l’assenza 
di elementi di regolare struttura secondaria e quindi la natura disordinata di PeptideE 
e PeptideK. Tale risultato è stato confermato dalla bassa dispersione spettrale degli 
spettri 1D [1H] e dalla quasi totale assenza di segnale negli spettri 2D [1H, 1H] 
NOESY, il che indicherebbe per entrambi i peptidi una elevata flessibilità ed una 
natuta disordinata/non foldata. Dalla valutazione delle deviazioni dei chemical shift 
degli Hα protonici dai valori random coil, che risultano essere in prevalenza piccole e 
positive, è stata confermata la presenza di strutture estese disordinate. Infine, lo 
stato disordinato di PeptideE e PeptideK è stato confermato ulteriormente dai pattern 
ROE ottenuti, che mostrano contatti sequenziali (Hαi–HNi+1) forti, tipici di peptidi non 
organizzati strutturalmente. I risultati dell'indagine NMR confermano, perciò, la 
flessibilità di tali peptidi e, quindi, la loro impossibilità ad assumere conformazioni ben 
definite.  Lo studio successivo di simulazioni di dinamica molecolare (MD) (Figura 3), 
condotto sui peptidi liberi, ha confermato tali risultati sulla flessibilità e l’assenza di 
una strutturazione, ma ha anche evidenziato la presenza di una rete di legami ad 
idrogeno intramolecolari temporanei e dinamici di tipo catena principale-catena 
principale (MM) e di interazioni con le molecole d'acqua.  
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a) b)
c) d)
 
Figure 3. Analisi delle simulazioni di dinamica molecolare condotte su PeptideE (in nero) e su 
PeptideK (in grigio) a pH fisiologico in solvente esplicito: a) deviazione della radice quadratica media 
(RMSD), b) fluttuazioni della radice quadratica media (RMSF), c) raggio di rotazione (gyration radius), 
and d) numero di legami idrogeno. 
 
Pertanto, le strutture dei due peptidi possono essere rappresentate come insiemi 
conformazionali caratterizzati da strutture secondarie irregolari e fluttuanti. Infatti, i 
peptidi non assumono un’unica e definita conformazione, ma vanno continuamente 
da un cluster ad un altro (Figura 4). Pertanto essi non possono essere correttamente 
descritti da un’unica struttura ma da un “conformational ensamble". 
 
Figura 4. Sovrapposizione dei cluster più popolati ottenuti per il PeptideE (8 clusters) e la PeptideK (9 
clusters) durante le loro dinamiche molecolare. 
 
Considerato che una delle maggiori difficoltà nella progettazione di un potenziale 
farmaco consiste nella sua veicolazione al sito di interesse, con tutte le 
problematiche ad esso connesse (come il superamento delle membrane cellulari), si 
è pensato di funzionalizzare l’estremità N-terminale dei peptidi E e K mediante code 
c) d) 
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idrofobiche e conferendo, pericò, una natura anfifilica ai peptidi liberi. I peptidi 
anfifilici sono largamente descritti in letteratura come ottimi canditati per il drug 
delivery di farmaci grazie alla la loro capacità di formare aggregati sopramolecolari 
(ad esempio vescicole e micelle), dovuta alla coesistenza di una porzione idrofilica 
ed una idrofobica. In tale contesto i peptidi anfifilici (PAs, Figura 5) (C18)2-PeptideE 
e (C18)2-PeptideK sono stati ottenuti coniugando due catene alifatiche di 18 atomi di 
C all’estremità N-terminale di entrambe le sequenze. In aggiunta, sono stati 
sintetizzati altri due derivati PAs: (C18)2-L-PeptideK e (C18)2-L-PeptideE, 
caratterizzati dalla presenza di un linker etossilico (AhOh) tra la sequenza peptidica e 
la coda idrofobica (Figura 5). Questo linker, lo stesso per entrambi i peptidi, permette 
di aumentare l'idrofilicità dei peptidi senza modificarne la carica. In questo modo si 
limitano possibili interazioni elettrostatiche intra e intermolecolari. Inoltre, esso 
permette di allontanare il peptide bioattivo dal guscio idrofobico degli aggregati. La 
lunghezza relativamente piccola di questo spaziatore è stata scelta per evitare la 
formazione di una tasca idrofila, in grado di nascondere le sequenze amminoacidiche 
[13].  
PAs
(C18)2-PeptideE
(C18)2-PeptideK
(C18)2-L-PeptideE
(C18)2-L-PeptideK
N
O
O
H
N
O
O
N
H
PEPTIDE
6
N
O
O
H
N
PEPTIDE
PeptideK = YGECPCK-Allyl
PeptideE = YGECPCE-Allyl
PEPTIDI
 
Figura 5. PeptideE e PeptideK liberi e i loro derivati PAs. (In blu é riportata la coda idrofobica e in 
rosso il linker introdotti). La catena PEG è delimitata da parentesi. 
 
Gli aggregati sopramolecolari dei peptidi PAs sono stati ottenuti solubilizzando e 
disperdendo i derivati anfifilici del PeptideE in tampone fosfato 10 mM (pH 7.4) e 
quelli del PeptideK in tampone TRIS 10 mM (pH 8.0). La scelta del tampone da 
utilizzare è stata imposta dalla differente propensione ad aggregare dei peptidi PAs. 
Come dimostrato da studi di fluorescenza e DLS, tutti i derivati anfifilici progettati 
sono in grado di auto-assemblare in aggregati con un diametro medio compreso tra 
80 e 110 nm, indipendentemente dalla carica all’estremità C-terminale e dalla 
presenza del linker. Le soluzioni di ogni PA aggregato mostrano una distribuzione 
monomodale, che indica la presenza di una sola popolazione di aggregati. In Tabella 
2 sono riportati i dati ottenuti dall’ analisi di per fluorescenza e DLS di tutti i composti: 
concentrazione critica micellare (CMC), raggio idrodinamico (RH), coefficienti di 
diffusione (D), e indice di polidispersità (PDI). 
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Tabella 2. Parametri strutturali ottenuti per gli aggregati da misure di fluorescenza (concentrazione 
critica micellare CMC) e misure DLS (raggio idrodinamico RH, coefficienti di diffusione D, e indici 
polidispersità PDI). 
Peptide CMC (mol kg-1) RH (nm) D x 10-12 (m2s-1) PDI 
(C18)2-PeptideK 7.0 x 10-6 80 ± 27 3.1 ± 1.0 0.270 
(C18)2-L-PeptideK 1.9 x 10-5 82 ± 34 3.1 ± 1.5 0.182 
(C18)2-PeptideE 3.9 x 10-5 
112 ± 44 
 
1.9 ± 0.7 0.264 
(C18)2-L-PeptideE 3.2 x 10-5 110 ± 39 2.4 ± 0.5 0.226 
 
Gli spettri CD ottenuti per i PAs derivati (acquisiti ad una concentrazione superiore a 
quella critica micellare) mostrano che la presenza del linker non influenza 
significativamente la struttura della loro porzione peptidica. Inoltre, tali spettri hanno 
evidenziato che la presenza di un residuo di Lys rispetto al residuo di Glu 
all’estremità C-terminale può indurre un riarrangiamento della struttura secondaria 
con un parziale folding della porzione peptidica, confermando l’importanza della 
carica in queste sequenze peptidiche. I composti da noi sintetizzati costituiscono i 
primi peptidi anfifilici contenenti la sequenza CPC in grado di aggregare e formare 
strutture sopramolecolari dotate di attività in vitro. Infatti, i test biologici, condotti sulle 
stesse cellule e alle medesime concentrazioni utilizzate per la molecola di riferimento 
AMD3100, hanno rivelato che, nonostante tutti peptidi non presentino una evidente 
affinità di legame per CXCR4 (dati non mostrati), essi sono in grado di indurre una 
produzione di cAMP più elevata di quella di AMD3100 e in maniera dose dipendente. 
Tali dati indicherebbero una significativa attività inibitoria dei peptidi sintetizzati verso 
CXCR4. I valori di cAMP di tutti i peptidi e quello relativo ad AMD3100 (molecola di 
riferimento) sono riassunti in Figura 6, dove tutti i valori sono espressi come 
concentrazione percentuale rispetto a due concentrazioni (1M e 10M). Il peptide 
CXCL12, ligando naturale di CXCR4, è stato considerato in tale indagine come 
controllo. 
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Figure 6. Confronto delle modulazioni di cAMP valutate per Fosfokolin (F), CXCL12, PeptideE, 
PeptideK, (C18)2-PeptideE, (C18)2-PeptideK, (C18)2-L-PeptideE, (C18)2-L-PeptideK e per la molecola 
di riferimento AMD3100, alle concentrazioni 1M e 10 M. 
 
Sebbene questi risultati siano da considerare preliminari e consapevoli che sono 
necessarie ulteriori analisi, è possibile sicuramente affermare che questi risultati 
sono incoraggianti e mostrano la validità dell'approccio multidisciplinare alla base di 
questa indagine scientifica. Il passo successivo andrà nella direzione di apportare 
ulteriori modifiche chimiche, utilizzando la reattività del gruppo allil estere, per 
l'ottenimento di nuovi composti sopramolecolari di natura peptidica, in grado di 
essere incapsulati nelle cellule e, quindi, di veicolare il peptide bioattivo e/o sonde 
per terapie mediche personalizzate e/o per indagini di imaging a risonanza 
magnetica (MRI).  
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Résumé 
Ce travail de thèse PhD concerne l'application d'une approche intégrée caractérisée par 
l'utilisation de différentes techniques expérimentales et de calculs pour obtenir une meilleure 
compréhension des détails structurels en solution et des interactions intermoléculaires 
impliquées dans les mécanismes d'action de deux systèmes: Akt-ligand hétérocyclique 
(Workpackage 1) et la chimiokine, CXCR4 (Workpackage 2). Il est connu que la 
dysrégulation de Akt et CXCR4, protéines normalement chargées de la régulation des 
processus dans la cellule tels que la prolifération, est surexprimée dans différents cancers 
humains. Pour cette raison, ces protéines sont considérées des cibles importantes dans le 
développement d'agents thérapeutiques potentiels contre le cancer. Des efforts récents dans 
le développement et l'évaluation biologique de petites entités moléculaires inhibitrices d’Akt, 
une sérine/thréonine protéine-kinase, ont conduit à l'identification de nouveaux inhibiteurs 
hétérocycliques. Parmi les composés hétérocycliques qui ont attiré une certaine attention en 
raison de leur large activité biologique, le système hétérocyclique pyrrolo[1,2-a]quinoxaline a 
été identifié comme édifice moléculaire particulièrement intéressant pour l'activité 
antiproliférative contre diverses lignées de cellules cancéreuses humaines. Ainsi, en tenant 
compte des résultats obtenus précédemment sur l’activité antiproliférative de dérivés de type 
pyrrolo[1,2-a]quinoxaline, une nouvelle série de ces dérivés 1a-l a été conçue et préparée 
via une stratégie de synthèse hétérocyclique multi-étapes. Leur cytotoxicité a été évaluée sur 
cinq lignées cellulaires de leucémie, Jurkat et U266 (lignées lymphoïdes), puis K562, U937 
et HL60 (lignées myéloïdes), ainsi que des cellules sanguines humaines mononucléaires 
normales. Cette nouvelle série a montré un potentiel cytotoxique prometteur contre toutes 
les lignées cellulaires leucémiques testées ; et certains composés ont montré une activité 
biologique supérieure à celle du composé de référence A6730. Parmi ces composés, les 
dérivés 1a, 1e, 1g et 1h semblent plus prometteurs en raison de leur haute activité contre 
ces leucémies et leur faible cytotoxicité contre des cellules hématopoïétiques normales. Des 
relations de structure-activité de ces nouveaux composés synthétiques 1a-l sont également 
discutées. En outre, des résultats préliminaires menés sur Akt puis sur le domaine de PH 
isolé d’Akt, ont montré que ces nouveaux composés peuvent être considérés comme des 
inhibiteurs allostériques potentiels. La seconde partie des travaux concerne la conception et 
la synthèse de deux nouvelles séquences peptidiques contenant quelques acides aminés et 
présentant une propension au désordre. De plus, ils présentent une unité CPC: motif se liant 
au ligand spécifique de CXCR4 à savoir la liaison CXCL12. Les structures préférentielles de 
ces peptides ont été analysées par les techniques CD et RMN qui ont fait ressortir leur 
flexibilité. Ces résultats ont également été confirmés par des simulations de MD qui ont 
démontré la capacité de ces peptides à assumer des ensembles de conformations 
stabilisées par un réseau de liaisons hydrogène, et caractérisées par des interactions avec 
des molécules d'eau. Ensuite, nous avons étudié la possibilité que ces peptides puissent être 
utilisés comme têtes polaires reliées à alkyl chaînes pour générer de nouveaux édifices 
moléculaires (peptides amphiphiles nommés, PAs) pour la vectorisation de médicaments 
dans les cellules surexprimant le récepteur CXCR4. Pour cela, nous avons étudié dans un 
premier temps l'effet de la chaîne alkyle sur le réarrangement de conformation des peptides 
intrinsèquement désordonnés. Des études de fluorescence et de DLS ont été réalisées pour 
évaluer les concentrations micellaires critiques et la dimension des agrégats 
supramoléculaires. Les tests biologiques ont souligné qu'une partie hydrophobe reliée à nos 
peptides pourrait améliorer leur activité sur CXR4. Ces édifices moléculaires montrent ainsi 
des activités prometteuses, voire plus que la molécule de référence (AMD3100). En nous 
basant sur ces résultats préliminaires, ces systèmes de peptides amphiphiles peuvent être 
en outre modifiés pour réaliser des composés supramoléculaires à base de peptides, 
susceptibles d'être encapsulés par des cellules vivantes pour une application biomédicale. 
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Introduction 
It is well known that the development of new drugs requires different steps, such as 
synthesis of new molecules and screening of their activities to elaborate new libraries 
of potential therapeutic agents. In this context, the modern computational techniques 
may contribute to this complex process. This last is very challenging from the point of 
view of the associated cost and time, 1-2 billion of dollars and 12-13 years, 
respectively [1]. In this context, QSAR methods, docking analysis and MD tecniques, 
can effectively contribute to a rationalization of the results obtained experimentally. 
The analysis at molecular level of conformational details involved in the interactions 
between biomolecules may give informations is of great interest in many 
biotechnological fields. In fact, it provides useful information for the design of 
molecules able to mimic the binding sites and thus, presenting potential therapeutic 
applications. Within this context, my PhD thesis has been focused on the application 
of an integrated approach composed by different experimental and computational 
techniques, such as molecular docking, MD (Molecular Dynamics), NMR (Nuclear 
Magnetic resonance), DLS (Dynamic Light Scattering) to have a better 
comprehension about the solution structure and the intermolecular interactions of two 
remarkable systems: Akt-heterocyclic ligand and CXCR4-chemokine. Both systems 
involve molecules that play important roles in physiological and pathological 
processes. The main goal of our investigation in solution was the determination of the 
protein conformational features that could be considered as fundamental for the 
interaction with the corresponding ligand. It is well known that protein-peptide and 
protein-small molecule interactions are mediated by specific domains. The analysis 
of the binding domain surface is of great interest in many biotechnological fields, as it 
provides useful information for the design of new molecules able to mimic the natural 
binder, thus presenting the potential application in the development of therapeutic 
agents. For this reason, we are focused in the design and synthesis of new 
molecules direct in the action of Akt (described in detail in the Workpackage 1) and 
CXCR4 (explained in the Workpackage 2), whose dysregulation is correlated to 
different pathologies. The activity of these molecules in the cells was evaluated by 
carrying out different types of biological tests. The analysis at molecular level of the 
interactions between these molecules and their natural target was conducted by 
molecular docking: in order to find a correlation between the ligand structure and its 
activity. The two considered systems and the respective protocols of analysis are 
reported below: 
Workpackage 1: Akt-heterocyclic ligand 
1. Chemical Synthesis 
2. NMR, IR, MS, X-ray crystallography (compound structural characterization) 
3. MTS cell proliferation assay (cytotoxicity test) 
4. Calculations of Clog P, Topological Polar Surface Area (TPSA), number of 
hydrogen bond acceptor (nON) and donor (nNH/OH) atoms (computational 
prediction of toxicity and drug relevant properties) 
5. Docking studies (structural details important in the Protein-ligand interaction) 
Workpackage 2: CXCR4-Intrinsically Disordered Peptide ligand  
1. Chemical Synthesis  
2. Fluorescence and DLS (aggregates formation prediction and their 
characterization) 
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3. NMR and Circular dichroism (conformational studies of peptide) 
4. Molecular modeling and dynamic simulations (Intrinsically disorder propensity 
of the peptides) 
5. Migration Assay, Binding Assay and cAMP Assay (functional characterization 
of the peptides on CXCR4 receptor) 
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1. Workpackage 1: Akt-heterocyclic ligand system 
 
1.1 Background 
 
1.1.1. Akt 
Akt is a member of the serine/threonine AGC protein kinase family involved in cellular 
metabolism, growth, proliferation and survival. To date, three mammalian isoforms 
(Akt1/PKB, Akt2/PKB, and Akt3/PKB) of the kinase have been identified that 
share a high degree of sequence and structural homology, even though a possible 
distinct role has been suggested for each of them [2-4]. (Figure 1) 
 
 
Figure 1. Overlapping and specific functions of the Akt isoforms.  
 
They have a N-terminal pleckstrin homology domain (PH) mediating protein-protein 
and protein-lipid interactions, inter-domain linker, kinase domain and a 21-residue 
carboxy C-terminal hydrophobic motif (HM) [5]. The basic activation process of the 
Akt isoforms appears to be uniform and is mediated by growth factors [6]. (Figure 2) 
 
 
Figure 2. Akt activation mechanism. PI3K protein convert PIP2 to PIP3 on the membrane surface. Akt 
and PDK1 protein translocate move to the membrane by PIP3. mTORC2 protein complex and PDK1 
phosphorylate the Ser 473/474/472 and the Thr 308/309/305, respectively. 
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It requires translocation from the cytosol to the plasma membrane followed by 
phosphorylation of both the threonine 308/309/305 and serine 473/474/472 residues 
(Akt1/Akt2/Akt3 respectively) which are regulated by multiple components of the well-
known PI3K/AKT/mTOR pathway. In this pathway, PI3K phosphorylates 
phosphatidylinositol-(3,4)-bisphosphate (PIP2) to phosphatidylinositol-(3,4,5)-
triphosphate(PIP3). The pleckstrin homology (PH) domains of both PI3K-dependent 
kinase-1 (PDK1) and AKT bind to PIP3 (located at the plasma membrane) thus 
allowing PDK1 to phosphorylate the activation loop of AKT at Thr 308/309/305. The 
activation process is completed with the phosphorylation of AKT at the C-terminal 
Ser 473/474/472 of the hydrophobic motif which occurs via the mTORC2/rictor 
complex. Once activated, AKT phosphorylates downstream target proteins including 
PRAS40, GSK3 (glycogen synthesis kinase 3), FOXO, BAD, endothelial nitric-oxid 
synthase and forkhead transcription factor (FHKR) [6]. (Figure 3) 
 
 
Figure 3. Schematic representation of the complex Protein network in which Akt play a crucial role by 
which performs its different functions. 
Additionally, AKT also suppresses the inhibitory effect via phosphorylation of TSC1 
and TSC2, thereby activating mTORC1 and ultimately leading to phosphorylation of 
4E-BP1 and S6K. Dysregulation of PI3K/AKT/mTOR signaling pathway regulates 
many normal cellular processes, including cell proliferation, survival, growth and 
motility, processes that are critical for tumorogenesis. Indeed, the role of this pathway 
in oncogenesis has been extensively investigated and altered expression or 
mutations of many components of this pathway have been implicated in human 
cancer. Thus, the kinase Akt represents an attractive target for drug development [7].  
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1.1.2. Akt inhibitors  
Different types of Akt inhibitors are reported in literature, which differ in their mode of 
action. There are inhibitors that interact with the PH domain of Akt and prevent the 
anchoring of the protein to the plasma membrane and, therefore, its activation such 
as Akt-in, a peptide that encompasses the A strand of the proto-oncogene TCL1, 
Akt kinase coactivator. [8; 9] There are other ones, ATP-competitive inhibitors, which 
prevent the action of the already activated Akt [10]. They are described as non-
selective against AKT isozymes, and poorly selective against closely related kinases. 
Efforts to identify new AKT specific and isozyme-selective inhibitors resulted in the 
discovery of novel selective allosteric AKT inhibitors [11; 12]. 
 
1.1.3. Akt allosteric inhibitors 
The allosteric inhibitors bind non-covalently the enzyme in a specific site, different 
from the active one. This interaction induces a reversible conformational change 
which makes the active site no more able to interact with the substrate. Recent 
studies have highlighted the presence of an equilibrium between an inactive Akt 
conformation with the PH domain folded on the kinase one (named “PH-in”), and an 
active form with the PH domain moved from the kinase one (named “PH-out”). The 
allosteric AKT inhibitors prevent both membrane association and activation by 
phosphorylation. [5] Different examples of Akt allosteric inhibitors are already 
reported. Among them, A6730 is one of the most interesting compound (Figure 4). A 
crystal structure of the complex between this inhibitor and the Akt1 protein is 
deposited on the Protein Data Bank with the code 3O96. [5] A recent work shows the 
conformation of the ATP binding site in the AKT1:Inhibitor A6730 crystal structure 
(PDB code: 3O96 [5]). This study clearly reveals that the closed “PH-in” conformer is 
unable to bind ATP or ATP-competitive inhibitors. Not only does Phe 293 block the 
site, but critical ATP binding site residues interact with PH domain residues. 
Therefore, it was hypothesized in the same study that ATP-competitive AKT 
inhibitors are unable to bind the ‘PH-in’conformer and only bind the membrane-
associated and phosphorylated ‘PH-out’ form, which has a properly configured ATP 
binding site. When the competitive inhibitor occupies the ATP binding site, the PH 
domain can not fully close onto the kinase domain and the phospholipid binding site 
remains exposed thus enhancing the propensity of AKT to localize to the membrane. 
In contrast, the AKT1:Inhibitor A6730 co-crystal structure shows the allosteric 
inhibitor locking AKT into a closed conformation with its phospholipid binding site 
blocked by thekinase domain. As a result, allosterically inhibited AKT remains 
cytosolic and is not activated via phosphorylation. In conclusion in this work, it was 
proved that ATP competitive inhibitors bind to AKT only when the protein assumes 
the open conformation. For this reason, there is a strong interest in the design of 
allosteric inhibitors that favor the inactive conformation [5].  
 
1.1.4. Pyrrolo[1,2-a]quinoxaline ring as potential scaffold 
In this context heterocyclic compounds are described as fundamental for the design 
and synthesis of potential Akt inhibitors. Among them, the pyrrolo[1,2-a]quinoxaline 
heterocyclic framework could constitute an useful basis. We have recently published 
three series (Series A-C) of new interesting substituted pyrrolo[1,2-a]quinoxalines 
(Figure 4) endowed with good activity towards the human leukemia cells [13-15]. 
These antiproliferative pyrrolo[1,2-a]quinoxaline derivatives have been previously 
designed as novel structural analogues of compound A6730, a well-described Akt 
inhibitor that presents antiproliferative activity against different human leukemia cell 
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lines [13-16]. Continuing our efforts in this field and considering the pharmacological 
activities of pyrroloquinoxalines on human leukemic cells, a new series (Series D) 
was designed and synthesized. Thus, by taking into accounts the best results 
obtained in series B (Figure 4), we decided to use the JG576 and JG572 pyrrolo[1,2-
a]quinoxaline moieties as a template for the design of new derivatives 1a-l in which 
the pyrrole nucleus is substituted in different positions by a phenyl and an ester 
function (Series D, Figures 4-5). In relation to a previous works, further 
pharmacomodulations on the piperidine core have been considered, such as the 
introduction of new substituted heterocyclic systems [13-15]. The antiproliferative 
profile of the obtained derivatives 1a-l was then evaluated in vitro against a panel of 
myeloid or lymphoid leukemic cell lines: U937, K562, Jurkat, U266 and HL60. 
Moreover, to determine their respective cytotoxicity, the new ethyl 4-[4-(4-
substitutedpiperidin-1-yl)]benzyl-phenylpyrrolo[1,2-a]quinoxaline-carboxylate 
derivatives 1a-l were tested on activated human peripheral blood mononuclear cells. 
Structure-activity relationships of these new synthetic compounds 1a-l are here 
discussed. Finally, we used simple computational programs to predict the drug-like 
characteristics through the calculated physicochemical and toxicological properties of 
these new ethyl 4-[4-(4-substitutedpiperidin-1-yl)]benzyl-phenylpyrrolo[1,2-
a]quinoxaline-carboxylate derivatives to determine their potential as new anti-
leukemia drugs. 
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Figure 4. Structure of bioactive compounds of previously described series A-C, and general structure 
of new synthesized substituted pyrrolo[1,2-a]quinoxaline derivatives 1a-l (series D). 
 
 
 
 
 
 
 
 
 
 
 
21 
 
1.2. Aim of Workpackage 1 
The Workpackage 1of my thesis relies on the design and synthesis of new potential 
antiproliferative compounds. A recent work shows the importance of the pyrrolo[1,2-
a]quinoxaline ring as scaffold and the relevance of the introduction of precise 
functionalizations to modulate its activity. In this context the presence of a phenyl ring 
and an ethyl ester group on the pyrrol moiety of the pyrrolo[1,2-a]quinoxaline ring 
seem to be important as revealed by the biological test conducted on different human 
cancer cell lines [13-15]. These results also showed the significant influence of a 
benzylpiperidinylbenzimidazolone and fluorobenzimidazole substituents for the 
activity of the compounds. As demonstrated in a previous work the critical step of the 
entire synthesis is the formation of the phenyl-1H-pyrrole-diesters ring. For this 
reason, different protocols reported in literature were compared in order to study the 
effect of different conditions (temperature, solvent and catalyst) on the reaction yield. 
The purpose was to determine the critical elements of the protocolsable to modulate 
significantly the formationof the phenyl-1H-pyrrole-diesters ring. Afterwards this 
structure was considered as starting material to synthesize the pyrrolo[1,2-
a]quinoxaline scaffolds differently substituted 6a-d, key intermediates in the synthesis 
of the final compounds 1.Different methodologies were used to obtain the different 
molecules. In this context, a classical multi steps strategy was compared to a 
methodology characterized by a one-pot reduction-cyclization step. The goal was to 
verify the effectiveness of the presence of an entropically favoured step on the entire 
process of formation of the molecules 6a-d. After this the final compounds 1a-l were 
obtained by using different strategies to introduce a long chain in the position 4 of the 
pyrrolo[1,2-a]quinoxaline scaffold. In different works the presence of a spacer 
between the scaffold and the long chain is considered useful to improve the activity 
of the molecules. For this reason, a benzyl piperidine spacer was introduced to 
separate the two portions of the molecule able to modulate their potential 
antiproliferative activity. The benzylpiperidinylbenzimidazolone and 
thebenzylpiperidinyl fluorobenzimidazole are described in literature as possible chain 
able to influence the antiproliferative activity of this scaffold. These modifications 
were compared to another one characterized by the presence of pyridine ring bound 
to a triazole structure in a precise way. The aim was the determination of a 
correlation between the rigidity of the aromatic group and the activity of the 
molecules. As reported in many works the microwaves could be able to transfer 
energy to the reaction mixture in a better way if compared to the conventional way of 
heating. Considering this, we evaluated the possibility to use this mode of heating to 
verify the possibility to improve the time and the yield of the reaction. NMR 
experiments were conducted in order to confirm the structure of the synthesized 
molecules. The MTS cell proliferation assay (Promega, France) is a colorimetric 
assay system, which measures the reduction of a tetrazolium component (MTS) into 
formazan produced by the mitochondria of viable cells. This assay was used in order 
to evaluate the antiproliferative activity of our new synthesized compounds 1a-l. 
Different human cancer cell lines were considered for the biological tests in order to 
compare different typologies of cancer cells where the Akt protein, normally involved 
in the proliferation regulation process, is overexpressed. The prediction of the 
possible toxicity of the molecules is very important in the design of new potential 
drugs. Within this context, the Molinspiration web-enabled software was used to 
predict their drug-like characteristics, such as the lipophilicity (calculating the Clog P) 
and the intestinal absorption (calculating the molecular polar surface areas, PSA). 
Afterwards, docking studies were conducted by using the Swiss Dock server 
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(http://www.swissdock.ch) [17; 18]. The protein input considered for the analysis was 
the crystal structure of the Akt entire protein. (pdb code: 3O96 [5]). The aim was the 
determination of structural elements in the chosen scaffold, in the spacer and in the 
introduced functionalizations important for the interaction between the ligand and the 
protein. Next, docking studies were carried out by considering only the Akt PH 
domain and the best scored molecules. The input target considered was the PH 
domain extracted from the crystal structure of PKB(pdb code: 1UNR [19]). This 
analysis was made in order to verify if our molecule can be considered as a potential 
allosteric inhibitor of the Akt protein or a simple PH domain binder. All informations 
acquired by docking studies were considered to set a possible correlation between 
the structure of the molecules and their biological activities.  
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1.3. Results and discussion 
 
1.3.1. Synthesis 
Series D 
 
 
Figure 5. Chemical structure of compounds 1a-l obtained by different functionalizations. 
 
All reported pyrrolo[1,2-a]quinoxaline derivatives 1a-l were synthesized from various 
substituted phenyl-1H-pyrrole-dicarboxylic acid ethyl ester 2a-d (Schemes 1-2). 
Different strategies using classical or microwaves heating were considered for the 
synthesis of the phenyl-1H-pyrrole-diesters 2a-d in order to introduce the phenyl and 
ester functions on the pyrrole ring (Table 1). The synthesis of the diethyl 4-phenyl-
1H-pyrrole-2,3-dicarboxylate 2a has been accomplished by treatment of ethyl 
isocyanide on ethyl phenylpropiolate under 1,3-bis(diphenylphosphino)propane 
(dppp) catalysis via a formal [3+2] cyclo-addition [20; 21]. (Scheme 1, Table 1) 
Various attempts were investigated for the preparation of the diethyl 3-phenyl-1H-
pyrrole-2,4-dicarboxylate 2b. At first, this pyrrole 2b was prepared by silver-catalyzed 
cycloaddition of commercialy available ethyl phenylpropiolate with ethyl 
isocyanoacetate in 1,4-dioxane or DMF at 80°C (Scheme 1, Methods A-C, Table 1) 
[22; 23]. The very low yields obtained (7-12%, Table 1) using classical or 
microwaves heating led us to investigate other methodologies. The copper-catalyzed 
reaction of ethyl isocyanide with the electron-deficient alkyne, ethyl phenylpropiolate, 
gave the diethyl 3-phenyl-1H-pyrrole-2,4-dicarboxylate 2b with 58 to 62% in dioxane 
at 100°C using classical or microwave heating (Table 1) [24; 25]. Pyrrole 2b could be 
also synthesized by reaction of ethyl isocyanoacetate with benzaldehyde in the 
presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in THF [26; 27]. 
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Table 1. Comparison of microwave-assisted synthesis of phenyl-1H-pyrrole-diester 2a-d under 
standard reaction conditions. 
 Reagents and conditions 
Conventional 
heating 
Microwaves heating 
(200W) 
Time Yield (%) Time Yield (%) 
2a (i) dppp, dioxane, 100 °C 2 h 87 2 h 88 
2b 
(ii) Method A: Ag2CO3, dioxane, 80 °C 1 h 9 ― ― 
(ii) Method B: 1) Ag2CO3, dioxane, 25 °C ; 
2) 80 °C 
1) 5 min 
2) 30 min 
10 
1) 5 min 
2) 30 min 
7 
(ii) Method C: 1) Ag2CO3, NMP, 25 °C ; 
2) 80 °C 
― ― 
1) 5 min 
2) 30 min 
12 
(iii) Method D : Cu2O, phenanthroline, 
dioxane, 100 °C 
2 h 58 40 min 62 
(iv) Method E : DBU, THF, 50 °C 5 h 21 1 h 35 
2c 
(vi) 1) H5C2OOC-C C-COOC2H5, DABCO, 
toluene, 80 °C; 2) 170 °C, P 
1) 6 min 
2) 2 h 
28 
1) 6 min 
2) 45 min 
28 
2d 
(viii) C6H5-CO-CH2-COOC2H5, 
Mn(OAc)3 2H2O, 40 °C 
2 h 42 ― ― 
 
The synthesis of the diethyl 5-phenyl-1H-pyrrole-2,3-dicarboxylate 2c has been 
accomplished in two steps starting from commercially available acetophenone via its 
oxime 3 (Scheme 1). The acetophenone oxime 3, synthesized by the reaction of 
hydroxylamine on acetophenone [28], was then reacted with diethyl acetylene in the 
presence of 1,4-diazabicyclo[2.2.2]octane (DABCO) to form pyrrole 2c via a thermal 
rearrangement by Trofimov reaction [29; 30]. Diethyl 5-phenyl-1H-pyrrole-2,4-
dicarboxylate 2d was prepared by manganese(III)-catalyzed formal [3+2] annulation 
of ethyl 2-azidoacrylate 4 and ethyl 3-oxo-3-phenylpropanoate [31]. The 2-
azidoacrylate 4 was previously synthesized by treatment of ethyl 2,3-
dibromopropanoate with three equivalents of sodium azide (NaN3) in aprotic polar 
solvent such as dimethylformamide (DMF) [32; 33].  
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Scheme 1. Synthesis of phenyl-1H-pyrrole-diesters 2a-d; Reagents and conditions : (i) dppp, dioxane, 
100 °C; (ii) Method A: Ag2CO3, dioxane, 80 °C; Method B: 1) Ag2CO3, dioxane, 25 °C ; 2) 80 °C; 
Method C: 1) Ag2CO3, NMP, 25 °C ; 2) 80 °C; (iii) Method D : Cu2O, phénanthroline, dioxane, 100 °C; 
(iv) Method E : DBU, THF, 50 °C; (v) H2NOH, HCl, Pyridine, EtOH, reflux; (vi) 1) H5C2OOC-C C-
COOC2H5, DABCO, toluene, 80 °C; 2) 170 °C, P; (vii) NaN3, DMF, 65 °C; (viii) C6H5-CO-CH2-
COOC2H5, Mn(OAc)3 2H2O, 40 °C. 
 
The preparation of N-aryl pyrroles 5a-d were obtained by nucleophilic substitution of 
the various pyrrole-2-carboxylates 2a-d with 2-fluoro-nitrobenzene using cesium 
carbonate as the base in refluxing DMF solution (Scheme 2) [14; 15]. The 
preparation of 5a-d was also performed under microwave irradiation. Reduction of 
the nitro moiety with iron in hot glacial acetic acid produced the spontaneous ring 
closure onto the ester in position 2 of the pyrrole moiety to afford the desired tricyclic 
pyrrolo[1,2-a]quinoxalines 6a-d through a one-pot reduction-cyclization step [14; 15].  
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Scheme 2. Synthesis of pyrrolo[1,2-a]quinoxalines 1a-l; Reagents and conditions : (i) 2-fluoro-
nitrobenzene, Cs2CO3, DMF, Δ; (ii) Fe, CH3COOH, Δ; (iii) CH3CN, RT; (iv) nitrostyrene, p-TsOH, Δ 
(v) POCl3, Δ; (vi) OHC-C6H4-B(OH)2, Pd[P(C6H5)3]4, K2CO3, toluene, EtOH, Δ; (vii) 4-(2-
ketobenzimidazolin-1-yl)piperidine or 4-(5-fluorobenzimidazolin-2-yl)piperidine or 2-(3-piperidin-4-yl-
1H-1,2,4-triazol-5-yl]pyridine, NaBH3CN, MeOH, Δ. 
 
Sanaeishoar et al. previously reported the synthesis of lactam 6a involving a three-
component reaction between o-phenylenediamine, acetylenic ester and -
nitrostyrene using p-toluene sulfonic acid (PTSA) as a catalyst [34]. By following their 
procedure, the reaction only led to the formation of the intermediate ethyl 2-[3,4-
dihydro-3-oxoquinoxaline-2(1H)-ylidene] acetate 7 [35; 36]. To convert this 
intermediate 7 into the lactam 6a, we decided to modify the reported experimental 
procedure by heating quinoxaline 7 with -nitrostyrene activated by PTSA in refluxing 
acetonitrile. This modified methodology afforded lactam 6a with a 51% yield. The 
lactames 6a-d were subsequently chlorodehydroxylated with phosphorous 
oxychloride, leading to the 4-chloroquinoxalines 8a-d. 4-(Pyrrolo[1,2-a]quinoxalin-4-
yl)benzaldehydes 9a-d were easily prepared by a direct Suzuki-Miyaura cross-
coupling reaction of 4-chloropyrroloquinoxalines 8a-d with 4-formylphenylboronic 
acid performed in the presence of Pd(PPh3)4 as a catalyst, and in the presence of 
potassium carbonate used as the base [13-15]. The aldehydes 9a-d were then 
engaged in a reductive amination with NaBH3CN and 4-(2-ketobenzimidazolin-1-
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yl)piperidine or 4-(5-chloro-2-ketobenzimidazolin-1-yl)piperidine or  2-(3-piperidin-4-
yl-1H-1,2,4-triazol-5-yl)pyridine to give the pyrrolo[1,2-a]quinoxalines 1a-l [13-15].  
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1.3.2. X-ray structures 
X-ray single crystal analysis was also performed on phenyl-1H-pyrrole-diesters 2b-d 
in order to confirm their structures (Figure 6).  
 
Figure 6. The ORTEP drawing of phenyl-1H-pyrrole-diesters 2b-2d with thermal ellipsoids at 30% 
level. 
 
In addition, the 3D spatial determinations of 1a, 1d, 1g and 1j were established by X-
ray crystallography (Figure 7), and confirmed the structures in the solid state as 
anticipated on the basis of IR and in solution by1H and 13C NMR data. 
 
 
Figure7. The ORTEP drawing of pyrrolo[1,2-a]quinoxalines 1a, 1d, 1g and 1j with thermal ellipsoids at 
30% level. 
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1.3.3. Biological activity 
 
1.3.3.1. Cytotoxicity in different human cancer cell lines 
The twelve new compounds 1a-l were tested by MTS assay for their in vitro 
antiproliferative activity against five human leukemic cell lines (U937, K562, Jurkat, 
U266 and HL60). Compound A6730 (Figure 4) was used in these tests as the 
reference standard drug. The results are summarized in Table 2. The pyrrolo[1,2-
a]quinoxalines 1c, 1f, 1g, 1h, 1i, 1k and 1l were found the most antiproliferative 
compounds on the growth of human myeloid U937 cell line with IC50 of 3-11 M. The 
two derivatives 1h and 1k with IC50 of 4 and 3 M respectively, showed a better 
activity in comparison with the reference compound A6730 (IC50 = 8 M). These two 
compounds 1h and 1k were substituted in position 4 by a benzylpiperidinyl 
fluorobenzimidazole group and in position 1 by a phenyl. In general, the substitution 
by a phenyl on position 1 of the pyrrole moiety led to active derivatives (1g-l 
excepted 1j). Interestingly, 1c, 1f, 1i and 1l were substituted by a benzylpiperidinyl 
triazolylpyridine moiety in position 4 of the pyrrolo[1,2-a]quinoxaline core. All other 
compounds derived from the incorporation of the benzylpiperidinyl benzimidazolone 
moiety (compounds 1a, 1d and 1j), which was present in the reference compound 
A6730, into the 4-position of the heterocyclic pyrroloquinoxaline ring were found 
inactive on the U937 cell line in comparison with their benzylpiperidinyl 
fluorobenzimidazole or benzylpiperidinyl triazolylpyridine analogues, excepted 1g 
that was found active (IC50 = 9 M). From a SAR point of view, these preliminary 
biological results on U937 cell line enlightened the importance of the substitution at 
C-4 position of the pyrroloquinoxaline scaffold by a benzylpiperidinyl 
fluorobenzimidazole group, and also the need of a phenyl functionalisation in position 
1 of the pyrrole ring (compounds 1h and 1k). The antiproliferative potencies of these 
new derivatives 1a-l were also examined towards the human myeloid leukaemia cell 
lines K562 and HL60. Among the twelve compounds tested for antiproliferative 
activities on K562 cell line, the five pyrrolo[1,2-a]quinoxalines 1a, 1b, 1e, 1k and 1l 
were found the most active compounds with an IC50 of 3-4 M. All the other 
pyrroloquinoxalines 1 also showed significant antiproliferative activity with IC50 
ranging from 7 to 14 M, better than the one found for the reference compound 
A6730 (IC50 = 17 M). Moreover, in terms of structure-activity relationships 
discussion, it could be also noticed that the four quinoxalines 1b, 1e, 1h and 1k, 
bearing the benzylpiperidinyl fluorobenzimidazole moiety in their 4-position, were 
always found the most active compounds with IC50 of 3-7 M in each subseries 
diversely substituted by a phenyl and an ester on the pyrrole ring. Against the HL60 
human acute promyeloid leukemia cell line, most of the tested compounds showed 
antiproliferative activity with IC50 values from 3 to 24 M, excepted 1a and 1j that 
were found inactive (IC50> 50 M). The two pyrroloquinoxalines 1d and 1f having an 
ester function and a phenyl respectively in position 2 and 3 exhibited better activities 
than their other homologues. Compounds 1d and 1k showed a better activity that the 
one noticed for the reference compound A6730: i.e. IC50 = 3.5 and 3 M for 1d and 
1k, respectively in comparison with 5.5 M for A6730. The antiproliferative activities 
of compounds 1a-l against the T-lymphocyte Jurkat cell line were also investigated, 
and the results exhibited potent cytotoxicity for pyrroloquinoxalines 1b-l (IC50 from 2 
to 6.5 M) as potent as the one observed for A6730 (IC50 = 3.5 M). Nevertheless, 
the pyrrolo[1,2-a]quinoxaline 1a showed low antiproliferative activity (IC50 = 41 M). 
Hence in the subseries functionalized by a phenyl and an ester at C2 and C3 
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respectively, the IC50 of 1b and 1c (5 M) was 8.2 times lower than those of 
compound 1a (IC50 = 41 M). Against the human myeloma cell line U266, the same 
pyrrolo[1,2-a]quinoxalines 1b, 1f, 1h, 1k and 1l, bearing a benzylpiperidinyl 
fluorobenzimidazole or a benzylpiperidinyl triazolylpyridine moiety in position 4 and 
substituted on the pyrrole ring, exhibited potent cytotoxicity (IC50 from 3 to 5 M). All 
the other tested pyrroloquinoxalines 1 (compounds 1d-e, 1g and 1i) were also found 
to be active on U266 cell line with IC50 ranging from 8 to 18 M, with the exception of 
1a, 1c and 1j that presented an IC50 superior to 50 M. 
 
1.3.3.2. Cytotoxicity activity in activated normal PBMNC cells 
The compounds 1a-l were tested on activated (PBMNC + PHA) human peripheral 
blood mononuclear cells to evaluate their respective cytotoxicity on normal cells 
(Table 2). As expected, most of the pyrrolo[1,2-a]quinoxalines 1a-l showed 
significant level of cytotoxicity against lymphocytes with IC50 ranging from 8 to over 
50 M. These preliminary results were used to determine their respective range of 
toxic concentration. Indexes of selectivity (IS) were defined as the ratio of the IC50 
value on the human mononuclear cells to the IC50 value on the K562, U937, HL60, 
Jurkat and U266 lines. Compounds that demonstrated high selectivity (high index of 
selectivity) should offer a potential of safer therapy. This led to identify compounds 
with index of selectivity >16.7 and >12.5 for compounds 1e and 1a, respectively, on 
the human myeloid leukemic cell lines K562; and >12.5 for compound 1g against the 
human leukemic cell lines Jurkat. We could notice that the more interesting new 
pyrroloquinoxaline structure (compound 1e) could be considered as a direct 
combination of our previously described bioactive derivatives JG572 and JG576 
(Series B, Figure 4). Moreover, we could notice that the compound 1a showed 
interesting selectivity towards K562 CML cell lines. The potential inhibitor 1h also 
showed interesting IS on U937 and U266 leukemic cell lines with value of 12.5. 
These four compounds could now constitute suitable candidates for further 
pharmacological studies. The reference compound A6730 showed interesting 
selectivity with index of selectivity value noticed at 14.3 on the Jurkat cell line. 
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Table 2. In vitro activity of compounds 1a-l (Series D, Figure 3b) on K562, U937, HL60, Jurkat and 
U266 cells, and cytotoxicity on human peripheral blood mononuclear cells PBMNC + PHA. 
IC50 values (M)a 
Inhibitors K562 U937 HL60 Jurkat U266 
Cytotoxicity on activated human 
peripheral blood mononuclear 
cells (PBMNC) 
PBMNC + PHA 
A6730 17  0.3 8  0.2 5.5  0.2 3.5  0.2 n.d.b >50 
1a 4  0.1 >50 >50 41  1.2 >50 >50 
1b 3  0.1 21  2.2 19  2.8 5  0.2 3.5  0.1 14  1 
1c 14  0.3 7  0.3 12  2.3 5  0.1 >50 16  2 
1d 9  0.3 >50 3.5  0.1 4  0.1 10  0.8 41.3  5 
1e 3  0.1 n.d. 10  0.9 5  0.2 18  1.1 >50 
1f 7  0.2 7  0.1 5  0.1 2  0.1 5  0.1 8  0.5 
1g 8  0.2 9  0.4 6  0.1 4  0.1 9  0.8 >50 
1h 7  0.3 4  0.1 8  0.2 6  0.15 4  0.1 50  4 
1i 12  0.4 11  0.9 24  3 5  0.1 8  0.5 50  6 
1j 8.5  0.3 >50 >50 6.5  0.1 >50 >50 
1k 3  0.1 3  0.1 3  0.1 3.5  0.1 3  0.1 13  1 
1l 3.5  0.1 8  0.2 7  0.3 3 3  0.1 12  1 
aThe IC50(M) values correspond to the mean ± standard deviation from three independent experiments. 
bn.d. = not determined. 
 
According to these results (Table 2), the molecules 1e, 1g, 1h and 1i exhibit the 
most promising activity on most of the cancer cell lines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
1.3.4. Prediction of toxicity and other drug relevant properties 
To speculate about any toxicity risks and evaluate the drug-like characteristics of 
these novel synthesized compounds, we computed a set of drug relevant properties 
from their 2D chemical structures (Table 3). The calculated properties indicated that 
our molecules 1 present the same toxicological profile as the anticancer reference 
compound A6730. These parameters were calculated by the molinspiration web 
services. [http://www.molinspiration.com/cgi-bin/properties. Accession date: 
July 20, 2015] All compounds 1a-l were found lipophilic with Clog P values between 
6.44 and 7.70. The Clog P of the reference compound A6730 was noticed at 5.55 
slightly lower than those of our compounds. To predict intestinal absorption, we 
estimated the molecular polar surface areas (PSA) of these new pyrroloquinoxaline 
compounds 1a-l from the calculated TPSA. PSA has been extensively used in 
medicinal chemistry for modeling absorption phenomena and to optimize a drug's 
ability to permeate cells. The PSA of a molecule is defined as the surface sum over 
all polar atoms, which primarily consist of oxygen and nitrogen as well as their 
attached hydrogens. Molecules with a polar surface area greater than 140 Å2 tend to 
be poor at permeating cell membranes, while a PSA of less than 60 Å2 is usually 
needed for molecules to penetrate the blood-brain barrier and thus act on the brain 
and other central nervous system tissues [33,34]. The PSA of our compounds could 
suggest an intestinal absorption (PSA < 140 Å2). On the other hand, these 
pyrroloquinoxalines seem to be unlikely to cross the blood-brain barrier (PSA > 60 
Å2). Thus, based on these predicted data, the calculated PSA values for these 
derivatives 1 could indicate a possible better oral bioavailability with a smaller chance 
of CNS toxicity. 
 
Table 3. Predicted drug-relevant properties of compounds 1a-l. 
Compound Clog P TPSA nON nOH/NH N violationsa 
A6730 5,55 95,50 8 2 2 
1a 7.19 84.65 8 1 2 
1b 7.70 75.53 7 1 2 
1c 6.49 101.32 9 1 2 
1d 7.19 84.65 8 1 2 
1e 7.70 75.53 7 1 2 
1f 6.49 101.32 9 1 2 
1g 7.13 84.65 8 1 2 
1h 7.65 75.53 7 1 2 
1i 6.44 101.32 9 1 2 
1j 7.13 84.65 8 1 2 
1k 7.65 75.53 7 1 2 
1l 6.44 101.32 9 1 2 
aNumber of violations to the Lipinski’s “rule of five”: log P5, molecular weight 500, number 
of hydrogen bond acceptors10, and number of hydrogen bond donors 5. 
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1.3.5. Docking studies 
 
1.3.5.1. Validation of Swiss Dock server method 
Firstly, docking study was carried out considering the reference molecule A6730 as 
ligand (Figure 8a). The best docked structure was compared to the X-ray structure of 
Akt1/A6730 (pdb code: 3O96 [5], Figure 8b) inhibitor complex. The superimposition 
of the two structures showed that A6730 molecule in the best docked pose has 
position and orientation almost identical to that assumed in the crystal structure (see 
Figure 8c). Furthermore, structure-activity relationship (SAR) studies have 
underlined the importance of the 2,3-diphenyl substituent and the N1 heteroatom 
(blue in the Figure 8a). All these results confirm what is reported in the reference 
work [5]. For this reason, they could be considered as a valuable evidence of the 
Swiss Dock server validity. 
a)
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Figure 8. a) Chemical structure of A6730 allosteric inhibitor; Blue the molecule portions involved in the 
Akt-ligand interaction. b) Reference complex: X-ray structure of Akt1/A6730 inhibitor complex (pdb 
code:3O96 [5]); Red for PH domain; Green for kinase domain.c) Superimposition of the reference 
complex (pdb: 3O96) and best docking pose of A6730; Red for reference Akt structure (pdb: 3O96); 
Blue for Akt structure used for docking analysis; Light blue for the ligand in the best docking pose of 
A6730; Pink for molecule A6730 in the reference complex (pdb code:3O96). 
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1.3.5.2. Docking analysis of the compounds 1a-l with Akt entire protein 
The results of docking studies conducted on our new synthesized molecules 1a-l are 
presented by visualizing the two Akt domains (PH and Kinase domains) separately to 
give a better comprehension of the main protein-ligand interactions.  
 
1.3.5.2.1. Compound 1a 
The first molecule studied in this work is the pyrroloquinoxaline 1a (Figure 5). The 
result of docking analysis consists of 256 models organized in 37 clusters. The first 
five clusters were considered to define the main interactions between ligand and 
protein. The Figure 9a shows the best docked structure (this represents the model 
with the lowest value of the FullFitness score) and in this figure only the Akt PH 
domain is visible. The protein residues making the highest number of contacts with 
the ligand are Gln79, Trp80 and Ile84. The Figure 9b contains the same docking 
pose but only the Kinase domain is represented.  The residues with the highest 
number of contacts with the ligand are Tyr272 and Arg273. This model is 
characterized by the absence of intermolecular protein/ligand hydrogen bonds.  
 
a)  b)  
 
Figure 9. Best docked structure for 1a. a) only PH domain is shown. Red: residues providing 10 
interactions or more; yellow for residues providing 9 interactions or less. b) only Kinase domain is 
reported. Blue for residues with 10 interactions or more. Cyan for residues with 9 interactions or less. 
 
1.3.5.2.2. Compound 1b 
The second molecule studied is the derivative 1b (Figure 5). The result of docking 
analysis consists of 256 models organized in 39 clusters. The first best scoring five 
clusters were analyzed to define the main interactions between ligand and protein. 
Most of the docking poses consist of the ligand fit in a cleft located at the interface 
between the Akt PH and Kinase domains. 
The Figure 10a shows the best solution (this represents the model with the lowest 
value of the FullFitness score) and only the Akt PH domain is visible. The PH domain 
residues making the highest number of contacts with the ligand are Gln79 and Trp80. 
The Figure 10b contains the same docking pose but only the Kinase domain is 
represented. The residues belonging to the Kinase domain that are making the 
highest number of contacts with the ligand are Val270 and Tyr272. This docking 
model contains also a hydrogen bond between the backbone oxygen atom of Cys296 
and the proton H31 of the benzimidazol portion of the ligand (Figure 10c).  
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a) b)  
c)  
 
Figure 10. Best docked structure for 1b. a) only PH domain is shown. Red: residues providing 10 
interactions or more; yellow for residues providing 9 interactionsor less. b) only Kinase domain. Blue 
for residues with 10 interactions or more. Cyan for residues with 9 interactions or less. c)Hydrogen 
bond analysis. Red for PH domain. Green for kinase domain. Gray for residue involved in the 
hydrogen bond. Orange for hydrogen bond length. 
 
1.3.5.2.3. Compound 1c 
The third molecule studied is the compound 1c (Figure 5). The result of docking 
analysis consists of 255 models organized in 36 clusters. The first best scoring five 
clusters were analyzed to define the main interactions between ligand and protein. 
Most of the docking poses consist of the ligand fit in a cleft located at the interface 
between the Akt PH and Kinase domains. 
The Figure 11a shows the best solution (this represents the model with the lowest 
value of the FullFitness score) and only the Akt PH domain is visible. The PH domain 
residues making the highest number of contacts with the ligand are Lys14, Asn54, 
Gln79 and Trp80. The Figure 11b contains the same docking pose but only the 
Kinase domain is represented. The residues belonging to the Kinase domain that are 
making the highest number of contacts with the ligand are Tyr272, Asp292 and 
Tyr326. This docking model contains also a hydrogen bond between the HG1 proton 
of Thr82 and the O1 oxygen atom of the ethyl ester group of the ligand (Figure 11c). 
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a) b)  
c)  
 
Figure 11. Best docked structure for 1c. a) only PH domain is shown. Red: residues providing 10 
interactions or more; yellow for residues providing 9 interactionsor less. b) only Kinase domain. Blue 
for residues with 10 interactions or more. Cyan for residues with 9 interactions or less. c)Hydrogen 
bond analysis. Red for PH domain. Green for kinase domain. Gray for residue involved in the 
hydrogen bond. Orange for hydrogen bond length. 
 
1.3.5.2.4. Compound 1d 
The fourth molecule studied is the pyrroloquinoxaline 1d (Figure 5). The result of 
docking analysis consists of 254 models organized in 45 clusters. The first best 
scoring five clusters were analyzed to define the main interactions between ligand 
and protein. Most of the docking poses consist of the ligand fit in a cleft located at the 
interface between the Akt PH and Kinase domains. 
The Figure 12a shows the best solution (this represents the model with the lowest 
value of the FullFitness score) and only the Akt PH domain is visible. The PH domain 
residues making the highest number of contacts with the ligand are Gln79 and Trp80. 
The Figure 12b contains the same docking pose but only the Kinase domain is 
represented. The residues belonging to the Kinase domain that are making the 
highest number of contacts with the ligand are Val270 and Tyr272. This docking 
model contains also a hydrogen bond between the backbone HN amide proton of 
Glu298 and the O atom of the benzimidazol-2-one portion of the ligand (Figure 12c). 
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a)  b)  
c)  
 
Figure 12. Best docked structure for 1d. a) only PH domain is shown. Red: residues providing 10 
interactions or more; yellow for residues providing 9 interactionsor less. b) only Kinase domain. Blue 
for residues with 10 interactions or more. Cyan for residues with 9 interactions or less. c)Hydrogen 
bond analysis. Red for PH domain. Green for kinase domain. Gray for residue involved in the 
hydrogen bond. Orange for hydrogen bond length. 
1.3.5.2.5. Compound 1e 
The fifth molecule studied is the molecule 1e (Figure 5). The result of docking 
analysis consists of 256 models organized in 41 clusters. The first five clusters were 
investigated to identify the relevantinteractions between ligand and protein. In Figure 
13a only the best model, provided with the lowest FullFitness score, is reported and 
the Akt PH domain is shown. The protein residues with the highest number of 
contacts with the ligand areGln79 and Trp80. The Figure 13b shows details of the 
corresponding docking pose in the Kinase domain cleft. Val270 and Tyr272 represent 
the residues of the Kinase domain making the highest number of contacts with the 
ligand. This model is characterized by the absence of intermolecular protein/ligand 
hydrogen bonds.  
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a) b)  
 
Figure 13. Best docked structure for 1e. a) only PH domain is shown. Red: residues providing 10 
interactions or more; yellow for residues providing 9 interactionsor less. b) only Kinase domain. Blue 
for residues with 10 interactions or more. Cyan for residues with 9 interactions or less. 
 
1.3.5.2.6. Compound 1f 
The sixth molecule studied is the compound 1f (Figure 5). The result of docking 
analysis consists of 256 models organized in 39 clusters. The first five clusters were 
considered to define the main interactions between ligand and protein. The Figure 
14a shows the best docked structure (this represents the model with the lowest value 
of the FullFitness score) and in this figure only the Akt PH domain is visible. The 
protein residue making the highest number of contacts with the ligand is Trp80. The 
Figure 14b contains the same docking pose but only the Kinase domain is 
represented.  The residues with the highest number of contacts with the ligand are 
Val270 and Tyr272. This model is characterized by the absence of hydrogen bonds 
with both domains. 
 
a) b)  
 
Figure 14. Best docked structure for 1f. a) only PH domain is shown. Red: residues providing 10 
interactions or more; yellow for residues providing 9 interactionsor less. b) only Kinase domain. Blue 
for residues with 10 interactions or more. Cyan for residues with 9 interactions or less. 
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1.3.5.2.7. Compound 1g 
The seventh molecule studied is pyrroloquinoxaline 1g (Figure 5). The result of 
docking analysis consists of 256 models organized in 38 clusters. The first five 
clusters were considered to define the main interactions between ligand and protein. 
The Figure 15a shows the best docked structure (this represents the model with the 
lowest value of the FullFitness score) and in this figure only the Akt PH domain is 
visible. The protein residues making the highest number of contacts with the ligand 
are Gln79 and Trp80. The Figure 15b contains the same docking pose but only the 
Kinase domain is represented. The residues with the highest number of contacts with 
the ligand are Val270 and Arg273. This model is characterized by the absence of 
intermolecular protein/ligand hydrogen bonds.  
 
a)  b)  
 
Figure 15. Best docked structure for 1g. a) only PH domain is shown. Red: residues providing 10 
interactions or more; yellow for residues providing 9 interactionsor less. b) only Kinase domain. Blue 
for residues with 10 interactions or more. Cyan for residues with 9 interactions or less.  
 
1.3.5.2.8. Compound 1h 
The eighth molecule studied is the derivative 1h (Figure 5). The result of docking 
analysis consists of 256 models organized in 38 clusters. The first five clusters were 
considered to define the main interactions between ligand and protein. In the Figure 
16a only the Akt PH domain is shown with the best model provided with the lowest 
FullFitness score. The protein residues with the highest number of contacts with the 
ligand are Gln79 and Trp80. The Figure 16b shows details of the corresponding 
model docked into the Kinase domain cleft. The residue making the highest number 
of contacts with the ligand is Val270. This model is characterized by the absence of 
hydrogen bonds with both domains.  
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a) b)  
 
Figure 16. Best docked structure for 1h. a) only PH domain is shown. Red: residues providing 10 
interactions or more; yellow for residues providing 9 interactionsor less. b) only Kinase domain. Blue 
for residues with 10 interactions or more. Cyan for residues with 9 interactions or less. 
 
1.3.5.2.9. Compound 1i 
The ninth molecule studied is the compound 1i (Figure 5). The result of docking 
analysis consists of 252 models organized in 36 clusters. The first five clusters were 
considered to define the main interactions between ligand and protein. The Figure 
17a shows the best docked structure (this represents the model with the lowest value 
of the FullFitness score) and in this figure only the Akt PH domain is visible. The 
protein residue making the highest number of contacts with the ligand is Trp80. The 
Figure 17b contains the same docking pose but only the Kinase domain is 
represented.  The residues with the highest number of contacts with the ligand are 
Lys268 andVal270. This model is characterized by the absence of intermolecular 
protein/ligand hydrogen bonds. 
 
a) b)  
 
Figure 17. Best docked structure for 1i. a) only PH domain is shown. Red: residues providing 10 
interactions or more; yellow for residues providing 9 interactionsor less. b) only Kinase domain. Blue 
for residues with 10 interactions or more. Cyan for residues with 9 interactions or less.  
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1.3.5.2.10. Compound 1j 
The tenth molecule studied is pyrroloquinoxaline 1j (Figure 5). The result of docking 
analysis consists of 256 models organized in 45 clusters. The first five clusters were 
considered to define the main interactions between ligand and protein. In the Figure 
18a only the Akt PH domain is shown with the best model provided with the lowest 
FullFitness score. The protein residues with the highest number of contacts with the 
ligand are Asn53, Gln79 and Trp80. The Figure 18b shows details of the 
corresponding model docked into the Kinase domain cleft. The residue making the 
highest number of contacts with the ligand is Val270. This model is characterized by 
the absence of hydrogen bonds with both domains.  
 
a) b)  
 
Figure 18. Best docked structure for 1j. a) only PH domain is shown. Red: residues providing 10 
interactions or more; yellow for residues providing 9 interactionsor less. b) only Kinase domain. Blue 
for residues with 10 interactions or more. Cyan for residues with 9 interactions or less. 
 
1.3.5.2.11. Compound 1k 
The eleventh molecule studied is the molecule 1k (Figure 5). The result of docking 
analysis consists of 256 models organized in 42 clusters. The first best scoring five 
clusters were analyzed to define the main interactions between ligand and protein. 
Most of the docking poses consist of the ligand fit in a cleft located at the interface 
between the Akt PH and Kinase domains. 
The Figure 19a shows the best solution (this represents the model with the lowest 
value of the FullFitness score) and only the Akt PH domain is visible. The PH domain 
residue making the highest number of contacts with the ligand is Trp80. The Figure 
19b contains the same docking pose but only the Kinase domain is represented. The 
residue belonging to the Kinase domain that is making the highest number of 
contacts with the ligand isLys268. This docking model contains also a hydrogen bond 
between the HD22 proton of Asn53 and the O1 oxygen atom of the ethyl ester group 
of the ligand (Figure 19c). 
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a) b)  
c)  
 
Figure 19. Best docked structure for 1k. a) only PH domain is shown. Red: residues providing 10 
interactions or more; yellow for residues providing 9 interactionsor less. b) only Kinase domain. Blue 
for residues with 10 interactions or more. Cyan for residues with 9 interactions or less. c) Hydrogen 
bond analysis. Red for PH domain. Green for kinase domain. Gray for residue involved in the 
hydrogen bond. Orange for hydrogen bond length. 
 
1.3.5.2.12. Compound 1l 
The last studied is the compound 1l (Figure 5). The result of docking analysis 
consists of 255 models organized in 36 clusters. The first best scoring five clusters 
were analyzed to define the main interactions between ligand and protein. Most of 
the docking poses consist of the ligand fit in a cleft located at the interface between 
the Akt PH and Kinase domains. The Figure 20a shows the best solution (this 
represents the model with the lowest value of the FullFitness score) and only the Akt 
PH domain is visible. The PH domain residues making the highest number of 
contacts with the ligand are Asn53, Gln79 and Trp80. The Figure 20b contains the 
same docking pose but only the Kinase domain is represented. The residue 
belonging to the Kinase domain that is making the highest number of contacts with 
the ligand isVal270. This docking model contains also an hydrogen bond between 
the HH21 proton of Arg273 and the N4 nitrogen atom of the triazole portion of the 
ligand (Figure 20c).  
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a) b)  
c)  
 
Figure 20. Best docked structure for 1l. a) only PH domain is shown. Red: residues providing 10 
interactions or more; yellow for residues providing 9 interactionsor less. b) only Kinase domain. Blue 
for residues with 10 interactions or more. Cyan for residues with 9 interactions or less. c) Hydrogen 
bond analysis. Red for PH domain. Green for kinase domain. Gray for residue involved in the 
hydrogen bond. Orange for hydrogen bond length. 
 
1.3.5.2.13. Comparison between different ligands  
All molecules fit pretty well in a cavity formed at the interface between the PH and 
Kinase domain; however, the molecule 1e has the best (i.e. lowest) value of the 
FullFitness (-2350.714) (See Figures 13a-b, Table 4). This compound seems to fit 
slightly better than the other molecules in the cleft between the PH and Kinase 
domains. Thus, it is possible that the presence of a phenyl ring on the third position 
combined with the introduction of the small ethyl ester group on the second position 
of the pyrrolo[1,2-a]quinoxaline moiety could promote a better interaction between 
the ligand and the protein. The pyrrolo[1,2-a]quinoxaline 1h appears as the worst 
ligand because has the highest value of the FullFitness score (-2328.7522) (See 
Figures 16a-b, Table 4). We could consider the hypothesis that the 5-
fluorobenzimidazole ring, associated with a phenyl and an ester function substituted 
in positions 1 and 3 respectively, could interact with the residues of the binding 
pocket more difficultly. 
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Table 4. FullFitness values of the best docked structures for each molecule of Series D (1a-l). 
Compound FullFitness 
1a -2343.2258 
1b -2346.2656 
 1c -2332.023 
 1d -2343.896 
1e -2350.714 
1f -2334.478 
1g -2341.46 
1h -2328.7522 
1i -2329.3647 
1j -2344.8442 
1k -2340.9988 
1l -2330.2043 
 
1.3.5.3. Docking analysis of the compounds 1a-l with Akt PH domain 
The results of docking studies with the PH domain reveal that 1e is the best scoring 
compound. The best model obtained for this molecule is presented in Figure 21. The 
protein residue with the highest number of contacts with the ligand isThr101. 
 
 
 
Figure 21. Best docked structure for 1e considering only PH domain (pdb code: 1UNR [19]). Red: 
residues providing 10 interactions or more; yellow for residues providing 9 interactionsor less.  
 
The 1e best docked structure obtained for Akt PH domain (Figure 21) was compared 
to a crystal structure of inositol-(1,3,4,5)-tetrakisphosphate (IP4) (Figure 22a) in 
complex with Akt1 PH domain (pdb code: 1UNQ [19]). The superimposition of the 
two complexes is reported in Figure 22b. 
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a) b)  
 
Figure 22. a) X-ray structure of Akt1 PH domain/IP4 complex (pdb code:1UNQ [19]) considered as 
reference. Cyan for the IP4 ligand. Blue for the Akt PH domain. b) Superimposition of best docking 
pose of 1e molecule for PH domain (in red) and reference structure (in blue). 
Molecule 1e fits on the PH domain surface in a pocket distinct from the inositol 
binding site (Figures 22b). In conclusion, docking results indicate that, more than 
single PH domain binders, the studied compound could behave as allosteric inhibitor 
able to interact with both the PH and kinase domains of Akt.  
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1.4. Conclusions 
Attenuation of protein kinases by selective inhibitors is an extremely active field of 
activity in anticancer drug development. Therefore, Akt, a serine/threonine protein 
kinase, also known as protein kinase B (PKB), represents an attractive potential 
target for therapeutic intervention. AKT is a member of the serine/threonine AGC 
protein kinase family involved in different cellular processes such as metabolism, 
growth, proliferation and survival. Its three human isoenzymes (Akt1, Akt2 and Akt3) 
are highly homologous multi-domain proteins with both overlapping and distinct 
cellular functions (Figure 1). Dysregulation of the AKT pathway has been identified in 
multiple human cancers. It is also well known that this protein is overexpressed in 
these cells. One of the possible consequences of this unusual protein expression is 
the uncontrolled proliferation of the cells. Therefore, the development of new 
potential antiproliferative molecules targeting this protein is required. Recent efforts in 
the design, synthesis and biological evaluation of small molecules, inhibitors of Akt, 
have led to the identification of novel inhibitors with various heterocycle scaffolds. 
Considering previous results obtained on the antiproliferative activities of new 
pyrrolo[1,2-a]quinoxalines (Series A-C, Figure 4), a novel series (Series D, Figure 5) 
was designed and synthesized from various substituted phenyl-1H-pyrrole-2-
carboxylicacid alkyl esters via a multistep heterocyclization process. The 
antiproliferative activity of the twelve new synthesized ethyl 4-[4-(4-
substitutedpiperidin-1-yl)]benzyl-phenylpyrrolo[1,2-a]quinoxaline-carboxylate 
derivatives 1a-l was then investigated on the human leukemic cell lines U937, K562, 
Jurkat, U266 and HL60. Amond them, the four pyrrolo[1,2-a]quinoxalines 1a, 1e, 1g 
and 1h showed high cytotoxic activity against some cancer cell lines (IC50 ranging 
from 3 to 9 M) and low toxicity against normal hematopoietic cells (estimated IC50 > 
50 M) (Table 2). These compounds, showing interesting index of selectivity, may 
constitute suitable candidates for further pharmacological studies. From a general 
SAR point of view, these preliminary biological results highlight the importance of 
substitution at the C-4 position of the pyrroloquinoxaline scaffold by a 
benzylpiperidinylfluorobenzimidazole group, and also the need for a functionalization 
on the pyrrole ring. Considering all biological results, the compound 1e seem to be 
the most promising Akt ligand. Moreover, it would be also interesting to enlarge the 
biological evaluation of these new pyrrolo[1,2-a]quinoxaline derivatives in order to 
precise now their mechanism of action. Some drug relevant properties of the 
synthesized compounds 1a-l were calculated by the molinspiration web services. All 
molecules exhibited the same toxicological profile of the anticancer reference 
compound A6730 (Table 3). One of the parameter considered was the hydrophilicity, 
represented by Clog P and correlated to the absorption or permeation of the 
molecules. Considering the range of Clog P values (6.44-7.70), the 
functioanalizations introduced in the pyrrolo[1,2-a]quinoxalines scaffold do not seem 
to improve the permeation of the molecules through the cell membrane. The 
molecular polar surface areas (PSA) has been extensively used in medicinal 
chemistry for modelling absorption phenomena and to optimize a drug's ability to 
permeate cells. The PSA values calculated for our compounds suggested an 
intestinal absorption (PSA < 140 Å2). On the other hand, these molecules are unlikely 
to cross the blood-brain barrier and other central nervous system tissues (PSA > 60 
Å2). According these results, the synthesized molecules are characterized by a 
potential better oral bioavailability with a smaller chance of CNS toxicity. Docking 
studies confirmed biological results. In fact, the molecule 1e exhibited the best (i.e. 
lowest) value of the FullFitness (-2350.714) (See Figures 13a-b). Furthermore, it 
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seems to fit slightly better than the other molecules in the cleft between the PH and 
Kinase domains. This lead us to speculate that the presence of a phenyl ring on the 
third position combined with the introduction of the small ethyl ester group on the 
second position of the quinoxaline ring could promote a better interaction between 
the ligand and the protein. In fact, the molecule 1h, characterized by the same 
functional groups but in different positions on the pyrrole ring, has the worst (i.e. 
highest) FullFitness score (-2328.7522) (See Figures 16a-b). The docking results 
acquired during the study conducted on the isolated PH domain showed a similar 
trend. In particular, they reveal that 1e is the best scoring compound. The 
superimposition of its best docked structure for Akt PH domain and the crystal 
structure of inositol-(1,3,4,5)-tetrakisphosphate (IP4) in complex with Akt1 PH domain 
(pdb code: 1UNQ [19]) (Figure 22a) highlights the presence of our ligand in a pocket 
distinct from the inositol binding site (Figures 22b). In conclusion docking results 
indicate that, more than single PH domain binders, the studied compound could be 
considered as an allosteric inhibitor for its ability to interact with both the PH and 
kinase domains of Akt. The possible toxicity of the molecules is a critical parameter 
to consider in the design of new potential drugs. In conclusion, a multidisciplinary and 
iterative protocol (synthesis, IR, crystallography, NMR, biological activities, docking 
and drug relevant properties predictions) was employed to obtain potential Akt 
ligands. This procedure could be repeated many times to improve the results as 
much as possible and to obtain new molecule suitable for in vivo studies. Very 
recently, in order to determine the possible mechanism of action of our compounds, 
we first evaluated their potency on isolated enzymes such as Akt 1, 2 and 3 as well 
as on mTOR. These tests have been performed by DiscoverX at 1 and 10 M 
(KINOMEScan® / DiscoveRx, 11180 Roselle Street, SuiteD San Diego, CA 92121 
United States). Nevertheless, only low effects have been detected. Akt2 activity was 
reduced of 38% and 35 % with derivatives 1e and 1j at 10 M, respectively. Such of 
enzymatic interaction could not explain the cell effects. Next assessment of apoptosis 
in K562 cell line was examined. Apoptosis induces loss of membrane asymmetry 
resulting in phosphatidyl serine (PS) exposure and alterations in mitochondrial 
membrane potential. Cells were incubated with or without increasing doses 1e for 3 
days. Compound 1e, which showed the most interesting index of selectivity on the 
human myeloid leukemic cell lines K562, induces a significantly increase in Annexin 
V positive cells from the second and third days (92% ± 2.8). These results could 
explain the inhibition of cell proliferation observed with this compound 1e. Additional 
biological tests are now required to better define the mechanism of action of our 
compounds. These investigations will carry out at the University of Bordeaux by Dr. 
Vanessa Desplat.  
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1.5. Material and methods 
 
1.5.1. Reactives  
Commercially reagents were used as purchased without additional purification. 
Microwave experiments were carried out using a focused microwave reactor (CEM 
Discover). 
 
1.5.2. Procedures 
 
1.5.2.1. Ethyl 2-azidoacrylate (4) 
To a solution of sodium azide (3.75 g, 57.7 mmol) in DMF (120 mL) at 65 °C was 
added ethyl 2,3-dibromopropionate (5.00 g, 19.3 mmol). After 10 min, the reaction 
mixture was cooled and poured into water (300 mL) and extracted with ether (3 x 120 
mL). The combined organic extracts were washed with water (3 x 120 mL), dried 
over MgSO4, filtered and evaporated in vacuo to afford ethyl 2-azidoacrylate as a 
yellow oil (79%). Rf=0.38 (cyclohexane/Et2O-98/2) [37].  
 
1.5.2.2. Diethyl 4-phenyl-1H-pyrrole-2,3-dicarboxylate (2a) 
Conventional heating: To a 1,4-dioxane solution (10.0 mL) of 1,3-
bis(diphenylphosphino)propane (dppp) (0.320 g, 0.780 mmol) were added ethyl 
isocyanoacetate (0.700 g, 6.19 mmol) and ethyl phenylpropiolate (0.900 g, 5.17 
mmol). The solution was stirred at 100 °C for 2 h. After the consumption of ethyl 
isocyanoacetate, the reaction mixture was cooled to room temperature, filtered and 
evaporated in vacuo. The crude was purified on silica gel (eluent: 
cyclohexane/AcOEt-90/10 then cyclohexane/AcOEt-70/30, Rf=0.33) to afford 2a as a 
colorless oil (87%). Microwave heating: To a 1,4-dioxane solution (18.0 mL) of 1,3-
bis(diphenylphosphino)propane (dppp) (0.640 g, 1.56 mmol) were added ethyl 
isocyanoacetate (1.40 g, 13.4 mmol) and ethyl phenylpropiolate (1.80 g, 10.3 mmol). 
After a pre-stirring of 30 s, the solution was irradiated during 2 h. The irradiation was 
programmed to maintain a constant temperature (100 °C) with a power of 200 W. 
The reaction mixture was cooled to room temperature, filtered and concentrated in 
vacuo. The crude was purified on silica gel as above to give 2a (88%) [20; 21]. 
 
1.5.2.3. Diethyl 3-phenyl-1H-pyrrole-2,4-dicarboxylate (2b) 
Method A: To a mixture of ethyl phenylpropiolate (2.50 g, 14.3 mmol) and Ag2CO3 
(0.264 g, 0.960 mmol) in 1,4-dioxane (40.0 mL) at 80 °C, ethyl isocyanoacetate (1.08 
g, 9.55 mmol) was slowly added. The solution was stirred at 100 °C for 30 min. After 
the consumption of ethyl isocyanoacetate, the reaction mixture was cooled to room 
temperature, filtered and evaporated in vacuo. The crude was purified on silica gel 
(eluent: cyclohexane/AcOEt-90/10 then cyclohexane/AcOEt-70/30, Rf=0.33) to afford 
2b as white crystals (9%). Method B: Conventional heating: A mixture of ethyl 
phenylpropiolate (2.50 g, 14.3 mmol) and Ag2CO3 (0.264 g, 0.960 mmol) in 1,4-
dioxane (40.0 mL) was heated at 80 °C for 5 min, then mixture was cooled with an 
ice bath. To this resulting solution cooled at room temperature, ethyl isocyanoacetate 
(1.08 g, 9.55 mmol) was added dropwise. The reaction mixture was stirred for 5 min 
at 25 °C, then heated for 30 min at 80 °C. The resulting slurry was concentrated 
under reduced pressure and taken up with dichloromethane. The organic layer was 
washed with brine, dried with Na2SO4, filtered and evaporated under vacuum. The 
crude was purified on silica gel as above leading to 2b (10%). Microwave heating: To 
a 1,4-dioxane suspension (40.0 mL) of Ag2CO3 (0.264 g, 0.960 mmol) was added 
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ethyl phenylpropiolate (2.50 g, 14.3 mmol). After a pre-stirring of 30 s, the solution 
was irradiated during 1 min. The irradiation was programmed to maintain a constant 
temperature (80 °C) with a power of 200 W. To the resulting solution cooled at room 
temperature, ethyl isocyanoacetate (1.08 g, 9.55 mmol) was added dropwise. After a 
pre-stirring of 30 s, the solution was irradiated during 6 min with a first step of 
irradiation of 1 min at 25 °C followed by a second one of 5 min at 80 °C. The power 
was set at 200 W in both steps. The resulting slurry was concentrated under reduced 
pressure and taken up with dichloromethane. The organic layer was washed with 
brine, dried with Na2SO4, filtered and evaporated under vacuum. The crude was 
purified on silica gel as above to give 2b (7%).Method C: To a N-methyl-2-
pyrrolidone (NMP) solution (40.0 mL) of Ag2CO3 (0.264 g, 0.960 mmol) was added 
ethyl phenylpropiolate (2.50 g, 14.3 mmol). After a prestirring of 30 s, the solution 
was irradiated during 1 min. The irradiation was programmed to maintain a constant 
temperature (80 °C) with a power of 200 W. To the resulting solution cooled at room 
temperature, ethyl isocyanoacetate (1.08 g, 9.55 mmol) was added dropwise. After a 
pre-stirring of 30 s, the solution was irradiated during 6 min with a first step of 
irradiation of 1 min at 25 °C followed by a second one of 5 min at 80 °C. The power 
was set at 200 W in both steps. The resulting slurry was concentrated under reduced 
pressure and taken up with dichloromethane. The organic layer was washed with 
brine, dried with Na2SO4, filtered and evaporated under vacuum. The crude was 
purified on silica gel as above to afford 2b (12%). Method D: Conventional heating: 
To a 1,4-dioxane solution (25.0 mL) of Cu2O (0.0850 g, 0.590 mmol) and 1,10-
phenanthroline (0.215 g, 1.19 mmol) were added ethyl isocyanoacetate (1.35 g, 11.9 
mmol) and ethyl phenylpropiolate (2.50 g, 14.3 mmol). The solution was stirred at 
100 °C for 2 h. After the consumption of ethyl isocyanoacetate, the reaction mixture 
was cooled to room temperature, filtered and evaporated in vacuo. The crude was 
purified on silica gel as above to give 2b (58%). Microwave heating: To a 1,4-dioxane 
solution (25.0 mL) of Cu2O (0.0850 g, 0.590 mmol) and 1,10-phenanthroline (0.215 g, 
1.19 mmol) were added ethyl isocyanoacetate (1.35 g, 11.9 mmol) and ethyl 
phenylpropiolate (2.50 g, 14.3 mmol). After a prestirring of 30 s, the solution was 
irradiated during 40 min. The irradiation was programmed to maintain a constant 
temperature (100 °C) with a power of 200 W. The reaction mixture was cooled to 
room temperature, filtered and concentrated in vacuo. The crude was purified on 
silica gel as above to give 2b (62%). Method E: Conventional heating: To a mixture 
of ethyl isocyanoacetate (1.98 g, 17.5 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU) (3.00 g, 19.7 mmol) dissolved in THF (30.0 mL) was added dropwise 
benzaldehyde (1.06 g, 9.99 mmol) in THF (10.0 mL) at 50 °C for a period of 15 min 
with stirring. After stirring for 5 h at same temperature, the reaction mixture was 
neutralized with acetic acid and then the solvent was removed under reduced 
pressure. The resulting residue was extracted with ethyl acetate and the extract was 
washed with hydrochloric acid and water, dried with Na2SO4, and then evaporated in 
vacuo. The crude was purified on silica gel as above to give 2b (21%). Microwave 
heating: To a THF solution (30.0 mL) of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) 
(3.00 g, 19.7 mmol) was added ethyl isocyanoacetate (1.98 g, 17.5 mmol). After a 
prestirring of 30 s, the solution was irradiated during 2 min. The irradiation was 
programmed to maintain a constant temperature (50 °C) with a power of 200 W. To 
the resulting solution at the same temperature, ethyl isocyanoacetate (1.08 g, 9.55 
mmol) was added dropwise. After a prestirring of 30 s, the solution was irradiated 
during 1 h. The irradiation was programmed to maintain a constant temperature (50 
°C) with a power of 200 W. The reaction mixture was neutralized with acetic acid and 
50 
 
then the solvent was removed under reduced pressure. The resulting residue was 
extracted with ethyl acetate and the extract was washed with hydrochloric acid and 
water, dried with Na2SO4, and then evaporated in vacuo. The crude was purified on 
silica gel as above to give 2b (35%) [22, 23, 26].  
 
1.5.2.4. Diethyl 5-phenyl-1H-pyrrole-2,3-dicarboxylate (2c) 
Conventional heating: To 1,4-diazabicyclo[2.2.2]octane (DABCO) (0.0830 g, 0.740 
mmol) and (E)-acetophenone oxime 3 (1.00 g, 7.40 mmol) in dry toluene (20.0 mL) 
was added diethyl acetylenedicarboxylate (1.26 g, 7.40 mmol). The reaction mixture 
was heated for 6 min at 80 °C, then for 2 h at 170 °C under pressure. The resulting 
residue was cooled to room temperature, filtered and concentrated in vacuo. The 
crude was purified on silica gel (eluent: EP/AcOEt-80/20, Rf=0.27) to give 2c as pink 
crystals (28%).Microwave heating: To 1,4-diazabicyclo[2.2.2]octane (0.0830 g, 0.740 
mmol) and oxime 3 (1.00 g, 7.40 mmol) in dry toluene (20.0 mL) was added diethyl 
acetylenedicarboxylate (1.26 g, 7.40 mmol), and the resultant mixture was subjected 
to the two-stage microwave irradiation sequence (stage 1: 80 °C, 6 min; stage 2: 170 
°C, 45 min). The power was set at 200 W in both steps. The reaction mixture was 
cooled to room temperature, filtered and concentrated in vacuo. The crude was 
purified on silica gel as above to give 2c (28%) [29, 30].  
 
1.5.2.5. Diethyl 5-phenyl-1H-pyrrole-2,4-dicarboxylate (2d) 
To a solution of ethyl 2-azidoacrylate 4 (1.70 g, 12.1 mmol) and ethyl 
phenylacetoacetate (3.47 g, 18.0 mmol) in MeOH (30.0 mL) was added AcOH (1.45 
g, 24.1 mmol) and manganese(III) acetate dihydrate (1.29 g, 4.81 mmol), and the 
solution was stirred at 40 °C for 2 h.  The reaction mixture was quenched with pH 9 
ammonium buffer (AcONH4 and NH4OH), and then extracted twice with AcOEt. The 
combined organic extracts were washed with brine, dried with Na2SO4, filtered and 
concentrated in vacuo. The resulting residue was cooled, triturated in Et2O and 
filtered.  The crystals formed were filtered, and dried under reduced pressure to give 
2d as white crystals (42%) [31].  
 
1.5.2.6. General procedure for diethyl 1-(2-nitrophényl)-phenyl-pyrrole-
dicarboxylate (5a-d) 
Conventional heating: To a solution of diethyl phenyl-1H-pyrrole-dicarboxylate 2a-d 
(2.75 mmol) in 11 mL of DMF was added cesium carbonate (3.30 mmol). The mixture 
was stirred at room temperature for 10 min, then 2-fluoro-nitrobenzene (4.12 mmol) 
was added. The reaction mixture was refluxed for 1 h 30 (15 h for 5d), then was 
diluted in AcOEt (35.0 mL). The organic layer was washed with water (2 x 30.0 mL), 
then brine (30.0 mL) and dried over sodium sulfate. The organic layer was 
concentrated under vacuo to give a brown oil. After triturating in Et2O a solid was 
obtained and filtered off, washed with Et2O and dried to give the desired product 5. 
Microwave heating: A suspension of diethyl phenyl-1H-pyrrole-dicarboxylate 2a-d 
(3.40 mmol), 1-fluoro-2-nitrobenzene (5.10 mmol) and cesium carbonate (4.06 mmol) 
in 12.0 mL of DMF was irradiated during 10 min. The irradiation was programmed to 
maintain a constant temperature (150 °C) with a maximal power output of 200 W. 
The reaction mixture was then diluted in AcOEt (60.0 mL), washed with water (2 x 
50.0 mL), then brine (50.0 mL) and dried over sodium sulphate. The organic layer 
was concentrated under vacuo to give products 5a-d as an oil. 
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1.5.2.6.1. Ethyl 1-(2-nitrophenyl)-4-phenyl-pyrrole-2,3-dicarboxylate (5a). Orange 
oil (85% / 89%). 1H NMR (CDCl3) : 8.13 (dd, 1H, J=7.90 and 1.35 Hz, H-3’), 7.74 
(ddd, 1H, J=7.90, 7.90 and 1.35 Hz, H-4’), 7.63 (ddd, 1H, J=7.90, 7.90 and 1.35 Hz, 
H-5’), 7.55-7.43 (m, 3H, H-6’, H-2 phenyl and H-6 phenyl), 7.40-7.28 (m, 3H, H-3 
phenyl, H-4 phenyl and H-5 phenyl), 7.02 (s, 1H, H-5), 4.39-4.30 (m, 2H, OCH2), 4.12 
(q, 2H, J=7.20 Hz, OCH2), 1.31 (t, 3H, J=7.20 Hz, CH3), 1.15 (t, 3H, J=7.20 Hz, CH3). 
HRMS-ESI m/z [M+Na]+ Calcd for C22H20N2O6Na: 431.1219, Found: 431.1224. 
 
1.5.2.6.2. Ethyl 1-(2-nitrophenyl)-3-phenyl-pyrrole-2,4-dicarboxylate (5b). Yellow 
oil (89% / 95%). 1H NMR (CDCl3) : 8.19 (dd, 1H, J=7.80 and 1.50 Hz, H-3’), 7.77 
(ddd, 1H, J=7.80, 7.80 and 1.50 Hz, H-4’), 7.67 (ddd, 1H, J=7.80, 7.80 and 1.50 Hz, 
H-5’), 7.59 (s, 1H, H-5), 7.51 (dd, 1H, J=7.80 and 1.50 Hz, H-6’), 7.39-7.35 (m, 5H, 
5H phenyl), 4.14 (q, 2H, J=7.20 Hz, OCH2), 3.89-3.80 (m, 2H, OCH2), 1.13 (t, 3H, 
J=7.20 Hz, CH3), 0.77 (t, 3H, J=7.20 Hz, CH3). HRMS-ESI m/z [M+Na]+ Calcd for 
C22H20N2O6Na: 431.1219, Found: 431.1236. 
 
1.5.2.6.3. Ethyl 1-(2-nitrophenyl)-5-phenyl-pyrrole-2,3-dicarboxylate (5c). Yellow 
oil (65% / 76%). 1H NMR (CDCl3) : 8.05-8.01 (m, 2H, H-3’ and H-6’), 7.62-7.56 (m, 
2H, H-2 phenyl and H-6 phenyl), 7.31 (t, 1H, J=7.50 Hz, H-4’), 7.25-7.04 (m, 4H, H-
5’, H-3 phenyl, H-4 phenyl and H-5 phenyl), 6.77 (s, 1H, H-4), 4.34 (q, 2H, J=6.90 Hz, 
OCH2), 4.12 (q, 2H, J=6.90 Hz, OCH2), 1.38-1.14 (m, 6H, 2CH3). HRMS-ESI m/z 
[M+Na]+ Calcd for C22H20N2O6Na: 431.1219, Found: 431.1248.  
 
1.5.2.6.4. Ethyl 1-(2-nitrophenyl)-5-phenyl-pyrrole-2,4-dicarboxylate(5d). Yellow 
oil (28%). 1H NMR (CDCl3) : 8.04 (dd, 1H, J=7.50 and 1.80 Hz, H-3’), 7.66 (s, 1H, H-
3), 7.52 (ddd, 1H, J=7.50, 7.50 and 1.80 Hz, H-4’), 7.46 (ddd, 1H, J=7.50, 7.50 and 
1.80 Hz, H-5’), 7.26-7.16 (m, 6H, H-6’ and 5H phenyl), 4.17 (q, 2H, J=6.90 Hz, 
OCH2), 4.15 (q, 2H, J=6.90 Hz, OCH2), 1.27 (t, 3H, J=6.90 Hz, CH3), 1.18 (t, 3H, 
J=6.90 Hz, CH3). HRMS-ESI m/z [M+Na]+ Calcd for C22H20N2O6Na: 431.1219, 
Found: 431.1240. 
 
1.5.2.7. General procedure for ethyl 4,5-dihydro-4-oxo-5H-
phénylpyrrolo[1,2-a]quinoxaline-carboxylate (6a-d) 
A suspension of 5 (2.60 mmol) and iron powder (9.55 mmol) in 11.0 mL of acetic acid 
was heated under reflux for 2 h. The reaction mixture was cooled, suspended in 20.0 
mL of a 1 M aqueous solution of HCl, agitated, then filtered off, washed with HCl 1 M 
(8.00 mL), water, Et2O and dried to give 6 as a fluffy white solid. 
 
1.5.2.7.1. Ethyl 4,5-dihydro-4-oxo-5H-2-phenylpyrrolo[1,2-a]quinoxaline-3-
carboxylate (6a). Beige crystals (69%), mp 240°C. IR (KBr) 3200, 2750 (NH), 1720 
(COO), 1660 (CON). 1H NMR (DMSO-d6) : 11.49 (s, 1H, NH), 8.58 (s, 1H, H-1), 
8.17 (d, 1H, J=8.10 Hz, H-9), 7.55 (d, 2H, J=7.50 Hz, H-2 phenyl and H-6 phenyl), 
7.45 (t, 2H, J=7.50 Hz, H-3 phenyl and H-5 phenyl), 7.34-7.27 (m, 4H, H-4 phenyl, H-
6, H-7 and H-8), 4.30 (q, 2H, J=7.20 Hz, OCH2), 1.25 (t, 3H, J=7.20 Hz, CH3). 13C-
NMR (DMSO-d6) : 157.0 (C-4), 155.2 (C-7), 129.7 (C-9a), 122.6 (C-5a), 117.7 (C-1), 
116.8 (C-3a), 116.0 (C-6), 112.3 (C-3), 111.0 (C-2), 108.9 (C-9), 100.8 (C-8), 55.4 
(CH3O). Anal. Calcd. for C12H10N2O2 : C, 67.28; H, 4.71; N, 13.08. Found: C, 67.40; 
H, 4.81; N, 12.94. 
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1.5.2.7.2. Ethyl 4,5-dihydro-4-oxo-5H-3-phenylpyrrolo[1,2-a]quinoxaline-2-
carboxylate (6b).Beige crystals (88%), mp>310°C. IR (KBr) 3200, 2800 (NH), 1720 
(COO), 1665 (CON). 1H NMR (DMSO-d6) : 11.25 (s, 1H, NH), 8.80 (s, 1H, H-1), 
8.28 (d, 1H, J=7.80 Hz, H-9), 7.34-7.27 (m, 7H, H-6, H-8 and 5H phenyl,), 7.21 (t, 1H, 
J=7.80 Hz, H-7), 4.09 (q, 2H, J=6.90 Hz, OCH2), 1.09 (t, 3H, J=6.90 Hz, CH3). 13C-
NMR (DMSO-d6) : 157.0 (C-4), 155.2 (C-7), 129.7 (C-9a), 122.6 (C-5a), 117.7 (C-1), 
116.8 (C-3a), 116.0 (C-6), 112.3 (C-3), 111.0 (C-2), 108.9 (C-9), 100.8 (C-8), 55.4 
(CH3O). Anal. Calcd. for C12H10N2O2 : C, 67.35; H, 4.78; N, 13.15. Found: C, 67.47; 
H, 4.92; N, 13.30.  
 
1.5.2.7.3. Ethyl 4,5-dihydro-4-oxo-5H-1-phenylpyrrolo[1,2-a]quinoxaline-3-
carboxylate (6c). White crystals (58%), mp=219°C. IR (KBr) 3200, 2700 (NH), 1700 
(COO), 1670 (CON). 1H NMR (DMSO-d6) : 11.50 (s, 1H, NH), 7.56-7.53 (m, 5H, 5H 
phenyl), 7.32 (d, 1H, J=7.70 Hz, H-9), 7.24 (t, 1H, J=7.70 Hz, H-8), 6.97 (d, 1H, 
J=7.70 Hz, H-6), 6.84 (t, 1H, J=7.70 Hz, H-7), 6.81 (s, 1H, H-2), 4.27 (q, 2H, J=6.90 
Hz, OCH2), 1.30 (t, 3H, J=6.90 Hz, CH3). Anal. Calcd. for C12H10N2O2 : C, 67.21; H, 
4.64; N, 13.01. Found: C, 67.33; H, 4.74; N, 12.76. 
 
1.5.2.7.4. Ethyl 4,5-dihydro-4-oxo-5H-1-phenylpyrrolo[1,2-a]quinoxaline-2-
carboxylate (6d). White crystals (84%), mp=230°C. IR (KBr) 3200, 2700 (NH), 1695 
(COO), 1665 (CON). 1H NMR (DMSO-d6) : 11.53 (s, 1H, NH), 7.61-7.53 (m, 3H, 3H 
phenyl), 7.50-7.47 (m, 2H, 2H phenyl), 7.44 (s, 1H, H-3), 7.29 (d, 1H, J=7.90 Hz, H-
6), 7.20 (t, 1H, J=7.90 Hz, H-8), 6.75 (t, 1H, J=7.90 Hz, H-7), 6.64 (d, 1H, J=7.90 Hz, 
H-9), 4.02 (q, 2H, J=6.90 Hz, OCH2), 1.30 (t, 3H, J=6.90 Hz, CH3). Anal. Calcd. for 
C12H10N2O2 : C, 67.31; H, 4.74; N, 13.11. Found: C, 67.43; H, 4.95; N, 12.86. 
 
1.5.2.8. General procedure for ethyl 4-chloro-phénylpyrrolo[1,2-
a]quinoxaline-carboxylate (8a-d) 
A solution of 5H-pyrrolo[1,2-a]quinoxalin-4-one 6 (4.00 mmol) in POCl3 (8.00 mL) 
was refluxed for 2 h. After removing excess of reactive under vacuum, the residue 
was carefully dissolved in water at 0°C and the resulting solution was made basic 
with sodium carbonate. The precipitate was filtered, dried and recrystallized from 
ethyl acetate to give 7. 
 
1.5.2.8.1. Ethyl 4-chloro-2-phenylpyrrolo[1,2-a]quinoxaline-3-carboxylate (8a). 
White crystals (77%), mp=110°C. IR (KBr) 1715 (COO). 1H NMR (CDCl3) : 7.97 (s, 
1H, H-1), 7.87 (dd, 1H, J=8.10 and 1.20 Hz, H-9), 7.80 (dd, 1H, J=8.10 and 1.20 Hz, 
H-6), 7.58-7.32 (m, 7H, H-7, H-8 and 5H phenyl), 4.41 (q, 2H, J=7.20 Hz, OCH2), 
1.34 (t, 3H, J=7.20 Hz, CH3). HRMS-ESI m/z [M+H]+ Calcd for C20H15N2O2ClNa: 
351.0900, Found: 351.0918. 
 
1.5.2.8.2. Ethyl 4-chloro-3-phenylpyrrolo[1,2-a]quinoxaline-2-carboxylate (8b). 
Beige crystals (96%), mp=145°C. IR (KBr) 1715 (COO). 1H NMR (CDCl3) : 8.56 (s, 
1H, H-1), 7.93 (dd, 1H, J=8.10 and 1.50 Hz, H-9), 7.88 (dd, 1H, J=8.10 and 1.50 Hz, 
H-6), 7.59 (ddd, 1H, J=8.10, 7.90 and 1.50 Hz, H-8), 7.52 (ddd, 1H, J=8.10, 7.90 and 
1.50 Hz, H-7), 7.44-7.37 (m, 5H, 5H phenyl), 4.19 (q, 2H, J=7.20 Hz, OCH2), 1.14 (t, 
3H, J=7.20 Hz, CH3). HRMS-ESI m/z [M+H]+ Calcd for C20H15N2O2ClNa: 351.0900, 
Found: 351.0933. 
 
53 
 
1.5.2.8.3. Ethyl 4-chloro-1-phenylpyrrolo[1,2-a]quinoxaline-3-carboxylate (8c). 
Beige crystals (94%), mp=109°C. IR (KBr) 1720 (COO). 1H NMR (CDCl3) : 7.91 (d, 
1H, J=8.10 Hz, H-9), 7.55-7.48 (m, 5H, 5H phenyl), 7.41 (t, 1H, J=8.10 Hz, H-8), 7.33 
(d, 1H, J=8.10 Hz, H-6), 7.17 (t, 1H, J=8.10 Hz, H-7), 7.09 (s, 1H, H-2), 4.44 (q, 2H, 
J=7.20 Hz, OCH2), 1.44 (t, 3H, J=7.20 Hz, CH3). HRMS-ESI m/z [M+H]+ Calcd for 
C20H15N2O2ClNa: 351.0900, Found: 351.0903. 
 
1.5.2.8.4. Ethyl 4-chloro-1-phenylpyrrolo[1,2-a]quinoxaline-2-carboxylate (8d). 
Orange crystals (90%), mp=178°C. IR (KBr) 1710 (COO). 1H NMR (CDCl3) : 7.86 
(dd, 1H, J=8.10 and 1.30 Hz, H-6), 7.63-7.55 (m, 4H, 3H phenyl and H-3), 7.50-7.46 
(m, 2H, 2H phenyl), 7.37 (ddd, 1H, J=8.10, 7.85 and 1.30 Hz, H-8), 7.10 (ddd, 1H, 
J=8.10, 7.85 and 1.30 Hz, H-7), 7.01 (dd, 1H, J=8.10 and 1.30 Hz, H-9), 4.19 (q, 2H, 
J=7.20 Hz, OCH2), 1.18 (t, 3H, J=7.20 Hz, CH3). HRMS-ESI m/z [M+H]+ Calcd for 
C20H15N2O2ClNa: 351.0900, Found: 351.0925. 
 
1.5.2.9. General procedure for ethyl 4-(4-formylphenyl)-phenylpyrrolo[1,2-
a]quinoxaline-carboxylate (9a-d) 
To suspension of compound 8a-d (4.64 mmol), and Pd(PPh3)4 (0.232 mmol) in a 
mixture of toluene/EtOH (75.0/4.10 mL) under nitrogen were added K2CO3 (5.10 
mmol) and 4-formylphenylboronic acid (5.10 mmol). The reaction mixture was 
refluxed for 24 h, and the cooled suspension was extracted with CH2Cl2 (3 x 80.0 
mL). The organic layer was washed with a saturated solution of NaCl (95.0 mL), and 
the combined organic extracts were dried over sodium sulfate, filtered, and 
evaporated under reduced pressure. The crude residue was triturated in ethanol. The 
resulting precipitate was filtered, washed with ethanol, and purified by column 
chromatography on silica gel using dichloromethane as eluent gave the pure product 
9a-d. 
 
1.5.2.9.1. Ethyl 4-(4-formylphenyl)-2-phenylpyrrolo[1,2-a]quinoxaline-3-
carboxylate (9a). Yellow crystals (83%), mp=77°C. IR (KBr) 1720 (COO), 1700 
(CHO). 1H NMR (CDCl3) : 10.13 (s, 1H, CHO), 8.12 (dd, 1H, J=8.10 and 1.30 Hz, H-
9), 8.10 (s, 1H, H-1), 8.04 (d, 2H, J=7.80 Hz, H-3’ and H-5’), 8.00 (dd, 1H, J=8.10 
and 1.30 Hz, H-6), 7.96 (d, 2H, J=7.80 Hz, H-2’ and H-6’), 7.67 (ddd, 1H, J=8.10, 
7.85 and 1.30 Hz, H-8), 7.64-7.52 (m, 3H, H-7 and 2H phenyl), 7.48-7.39 (m, 3H, 3H 
phenyl), 3.63 (q, 2H, J=6.90 Hz, OCH2), 0.89 (t, 3H, J=6.90 Hz, CH3). HRMS-ESI m/z 
[M+H]+ Calcd for C27H20N2O3Na: 421.1552, Found: 421.1552. 
 
1.5.2.9.2. Ethyl 4-(4-formylphenyl)-3-phenylpyrrolo[1,2-a]quinoxaline-2-
carboxylate (9b). Yellow crystals (60%), mp=161°C. IR (KBr) 1715 (COO), 1700 
(CHO). 1H NMR (CDCl3) : 9.93 (s, 1H, CHO), 8.69 (s, 1H, H-1), 8.09 (d, 1H, J=7.80 
Hz, H-9), 8.05 (d, 1H, J=7.80 Hz, H-6), 7.66 (t, 1H, J=7.80 Hz, H-8), 7.58 (t, 1H, 
J=7.80 Hz, H-7), 7.53 (d, 2H, J=7.20 Hz, H-3’ and H-5’), 7.38 (d, 2H, J=7.20 Hz, H-2’ 
and H-6’), 7.03-6.95 (m, 5H, 5H phenyl), 4.23 (q, 2H, J=6.90 Hz, OCH2), 1.20 (t, 3H, 
J=6.90 Hz, CH3). HRMS-ESI m/z [M+H]+ Calcd for C27H20N2O3Na: 421.1552, Found: 
421.1532. 
 
1.5.2.9.3. Ethyl 4-(4-formylphenyl)-1-phenylpyrrolo[1,2-a]quinoxaline-3-
carboxylate (9c). Pale yellow crystals (79%), mp=179°C. IR (KBr) 1720 (COO), 1695 
(CHO). 1H NMR (CDCl3) : 10.14 (s, 1H, CHO), 8.09-8.06 (m, 1H, H-9), 8.04 (d, 2H, 
J=8.10 Hz, H-3’ and H-5’), 7.97 (d, 2H, J=8.10 Hz, H-2’ and H-6’), 7.58-7.56 (m, 5H, 
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5H phenyl), 7.48-7.44 (m, 2H, H-6 and H-8), 7.25-7.20 (m, 1H,H-7), 7.21 (s, 1H, H-2), 
3.80 (q, 2H, J=7.20 Hz, OCH2), 0.99 (t, 3H, J=7.20 Hz, CH3). HRMS-ESI m/z [M+H]+ 
Calcd for C27H20N2O3Na: 421.1552, Found: 421.1573. 
 
1.5.2.9.4. Ethyl 4-(4-formylphenyl)-1-phenylpyrrolo[1,2-a]quinoxaline-2-
carboxylate (9d). Yellow crystals (89%), mp=183°C. IR (KBr) 1700 (COO and CHO). 
1H NMR (CDCl3) : 10.18 (s, 1H, CHO), 8.20 (d, 2H, J=7.95 Hz, H-3’ and H-5’), 8.12 
(d, 2H, J=7.95 Hz, H-2’ and H-6’), 8.02 (d, 1H, J=7.80 Hz, H-6), 7.62-7.48 (m, 6H, 5H 
phenyl and H-3), 7.42 (t, 1H, J=7.80 Hz, H-8), 7.13-7.09 (m, 2H, H-7 and H-9), 4.16 
(q, 2H, J=7.20 Hz, OCH2), 1.13 (t, 3H, J=7.20 Hz, CH3). HRMS-ESI m/z [M+H]+ 
Calcd for C27H20N2O3Na: 421.1552, Found: 421.1566. 
 
1.5.2.10. General procedure for ethyl 4-{4-[(4-(2-oxo-2,3-dihydro-1H-
benzimidazol-1-yl)piperidin-1-yl)benzyl]}-phenylpyrrolo[1,2-a]quinoxaline-
carboxylate, ethyl 4-{4-[(4-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-
yl)benzyl]}-phenylpyrrolo[1,2-a]quinoxaline-carboxylate and ethyl 4-{4-[4-(3-
(pyridin-2-yl)-1,2,4-triazol-5-yl)piperidin-1-yl)benzyl]}-phenylpyrrolo[1,2-
a]quinoxaline-carboxylate (1a-l) 
The pH of a solution of the aldehyde 9a-d (0.784 mmol) and 4-(2-ketobenzimidazolin-
1-yl)piperidine or 4-(5-chloro-2-ketobenzimidazolin-1-yl)piperidine or  2-(3-piperidin-4-
yl-1H-1,2,4-triazol-5-yl)pyridine (0.941 mmol) in 15.0 mL methanol was adjusted to 6 
by the dropwise addition of acetic acid. Powered sodium cyanoborohydride (2.15 
mmol) was then added, and the resultant mixture was refluxed for 5 h. After removal 
of the methanol by rotary evaporation, the residue was triturated in water and 
extracted with dichloromethane. The organic layer was washed with water, dried over 
magnesium sulfate and evaporated to dryness. Column chromatography of the 
residue on silica gel using ethyl acetate - cyclohexane (1/1) then methanol-
chloroform (1/9) as eluents gave the crude product. This solid was then triturated with 
diethyl ether, filtered, washed with diethyl ether and dried under reduced pressure to 
give the compounds 1a-l. 
 
1.5.2.10.1. Ethyl 4-{4-[(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-
yl)benzyl]}-2-phenylpyrrolo[1,2-a]quinoxaline-3-carboxylate (1a). White crystals 
(53%), mp 186°C. 1H NMR (CDCl3) : 10.08 (s, 1H, NH), 8.11 (d, J=7.8 Hz, 1H, H-9), 
8.09 (s, 1H, H-1), 7.97 (d, J=7.6 Hz, 1H, H-6), 7.79 (d, J=7.6 Hz, 2H, H-2’ and H-6’), 
7.64-7.54 (m, 4H, H-7, H-8, H-3’ and H-5’), 7.46-7.37 (m, 5H, H-4 benzimid., H-2 
phenyl, H-3 phenyl, H-5 phenyl and H-6 phenyl), 7.12-7.05 (m, 4H, H-4 phenyl, H-5 
benzimid., H-6 benzimid. and H-7 benzimid.), 4.46-4.43 (m, 1H, CH pip.), 3.68 (q, 
J=6.9 Hz, 2H, CH2), 3.50 (s, 2H, CH2N), 3.14-3.09 (m, 2H, NCH2 pip.), 2.53-2.24 (m, 
4H, CH2 pip. and NCH2 pip.), 1.88-1.84 (m, 2H, CH2 pip.), 0.94 (t, J=6.9 Hz, 3H, 
CH3). 13C NMR (CDCl3) : 165.52 (C=O), 157.82 (C-4), 154.95 (C=O benzimid.), 
140.15 (C-4’), 138.42 (C-1 phenyl, C-1’ and C-5a), 136.42 (C-3a), 133.31 (C-6 and 
C-3a benzimid.), 130.42 (C-2’, C-6’ and C-7a benzimid.), 129.81 (C-7), 129.26 (C-3’ 
and C-5’), 128.95 (C-8), 128.45 (C-3 phenyl, C-4 phenyl and C-5 phenyl), 127.99 (C-
2 phenyl and C-6 phenyl), 127.64 (C-9a), 125.81 (C-2), 123.69 (C-3, C-5 benzimid. 
and C-6 benzimid.), 121.10 (C-1), 113.76 (C-9), 109.66 (C-4 benzimid. and C-7 
benzimid.), 64.88 (CH2N), 61.04 (CH2), 53.15 (NCH2 pip.), 50.71 (CH pip.), 29.23 
(CH2 pip.), 13.68 (CH3). HRMS-ESI m/z [M+Na]+ Calcd for C39H35N5O3Na: 644.2637, 
Found: 644.2634. 
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1.5.2.10.2. Ethyl 4-{4-[(4-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl)benzyl]}-2-
phenylpyrrolo[1,2-a]quinoxaline-3-carboxylate (1b). Cream crystals (61%), mp 
163°C. 1H NMR (CDCl3) : 8.08 (s, 1H, H-1), 8.04 (d, J=7.8 Hz, 1H, H-9), 7.96 (d, 
J=7.8 Hz, 1H, H-6), 7.70 (d, J=7.2 Hz, 2H, H-2’ and H-6’), 7.59 (t, J=7.2 Hz, 1H, H-7), 
7.55-7.47 (m, 3H, H-3’, H-5’ and H-8), 7.44-7.33 (m, 7H, H-2 phenyl, H-3 phenyl, H-5 
phenyl, H-6 phenyl, H-4 benzimid., H-6 benzimid. and H-7 benzimid.), 6.93 (t, J=7.2 
Hz, 1H, H-4 phenyl), 3.61 (q, J=7.0 Hz, 2H, CH2), 3.54 (s, 2H, CH2N), 2.91 (d, 2H, 
J=10.2 Hz, NCH2 pip.), 2.84 (t, J=11.4 Hz, 1H, CH pip.), 2.05 (t, J=10.8 Hz, 2H, CH2 
pip.), 1.99 (d, J=11.4 Hz, 2H, NCH2 pip.), 1.94-1.85 (m, 2H, CH2 pip.), 0.87 (t, J=7.0 
Hz, 3H, CH3). 13C NMR (CDCl3) : 165.68 (C=O), 160.05 (d, JCF=234 Hz, C-5 
benzimid.), 158.46 (C-4), 139.78 (C-4’), 138.14 (C-1 phenyl, C-1’, C-2 benzimid., C-
5a and C-3a benzimid.), 135.91 (C-3a and C-5a), 133.21 (C-6 and C-7a benzimid.), 
130.55 (C-2’ and C-6’), 129.99 (C-3’ and C-5’), 129.23 (C-7), 128.91 (C-8), 128.51 
(C-4 phenyl), 127.95 (C-2 phenyl, C-3 phenyl, C-5 phenyl and C-6 phenyl), 127.73 
(C-9a), 125.85 (C-2), 123.62 (C-3), 113.95 (C-9), 113.48 (C-1 and C-7 benzimid.), 
113.24 (C-4 benzimid. and C-6 benzimid.), 64.88 (CH2N), 61.04 (CH2), 53.15 (NCH2 
pip.), 50.71 (CH pip.), 29.23 (CH2 pip.), 13.68 (CH3). HRMS-ESI m/z [M+H]+ Calcd for 
C39H35N5O2F: 624.2775, Found: 624.2751. 
 
1.5.2.10.3. Ethyl 4-{4-[4-(3-(pyridin-2-yl)-1,2,4-triazol-5-yl)piperidin-1-yl)benzyl]}-2-
phenylpyrrolo[1,2-a]quinoxaline-3-carboxylate (1c). White crystals (56%), mp 143°C. 
1H NMR (CDCl3) : 8.73 (d, J=3.0 Hz, 1H, H-6 pyr.), 8.22 (d, J=7.8 Hz, 1H, H-5 pyr.), 
8.08 (d, J=8.4 Hz, 1H, H-6), 8.06 (s, 1H, H-1), 7.94 (d, J=8.4 Hz, 1H, H-9), 7.84 (t, 
J=7.8 Hz, 1H, H-4 pyr.), 7.74 (d, J=7.8 Hz, 2H, H-2’ and H-6’), 7.58 (t, J=7.8 Hz, 1H, 
H-7), 7.56-7.49 (m, 4H, H-3’, H-5’, H-2 phenyl and H-6 phenyl), 7.44-7.40 (m, 2H, H-
3 phenyl and H-5 phenyl), 7.38-7.34 (m, 2H, H-4 phenyl and H-3 pyr.), 7.28 (m, 1H, 
H-8), 3.65 (s, 2H, CH2N), 3.64 (q, J=7.2 Hz, 2H, CH2), 3.06 (d, 2H, J=10.8 Hz, NCH2 
pip.), 2.97-2.89 (m, 1H, CH pip.), 2.23 (t, J=10.2 Hz, 2H, CH2 pip.), 2.12 (d, J=12.0 
Hz, 2H, NCH2 pip.), 2.10-2.00 (m, 2H, CH2 pip.), 0.91 (t, J=7.2 Hz, 3H, CH3). 13C 
NMR (CDCl3) : 165.56 (C=O), 154.36 (C-4, C-3 Triazole and C-2 pyr.), 149.50 (C-6 
pyr.), 147.15 (C-5 Triazole), 138.36 (C-4’ and C-4 pyr.), 137.48 (C-1 phenyl, C-1’ and 
C-5a), 136.04 (C-3a), 133.31 (C-6), 130.40 (C-2’ and C-6’), 129.41 (C-3’,  C-5’ and 
C-7), 128.97 (C-8), 128.47 (C-4 phenyl), 128.31 (C-2 phenyl and C-6 phenyl), 127.95 
(C-3 phenyl and C-5 phenyl), 127.62 (C-9a), 125.83 (C-2), 124.60 (C-3 pyr.), 123.69 
(C-3), 121.79 (C-5 pyr.), 113.78 (C-9), 113.32 (C-1), 63.02 (CH2N), 61.19 (CH2), 
53.39 (CH pip. and NCH2), 30.74 (CH2 pip.), 13.68 (CH3). HRMS-ESI m/z [M+Na]+ 
Calcd for C39H35N7O2Na: 656.2750, Found: 656.2768. 
 
1.5.2.10.4. Ethyl 4-{4-[(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-
yl)benzyl]}-3-phenylpyrrolo[1,2-a]quinoxaline-2-carboxylate (1d). White crystals 
(60%), mp 260°C. 1H NMR (CDCl3) : 9.95 (s, 1H,NH), 8.67 (s, 1H, H-1), 8.07 (d, 
J=8.0 Hz, 1H, H-6), 8.03 (d, J=8.0 Hz, 1H, H-9), 7.61 (t, J=8.0 Hz, 1H, H-7), 7.55 (t, 
J=8.0 Hz, 1H, H-8), 7.34 (d, J=7.2 Hz, 1H, H-4 benzimid.), 7.23 (d, J=7.8 Hz, 2H, H-
2’ and H-6’), 7.15-7.07 (m, 3H, H-5 benzimid., H-6 benzimid., H-7 benzimid.), 7.06-
6.96 (m, 7H, H-3’, C-5’, H-2 phenyl, H-3 phenyl, H-4 phenyl, H-5 phenyl and H-6 
phenyl), 4.45 (t, 1H, CH pip.), 4.23 (q, 2H, CH2), 3.46 (s, 2H, CH2N), 3.00 (d, J=10.2 
Hz, 2H, NCH2 pip.), 2.52  (q, J=7.2 Hz, 2H, CH2 pip.), 2.15 (t, J=11.4 Hz, 2H, NCH2 
pip.), 1.88 (d, J=10.8 Hz, 2H, CH2 pip.), 1.19 (t, J=7.2 Hz, 3H, CH3). 13C NMR 
(CDCl3) : 165.54 (C=O), 158.05 (C-4), 156.58 (C=O benzimid.), 140.33 (C-4’), 
137.93 (C-1’), 137.56 (C-3a and C-5a), 135.22 (C-1 phenyl), 132.62 (C-3a benzimid., 
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C-3 phenyl, C-4 phenyl and C-5 phenyl), 131.80 (C-6), 130.70 (C-7a benzimid.), 
130.06 (2’ and C-6’), 129.54 (C-7, C-3’ and C-5’), 128.20 (C-2 phenyl and C-6 
phenyl), 127.80 (C-8), 126.81 (C-9a), 124.41 (C-2), 122.61 (C-5 benzimid.), 122.52 
(C-6 benzimid.), 120.66 (C-3), 119.65 (C-1), 115.21 (C-9) 111.25 (C-7 benzimid.), 
111.17 (C-4 benzimid.), 64.03 (CH2N), 61.79 (CH2), 54.50 (NCH2 pip.), 52.37 (CH 
pip.), 30.81 (CH2 pip.), 15.53 (CH3). HRMS-ESI m/z [M+H]+ Calcd for C39H36N5O3: 
622.2818, Found: 622.2795. 
 
1.5.2.10.5. Ethyl 4-{4-[(4-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl)benzyl]}-3-
phenylpyrrolo[1,2-a]quinoxaline-2-carboxylate (1e). White crystals (78%), mp 246°C. 
1H NMR (CDCl3) : 9.87 (s, 1H,NH), 8.67 (s, 1H, H-1), 8.04 (d, J=7.0 Hz, 1H, H-9), 
8.03 (t, J=7.0 Hz, 1H, H-6), 7.61 (t, J=7.0 Hz, 1H, H-7), 7.54 (t, J=7.0 Hz, 1H, H-8), 
7.18 (d, J=8.0 Hz, 2H, H-2’ and H-6’), 7.06-6.96 (m, 7H, H-3’, H-5’, H-2 phenyl, H-3 
phenyl, H-4 phenyl, H-5 phenyl, H-6 phenyl, H-4 benzimid., H-6 benzimid. and H-7 
benzimid.), 4.23 (q, J=7.2 Hz, 2H, CH2), 3.41 (s, 2H, CH2N), 2.97-2.86 (m, 3H, NCH2 
pip. and CH pip.), 2.11 (d, J=11.6 Hz, 2H, CH2 pip.), 2.08 (t, J=11.6 Hz, 2H, NCH2 
pip.), 1.93 (m, 2H, CH2 pip.), 1.20 (t, J=7.2 Hz, 3H, CH3). 13C NMR (CDCl3) : 165.56 
(C=O), 161.10 (d, JCF=236 Hz, C-5 benzimid.), 158.21 (C-4), 140.16 (C-4’), 138.00 
(C-1 phenyl, C-1’, C-2 benzimid. and C-3a benzimid.), 137.57 (C-3a and C-5a), 
135.19 (C-7a benzimid.), 131.62 (C-6), 130.11 (C-2’ and C-6’), 129.64 (3’ and C-5’), 
129.54 (C-7), 128.19 (C-8), 128.04 (C-2 phenyl, C-3 phenyl, C-4 phenyl, C-5 phenyl 
and C-6 phenyl), 127.77 (9a), 124.44 (C-2), 120.69 (C-3), 119.69 (C-1), 115.31 (C-9 
and C-7 benzimid.), 111.90 (C-4 benzimid. and C-6 benzimid.), 64.24 (CH2N), 61.92 
(CH2), 54.66 (NCH2 pip.), 38.34 (CH pip.), 32.34 (CH2 pip.), 15.60 (CH3). HRMS-ESI 
m/z [M+H]+ Calcd for C39H35N5O2F: 624.2775, Found: 624.2783. 
 
1.5.2.10.6. Ethyl 4-{4-[4-(3-(pyridin-2-yl)-1,2,4-triazol-5-yl)piperidin-1-yl)benzyl]}-3-
phenylpyrrolo[1,2-a]quinoxaline-2-carboxylate (1f). Pale yellow crystals (53%), mp 
139°C. 1H NMR (CDCl3) : 8.73 (d, J=3.0 Hz, 1H, H-6 pyr.), 8.64 (s, 1H, H-1), 8.23 
(d, J=7.8 Hz, 1H, H-5 pyr.), 8.02 (d, J=8.4 Hz, 1H, H-9), 7.99 (d, J=8.4 Hz, 1H, H-6), 
7.84 (t, J=7.8 Hz, 1H, H-4 pyr.), 7.56 (t, J=7.8 Hz, 1H, H-7), 7.50 (t, J=7.2 Hz, 1H, H-
8), 7.36 (t, J=6.0 Hz, 1H, H-3 pyr.), 7.17 (d, J=7.2 Hz, 2H, H-2’ and H-6’), 7.06-7.02 
(m, 1H, H-4 phenyl),7.01-6.94 (m, 6H, H-3’, H-5’, H-2 phenyl, H-3 phenyl, H-5 phenyl, 
and H-6 phenyl), 4.20 (q, J=7.2 Hz, 2H, CH2), 3.49 (s, 2H, CH2N), 3.01-2.93 (m, 3H, 
NCH2 pip. and CH pip.), 2.23-2.13 (m, 4H, NCH2 pip. and CH2 pip.), 2.12-2.03 (m, 
2H, CH2 pip.), 1.17 (t, J=7.2 Hz, 3H, CH3). 13C NMR (CDCl3) : 164.07 (C=O), 156.45 
(C-4, C-3 Triazole and C-2 pyr.), 149.47 (C-6 pyr.), 147.36 (C-5 Triazole), 138.47 (C-
4’ and C-4 pyr.), 136.63 (C-1 phenyl and C-1’ ), 135.97 (C-5a), 133.63 (C-3a), 130.21 
(C-6), 128.64 (C-2’ and C-6’), 128.48 (C-3’ and  C-5’), 128.09 (C-7), 126.77 (C-8), 
126.49 (C-3 phenyl, C-4 phenyl and C-5 phenyl), 126.42 (C-2 phenyl and C-6 
phenyl), 126.31 (9a), 125.41 (C-3 pyr.), 122.87 (C-2), 121.87 (C-5 pyr.), 119.12 (C-
3), 118.26 (C-9), 113.76 (C-1), 62.64 (CH2N), 60.34 (CH2), 53.03 (NCH2 pip.), 35.19 
(CH pip.), 30.41 (CH2 pip.), 14.07 (CH3). HRMS-ESI m/z [M+H]+ Calcd for 
C39H36N7O2: 634.2930, Found: 634.2952. 
 
1.5.2.10.7. Ethyl 4-{4-[(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-
yl)benzyl]}-1-phenylpyrrolo[1,2-a]quinoxaline-3-carboxylate (1g). Pale yellow crystals 
(66%), mp 168°C.1H NMR (CDCl3) : 10.52 (s, 1H,NH), 8.10 (d, J=8.0 Hz, 1H, H-6), 
7.82 (d, J=7.6 Hz, 2H, H-2’ and H-6’), 7.62-7.53 (m, 8H, H-4 benzimid., H-2 phenyl, 
H-3 phenyl, H-4 phenyl, H-5 phenyl, H-6 phenyl, H-3’ and H-5’), 7.44 (d, J=8.0 Hz, 
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1H, H-9), 7.43 (t, J=8.0 Hz, 1H, H-7), 7.33 (d, J=8.0 Hz, 1H, H-5 benzimid.), 7.21-
7.02 (m, 4H, H-2, H-8, H-6 benzimid. and C-7 benzimid.), 4.52-4.36 (m, 1H, CH pip.), 
3.79 (q, J=7.2 Hz, 2H, CH2), 3.69 (s, 2H, CH2N), 3.13 (d, J=10.8 Hz, 2H, NCH2 pip.), 
2.62-2.48 (m, 2H, CH2 pip.), 2.27 (t, J=10.8 Hz, 2H, NCH2 pip.), 1.86 (d, J=14.8 Hz, 
2H, CH2 pip.), 0.98 (t, J=7.2 Hz, 3H, CH3). 13C NMR (CDCl3) : 166.54 (C=O), 156.74 
(C=O benzimid.), 155.97 (C-4), 141.21 (C-3a and C-4’), 140.77 (C-5a), 134.78 (C-1’), 
133.44 (C-1 phenyl and C-3a benzimid.), 131.68 (C-6), 131.12 (C-3’ and C-5’), 
130.56 (C-7a benzimid.), 130.37 (C-2 phenyl, C-3 phenyl, C-4 phenyl, C-5 phenyl 
and C-6 phenyl), 129.64 (C-2’ and C-6’), 129.46 (C-7), 128.66 (C-8), 127.22 (C-9a), 
122.56 (C-1, C-3 and C-5 benzimid.), 120.22 (C-2 and C-6 benzimid.), 118.10 (C-9), 
111.22 (C-7 benzimid.), 111.19 (C-4 benzimid.), 64.09 (CH2N), 62.27 (CH2), 54.60 
(NCH2 pip.), 52.18 (CH pip.), 30.69 (CH2 pip.), 15.27 (CH3). HRMS-ESI m/z [M+H]+ 
Calcd for C39H36N5O3: 622.2818, Found: 622.2802. 
 
1.5.2.10.8. Ethyl 4-{4-[(4-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl)benzyl]}-1-
phenylpyrrolo[1,2-a]quinoxaline-3-carboxylate (1h). Pale yellow crystals (60%), mp 
157°C. 1H NMR (CDCl3) : 11.40 (s, 1H,NH), 8.02 (d, J=7.6 Hz, 1H, H-6), 7.74 (d, 
J=8.0 Hz, 2H, H-2’ and H-6’), 7.61-7.52 (m, 5H, H-2 phenyl, H-3 phenyl, H-4 phenyl, 
H-5 phenyl and H-6 phenyl), 7.46 (d, J=8.0 Hz, 1H, H-9), 7.44-7.37 (m, 3H, H-7, H-3’ 
and H-5’), 7.21-7.15 (m, 4H, H-2, H-8, H-4 benzimid. and H-7 benzimid.), 6.96 (td, 
J=9.2 Hz and 1.6 Hz, 1H, H-6 benzimid.), 3.72 (q, J=7.2, 2H, CH2), 3.55 (s, 2H, 
CH2N), 2.98-2.84 (m, 3H, NCH2 pip. and CH pip.), 2.13-1.98 (m, 4H, NCH2 pip. and 
CH2 pip.), 1.96-1.81 (m, 2H, CH2 pip.), 0.92 (t, J=7.2 Hz, 3H, CH3). 13C NMR (CDCl3) 
: 166.61 (C=O), 160.7 (d, JCF=235 Hz, C-5 benzimid.), 156.16 (C-4), 141.49 (C-4’), 
140.40 (C-3a and C-5a), 138.66 (C-2 benzimid. and C-3a benzimid.), 134.65 (C-1 
phenyl), 133.67 (C-7a benzimid.), 131.22 (C-3’ and C-5’), 131.11 (C-3 phenyl, C-4 
phenyl and C-5 phenyl), 130.63 (C-6, C-2 phenyl and C-6 phenyl), 130.39 (C-7), 
129.35 (C-2’ and C-6’), 128.72 (C-8), 128.54 (C-9a), 127.38 (C-1, C-3 and C-7 
benzimid.), 120.33 (C-6 benzimid.), 118.21 (C-9), 111.50 (C-4 benzimid.), 64.19 
(CH2N), 62.32 (CH2), 54.70 (NCH2 pip.), 38.34 (CH pip.), 32.34 (CH2 pip.), 15.21 
(CH3). HRMS-ESI m/z [M+H]+ Calcd for C39H35N5O2F: 624.2775, Found: 624.2800. 
 
1.5.2.10.9. Ethyl 4-{4-[4-(3-(pyridin-2-yl)-1,2,4-triazol-5-yl)piperidin-1-yl)benzyl]}-1-
phenylpyrrolo[1,2-a]quinoxaline-3-carboxylate (1i).Pale yellow crystals (69%), mp 
146°C. 1H NMR (CDCl3) : 9.12 (s, 1H, NH), 8.66 (d, J=4.0 Hz, 1H, H-6 pyr.), 8.19 (d, 
J=8.0 Hz, 1H, H-5 pyr.), 8.07 (dd, J=8.2 and 1.6 Hz, 1H, H-6), 7.86 (td, J=7.6 and 1.6 
Hz, 1H, H-4 pyr.), 7.79 (d, J=7.4 Hz, 2H, H-2’ and H-6’), 7.58-7.55 (m, 5H, H-2 
phenyl, H-3 phenyl, H-4 phenyl, H-5 phenyl and H-6 phenyl), 7.53 (d, J=7.4 Hz, 2H, 
H-3’ and H-5’), 7.45 (d, J=8.2 Hz, 1H, H-9), 7.43 (t, J=7.2 Hz, 1H, H-7), 7.40 (dd, 
J=6.4 and 1.2 Hz, 1H, H-9), 7.37 (d, J=7.2 Hz, 1H, H-3 pyr.), 7.18 (td, J=7.2 Hz and 
1.6 Hz, 1H, H-8), 7.17 (sl, 1H, H-2), 3.78 (q, J=7.2, 2H, CH2), 3.71 (s, 2H, CH2N), 
3.10 (d, J=11.2 Hz, 2H, NCH2 pip.), 3.05-2.88 (m, 1H, CH pip.), 2.19 (t, J=8.0 Hz, 2H, 
CH2 pip.), 0.97 (t, J=7.2 Hz, 3H, CH3). 13C NMR (CDCl3) : 156.67 (C-4 and C-2 pyr.), 
152.37 (C-3 Triazole), 151.01 (C-6 pyr.), 147.10 (C-5 Triazole), 142.04 (C-1’), 141.03 
(C-4’), 138.80 (C-4 pyr.), 134.91 (C-1 phenyl), 133.39 (C-5a), 131.80 (C-6), 130.85 
(C-3’ and C-5’), 130.59 (C-2 phenyl, C-3 phenyl, C-4 phenyl, C-5 phenyl and C-6 
phenyl), 129.91 (C-9a, C-2’ and C-6’), 128.43 (C-8), 127.27 (C-7 and C-3 pyr.), 
126.22 (C-1 and C-3), 122.91 (C-5 pyr.), 120.27 (C-2), 118.17 (C-9), 62.30 (CH2N), 
61.18 (CH2), 56.03 (CH pip.), 55.73 (NCH2 pip.), 32.27 (CH2 pip.), 15.36 (CH3). 
HRMS-ESI m/z [M+H]+ Calcd for C39H36N7O2: 634.2930, Found: 634.2959. 
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1.5.2.10.10. Ethyl 4-{4-[(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-
yl)benzyl]}-1-phenylpyrrolo[1,2-a]quinoxaline-2-carboxylate (1j). White crystals 
(70%), mp 166°C. 1H NMR (CDCl3) : 10.19 (s, 1H, NH), 8.03 (d, J=7.8 Hz, 1H, H-6), 
8.02 (d, J=7.8 Hz, 2H, H-2’ and H-6’), 7.67-7.57 (m, 6H, H-7, H-3 phenyl, H-4 phenyl, 
H-5 phenyl, H-3’ and H-5’), 7.55 (s, 1H, H-3), 7.54-7.51 (m, 2H, H-2 phenyl and H-6 
phenyl), 7.41-7.33 (m, 2H, H-9 and H-4 benzimid.), 7.14-7.05 (m, 4H, H-8, H-5 
benzimid., H-6 benzimid., H-7 benzimid.), 4.47 (t, J=12.0 Hz, 1H, CH pip.), 4.17 (q, 
J=7.2 Hz, 2H, CH2), 3.73 (s, 2H, CH2N), 3.23-3.08 (m, 2H, NCH2 pip.), 2.65-2.50 (m, 
2H, CH2 pip.), 2.37-2.23 (m, 2H, NCH2 pip.), 1.89 (d, J=10.2 Hz, 2H, CH2 pip.), 1.13 
(t, J=7.2 Hz, 3H, CH3).13C NMR (CDCl3) : 165.59 (C=O), 156.75 (C-4), 156.60 (C=O 
benzimid.), 139.29 (C-5a and C-3a benzimid.), 138.22 (C-1’), 136.20 (C-3a and C-1 
phenyl), 131.88 (C-6), 131.85 (C-2 phenyl and C-6 phenyl), 130.85 (C-7a benzimid.), 
130.80 (C-4 phenyl), 130.51 (C-3’ and C-5’), 130.24 (C-7), 130.12 (C-3 phenyl and 
C-5 phenyl), 129.67 (C-2’ and C-6’), 128.19 (C-8), 127.34 (C-9), 126.61 (C-2), 120.81 
(C-1), 118.12 (C-5 benzimid. and C-6 benzimid.), 111.94 (C-3 and C-4 benzimid.), 
111.20 (C-7 benzimid.), 64.01 (CH2N), 61.61 (CH2), 54.61 (NCH2 pip.), 52.15 (CH 
pip.), 30.67 (CH2 pip.), 15.42 (CH3). HRMS-ESI m/z [M+H]+ Calcd for C39H36N5O3: 
622.2818, Found: 622.2846. 
 
1.5.2.10.11. Ethyl 4-{4-[(4-(5-fluoro-1H-benzimidazol-2-yl)piperidin-1-yl)benzyl]}-1-
phenylpyrrolo[1,2-a]quinoxaline-2-carboxylate (1k). White crystals (46%), mp 196°C. 
1H NMR (CDCl3) : 7.97 (d, J=7.8 Hz, 1H, H-6), 7.93 (d, J=7.2 Hz, 2H, H-2’ and H-6’), 
7.64-7.56 (m, 3H, H-7, H-9 and H-4 phenyl), 7.55-7.47 (m, 6H, H-3, H-3 phenyl, H-5 
phenyl, H-3’, H-5’ and H-4 benzimid.), 7.36 (t, J=6.6 Hz, 2H, H-2 phenyl and H-6 
phenyl), 7.09 (d, J=7.8 Hz, 1H, H-8), 7.08 (d, J=7.8 Hz, 1H, H-7 benzimid.), 6.98 (t, 
J=7.8 Hz, 1H, H-6 benzimid.), 4.16 (q, J=7.2 Hz, 2H, CH2), 3.62 (s, 2H, CH2N), 2.99 
(d, J=11.4 Hz, 2H, NCH2 pip.), 2.94 (t, J=12 Hz, 1H, CH pip.),  2.15 (t, J=11.4 Hz, 2H, 
NCH2 pip.), 2.06 (d, J=11.4 Hz, 2H, CH2 pip.), 1.98-1.89 (m, 2H, CH2 pip.), 1.11 (t, 
J=7.2 Hz, 3H, CH3). 13C NMR (CDCl3) : 165.75 (C=O), 160.57 (d, JCF=235 Hz, C-5 
benzimid.), 156.90 (C-4), 142.10 (C-4’), 139.21 (C-5a), 137.97 (C-1’), 136.42 (C-2 
benzimid. and C-3a benzimid.), 134.60 (C-1 phenyl), 132.51(C-9a), 131.90 (C-3’ and 
C-5’), 131.52 (C-3a), 130.91 (C-6), 130.84 (C-3 phenyl and C-5 phenyl), 130.32 (C-
7a benzimid.), 130.05 (C-7, C-9 and C-4 phenyl.), 129.58 (C-2’ and C-6’), 128.37 (C-
8), 127.52 (C-2 phenyl and C-6 phenyl), 120.93 (C-1 and C-2), 118.28 (C-7 
benzimid.), 111.82 (C-3 and C-6 benzimid.), 111.64 (C-4 benzimid.), 64.24 (CH2N), 
61.79 (CH2), 54.74 (NCH2 pip.), 38.31 (CH pip.), 32.35 (CH2 pip.), 15.41 (CH3). 
HRMS-ESI m/z [M+H]+ Calcd for C39H35N5O2F: 624.2775, Found: 624.2747. 
 
1.5.2.10.12. Ethyl 4-{4-[4-(3-(pyridin-2-yl)-1,2,4-triazol-5-yl)piperidin-1-yl)benzyl]}-1-
phenylpyrrolo[1,2-a]quinoxaline-2-carboxylate (1l). White crystals (42%), mp 145°C. 
1H NMR (CDCl3) : 8.69 (d, J=4.6 Hz, 1H, H-6 pyr.), 8.19 (d, J=7.8 Hz, 1H, H-5 pyr.), 
7.99 (d, J=7.0 Hz, 1H, H-6), 7.94 (d, J=7.0 Hz, 2H, H-2’ and H-6’), 7.83 (td, J=7.6 and 
1.6 Hz, 1H, H-4 pyr.), 7.62-7.45 (m, 8H, H-3, H-7, H-9, H-3 phenyl, H-4 phenyl, H-5 
phenyl, H-3’ and H-5’), 7.40-7.29 (m, 3H, H-2 phenyl, H-6 phenyl and H-3 pyr.), 7.04 
(d, J=7.0 Hz, 1H, H-8), 4.14 (q, J=7.1 Hz, 2H, CH2), 3.67 (s, 2H, CH2N), 3.07 (d, 
J=11.0 Hz, 2H, NCH2 pip.), 2.99-2.79 (m, 1H, CH pip.),  2.34-1.90 (m, 6H, NCH2 pip. 
and 2 x CH2 pip.), 1.10 (t, J=7.1 Hz, 3H, CH3). 13C NMR (CDCl3) : 165.65 (C=O), 
156.79 (C-4 and C-2 pyr.), 150.99 (C-3 Triazole and C-6 pyr.), 148.41 (C-5 Triazole), 
139.39 (C-4’), 138.86 (C-5a and C-4 pyr.), 138.18 (C-1’), 134.72 (C-1 phenyl), 131.94 
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(C-3a, C-3’ and C-5’), 130.98 (C-6), 130.86 (C-3 phenyl and C-5 phenyl), 130.11 (C-
7, C-9 and C-4 phenyl), 129.56 (C-2’ and C-6’), 128.22 (C-8), 127.37 (C-3 pyr., C-2 
phenyl and C-6 phenyl), 123.11 (C-2, C-9a and C-5 pyr.), 120.84 (C-1), 112.01 (C-3), 
64.51 (CH2N), 61.68 (CH2), 55.03 (NCH2 pip.), 32.32 (CH2 pip. and CH pip.), 15.49 
(CH3). HRMS-ESI m/z [M+H]+ Calcd for C39H36N7O2: 634.2930, Found: 634.2962. 
 
1.5.3. Melting point, IR, TLC, LC, and ESI-MS 
Melting points were determined with an SM-LUX-POL Leitz hot-stage microscope 
and are uncorrected. IR spectra were recorded on a NICOLET 380FT-IR 
spectrophotometer. Analytical TLC were carried out on 0.25 precoated silica gel 
plates (POLYGRAM SIL G/UV254) and visualization of compounds after UV light 
irradiation. Silica gel 60 (70-230 mesh) was used for column chromatography. High 
resolution mass spectra (electrospray in positive mode, ESI+) were recorded on a 
Waters Q-TOF Ultima apparatus. Elemental analyses were found within ±0.4% of the 
theoretical values. 
 
1.5.4. NMR experiments 
All the synthetic molecules were characterized by 1D [1H] and 2D [1H, 1H] NMR 
spectroscopy. Different types of NMR experiments were recorded to obtain a full 
assignment of 1H and 13C atoms. Most 1H and 13C NMR spectra were recorded at 
300 MHz on a Bruker Avance 300 spectrometer equipped with a z-gradient 5 mm 
triple-resonance probe. Additional proton spectra were recorded on a 600 MHz 
Varian instrument provided with a cold-probe.  Experiments were acquired at 298 K; 
samples consisted of compounds (~2 mg) dissolved in 600 µl of Chloroform-d (99.8% 
D, Sigma-Aldrich, USA). 1D proton spectra were recorded with 64-128 scans and a 
relaxation delay of 1 s. 1D, proton decoupled, 13C spectra were acquired with 7000-
10000 scans and d1=5-10 s. 2D [1H, 1H] TOCSY (Total Correlation Spectroscopy) 
[38] and 2D [1H, 1H] ROESY (Rotating frame Overhauser Enhancement 
Spectroscopy) [39] experiments (2048*256 total data points and 32-64 scans per t1 
increment) were recorded with mixing times of 70 ms and 200 ms respectively. A 2D 
[1H, 1H] DQFCOSY (2048*256 total data points and 64-128 scans pet t1 increment) 
(Double Quantum Filter Correlation Spectroscopy) [40] experiment was also acquired 
to complete proton chemical shift assignment. [1H, 13C] HMBC [41] (1024*128-256 
total data points and 128 scans pet t1 increment) and [1H, 13C] HMQC [42] (1024*128 
total data points and 64-128 scans pet t1 increment) spectra were recorded to 
complete and verify 13C assignments. Chemical shifts were referenced to residual 
CDCl3 at 7.24 ppm for 1H spectra and 77.0 ppm for 13C experiments. Spectra were 
processed with Varian software (vnmrj_1.1D). 2D experiments were analyzed with 
the program NEASY [43] as implemented in Cara (http://www.nmr.ch). Chemical shift 
values are compatible with those previously reported for similar molecules. [14] 
Splitting patterns have been designated as follows: s = singlet; bs = broad singlet; d = 
doublet; t = triplet; q = quartet; dd = double doublet; ddd = double double doublet; dt 
= double triplet; m = multiplet. 
 
1.5.5. X-ray Data 
Colorless single crystal of 2b was obtained by slow evaporation from chloroform: 
monoclinic, space group P21/c, a=11.9390(11) Å, b=13.8893(9) Å, c=18.5001(19) Å, 
=90°, =100.959(7)°, =90°, V=3011.8(5) Å3, Z=8, (calcd)= 1.267 Mg.m-3, 
FW=287.31 for C16H17NO4, F(000)=1216. Colorless single crystal of 2c was obtained 
by slow evaporation from methanol/dichloromethane (20/80) solution: monoclinic, 
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space group P21/n, a=14.653(3) Å, b=5.1458(12) Å, c=18.842(4) Å, =90°, 
=94.447(14)°, =90°, V=1416.4(5) Å3, Z=4, (calcd)= 1.347 Mg.m-3, FW=287.31 for 
C16H17NO4, F(000)=608. Colorless single crystal of 2d was obtained by slow 
evaporation from methanol/dichloromethane (20/80) solution: triclinic, space group P-
1, a=8.628(9) Å, b=9.798(2) Å, c=10.095(3) Å, =73.02(2)°, =71.00(3)°, =73.95(5)°, 
V=756.1(8) Å3, Z=1, (calcd)= 1.262 Mg.m-3, FW=574.61 for C32H34N2O8, 
F(000)=304. Colorless single crystal of 1a was obtained by slow evaporation from 
methanol/dichloromethane (30/70) solution: triclinic, space group P-1, a=10.0140(10) 
Å, b=10.877(2) Å, c=17.580(2) Å, =79.642(9)°, =86.041(8)°, =65.016(8)°, 
V=1707.3(4) Å3, Z=2, (calcd)= 1.311 Mg.m-3, FW=673.96 for 
C39H35N5O3,0.48(CH2Cl2O2),0.19(O), F(000)=710. Colorless single crystal of 1d was 
obtained by slow evaporation from methanol/dichloromethane (30/70) solution: 
triclinic, space group P-1, a=8.3759(10) Å, b=12.6418(13) Å, c=16.6718(18) Å, 
=109.502(7)°, =96.482(8)°, =103.928(7)°, V=1578.7(3) Å3, Z=2, (calcd)= 1.308 
Mg.m-3, FW=621.72 for C39H35N5O3, F(000)=656. Colorless single crystal of 1g was 
obtained by slow evaporation from methanol/dichloromethane (20/80) solution: 
triclinic, space group P-1, a=9.6882(14) Å, b=11.2689(13) Å, c=19.639(2) Å, 
=77.504(8)°, =83.067(11)°, =72.264(11)°, V=1990.4(4) Å3, Z=2, (calcd)= 1.347 
Mg.m-3, FW=807.16 for C39H35N5O3,1.56(CHCl3), F(000)=836. Colorless single 
crystal of 1j was obtained by slow evaporation from methanol/dichloromethane 
(30/70) solution: triclinic, space group P-1, a=9.7518(8) Å, b=11.1004(8) Å, 
c=17.9247(12) Å, =86.622(5)°, =82.713(5)°, =66.141(5)°, V=1760.1(2) Å3, Z=2, 
(calcd)= 1.398 Mg.m-3, FW=741.09 for C39H35N5O3,CHCl3,  F(000)=772. Pale-yellow 
single crystal of 1k was obtained by slow evaporation from 
methanol/dichloromethane (30/70) solution: monoclinic, space group C2/c, 
a=18.0617(14) Å, b=9.4210(8) Å, c=43.021(3) Å, =90°, = 93.345(5)°, =90°, 
V=7307.9(10) Å3, Z=8, (calcd)= 1.296 Mg.m-3, FW=712.78 for C39H34FN5O2,5(H2O) 
F(000)=3016. Full crystallographic results have been deposited at the Cambridge 
Crystallographic Data Centre (CCDC-1014944, CCDC-891817, CCDC-891816, 
CCDC-891812, CCDC-891811, CCDC-891813, CCDC-891814, CCDC-891815, 
respectively), UK, as supplementary material. [44] The data were corrected for 
Lorentz and polarization effects and for empirical absorption correction. [45] The 
structure was solved by direct methods Shelx 2013 [46] and refined using Shelx 2013 
[46] suite of programs. 
 
1.5.6. Biological activity 
 
1.5.6.1. Cell culture 
The human leukemic cell lines U937, K562, HL60, U266 and Jurkat were grown in 
RPMI 1640 medium (Life Technology, France) supplemented with 10% fetal calf 
serum (FCS), antibiotics (100 U/mL penicillin, 100 µg/mL streptomycin) and L-
glutamin, (Eurobio, France) at 37°C, 5% CO2 in air. The toxicity of various molecules 
was also evaluated on non-activated, freshly isolated normal human peripheral blood 
mononuclear cells (PBMNC), as well as phytohemagglutinin (T lymphoproliferative 
agent) (PHA)-induced cells. PBMNC from blood of healthy volunteers were obtained 
following centrifugation on Ficoll gradient. Cells were then incubated in medium alone 
or induced to enter cell cycle by the addition of PHA (5.00 µg/mL, Murex Biotech 
Limited, Dartford, UK). 
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1.5.6.2. Cytotoxicity Test 
The MTS cell proliferation assay (Promega, France) is a colorimetric assay system, 
which measures the reduction of a tetrazolium component (MTS) into formazan 
produced by the mitochondria of viable cells. Cells were washed twice in PBS 
(Phosphate Buffer Saline) and plated in quadruplicate into microtiter-plate wells in 
100 L culture media with or without our various compounds at increasing 
concentrations (0, 1, 5, 10, 20 and 50 M) during 1, 2 and 3 days. After 3 hours of 
incubation at 37°C with 20 L MTS/well, the plates were read by using an ELISA 
microplate reader (Thermo, Electrocorporation) at 490 nm wavelength. The amount 
of colour produced was directly proportional to the number of viable cells. The results 
are expressed as the concentrations inhibiting cell growth by 50% after a 3 days 
incubation period. The 50% cytotoxic concentrations (CC50) were determined by 
linear regression analysis, expressed in μM ± SD (Microsoft Excel). 
 
1.5.7. Computational prediction of toxicity and drug relevant properties 
Calculations of Clog P and calculations of Topological Polar Surface Area (TPSA), 
number of hydrogen bond acceptor (nON) and donor (nNH/OH) atoms, and any 
violations to the Lipinski's “rule of five” (logP 5, molecular weight 500, number of 
hydrogen bond acceptors 10, and number of hydrogen bond donors 5 [46]; were 
performed using the MIPC server at http://www.molinspiration.com/cgi-bin/properties. 
[47] 
 
1.5.8. Docking Studies 
Computational dockingstudies were conducted withthe Swiss Dock server 
(http://www.swissdock.ch) that is based on the software EADock DSS [17], the 
Evolutionary Algorithm for Docking. Evolutionary algorithms are iterative stochastic 
optimization procedures where an initial population of solutions is generated and 
evaluated with respect to a set of constraints, described by the fitness function. In the 
docking problem, the fitness function describes the interactions between the ligand 
and the receptor.  
For preliminary docking studies the input target consisted of the entire human Akt1 
protein (including PH and Kinase domains) extracted from the crystal structure of the 
complex Akt1/allosteric inhibitor (pdb code: 3O96 [5], (Figure 8b). All the molecules 
considered as ligands (Series D, Figure 6) and used as input files in the SwissDock 
server were generated with Chem3DPro 11.0 and then converted in .mol2 format 
with UCSF Chimera [48].  
Next, docking studies were carried out by considering only the Akt PH domain. The 
input target consideredwas the PH domainextracted from the crystal structure of the 
complex PKB/IP4 (pdb code: 1UNQ [19]), where IP4 represents the skeleton of the 
phosphatidylinositol (3,4,5) triphosphate (PIP3), a natural ligand of the Akt PH 
domain. (Figure 23) 
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2. Workpackage 2: CXCR4-Intrinsically disordered peptide ligand system 
2.1. Background 
2.1.1. Chemokines 
Chemokines are a superfamily of 8-12-kDa hemoattractive cytokines constitutively 
secreted by stromal cells, including fibroblasts and endothelial cells. At present, >50 
chemokines have been identified and they can be divided into four groups (C, CC, 
CXC and CX3C) based on the number and position of conserved cysteines, where C 
represents the number of cysteine residues and X denotes the number of amino 
acids between the conserved cysteines. Chemokines were initially discovered as 
essential mediators in the process of the directional migration of leukocytes to the 
infection and inflammation sites and have been increasingly demonstrated to 
regulate tumor development and metastasis [49].  
To date, at least 20 chemokine receptors are already reported and classified into four 
subtypes [CXC chemokine receptors (CXCRs), CC chemokine receptors (CCRs), 
XCR and CX3CR] on the basis of their specific preference for some chemokines. It is 
confirmed that these chemokines can bind to different receptors but also that more 
than one chemokine is able to bind to the same receptor to a certain extent [49]. 
However, certain chemokines only interact with a single receptor. The binding of 
chemokines to their receptors stimulates the activation of several downstream 
signaling pathways that regulate tumor progression and metastasis [49].  
 
2.1.2. CXCR4 
Chemokine receptor 4 (CXCR4) is a rhodopsin-like seven-transmembrane G-protein 
coupled receptor, initially discovered as co-receptor facilitating the entry of T-tropic 
(X4) HIV viruses into CD4+ T cells. It is exclusively binds to CXCL12 [50]. It has been 
found that CXCR4 is expressed in a wide range of tissues, including brain, lymph 
node and small intestine tissues [50], as well as in monocytes, B cells, naïve T cells 
and early hematopoietic progenitor cells in the immune system [49]. CXCR4 receptor 
activation is mediated by coupling to an intracellular heterotrimeric G-protein 
associated with the inner surface of the plasma membrane [51].  
 
2.1.3. CXCL12 
Chemokine 12 (CXCL12), also designated as stromal cell-derived factor-1 (SDF-1), 
as mentioned above is a member of the CXC subfamily of chemokines. It is widely 
expressed in a number of organs, such as the lungs, liver, skeletal muscle, brain, 
kidneys, heart, skin and bone marrow. The involvement of CXCL12 in the metastasis 
of various types of cancer has also been previously demonstrated. [52] However, it 
has been reported that there are minimal or negligible effects on the survival and 
growth of myeloma in the presence of CXCL12 in vitro. [53] On the one hand, the 
expression of CXCL12 can be affected by a number of factors such as DNA-
damaging agents and granulocyte colony-stimulating factor (G-CSF) [54].  
On the other hand, CXCL12 can stimulate the secretion of other factors. It has 
previously been demonstrated that matrix metalloproteinase-9 (MMP-9) expression is 
upregulated in the presence of CXCL12 when investigating the involvement of the 
CXCL12-CXCR4 axis in the metastasis of prostate cancer and OS [55].  
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2.1.4. Downstream pathways involved in the CXCL12-CXCR4/CXCR7 
interaction 
It is already accepted that the binding of CXCL12 to CXCR4 or CXCR7 leads to the 
activation of several downstream pathways that regulate cell chemotaxis, survival, 
proliferation and migration [49]. (Figure 23) 
 
 
 
Figure 23.  Scheme of the CXCL12/CXCR4 intracellular signal transduction pathways. 
 
Among them, it is useful to describe the mechanism involving adenylate cyclase (see 
Figure 24a). CXCR4 after the binding to CXCL12 promotes the conformational 
change of the Gα subunit and replacement of the bound GDP by guanine nucleotide 
triphosphate (GTP). This exchange triggers the further conformation changes within 
the Gα subunit, which allows the trimeric G protein to be released from the receptor, 
and to dissociate into the GTP-bound Gα subunit and Gβ/Gγ dimer. Both the 
activated components interact with various effector proteins. In particular, Gα 
regulates adenylyl cyclase (AC) that serves as an effector enzyme that catalyzes 
5′adenosine triphosphate into cyclic adenosine monophosphate (cAMP) and thereby 
activates cAMP-dependent protein kinase, which regulates a host of other 
downstream effectors including MAPK signaling pathway. When a peptide antagonist 
binds to CXCR4, it inhibits this mechanism. (Figure 24b) 
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a) b)
 
 
Figure 24.  Scheme of the CXCL12/CXCR4 pathway with the adenylate cyclase a) when CXCL12 
promote the receptor activity and b) when a peptide antagonist inhibits CXCR4.  
 
Because CXCR4 is overexpressed in several human cancers, the blockade of 
CXCR4–CXCL12 interactions has been extensively investigated as a potential 
cancer therapeutic. The lead CXCR4 antagonist, plerixafor (previously known as 
AMD3100), is the most clinically advanced compound. Since December 2008, it is an 
FDA-approved drug, in combination with granulocytecolony-stimulating factor, for 
hematopoietic stem and progenitorcell mobilization in patients with non-Hodgkin 
lymphoma and multiple myeloma even if it is a metal-chelating bicyclamthat has been 
shown to determine cardiotoxicity as reported inits clinical trial against HIV. 
Therefore, this suggests the need for new antagonists able to block, without any 
other compliance, the binding between CXCL12 and CXCR4 and/or that between 
CXCL12 and CXCR7 [51].  
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2.1.5. IDP 
Taking into account the high specificity that the peptides could have [57] the 
development of therapeutic tools and diagnostic peptide-besed have recently 
gathered interest. In this cotext the intrinsically disorder peptides (IDP) currently 
represent an innovative and interesting starting point. More detailed analysis 
revealed that in comparison with “normal” ordered proteins, IDPs were significantly 
depleted in so-called order-promoting amino acids such as Ile, Leu, Val, Trp, Tyr, 
Phe, Cys, and Asn, being substantially enriched in disorder-promotingamino acids, 
Ala, Arg, Gly, Gln, Ser, Glu, Lys, and Pro [58]. Their peculiar flexibility results in the 
formation of transient complexes with binding partners characterized by low affinity 
because of the entropic cost associated with the disorder-to-order transition upon 
binding. A control of this transition between different structural states of an IDP may 
be useful in different fields. A possible way to achieve this goal consists in the 
peptide amphiphiles, a class of molecules in which a bioactive peptide is covalently 
conjugated to a hydrophobic moiety. This characteristic gives to PAs the ability to 
self-assemble spontaneously into a variety of nanostructures. In this way PAs could 
be considered as useful tools to overcome different cell barriers and to improve the 
ligand specificity against CXCR4 receptor. In a recent work, an IDP (R11) and its two 
lipophilic derivates PAs, (C18)2-R11 and (C18)2-L-R11and their structural properties 
in solution were investigated using CD and NMR [n= ref.]. As described in this study, 
(C18)2-R11 and (C18)2-L-R11display typical features of PAs, such as the formation of 
micelles and unilamellar vesicles. In addition, their surface properties were studied 
using Langmuir monomolecular films and the results obtained support the formation 
of molecular aggregates upon compression of the PA films. The presence of the alkyl 
chains induces not only the self-assembly of these new PAs into supramolecular 
aggregates but also a gain of structure within the disordered peptide [57].  
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2.2. Aim of the Workpackage II 
The chemokines and their receptors play a key role in immune and inflammatory 
responses by promoting recruitment and activation of different sub populations of 
leukocytes. In this context, we focused our interest on CXCR4, a G-protein-coupled 
receptor involved in a number of physiological processes in the hematopoietic and 
immune systems. A recent work has described the structural behaviour and the 
biological binding between CXCR4 and its natural ligand CXCL12 [51]. This axis 
possesses a pivotal role in diseases, such as HIV, cancer, WHIM syndrome, 
rheumatoid arthritis, pulmonary fibrosis, and lupus and, hence, indicated as putative 
therapeutic target [61]. Nevertheless, the therapeutic utility of blocking the interaction 
of the chemokine receptors with their natural ligands is not so obvious. In effect, 
although they are markers of disease progression, it is not possible to say that they 
are its sole cause [59]. However, Horuk suggested that, to obtain an effective 
therapeutic role by inhibitory molecules, a potential solution could be to develop 
drugs that target more than one receptor [60]. Considering that CXCL12 binds to 
CXCR4 as well as CXCR7, we decided to design new linear peptides, charaterized 
by unorder residues [58], that could be able to interact with both G-protein-coupled 
receptors. In this context, intrinsically disordered peptides (IDPs) represent an 
innovative and interesting starting point to employ the conformational disorder in the 
design of potential drug agents in the after specific binding modifications. These 
peptides present a number of advantages with respect to structured peptides, such 
as a large interaction surface, involvement in high specificity/low affinity interactions, 
enhanced binding kinetics and conformational plasticity to bind several targets. 
Instead, they dynamically explore an ensemble of unfolded configurations, adopting 
more stable, ordered structures only after binding to their ligands. Two peptides with 
a high content of disorder promoting residues, PeptideE (H-YGECPCE-Allyl) and 
PeptideK (H-YGECPCK-Allyl) were designed using the N-terminal region of CXCL12 
as template and the CPC sequence, the binding motif for CXCR4 receptor [51] that 
represents a well-known target for cancer therapies. The allyl group is introduced at 
C-terminus of both peptides in order to have a site for further new functionalizations. 
The peptides were analysed by solution CD and NMR techniques in order to study 
their conformational behaviour in solution. Fluorescence and DLS experiments were 
carried out in order to predict aggregates formation and to define their topology. 
Molecular simulation studies were conducted to verify if these peptides undergo 
structural changes upon binding or simply bind to pre-existing conformers that are 
populated within the IDP’s structural ensemble. We have also perfomed biological 
tests to evaluate if PeptideE and PeptideK and their PA aggregates were able to 
interact with the CXCR4 receptor, to inhibit CXCL12-induced migration and to reduce 
cAMP monophosphate levels. The results of biological properties of all peptides were 
analalyzed with the purpose of comparing our compounds respect the most clinically 
advanced CXCR4 antagonist, i.e. plerixafor (previously known as AMD3100). 
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2.3. Results and discussion 
 
2.3.1. Design and Synthesis 
Two linear intrinsically disordered peptides have been designed choosing a few 
amino acids with disorder propensity: PeptideE (YGECPCE-Allyl) and PeptideK 
(YGECPCE-Allyl) (top of Figure 25). 
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Figure 25. Peptide sequences and their PAs derivatates. Blue for the hydrophobic moiety. Red fo the 
linker. In brackets the PEG chain. 
 
The charged amino acids, Lys and Glu, were introduced in order to evaluate the 
influence of charges in modulating the free peptide binding properties and on the 
aggregation tendency of their PAs derivates. As reported in Figure 25, two peptide 
amphiphiles (PA): (C18)2-PeptideE and (C18)2-PeptideK, were also obtained by 
conjugating two aliphatic chains (in blu) of eighteen carbon atoms at the N-terminus 
of both sequences. Two other PA derivatives, indicated in Figure 25 as (C18)2-L-
PeptideE and (C18)2-L-PeptideK, were obtained by inserting the AhOh exoethylene 
linker (red tract in Fugure 25) between the peptide sequence and the hydrophobic 
double-tail. As it is well-known from the literature [62], the presence of PEG chains 
can increase the in vivo blood circulation of self-assembled PA aggregates. This 
linker, the same for both peptides, allows us to increase the hydrophilicity of PAs with 
out modifying their final charge. In this way, avoiding intra- and inter- electrostatic 
interactions, the linker leads to a distancing between the bioactive peptide and the 
hydrophobic shell of the aggregates. The relatively short length of the peptide 
sequence was chosen in order to avoid possible formation of a hydrophilic pocket, 
able to hide the amino acid sequence. PAs (Figure 25) were synthesized according 
to standard solid phase peptide synthesis protocols using 2-Cl-(Trt)-Cl preloaded 
resin as a polymeric support. (In Material and Methods section synthesis details are 
reported). The ethoxylic moiety and the two alkyl chains at the N-terminus of both 
peptide sequences were added as previously reported [63]. After RP-HPLC 
purification, the products were identified by ESI-MS spectrometry. The 
conformational features of both peptides were investigated in solution by CD, DLS, 
NMR, MD techniques. 
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2.3.2. Structural characterization 
 
2.3.2.1. PeptideE and PeptideK 
 
2.3.2.1.1. CD analysis 
 
The secondary structure of PeptideE and PeptideK was studied in PBS by CD. As 
expected for very short peptide sequences, both peptides did not show any tendency 
to fold under this experimental condition [64]. Infact, CD spectra (Figure 26) show a 
typical shape of an unordered structure with a negative band between 197 and 201 
nm. 
 
 
Figure 26 a) CD spectra of PeptideK and PeptideE. b) CD analysis by CAPITO tool where both 
peptides are indicated as unfolded peptides. 
 
This behavior is also confirmed by CAPITO analysis [65] (http://capito.nmr.fli-
leibniz.de), where spectra values (indicated as mean residue ellipticity (θ)) at λ = 200 
nm are plotted versus λ = 222 nm. In fact, both the peptides are located in unfolded 
regions. (see Figure 26) It is important to notice that the CD spectrum of PeptideK 
presents also a maximum centered at 225 nm that that is associated to the presence 
of fluctuating Polyproline II (PII) helices [66; 67, 68]. Conformational behaviours of 
PeptideE and PeptideK amphiphiles derivates ((C18)2- and (C18)2-L- derivates), 
were investigated by CD spectroscopy. Lyophilized peptides were dissolved in the 
suitable weakly basic buffer (TRIS or PBS, see paragraph Material and Methods) at 
concentrations above the CMC value (2 x 10-4 mol/L for all peptides) to foster the 
presence of aggregates in all solutions. 
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2.3.2.1.2. NMR Analysis 
 
In aqueous solution, the poor spectral dispersion of the 1D [1H] spectra and the 
almost complete absence of signal in the 2D [1H, 1H] NOESY [69] experiments 
indicated that both free peptides were very flexible (Figures A1 and A2 in the 
Appendix). However, complete proton resonance assignments were achieved by 
combined analysis of the 2D [1H, 1H] TOCSY [38] and ROESY [39] spectra (Figures 
27 and 28; Tables A1 and A2).  
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Figure 27. Comparison of 2D [1H, 1H] TOCSY (left) and ROESY (right) spectra of PeptideE in 
H2O/D2O (90/10). The HN-aliphatic protons correlation regions are shown in each panel; spin system 
assignments are indicated in the left side. In the right panel, sequential ROE contacts are highlighted 
by rectangles and the corresponding assignments are indicated. 
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Figure 28. Comparison of 2D [1H, 1H] TOCSY (left) and ROESY 200 (right) spectra of PeptideK in 
H2O/D2O (90/10). The two sides of the figure show spectral regions containing HN/aliphatic protons 
correlations; spin system assignments are indicated in the TOCSY left panel. In the right panel, 
sequential ROE contacts are shown. 
 
Moreover, we evaluated chemical shifts deviations of Hα protons from random coil 
values, which resulted in prevalence small and positive and characteristic of an 
extended disordered conformation [70]. (Figures 29 and 30, Tables A3 and A4) 
 
 
 
Figure 29. Chemical shift deviations from random coil values (CSD) for PeptideE (D.S. Wishart et al., 
1991). All residues are reported by one-letter code. The CSD value for Allyl-E is not shown. 
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Figure 30. Chemical shift deviations from random coil values (CSD) for PeptideK (D.S. Wishart et al., 
1991). All residues are reported by one-letter code. The CSD value for Allyl-K is not shown. 
 
The disorder state of both peptides was confirmed by ROE patterns (Figure 31) 
which showed strong and sequential Hαi–HNi+1 contacts typical of flexible peptides 
[71]. Due to the proximity of chemical shifts between Cys4 Hα proton and water in 
both PeptideE and PeptideK, we could not clearly identify the configuration (i.e., cis 
or trans) of the Cys4–Pro5 peptide bond. 
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Figure 31. NOE intensity pattern in H2O: a) PeptideE and b) PeptideK. Only principal short and 
medium range NOEs are reported. Different residues are specified with the one-letter amino acid 
code; “dξζ (b, c)” designates a NOE contact between the Hξ and Hζ protons in the b and c residues 
respectively. 
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2.3.2.1.3. MD 
Molecular dynamics studies were conducted on the two peptides, which were linearly 
modeled by using a precise method (Material and Methods), at neutral pH. On the 
basis of the distances between structures, like RMSD values, a set of clusters, 
reflecting the range of conformations accessible and their relative weights, was found 
by using a clustering algorithm implemented in GROMACS as reported also in recent 
papers [59; 66]. The plots of the Root Mean Square Deviation (RMSD) were 
computed by overlapping the various structures during simulations in respect to the 
initial conformation. In Figure 32a the RMSD plots of PeptideK and PeptideE 
reported. They evidenced high levels of fluctuation, thus suggesting that these 
peptides are flexible. This result was confirmed by Root Mean Square Fluctuation 
(RMSF) plots where the residues located at N- and C-termini have higher values of 
RMSF (Figure 32b). Instead, the gyration radii decreased during the simulations 
(Figure 32c) reaching a value of 0.5 nm. This suggests an increasing compactness 
of the two peptides, which result as if they were stabilized by a certain number of H-
bonds of main chain–main chain (MM), main chain–side chain (MS) and side chain–
side chain (SS) types (Figure 32d). This is the reason why the two peptides tend to 
become more compact and their radius of gyration to decrease (see Figure 32c). 
Considering CD and NMR data in aqueous solution, the analysis of the secondary 
structure evolution clearly showed the high flexibility of both peptides during the 
simulations, which makes difficult the formation of stable regular secondary structure 
elements, i.e., helix and β-strand.  
 
a) b)
c) d)
 
 
Figure 32. Analysis of molecular dynamics simulations conducted on PeptideE (in black) and 
PeptideK (in grey) at physiological pH in terms of: a) root mean square deviation (RMSD) plot, b) root 
mean square fluctuation (RMSF), c) gyration radius plot, and d) H-bonds plot. 
 
A very flexible peptide structure is normally characterized by several conformers at 
equilibrium, hence they could be well described by a conformational ensemble. 
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Having taken this property into proper account, we have firstly performed a cluster 
analysis to determine the groups of structures that share similar conformational 
features according to their RMSD values. (see Figure 33) 
 
a) b)  
 
Figure 33. Superimposition of a) 8 clusters obtained for PeptideE and b) 9 clusters for PeptideK 
during MD simulations. 
 
The most populated clusters are 8 for PeptideE and 9 for PeptideK. These clusters 
are mainly stabilized by MM H-bonds (Figure 34) that involved the atomic groups of 
the peptide backbone.  
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Figure 34. The map MM H-bonds in the 8 and 9 clusters calculated for the a) PeptideE and b) 
PeptideK, respectevely, during MD simulations. We used the same colors the residues involved in the 
same MM H-bonds. 
 
This structural organization was observed by Pappu et al. [74] for charged peptides: 
it closely resembles the organization of collapsed and slightly soluble globules.  
Since CD spectra of PeptideK pointed out the presence of PII, we verified its possible 
occurrence in the most populated clusters by using the angular ranges following 
reference parameters for the angles: −110° ≤ φ ≤ −40° and 130° ≤ ψ ≤ 180° in the 
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Ramachandran map [75]. No residues in PII were present in eight clusters of 
PeptideE whereas in 5 out of 9 clusters of PeptideK we identified residues in PII 
(Figure 35), according to CD analysis.  
 
a)  
b)  
 
Figure 35. Ramachandran Plot for nine and eight clusters obtained for a) PeptideE and b) PeptideK, 
respectively. Red circle for the the residues in polyproline II region. 
 
It is well known that the peptide dynamics depend on the surrounding solvent, which 
mediates interactions among residues. The total number of water molecules in the 
system was analysed as well as their possible role [76]: the simulation box for 
PeptideE and PeptideK contained 2956 and 2611 water molecules, respectively. The 
total average number of water molecules that formed H-bonds resulted slightly higher 
for PeptideE if compared to PeptideK: 33 and 30 in PeptideE and PeptideK, 
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respectively. This trend could be due to the different amino acid sequence of the two 
peptides; in fact, PeptideK has got two oppositely charged residues in 3 and 7 
positions, hence it may assume a more compact structure. In both peptides most of 
H-bonds (indicatively 60%) resulted to involve the peptide backbone, being of main 
chain—water oxygen type (MH) or of the water oxygen and main chain type (HM). A 
detailed analysis of the residues involved in H-bonds with water molecules revealed 
that the residues in positions 1, 3 and 7 (Y, E and E in PeptideE and Y, E and K in 
PeptideK) participate to a higher number of H-bonds with water molecules if 
compared with the residues located in the other four positions (Table 6).  
 
Table 6. The average number of H-bonds that each residue in PeptideE and PeptideK formed with 
water molecules during MD simulations. 
Residue  PeptideE PeptideK 
Y 7 8 
G 3 2 
E 9 6 
C 2 1 
P 1 3 
C 2 4 
E or K 9 6 
 
Furthermore, the average number of H-bonds developed by E and K with water 
molecules was lower than the average number of the H-bonds developed by E and E 
with water molecules in PeptideE. Hence, these results confirmed that PeptideE 
tended to assume more extended conformations being that it contains two negatively 
charged residues that could allow large interactions with water molecules.  
Taking into account all data the structure of both peptides is very flexible, and can be 
dynamically stabilized by a network of MM H-bonds. Hence, their structures can be 
adequately represented as conformational ensembles characterized by fluctuating 
irregular secondary structures. (Figure 34) In fact, the peptides do not assume stable 
and fixed conformations: they go continuously from one cluster to another. The 
calculation a 3D model based on NMR parameters was hampered by the high 
flexibility of peptides. For this reason, the MD was very useful to understand how 
these peptides can move as well as to understand that the best conformers needed 
to be put together to have a clear representation. In particular, the two peptides do 
not explore the full space, but rather, the rapid interchange among the flexible 
conformers induce quick changes between clusters. This is coherent with the data 
reported in Figure 4B where it is visible that the more flexible residues are located in 
the terminal ends. 
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2.3.2.2. PAs derivates 
 
2.3.2.2.1. Aggregates preparation and Fluorescence 
Supramolecular aggregates of pure PA derivatives were obtainedby dissolving the 
lipophilic derivatives in 10 mM phosphate buffer (pH 7.4) for PeptideE and in 10 mM 
TRIS buffer (pH 8.0) for PeptideK. The choice of buffers to be used for solubilizing 
monomers was imposed by their different propensities to aggregate. All the 
aggregates properties were investigated by fluorescence spectroscopy and DLS. 
Critical micellar concentration (CMC) values were estimated by fluorescence 
spectroscopy by using ANS as a fluorescent probe. The fluorescence intensity of 
ANS depends on thesurrounding environment. Infact this fluorophore emits only in a 
hydrophobic environment, such as the hydrophobic core of amicellar aggregate, 
whereas it does not emit in water solution. CMC values can be estimated break-point 
in the graphics reported in Figure 36.  
 
 
 
Figure 36. Fluorescence intensity of the ANS fluorophore at 470 nm as a function of a) (C18)2-L-
PeptideK and b) (C18)2-PeptideK concentration; data are multiplied by a scale factor for a better 
comparison. CMC values are obtained from graphical break points. 
 
These data have been obtained by plotting the fluorescence intensity of ANS in the 
emission maximum at 470 nm, as a function of the PA derivative concentration. The 
CMC values (7.0 x 10-6 mol kg-1 and 1.9 x 10-5 mol kg-1, respectively for (C18)2-
PeptideK and (C18)2-L-PeptideK) indicate that the introduction of the ethoxylic linker 
slightly affects the formation of aggregates capable of capturing the ANS, but they 
also confirm the high stability of both the resulting aggregates. (Table 5) The same 
trend was found for PeptideE. Nonetheless, the CMC values of both the amphiphilic 
derivatives of PeptideE are higher than the corresponding ones for PeptideK. (Table 
5) 
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Tabella 5. Structural parameters for the aggregates obtained by fluorescence measurements (critical 
micellar concentration value, CMC) and by dynamic light scattering measurements (diffusion 
coefficients, D, hydrodynamic radii, RH, and polydispersity indices). 
Peptide CMC (mol kg-1) RH (nm) D x 10-12 (m2s-1) PDI 
(C18)2-PeptideK 7.0 x 10-6 80 ± 27 3.1 ± 1.0 0.270 
(C18)2-L-PeptideK 1.9 x 10-5 82 ± 34 3.1 ± 1.5 0.182 
(C18)2-PeptideE 3.9 x 10-5 112 ± 44 1.9 ± 0.7 0.264 
(C18)2-L-PeptideE 3.2 x 10-5 110 ± 39 2.4 ± 0.5 0.226 
 
This behavior indicates that PeptideE owns a lower propensity to aggregate if 
compared to PeptideK; this may depend on the different interaction of the charges 
with the buffer salts.  
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2.3.2.2.2. DLS 
DLS data (hydrodynamic radii, RH; the diffusion coefficients, D; and the 
polydispersity indices, PDI) are reported in Table 5. The measurements for the self-
assembled PAs were performed at y = 1731 at a concentration of 2 x 10-4 mol kg-1 
(above the CMC values of all amphiphilic peptides) in the previously reported buffer 
solution. The Stokes–Einstein equation (1) is used to evaluate the hydrodynamic 
radius (RH) at infinite dilution where D0 is the translational diffusion coefficient at 
infinite dilution, KB is the Boltzmann constant, T is the absolute temperature, and  is 
the solvent viscosity. Due to the high solution dilution (C = 1 x 10-4 M) of the systems 
under study, we have approximately D ~ D0, and equation (1) can be reasonably 
used to estimate the hydrodynamic radius of the aggregates. 
 
  (1) 
 
Taking into account all DLS results, it was possible to oberve that all aggregate 
solutions show a monomodal distribution, which indicates the presence of just one 
population of aggregates with an average diameter ranging between 80 and 110 nm. 
An increase of the radius of 20% was observed for (C18)2-PeptideE (100 nm) with 
respect to (C18)2-PeptideK (80 nm) (see Figure 37). Whereas only a slight difference 
in radii can be detected for the derivatives containing the spacer. (Table 5) 
 
 
 
Figure 37. DLS profiles of (C18)2-PeptideK a) and (C18)2-PeptideE b) peptide amphiphiles at a 
concentration of 2 x 10-4 M. 
 
Fluorescence measurements were carried out by exciting buffer solutions at 275 nm 
to evaluate the eventual shifts of tyrosine fluorophore emission as a consequence of 
aromatic quenching on the surface of the aggregates. In the Figure 38a emission 
spectra for all PeptideE derivatives are reported.  
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a)  b)  
 
Figure 38. Fluorescence emission spectra recorded by exciting buffer solutions at 275 nm for a) 
PeptideE derivatives and b) PeptideK derivatives. 
 
The behaviour of tyrosine does not show significant differences in intensity or in the 
wavelength shift. These results seem to exclude interaction among peptide side 
chains on the surfaces of aggregates. Similar results have been obtained for 
PeptideK derivatives (Figure 38b). 
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2.3.2.2.3. CD analysis 
 
a)  
 
b)  
 
Figure 39. CD spectra of: a) (C18)2-PeptideE and (C18)2-L-PeptideE; and b) (C18)2-PeptideK and 
(C18)2-L-PeptideK. 
 
In Figure 39 the CD spectra of all PA derivates are depicted. The CD spectrum of 
(C18)2-PeptideE does not show any tendence to fold as indicated by CD spectra, 
presenting a negative minimum at around 198 nm, typical for unordered structures 
(Figure 39a). Moreover, the presence of the ethoxylic spacer does not influence 
significantly the dichroic bent of the PA. This trend was also confirmed by CAPITO 
analysis (data not shown) [65]. Furthermore, two weak maxima at 208 and 232 nm 
are also detectable in the CD spectra of PeptideK derivatives (see Figure 39b), in 
addition to the minimum at 196 nm. These spectra suggest that the replacement of 
the glutamic acid with the lysine at the C-terminus induces a rearrangement of the 
secondary structure with a partial folding of the IDP.  
 
2.3.2.2.4. NMR Analysis  
 
The high aggregation levels of PeptideE and PeptideK derivatives prevented any 
attempts to confirm the CD data with more precise conformational studies by NMR 
spectroscopy. Indeed, this aggregation produced sample precipitationand/or 
complete disappearance of signals in 1D [1H]. 
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2.3.3. Functional Characterization on CXCR4 Receptor 
All peptides have been tested in order to otain different information about our peptide 
activity on the CXCR4 receptor. In order to assess the inhibitory capability of 
PeptideK and PeptideE on CXCR4 function, we have evaluated peptides binding to 
the receptor through an indirect binding assay; then, in addition we have assessed 
the inhibition of CXCL12-induced migration and, considering the correlation between 
the CXCR4 and adenylate cyclase activities (Figure 40), the percentage of cAMP. 
The binding of the four peptides to CXCR4 was evaluated in CCRF-CEM using a 
CXCR4 12G5 monoclonal antibody as previously described, [56] and two 
concentrations (1 mM and 10 mM) which are matching the ones previously used in 
CXCR4 binding assays. All peptides did not displace 12G5 antibody if compared with 
AMD3100, which strongly reduced antibody binding to CXCR4. This result could be 
justified by the presence of different binding sites on AMD3100/12G5 antibody and 
the four highly flexible disordered peptides. The migration assay revealed that 
PeptideE and PeptideK reduce the migration of CCRF-CEM cells towards CXCL12 
even if they showed less activity than AMD3100 (data not shown). Similar results 
were obtained for PAs derivates, indicating the absence of influence of the 
hydrophobic and/or linker on the migration. As a consequence of the activity of 
CXCR4 on the G-protein (mediated by CXCL12), the adenylate cyclase is inhibited. 
For this reason, we also evaluated the cAMP levels after treatment with the all 
peptides. The results indicate that in the presence of CXCL12 (100 ng mL-1) and 
Forskolin (1 mM):  
i. All synthetic peptides show a dose dependent increase of the cAMP 
(average value of 66% anf 84% at 1 mM and 10 mM), respectively. 
ii. At 10 mM, (C18)2-L-PeptideK increases cAMP levels up to 93% and 
(C18)2-PeptideE increases the cAMP level to 95%; 
iii. AMD3100 exhibits less efficient activities on the adenylate cyclase when  
compared to the four peptides (Figure 36). 
 
 
 
Figure 40. Comparison of cAMP modulation by PeptideE, PeptideK, (C18)2-PeptideE, (C18)2-L-
PeptideE, (C18)2-PeptideK, (C18)2-L-PeptideK and AMD3100 at 1 M and 10 M. 
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2.4. Conclusions 
As CXCR4 is overexpressed in several human cancers, the blockade of CXCR4–
CXCL12 interaction represents from many years an interesting drug-target [51]. 
Nowadays, the most clinically advanced compound targeting this route, plerixafor 
(previously known as AMD3100), shows cardiotoxicity, as reported in its clinical trial 
against HIV [77]. From this, the need to design e synthesize new antagonists able to 
block, without side effects, the binding between CXCL12 and CXCR4. We started to 
study the structural preferences in solution of two synthetic linear peptides, PeptideE 
and PeptideK, characterized by few amino acids with disorder propensity, and by an 
allylic ester group at the C-terminal end. NMR and CD spectra evidenced the 
absence of regular secondary structure elements thus confirming the natively 
disordered nature of these peptides. MD simulations confirmed their flexibility but 
also revealed that they are stabilized by a network of transient and dynamic intra-
molecular H-bonds of MM type and by interactions with water molecules. In 
conclusion, NMR and computational studies pointed out to us the flexibility of 
PeptideE and PeptideK, their inability to adopt a single ordered conformation and, 
hence, the need to represent them by conformational ensembles characterized by 
the presence of transient and dynamic MM H-bonds. Afterwards, we have explored 
the possibility that intrinsically disordered peptides could be connected to alkyl chains 
to generate new molecular buildings for drug delivery vehicles in cells over-
expressing the CXCR4 receptor. The peptides are used as polar heads of these 
buildings whereas alkyl chains as a hydrophobic moiety. In detail, we investigated the 
opportunity to modulate conformational changes by introducing C18 chains and/or an 
ethoxylic linker. DLS and fluorescence data revealed that the insertion of aliphatic 
moieties into peptides favors the self-assembling in supramolecular aggregates of 
the resulting amphiphilic molecules. The average diameter ranges between 80 and 
110 nm, independently from their charge and from the presence of the PEG spacer. 
Once confined on the external surface of the aggregates, peptides could undergo a 
disorder-to-order transition [57]. The low solubility at high concentrations (0.50–1.0 
mM) and the strong aggregation of all PAs hampered their structural characterization 
by NMR techniques, even after changing the experimental conditions such as 
implementing buffers at different pH and temperatures. CMC values agree with those 
previously reported for amphiphilic peptides with the same hydrophobic moiety and 
they pointed out the high stability of the aggregates [78; 79]. The lower CMC values 
of PeptideK PAs derivates indicate a higher propensity to aggregate if compared with 
the corresponding PeptideE derivatives. Furthermore, the insertion of the 
hydrophobic portion in PeptideE seem not to influence its tendency towards the 
disordered/unfolded state from the conformational point of view. Whereas both the 
PeptideK derivatives show a partial folding, with respect to the free peptide 
sequence. To the best of our knowledge, these compounds are the first CPC motif 
containing amphiphilic peptides which are able to aggregate. Comparing all peptides 
with AMD3100, the studies of functional characterization on CXCR4 Receptor, show 
no significant binding affinity of all peptides for CXCR4. Concerning migration 
assays, the best results about the migration were obtained for PeptideE sequences, 
indicating the importance of the choice of charge in the desing of bioactive peptide. 
As indicated by the highest cAMP percentages of (C18)2-L-PeptideE-(93%) and 
(C18)2-PeptideK (95%), obtained at 10 mM (Figure 36), the presence of the linker 
could influence the activity of PAs. Although these results should be considered as 
preliminary, requiring further analysis, we can assume that all data obtained for the 
amphiphilic peptides designed and synthesized were encouraging and indicate the 
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validity of multidisciplinary approach described in this work. Further chemical 
modifications using the reactivity of the ester group could be introduced to obtain new 
molecules able to form supramolecular aggregtes peptide-based, capable of being 
encapsulated by living cells and, therefore, convey the bioactive peptide and / or 
probes. All this can find applications in the field of medical therapies personalized, 
investigations MRI (magnetic resonance imaging) and also for biotechnological 
industry.  
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2.5. Material and Methods 
 
2.5.1. Reagents 
Protected fluorenylmethoxycarbonyl (Fmoc)N -Fmoc-amino acid derivatives, 2-
chlorotrityl chloride resin pre-loaded with Fmoc-Glu-OAllyl and Fmoc-Lys-OAllyl and 
coupling reagents were purchased from Novabiochem, Iris Biotech GMBH or from 
Inbios (Napoli, Italy). All other chemicals were commercially available by Sigma-
Aldrichand Acros. Fmoc-21-amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid 
(Fmoc-Ahoh-OH) was purchased from Neosystem (Strasbourg, France). N,N-
Dioctadecylsuccinamic acid was synthesized according to the published methods 
[80]. The purity of these products was determined by analytic reverse-phase HPLC 
using a VWR Hitachi instrument equipped with an L-2450 auto sampler, two L-2130 
pumps, a Satisfaction RP18-AE column (5 μm, 250 × 4.6 mm) and a L-2450 diode 
array detector, at a flow rate of 0.80 mL/min. The free peptides were purified by 
preparative reverse-phase HPLC using a VWR LaPrep system consisted of a P202 
injector, two P110 pumps, a Satisfaction RP18-AB C18 column (5 μm, 250 × 20 mm) 
and a P314 UV detector, at a flow rate of 10.0 mL/min. The following eluents were 
used in a gradient mode: (A) 0.1% trifluoroacetic acid (TFA) in H2O/CH3CN (95/5) 
and (B) 0.1% TFA in CH3CN/H2O (95/5). Water was of Milli-Q quality and was 
obtained after filtration of distilled water through a Milli-Q® cartridge system. CH3CN 
and TFA were of HPLC use quality. Degassing of solvents was performed using 
argon bubbling. Gradient used for the analytic and preparative RP-HPLC was 
respectively from 0% B to 100% B in 15 min and from 0% to 70% B in 70 min; UV 
detection at 214 nm. CH3CN was evaporated and the aqueous solution was freeze-
dried to give purified PeptideK and PeptideE as white solids (68% and 54% yield, 
respectively). Peptide identity was confirmed by mass spectrometry analyses 
performed on an Ultraflex III TOF/TOF system (Bruker Daltonics, Bremen, Germany), 
equipped with 200 Hz smartbeam laser (355 nm) and operating in reflectron positive 
ion mode. Mass spectra were acquired over the m/z range 450–5000 by 
accumulating data from 1000 laser shots for each spectrum. The instrumental 
conditions employed to analyze molecular species were the following: ion source 1: 
25.08 kV; ion source 2: 21.98 kV, lens: 11.03 kV, pulsed ion extraction: 30 ns, 
reflector: 26.39 kV, reflector 2: 13.79 kV. Matrix suppression was activated by 
deflection mode: suppression up to 450 Da. Mass calibration was performed for each 
samples in range of ∼700 Da–3200 Da with a peptide calibration mixture (8206195, 
Peptide Calibration Standard, Bruker Daltonics). The instrument was controlled using 
Bruker's flexControl 3.4 software and mass spectra were analyzed in Bruker's 
FlexAnalysis 3.4 software. Concerning PAs derivates, all molecules were purified on 
on a LC8 Shimadzu HPLC system (Shimadzu Corporation, Kyoto, Japan) equipped 
with a UV lambda-Max Model 481 detector using a Phenomenex (Torrance, CA) C4 
(300 Å, 250 x 21.20 mm, 5 ) column. Elution solvents are H2O/0.1% TFA (A) and 
CH3CN/0.1% TFA (B), from 20% to 95% over 20 minutes at 20.0 mLmin-1 flow rate. 
The purity and identity of the products were assessed by analytical LC–MS analyses 
by using Finnigan Surveyor MSQ single quadrupole electrospray ionization 
(Finnigan/Thermo Electron Corporation San Jose, CA), column C4-Phenomenex 
eluted with an H2O/0.1% TFA (A) and CH3CN/0.1% TFA (B) from 20% to 95% over 
20 minutes at 0.80 mL min-1 flow rate. 
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2.5.2. Synthesis 
All peptides were synthesized following a solid phase peptide standard protocol using 
Fmoc chemistry on 2-chlorotrityl chloride resin pre-loaded (0.24 scale mmol) with the 
side chain of a Fmoc-Lys-OAllyl and a Fmoc-Glu-OAllyl, respectively. The sequence 
H-YGECPC was built on both resins. In particular, the resins were allowed to swell in 
dichloromethane (DCM) and Fmoc-deprotection steps were performed by treating the 
resin for 30 min in a dimethylformamide (DMF)/Piperidine (Pip) (80/20, v/v) solution. 
For coupling steps the resin was suspended in DMF containing three equivalents of 
the Fmoc-protected amino acid, O-benzotriazole-tetramethyl-uronium-hexafluoro-
phosphate (HBTU) (3eq), and diisopropylethylamine (DIEA) (6 eq.), and the reaction 
mixture was shaken for 2 h at room temperature. Washing steps after coupling and 
deprotection steps were performed by treating resin in DMF (3 × 1 min), MeOH (1 × 1 
min), and DCM (3 × 1 min), successively. The Fmoc ethoxylic spacer and lipophilic 
N,N-dioctadecylsuccinic acid were coupled, by using a procedure already reported in 
literature [63]. Peptides were cleaved by soaking the resin in 
TFA/H2O/triisopropylsilane (TIS) (3.00 mL, 95/2.5/2.5, v/v/v) for 3 h. The peptide was 
cleaved by immersing the resin in TFA/H2O/triisopropylsilane (TIS) (30.0 mL, 
95/2.5/2.5, v/v/v) for 3 h. The resulting white solids were dissolved in a water and 
acetonitrile 4 : 1 v : v (10.0 mL) mixture and freeze-dried to obtain a white powder 
that was analyzed for purity and purified by preparative RP-HPLC. Mass values were 
obtained by LC-ESI-MS (see Table 7). 
Table 7. Experimental masses of Pas derivates. 
Peptide Experimental Mass  
(C18)2-PeptideE 1443 a.m.u. 
(C18)2-PeptideK 1442 a.m.u. 
(C18)2-L-PeptideE 1777 a.m.u. 
(C18)2-L-PeptideK 1776 a.m.u. 
 
2.5.3. Preparation of aggregate solutions 
Lyophilized PAs were dissolved in aqueous solutions. In detail, (C18)2-PeptideK and 
(C18)2-L-PeptideK were solubilzed in 10 mM TRIS buffer at pH 8.0, whereas (C18)2-
PeptideE and (C18)2-L-PeptideE in 10 mM phosphate buffer (PBS) at pH 7.4. The 
calibration of the pH-meter was carried out by using three standards (pH 4.00, pH 
7.00 and pH 10.00). In most cases the samples to be measured were prepared from 
stock solutions. The concentrations of all solutions were determined by UV-Vis 
absorbance measurements carried out on a Thermo Fisher Scientific Inc 
(Wilmington, Delaware USA) Nanodrop 2000c spectrophotometer equipped with a 
1.0 cm quartz cuvette (Hellma) using a molar absorptivity () of 1390 M-1 cm-1 at  = 
275 nm, which corresponds to the wavelength of the tyrosine residue. 
 
2.5.4. Fluorescence measurements 
CMC values of PAs derivates were obtained by fluorescence measurements. 
Fluorescence spectra were recorded at room temperature on a Jasco Model FP-750 
spectrofluorophotometer (Jasco Int. Co. Ltd, Tokio, Japan) in a 1.0 cm path length 
quartz cell. Equal excitation and emission bandwidths were used throughout the 
experiments, with a recording speed of 125 nm min-1 and automatic selection of the 
time constant. The 8-anilino-1-naphthalene sulfonic acid ammonium salt (ANS) was 
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used as fluorescent probe [80]. Small aliquots of peptide aqueous solution were 
added to a fixed volume (1.00 mL) of 2.0 x 10-5 M ANS fluorophore directly in the 
quartz cell. CMC values were determined by linear least-squares fitting of the 
fluorescence emission at 480 nm, upon excitation at 350 nm versus the amphiphile 
concentration. Fluorescence emission spectra of the tyrosine residue in the 
anphiphilic peptides were recorded at 5 x 10-5 M concentration and 25 °C exciting the 
peptide solution at 275 nm. 
 
2.5.5. DLS 
Dynamic light scattering (DLS) measurements were carried out using a Zetasizer 
Nano ZS (Malvern Instruments, Westborough, MA) that employs a 173° backscatter 
detector. Other instrumental settings are measurement position (mm): 4.65; 
attenuator: 8; temperature 25 1C; cell: disposable sizing cuvette. DLS samples were 
prepared at a final concentration of 2.0 10-4 M and centrifuged at room temperature 
at 13 000 rpm for 5 min. 
 
2.5.6. CD  
Far-UV CD spectra were recorded from 190 to 260 nm on a Jasco J-810 
spectropolarimeter equipped with a NesLab RTE111 thermal controller unit using a 1 
mm quartz cell at 25 °C. Circular dichroism measurements were carried out on 
lyophilized peptides dissolved in 10 mM phosphate buffer at pH 7.4 M at a peptide 
concentration of 5·10-6 M. CD spectra of PAs derivatives of PeptideE and PeptideK 
were acquired at 2.0 x 10-4 M concentration in 2.0 mM phosphate buffer and 10 mM 
TRIS, respectively. Other experimental settings were: scan speed, 10 nm min-1; 
sensitivity, 50 mdeg; time constant, 16 s; bandwidth, 1 nm. Each spectrum was 
obtained averaging three scans, and by subtracting contributions from other species 
in solution and converting the signal to mean residue ellipticity in units of deg cm2 
dmol-1 res-1. 
 
2.5.7. NMR Analysis 
NMR spectra were recorded at 25 °C on a Varian Unity Inova 600 MHz spectrometer 
provided with a cold probe. The process of proton resonance assignments was 
carried out with a canonical protocol [71] based on analysis of the following two 
dimensional [1H, 1H] spectra: TOCSY (70 ms mixing time) [38], DQFCOSY [40], 
NOESY [69] (300 ms mixing time) and ROESY (Rotating frame Overhauser 
Enhancement Spectroscopy) ) [39] (200 ms mixing time). Chemical shifts were 
referenced with respect to the TSP, 99% d, Armar Scientific, Switzerland) signal at 
0.0 ppm. 1D spectra were acquired with a relaxation delay of 1s and 32-128 scans. 
2D experiments were generally acquired with 32-64 scans, 128-256 FIDs in t1, 1024 
or 2048 data points in t2. The DPFGSE sequence [82] was used to suppress water 
signal. Spectra were processed with the Varian software VNMRJ 1.1D (Varian by 
Agilent Technologies, Italy) and analyzed with the NEASY [43] program that is 
included in the CARA software package (http://www.nmr.ch/). NMR analysis was 
performed for both free peptides by dissolving 1 mg of peptide in a solution volume 
equal to 600 µL. NMR analysis was performed in H2O containing 10% v/v D2O 
(99.8% d, Armar Scientific, Switzerland). NMR studies of amphiphilic peptides were 
not possible because of their high propensity to aggregate.   
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2.5.8. Molecular Modeling and Dynamics simulations 
PeptideK and PeptideE have been built by using the Builder module in InsightII and 
then subjected to molecular dynamics (MD) simulations performed with the 
GROMACS software package (v3.3.1) [83]. In detail, each peptide was put in a cubic 
box filled with SPC216 water molecules, and GROMOS43a1 was selected as force 
field because it is commonly used as force field for MD simulations on peptides and 
our group has already used it in other previous papers in which we reported some 
conformational studies on different peptides where the results obtained from MD 
simulations resulted in excellent agreement with CD and/or NMR studies [66; 51; 59]. 
In order to optimize the systems, the peptides were previously subjected to energy 
minimization and position restraints cycles. The simulations were carried out with 
periodic boundary conditions by adding chloride ions so that the net electrostatic 
charge of the system was zero. The bond lengths were constrained by the linear 
constraint solver algorithm. Particle mesh Ewald algorithm was used for the 
electrostatic interactions with a cutoff of 0.9 nm, according to our recent papers [66; 
51; 72]. All simulations were run for 20 ns at neutral pH and room temperature (300 
K) coupling to the system an external bath. GROMACS routines RMSD and RMSF, 
gyration radius, number of H-bonds and secondary structure evolution) were utilized 
to check the trajectories and the quality of the simulations. Additionally, on the basis 
of the distances between structures, like RMSD values, we founded a set of clusters 
that reflects the range of conformations accessible and the relative weight of each of 
these by using a clustering algorithm implemented in GROMACS as reported also in 
our recent papers [66; 59]. The presence of putative H-bonds between the residues 
and with water molecules was evaluated by Hbplus [84]. 
 
2.5.8. Functional Characterization on CXCR4 Receptor 
 
2.5.8.1. Binding assay 
PeptideK and PeptideE binding to CXCR4 was evaluated as previously described. 
[85] CCRF–CEM cells (2.5x105) were pre-incubated with antagonist peptides (10 μM) 
in binding buffer (PBS 1x plus 0.2% BSA and 0.1% NaN3) for 1h at 37°C, 5% CO2 
and then labeled for 45 minutes with anti-CXCR4 PE-antibody (FAB170P, clone 
12G5, R&D Systems, Minneapolis, MN, USA). Cells were washed in PBS and 
analyzed by FACS Canto II cytofluorimeter (Becton Dickinson Immunocytometry 
Systems, Mountain View, CA, USA). 
 
2.5.8.2. Migration Assay 
CCRF-CEM cells migration was assayed in 24-well Transwell chambers (Corning 
Inc., Corning, NY) using inserts with an 8-m pore membrane. Membranes were 
precoated with collagen (human collagen type I/III) and fibronectin (20.0 mg/mL 
each). CCRF-CEM cells were placed in the upper chamber (1x105 cells/well) in 
RPMI containing 1% BSA (migration media). Cells were pre-incubated for 45 min 
with CXCR4 antagonist and allowed to migrate toward 100ng/ml CXCL12 in the 
lower chamber. After 16 h incubation, migrated cells were collected from the lower 
chamber and counted. The migration index was defined as the ratio between 
migrating cells in the experimental group and migrated cells in the control group. 
 
2.5.8.3. cAMP Assay 
We have conducted c-AMP assay by using CCRF-CEM cells (1 x 106) that were 
incubated in the presence of four peptides or Plerixafor (known as AMD3100: a 
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CXCR4 antagonist) that has provided evidence of concept for inhibition of the 
CXCR4 pathway [56] at two different concentrations (1 and 10 mM) in combination 
with forskolin (F) 1 mM for 20 min, followed by stimulation with CXCL12 (100 ng mL-
1) for 10 min. Controls include cells stimulated with CXCL12 and forskolin or forskolin 
alone in the absence of anti-CXCR4 inhibitors. Cells have been harvested and lysed 
with 0.1 M HCl and cAMP levels have been assayed by a direct competitive enzyme 
immunoassay (BioVision Incorporated) according to manufacture instructions. 
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2.6. Appendix 
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       Figure A1. 2D [1H, 1H] NOESY 300              Figure A2. 2D [1H, 1H] NOESY 300 
            spectrum of PeptideE in H2O.       spectrum of PeptideK in H2O. 
 
Table A1. Chemical shift for PeptideE (±0.01)       Table A2. Chemical shift for PeptideK (±0.01) in 
H2O evaluated at 298 K.   in H2O evaluated at 298 K. 
  
Residue HN Hα Hβ Hγ Others
♦1Y 4.23 3.13
Hδ 7.16
Hε 6.88
2G 8.56
3.98
3.82
3E 8.46 4.33
2.08
1.97
2.42
4C 8.47 4.77
2.94
2.87
5P 4.45 2.30
2.03
1.96
Hδ
3.77
6C 8.38 4.49 2.94
7Allyl-E 8.58 4.48
2.22
2.02
2.46
Allyl group
5.96, 5.36, 
5.30, 4.75
     
Residue HN Hα Hβ Hγ Others
 1Y 4.24 3.13
Hδ 7.16, 7.11 
Hε 6.88, 6.84
2G 8.57
3.98
3.82
3E 8.50 4.32
2.04
1.96
2.39
4C 8.53 4.78 2.91
5P 4.45 2.30
2.02
1.95
Hδ
3.78
6C 8.39 4.49 2.93
7Allyl-K 8.61 4.42
1.94
1.80
1.45
Hε 2.99
Hδ 1.68
Allyl group
5.95, 5.34, 
5.28, 4.67
 
♦The one letter amino acid code, preceded by sequence number, is used to indicate peptide residues. 
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Table A3. Chemical shift deviations from random coil values (CSD) for PeptideE (D.S. Wishart et al., 
1991). All residues are reported by one-letter code. The CSD value for Allyl-E is not shown. 
 
 
♦The one letter amino acid code, preceded by sequence number, is used to indicate peptide residues. 
 
Table A4. Chemical shift deviations from random coil values (CSD) for PeptideK (D.S. Wishart et al., 
1991). All residues are reported by one-letter code. The CSD value for Allyl-K is not shown. 
 
 
♦The one letter amino acid code, preceded by sequence number, is used to indicate peptide residues. 
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1  Introduction
Currently, intrinsically disordered proteins (IDPs) [1,2] 
receive great attention from the scientific community. 
IDPs are indeed involved in many important physiological 
processes related to signaling and regulation of 
transcription [3], moreover, they take part in several 
human diseases [4,5]. 
IDPs are natively disordered proteins that lack in 
whole or in part a single organized three dimensional 
structure [1,2]. Recent studies indicate that in eukaryotes 
more than a third of the proteins are provided with 
intrinsically disordered regions (IDRs) that are made up 
of at least thirty residues [2]. It is thought that disorder 
is actually encoded in the primary sequence and that 
IDPs are generally enriched in certain types of amino-
acids [2,6]. Detailed studies relying on comparison 
of natively folded and natively unfolded proteins 
demonstrate that IDPs have generally a low content of 
“order-promoting” amino acids such as Ile, Leu, Val, 
Trp, Tyr, Phe, Cys, Asn, whereas, they are considerably 
enriched in “disorder-promoting” residues (i.e., Ala, 
Arg, Gly, Gln, Ser, Glu, Lys and Pro) [1]. Intrinsically 
disordered regions (IDRs) have in common several 
characteristics such as flexibility, β-sheet propensity, 
low average hydrophobicity and high net charge; these 
features are hallmarks of IDPs and have been used to 
develop specific predictors of disorder [1]. 
IDPs can be considered “promiscuous”, as they can 
bind through several interactions, different targets [7]. 
Binding of IDPs to partners may result in formation of 
highly dynamic complexes [8-10] or be accompanied by a 
folding process with a generation of an ordered structure. 
This latter process allows IDPs to gain a particular 
biological function. 
Abstract: In the last few years intrinsically disordered 
proteins (IDPs) have received great attention from the 
scientific community as they participate in several 
important biological processes and diseases. The intrinsic 
disorder and flexibility of IDPs grant them a number of 
advantages with respect to ordered proteins, such as 
conformational plasticity to bind several targets, a large 
interaction surface, involvement in high specificity/low 
affinity interactions, enhanced binding kinetics. It is 
assumed that post-translational modifications such as 
phosphorylation can stimulate structural rearrangement 
in IDPs and facilitate their binding to partners. To 
better understand at a structural level the multifaceted 
mechanisms that govern molecular recognition processes 
involving IDPs, we designed, synthesized by solid phase 
methods, and structurally characterized unstructured 
peptides. These molecules contain a putative disordered 
module, flanked at either the N- or C-terminal ends by a 
different phosphorylated amino acid (serine or threonine) 
to mimick the effects of phosphorylation. The absence 
of an ordered state in the designed peptides was proved 
experimentally by CD and NMR conformational studies 
that were carried out under different solution conditions.
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2.2  Chemicals
All solvents were reagent grade. Nα-Fmoc-protected 
amino acids and activating agents were purchased from 
Inbios (Pozzuoli, Italy), Nα-Fmoc-protected-D-phospho-
Threonine (pt) and Nα-Fmoc-protected-L-phospho-
Serine (pS) from AnaSpec, Inc. (Fremont, CA). Resin for 
peptides synthesis was purchased from Novabiochem 
(Läufelfingen, Switzerland). All other chemicals were 
commercially available from Sigma-Aldrich, Fluka (Buchs, 
Switzerland) or LabScan (Stillorgan, Dublin, Ireland) 
and were used as received, unless otherwise stated. 
HPLC chemicals were purchased from Lab-Scan (Dublin, 
Ireland). 
2.3  Peptide synthesis 
IDP-phosphopeptides and IDP-allyl-glycine (see Table 1) 
were synthesized in batch by using standard solid-phase 
9-fluorenylmethoxycarbonyl (Fmoc) procedures [15] on 
Rink-amide 4-methylbenzhydrylamine (MBHA) resin 
(0.65 mmol g-1, 0.020 mmol scale). Peptide elongation 
was achieved by sequential addition of Fmoc-AA-OH 
using 1-hydroxybenzotriazole (HOBt)/ O-benzotriazole-
tetramethyl-uronium-hexafluoro-phosphate (HBTU)/
diisopropylethylamine (DIPEA) (1/1/2 v/v/v) as coupling 
reagents, in dimethylformamide (DMF) in preactivation 
mode. All couplings were performed for 30 minutes, 
by using an excess of 5 equivalents for the single 
amino acid derivative. Fmoc removal was achieved by 
piperidine/DMF (3:7, v/v) treatment for 10 min. Peptides 
deprotection and cleavage from the solid support were 
achieved by treatment with a trifluoroacetic acid (TFA)/
triisopropylsilane (TIS)/water (95/2.5/2.5, v/v/v) mixture 
for 90 min at room temperature. The crude peptides were 
precipitated at 0 °C with ethyl ether, dissolved in a water/
acetonitrile (1:1, v/v) mixture and lyophilized. Crude 
products were purified by RP-HPLC chromatography. 
Preparative RP-HPLCs were carried out on a LC8 Shimadzu 
HPLC system (Shimadzu Corporation, Kyoto, Japan) 
Interestingly, it has been reported that several 
peptides, such as the CCK8, to interact selectively with 
their receptors require an initial disordered conformation 
[11].
For the coupled “binding-folding” of IDPs a “fly-
casting” mechanism has been proposed that is basically 
responsible for enhanced interaction kinetics [12,13]. In 
contrast to ordered proteins, the large chain flexibility 
in IDPs supplies a bigger capture radii; according to the 
“fly-casting” model, a flexible region, that represents the 
unfolded state, will first interact partially and weakly with 
its target relatively far from the binding site and then, will 
fold while approaching to it [13].
IDPs often contain post-translational modifications 
(PTM), such as phosphorylation, that can stimulate 
structural rearrangements. It is hypothesized that the 
location of PTM sites in proximity of a disordered segment 
may facilitate the binding of the enzyme catalyzing the 
PTM in several targets [1,5].
To get better understanding of the complex machineries 
that govern molecular recognition processes involving 
IDPs, we have undertaken studies of predicted unstructured 
peptides (See Table 1). In major detail, peptide sequences 
enriched in disorder promoting amino acids [1] flanked 
at either the N- or C-terminal end by a phosphorylated 
residue, were designed and synthesized by solid phase 
synthesis methods. In addition, the conformational 
behavior of the following unphosphorylated peptide 
sequence (IDP), NH2-AQIREASSPSLQVDNQSDQTg-CONH2 
(g=Allyl-glycine), was also investigated. The absence of 
one single ordered conformation in these peptides was 
established experimentally by CD and NMR analyses that 
were conducted under different solution conditions (i.e.: 
aqueous buffer, water/trifluoroethanol (TFE) mixtures, 
dimethylsulfoxide (DMSO)).
These peptides may represent new disordered 
scaffolds which, by preserving most of the advantages 
of IDPs, could eventually take part in several molecular 
recognition processes and exert biological actions.
2  Experimental Procedures
2.1  Disorder prediction
A peptide sequence with a high disorder propensity, i.e. 
a region enriched in “disorder promoting residues” (A, R, 
Q, S, P and E) [1] was designed and checked for disorder 
prediction using the MeDor metaserver (http://www.
vazymolo.org/MeDor/index.html) [14].
Peptide Sequences MW (Da)
IDP1 NH2-AQIREASSPSLQVDNQSDQpt-CONH2 2254.2
IDP2 NH2-ptAQIREASSPSLQVDNQSDQT-CONH2 2355.4
IDP3 NH2-pSAQIREASSPSLQVDNQSDQT-CONH2 2341.4
IDP    NH2-AQIREASSPSLQVDNQSDQTg-CONH2 2270.2
Table 1.  Peptide sequences and their molecular weight.
pt=D-phospho-Threonine; pS=L-phospho-Serine, g=Allyl-glycine
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equipped with an UV lambda-Max Model 481 detector, by 
using a Phenomenex (Torrance, CA) -C18 Jupiter column 
(90 Å; 10 mm) and by using as elution solvents  0.1% 
TFA in water (a) and 0.1% TFA in acetonitrile (b) from 5 
to 70% over 30 min (flow rate: 20 mL/min). Peptides 
purity and integrity were assessed by analytical LC–MS 
analysis with a Finnigan Surveyor MSQ single quadrupole 
electrospray ionization spectrometer (Finnigan/ Thermo 
Electron Corporation San Jose, CA), by eluting with 0.1% 
TFA in water (a) and 0.1% TFA in acetonitrile (b) from 5 
to 70% over 15 min (0.8 mL/min). Characterization was 
conducted under standard conditions of peptide analysis. 
The expected and experimental mass of our peptides are 
the following: M.W. IDP1=2254.2 Da and [M+2H+]/2=1128.1 
m/z; M.W. IDP2=2355.4 Da and [M+2H+]/2=1178.7 m/z; M.W. 
IDP3=2341.4 Da and [M+2H+]/2=1171.7 m/z; M.W. IDP= 
2270.2 Da and [M+2H+]/2= 1135.1 m/z.
2.4  Circular dichroism measurements
Far-UV CD spectra of IDP1 were recorded from 190 to 260 
nm on a Jasco J-810 spectropolarimeter equipped with 
a NesLab RTE111 thermal controller unit using a 0.1 cm 
quartz cell at 25 °C. Circular dichroism measurements 
were carried out on peptide solutions at 1·10-4 M 
concentration. Solutions were prepared by promptly 
dissolving lyophilized pure peptide powder in net H2O 
at a final pH ~ 5 (the acidic pH was due to the residual 
TFA used during peptide cleavage and purification). CD 
spectra were also recorded for an IDP1 sample dissolved 
in a mixture of water/trifluoroethanol (TFE) (50/50) and of 
water/TFE (25/75). 
Other experimental settings were: scan speed, 10 nm 
min-1; sensitivity, 50 mdeg; time constant, 4 s; bandwidth, 
2 nm. Each spectrum was obtained by averaging three 
scans, subtracting contributions from other species 
in solution and converting the signal to mean residue 
ellipticity in units of deg cm2 dmol-1 res-1.
2.5  Nmr measurements and solution structure 
calculations
NMR analysis was performed for IDP, IDP1, IDP2 and IDP3. 
NMR samples were prepared by dissolving about 0.5 mg 
of each peptide in a solution volume equal to 600 µL. 
NMR analysis of IDP1 was performed in H2O containing 
10% v/v D2O (99.8% d, Armar Scientific, Switzerland) 
and in a mixture H2O/trifluoroethanol-d3 (98% d, Armar 
Chemicals, Switzerland) 17/83 v/v. Solution conformational 
studies of IDP were conducted in H2O/trifluoroethanol-d3 
(98% d, Armar Chemicals, Switzerland) 17/83 v/v. NMR 
characterizations of IDP2 and IDP3 were carried out in 
DMSO-d6 (99.9% d, Armar Chemicals, Switzerland).
NMR spectra were recorded at 25 °C on a Varian 
Unity Inova 600 MHz spectrometer provided with a cold 
probe. The process of proton resonance assignments 
(See Supplemental Tables S1, S2, S3 and S4) was carried 
out with a canonical protocol [16] based on analysis of 
the following two dimensional [1H, 1H] spectra: TOCSY 
(Total Correlation Spectroscopy) (70 ms mixing time) 
[17], DQFCOSY (Double Quantum Filter Correlation 
Spectroscopy) [18], NOESY (Nuclear Overhauser 
Enhancement Spectroscopy) [19] (200 and 300 ms mixing 
times). Chemical shifts were referenced with respect to the 
TSP (Trimethylsilyl-3-propionic acid sodium salt-d4, 99% 
d, Armar Scientific, Switzerland) signal at 0.0 ppm. 
1D spectra were acquired with a relaxation delay of 1s 
and 32-128 scans. 2D experiments were generally acquired 
with 32-64 scans, 128-256 FIDs in t1, 1024 or 2048 data 
points in t2. 
The DPFGSE (Double Pulsed Field Gradient Selective 
Echo) sequence [20] was used to suppress water signal. 
Spectra were processed with the Varian software VNMRJ 
1.1D (Varian by Agilent Technologies, Italy) and analyzed 
with the NEASY [21] program that is included in the 
CARA (Computer Aided Resonance Assignment) software 
package (http://www.nmr.ch/). 
Peptide structure calculations were carried out with 
the software CYANA (version 2.1) [22]. A D-phospho-
Threonine and L-phospho-Serine were introduced in the 
CYANA standard residue library [23]. Distance constraints 
for structure calculations were gained from NOESY 
experiments (300 ms mixing time). The GRIDSEARCH 
module of CYANA was used to generate angular constraints. 
Calculations started from 100 random conformers; the 20 
conformers with the lowest CYANA target functions were 
finally checked with the program MOLMOL [24] and iCing 
(http://proteins.dyndns.org/cing/iCing.html) [25].
3  Results and Discussion
Four intrinsically-disordered peptides (IDP, IDP1, IDP2 
and IDP3; see Table 1) were designed and analyzed. Their 
primary sequences include a predicted disordered region 
(-AQIREASSPSLQVDNQSDQ-) (See also Material and Methods 
for details ) and a phosphorylated amino acid at C-terminus 
(IDP1 with phospho-Threonine) or N-terminus (IDP2 
with phospho-Threonine and IDP3 with phospho-Serine, 
respectively) or an Allyl-glycine at the C-terminus (IDP).
The high disorder propensity of the common 
-AQIREASSPSLQVDNQSDQ- peptide core was evaluated 
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with the MeDor server [14] (Supplemental Figure S1, upper 
panel) while its tendency towards β-aggregation was 
investigated with the software TANGO [26] which indicated 
that its sequence is not inclined to form β-aggregates 
(Supplemental Figure S1, lower panel).
Conformational features of IDP, IDP1, IDP2 and IDP3 
were studied in solution by CD and NMR techniques.
3.1  Circular Dichroism
CD spectra of IDP1 in water and in the water/TFE mixtures 
(50/50 and 25/75 v/v) were recorded between 190 and 260 
nm. IDP2 and IDP3 peptide sequences were not soluble 
under the same experimental conditions. The shape of CD 
spectrum of IDP1 in water, with a negative band between 
197 and 201 nm, suggests an unordered structure (see 
Figure 1A). The addition of TFE induces a conformational 
rearrangement from random coil to β-structure. This 
rearrangement can be better appreciated by difference 
spectra (Figure 1B), which show a pronounced negative 
maximum around 220 nm and a positive maximum around 
200 nm, which are characteristic of β-sheet conformation. 
However, the low structural content gained by the peptide, 
even in TFE, supports its high flexibility. Similar CD 
spectra were also detected for the unphosphorylated IDP 
peptide at different water/TFE ratios (data not shown).
3.2  NMR studies
Detailed NMR studies of IDP, IDP1, IDP2 and IDP3, 
including acquisition and analysis of 1D [1H] and 2D [1H, 
1H] spectra, were conducted at 25°C. 
We first investigated the conformational preferences 
of IDP1 in H2O/D2O (90/10 v/v). Under these experimental 
conditions, the poor spectral dispersion of the 1D [1H] 
spectrum (Figure 2A) and the almost complete absence 
of signal in the 2D [1H, 1H] NOESY experiment indicated 
that IDP1 was very flexible and disordered (Supplemental 
Figure S2A). 
Next we treated IDP1 with TFE that is a useful 
co-solvent to investigate the inherent conformational 
preferences of proteins and peptides [27] and has already 
been used in IDPs studies [28-30]. Since CD data indicated 
a gain of structure in IDP1 only at high TFE concentration, 
we conducted NMR characterization of the peptide in 
presence of 83% TFE.
A gain of ordered structure induced by TFE can 
already be appreciated in the HN region of the 1D proton 
experiment (Figure 2A) where an improvement of the 
spectral dispersion is evident. Nevertheless, many cross-
peaks appear in the 2D [1H, 1H] NOESY spectrum as well 
(Figure 2C) possibly indicating a decrease of flexibility 
in the peptide. The high quality of the spectra, recorded 
in presence of TFE, allowed us to carry out a complete 
structural characterization and obtain proton resonance 
assignments (Figure 2 and Supplemental Table S1). We 
evaluated chemical shift deviations (CSD) of Hα protons 
from random coil values (Supplemental Figure S3) and 
noticed that they did not point to any specific secondary 
structure element. In fact, most of the CSD were low 
(i.e. with absolute values lower that 0.1) and positive 
(positive deviations are generally indicative of extended 
conformations) [31]. Afterwards, we analyzed short and 
medium range NOEs (Figures 3A and S4). For most of IDP1 
Figure 1. Far UV CD spectra of: A) IDP1 at 0, 50 and 75% of TFE and of B) IDP1 at 50% (solid line) and 75% (dash line) of TFE after subtraction 
of IDP1 at 0% TFE.
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Figure 2.  (A) Overlay of 1D proton spectra of IDP1 recorded in H2O/D2O (90/10 v/v) (red) and in H2O/TFE-d3 (17/83 v/v) (blue). (B) 2D [1H, 
1H] TOCSY and (C) 2D [1H, 1H] NOESY 300 spectra of IDP1 acquired in H2O/TFE-d3 (17/83 v/v); the HN/aliphatic protons correlation 
regions of both spectra are shown; spin system assignments are indicated in (B).
primary sequence sequential NOE contacts of the type Hαi-
HNi+1 (indicated as dαN(i, i+1)  in Fig. 3A), Hβi-HNi+1 (dβN(i, i+1)  in 
Fig. 3A) and HNi-HNi+1 (dNN(i, i+1) in Fig. 3A) are predominant 
and not clearly indicative of any ordered conformation [16]. 
Interestingly,  the NOE pattern improves in the segment 
encompassing residues from Ser10 to Gln16, where 
medium range contacts typical of helical structures (i.e. 
dαβ(i, i+3) and dαΝ(i, i+3)) can be observed [16]. The Pro residue is 
mainly in trans configuration as shown by the strong NOE 
cross peak in between the Hα proton of Ser8 and the Hδ 
protons of Pro9, however, a weaker NOE between the Hα 
protons of Ser8 and Pro9 is evident as well and points to 
some proline cis-trans isomerization [16].
Indeed, structural calculations, carried out with 
the software CYANA [22] (See Table 2 and Figure 3), 
demonstrate that the peptide is rather flexible and assumes 
a more ordered pseudo-helical turn only between residues 
Val13 and Gln16 (Figure  3B,C). This small helical/turn 
contribution to the overall IDP1 disordered conformation 
in TFE cannot be appreciated by CD experiments which 
mainly underline the prevalence of extended structures 
(Figure 1). 
The disorder of the peptide is represented by the 
high RMSD values measured for the NMR ensemble 
(Figure 3B and Table 2). In summary, these data, in 
agreement with CD results, indicate that the propensity 
of IDP1 to gain an ordered secondary structure is rather 
low even under strong structuring conditions (i.e. high 
percentage of TFE in solution). For comparison purpose, 
we also carried out similar NMR studies in aqueous 
solution, containing 83% TFE, of the analogue peptide: 
AQIREASSPSLQVDNQSDQTg (where g= Allyl-glycine) 
which lacks a phosphorylated residue (Supplemental 
Figure S5 and Table S2). This peptide exhibits identical 
conformational behavior as IDP1, as indicated by similar 
CD spectrum (data not shown) and NMR parameters 
such as CSD (Supplemental Figure S6) and NOE pattern 
(Supplemental Figure S7). These data likely demonstrate 
that the presence of a phosphate group does not 
dramatically influence the overall conformational 
disorder of our IDP peptides.
Attempts to carry out structural studies of IDP2 and 
IDP3 in water and in water/TFE mixtures were hampered 
by the low solubility of both peptides. Thus, we analyzed 
their structural features in DMSO, a solvent in which it 
was possible to record high quality NMR data (Figures 
4 and 5) and obtain proton resonance assignments 
(Supplemental Tables S3 and S4). In DMSO, IDP2 and 
IDP3 show a very similar conformational behavior. 2D 
[1H, 1H] NOESY spectra of both peptides (Figure 4B and 
5B) contain many cross-peaks and resemble typical 
experiments recorded for rigid folded species. Detailed 
analysis of NOE patterns reveals a clear prevalence 
of sequential contacts, such as Hαi-ΗNi+1, Hβi-HNi+1, 
HNi-HNi+1, (See Figure 4C) that alone are not sufficient 
to indicate any specific ordered secondary structure 
element [16]. However, these kinds of NOEs co-exist with 
several medium range contacts in between side chain 
protons two residues apart in the sequence, and with 
sequential Hα-Hα contacts, the latter are concentrated 
in the peptide region 15-DNQSDQ-20, and are generally 
more characteristic of beta type structures. Moreover, in 
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analogy with the IDP1 peptide, the Pro residue in IDP2 
and IDP3 contributes to the overall disorder. Indeed the 
trans configuration is predominant but some cis-trans 
interconversion is evident as well [16]. Tentative complete 
structure calculations were carried out and demonstrated 
the intrinsic conformational disorder of IDP2 and IDP3 
(See Figure S8). The presence of several types of NOEs 
in the spectra of IDP2 and IDP3 may indeed point to 
the occurrence of either inter-conversion of unfolded 
and partially ordered states or towards aggregation 
processes that lower the flexibility of the two peptides 
in DMSO. It’s worth nothing that many intrinsically 
disordered peptides exhibit high tendency to aggregate, 
and in fact, under physiological conditions, are able to 
form beta fibrils (“amyloids”) [32,33] and play roles in 
pathological processes like Alzheimer’s and Parkinson’s 
diseases [34-36]. Based only on the low computationally 
predicted tendency towards β-aggregation of the peptide 
core -AQIREASSPSLQVDNQSDQ- (Supplemental Figure 
S1, lower panel), this latest scenario appears unlikely 
for IDP2 and IDP3. On the other side, we cannot exclude 
that the addition of a phosphorylated amino acid may 
change the predicted aggregation propensity and/or the 
implemented non physiological conditions may favor 
peptide aggregation.
4  Conclusions
IDPs represent targets in drug discovery for several diseases 
(for example tumor, Parkinson’s disease, Alzheimer’s 
disease, type II diabetes) [5,6,37]. In order to create novel 
and efficient drug discovery strategies for such proteins, 
it is essential to fully unveil distinctive characteristics of 
intrinsically disordered regions. To this aim we designed 
and synthesized three intrinsically disordered peptides, 
made up of a predicted disordered segment flanked at 
either the N- and C-terminal side by a phospho-Serine or 
a phospho-Threonine (See Table  1). We performed NMR 
Figure 3.  (A) NOE intensity pattern for IDP1 in H2O/TFE-d3. Only prin-
cipal short and medium range NOEs are reported. Different 
residues are specified with the one-letter amino acid code; 
“dξζ (b, c)” designates a NOE contact between the Hξ and Hζ 
protons in the b and c residues respectively. (B) Overlay on 
the backbone atoms (residues 12-18, RMSD=0.70 ± 0.33 Å) 
of 20 IDP1 structures. (C) Ribbon representation of the best 
IDP1 CYANA conformer (i.e. the one with the lowest target 
function). The D-phospho-Threonine side chain is reported 
in neon representation. The final CYANA calculation 
included 143 upl (upper distance limits) of which 60 intra-
residue, 73 short- and 10 medium-range.
NOE upper distance limits 143
Angle constraints 88
Residual target function, Å2 0.22±0.07
Residual NOE violations
Number > 0.1 Å# 2
Number 7
Residual angle violations
Number 0
Atomic pairwise RMSD@, Å
Backbone atoms (a.a. 2-19) 2.39±0.54
Heavy atoms (a.a. 2-19) 3.57±0.66
Table 2.  Structure statistics for the IDP1 NMR ensemble calculated 
in H2O/TFE-d3 (17/83 v/v).
# Average CYANA violation; @Calculated by iCing
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non physiological conditions, IDP2 and IDP3 exhibited 
identical conformational behavior, characterized by 
the absence of one single ordered state and probably by 
aggregation phenomena.
As concerning the possible applications of the 
disordered IDP1, IDP2 and IDP3 peptides, we can certainly 
envision their use to generate novel peptide amphiphiles 
(PAs) to be implemented in the field of biomedicine and 
biocompatible materials [11,38-41].
In fact, we have very recently described novel PAs, 
obtained by coupling an intrinsically disordered short 
peptide to different alkyl-chains, that are able to self-
assemble in supramolecular aggregates (i.e., unilamellar 
vesicles and micelles) with a consequent reduction of 
flexibility and a gain of structure with respect to the free 
peptide [41]. 
Moreover, we cannot exclude that our IDP1, IDP2 and 
IDP3 peptides, being provided with characteristic features 
of intrinsically disordered proteins, may take part in 
different protein-protein interaction networks and have a 
particular biological action, but of course deep studies in 
a cellular environment are needed to prove this scenario.
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and CD solution conformational studies. In particular we 
first analyzed the peptide IDP1, that contains a phospho-
Threonine at the C-terminal end. The absence of precise 
secondary structure elements was proved in water 
and water/TFE mixtures. The addition of TFE in high 
percentage only slightly decreases IDP1 conformational 
flexibility thus stressing out the natively disordered 
nature of this peptide. The same conformational trend in 
a solution containing TFE, is exhibited by the analogue 
unphosphorylated IDP peptide (See Table 1); these data 
likely indicate that phosphorylation does not affect 
relevantly the structure of our peptides.
We next analyzed IDP2 and IDP3 whose primary 
sequences differ only in the first N-terminal residue: 
either a phospho-Threonine or a phospho-Serine. 
Solubility issues did not allow us to characterize these 
two peptides in aqueous buffer, we thus investigated 
their conformational preferences in DMSO. Under these 
Figure 4.  Comparison of (A) 2D [1H, 1H] TOCSY and (B) NOESY 300 
spectra of IDP2 recorded in DMSO-d6. The HN correlation 
regions of the spectra are shown. (C) NOE intensity pattern 
for IDP2.
Figure 5.  Expansion of a region of (A) 2D [1H, 1H] TOCSY and (B) 2D 
[1H, 1H] NOESY 300 of  IDP3 where correlations arising from 
HN protons can be observed. Spectra were acquired in 
DMSO-d6. 
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Abstract: This work reports on the design and the synthesis of two short linear peptides 
both containing a few amino acids with disorder propensity and an allylic ester group at the 
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C-terminal end. Their structural properties were firstly analyzed by means of experimental 
techniques in solution such as CD and NMR methods that highlighted peptide flexibility. 
These results were further confirmed by MD simulations that demonstrated the ability of 
the peptides to assume conformational ensembles. They revealed a network of transient 
and dynamic H-bonds and interactions with water molecules. Binding assays with a  
well-known drug-target, i.e., the CXCR4 receptor, were also carried out in an attempt to 
verify their biological function and the possibility to use the assays to develop new specific 
targets for CXCR4. Moreover, our data indicate that these peptides represent useful tools 
for molecular recognition processes in which a flexible conformation is required in order to 
obtain an interaction with a specific target. 
Keywords: intrinsically disordered protein (IDP); intrinsically disordered region (IDR); 
conformational ensemble; MD; NMR; CD; chemokine 
 
1. Introduction 
In the last decade, several proteins with native disordered structure—named Intrinsically Disordered 
Proteins (IDPs)—were reported to be involved in numerous key biological processes, including cell 
cycle control, regulation, signaling and binding events involving biological macromolecules [1–5]. 
Intrinsic disorder depends on the type of amino acids composing a certain protein [6–8]. The structural 
plasticity of proteins is mainly induced by the presence of residues inherently flexible, polar and 
charged. Through inherent flexibility, the mentioned residues have the ability to recognize different 
ligands, including other proteins, membranes, and nucleic acids [8]. Further studies have also shown 
that a flexible intrinsically disordered region (IDR) in a given protein can fold in several ways as a 
consequence of its binding to distinct partners. Moreover, the residue flexibility may also allow 
different protein sequences to recognize the same binding site on a specific partner [9]. Often, IDPs or 
IDRs are critically involved in receptor signaling, where they modulate the native and functional state 
of many proteins [10]. However, there is a limit to the understanding of the molecular mechanisms that 
regulate biological functions in which IDPs are involved: there is a lack of knowledge about the 
physical basis on which these processes rely [11]. Recently, authors have demonstrated that each IDP 
dynamically explores an ensemble of unfolded configurations, then each IDP assumes more stable and 
ordered structures after binding to their ligands is complete [12,13]. Molecular dynamics (MD) 
simulations can provide useful information about these issues in the spatio-temporal resolution. In fact, 
the flexibility of a protein can be derived from the trajectory of a MD simulation by calculating the 
root mean-squared fluctuations (RMSFs) of single atoms after removing the translational and 
rotational movements. Vibrations around equilibrium are not random but depend on local structure 
flexibility. Hence, RMSFs capture the fluctuation of each atom around average positions. Usually, the 
analysis of the average atomic mobility of backbone atoms (N, Cα and C atoms) during MD simulation 
gives insight into the flexible and rigid regions of proteins [14]. 
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In this paper we designed short peptides as IDRs model systems in order to better understand 
molecular recognition processes involving IDPs. In particular, we focused on the two following 
synthetic linear peptides: PepK: Y-G-E-C-P-C-K-OAllyl; PepE: Y-G-E-C-P-C-E-OAllyl. 
Both these peptides were designed by choosing a few residues with disorder propensity. At the  
C-termini of PepK and PepE a Lys and Glu residues were added, respectively, aiming to study the 
effect of charges in modulating the binding properties on a general target. The reactive allylic ester group 
was added to easily allow further chemical modifications finalized to improve biological activities. 
The conformational behavior of the two peptides was firstly analyzed by CD (Circular Dichroism) 
and 1D [1H] and 2D [1H, 1H] NMR (Nuclear Magnetic Resonance) spectroscopies in order to establish 
their high flexibility and their inability to adopt a single ordered conformation. In addition, MD simulations 
indicated that the two peptides could be adequately represented by conformational ensembles. 
In an attempt to define a biological significance for the above mentioned peptides, we have 
investigated their role as interactors of a known drug-target, i.e., the CXCR4 receptor. Its 
overexpression results in metastatic dissemination of breast cancer cells to the lungs and lymph nodes 
and they contribute to melanoma tumor cell dissemination selectively to the lungs but not to the  
lymph nodes [15,16]. Moreover, CXCR4 has also been found to be a prognostic marker in multiple 
cancers including melanoma, colon cancer, leukemia, breast cancer, and gliomas [15,16]. Therefore, as 
CXCR4 is overexpressed in several human cancers, the blockade of CXCR4–CXCL12 interaction has 
been extensively investigated as a potential cancer therapeutic. Recently, we designed and synthesized 
two short flexible peptides, they both possess a CPC motif. Then we analyzed their structure by means 
of experimental and computational methods. Finally, we evaluated their interaction with CXCR4 by 
means of in vitro studies at 1 and 10 µM concentrations [15]. 
Hence, in this work we carried out biological tests to evaluate if PepE and PepK were able to:  
(i) interact with the CXCR4 receptor; (ii) inhibit CXCL12-induced migration; and (iii) reduce cAMP 
(Cyclic Adenosine Monophosphate) levels. Our data pointed out that PepE and PepK target the 
CXCR4 receptor by modulating the adenylate cyclase and they represent the starting point to design 
useful “instruments” for molecular recognition processes in which a flexible conformation is needed 
for the interaction with a specific target. 
2. Results and Discussion 
The two linear intrinsically disordered peptides PepK and PepE have been designed choosing a few 
amino acids with disorder propensity. A Lys residue has been added at C-terminal side of PepK and a 
Glu residue has been added at the C-terminal side of PepE. The conformational features of both 
peptides were studied in solution by CD, NMR and MD techniques. 
2.1. Circular Dichroism 
The secondary structure of PepE and PepK in PBS was studied by circular dichroism (CD) 
spectroscopy and analyzed by the CAPITO web server (http://capito.nmr.fli-leibniz.de). As expected 
for very short peptide sequences, both peptides did not show any tendency to fold under this 
experimental condition [17]. CD spectra (Figure 1) show a typical shape of an unordered structure with 
a negative band between 197 and 201 nm. This behavior is also confirmed by CAPITO analysis [18], 
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where spectra values—such as mean residue ellipticity (θ)—at λ = 200 nm are plotted versus  
λ = 222 nm. In fact, both the peptides are located in unfolded regions. It is important to notice that the 
CD spectrum of PepK presents also a maximum centered at 225 nm that has been already associated to 
the presence of fluctuating Polyproline II (PII) helices by various authors in recent papers [13,19,20]. 
 
Figure 1. CD spectra of PepK and PepE (upper panel) and CD analysis by CAPITO tool 
(lower panel) where both peptides are indicated as unfolded peptides. 
2.2. NMR Characterization 
In aqueous solution, the poor spectral dispersion of the 1D [1H] spectra and the almost complete 
absence of signal in the 2D [1H, 1H] NOESY [21] experiments indicated that both peptides were very 
flexible (data not shown). However, complete proton resonance assignments were achieved by 
combined analysis of the 2D [1H, 1H] TOCSY [22] and ROESY [23] spectra (Figures 2 and 3;  
Tables S1 and S2). 
Moreover, we evaluated chemical shifts deviations of Hα protons from random coil values  
(Tables S3 and S4), which resulted in prevalence small and positive and characteristic of an extended 
disordered conformation [24]. The disorder state of both peptides was further strengthened by ROE 
patterns (Figure S1) which showed strong and sequential Hαi–HNi+1 contacts typical of flexible 
peptides [25]. Due to the proximity of chemical shifts between Cys4 Hα proton and water in both PepE 
and PepK, we could not clearly identify the configuration (i.e., cis or trans) of the Cys4–Pro5  
peptide bond. 
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Figure 2. Comparison of 2D [1H, 1H] TOCSY (left) and ROESY (right) spectra of PepE 
in H2O/D2O (90/10). The HN-aliphatic protons correlation regions are shown in each panel; 
spin system assignments are indicated in the left side. In the right panel, sequential ROE 
contacts are highlighted by rectangles and the corresponding assignments are indicated. 
 
Figure 3. Comparison of 2D [1H, 1H] TOCSY (left) and ROESY 200 (right) spectra of 
PepK in H2O/D2O (90/10). The two sides of the figure show spectral regions containing 
HN/aliphatic protons correlations; spin system assignments are indicated in the TOCSY left 
panel. In the right panel, sequential ROE contacts are shown. 
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2.3. Molecular Dynamics Simulations on the Two Peptides 
Molecular dynamics simulations were performed on the two peptides, which were linearly modeled 
as reported in the Material and Methods Section, at neutral pH. In Figure 4A, we show the plots of  
the Root Mean Square Deviation (RMSD), computed by overlapping the various structures during 
simulations in respect to the initial conformation. RMSD plots of PepK and PepE evidence high levels 
of fluctuation, thus suggesting that these peptides are flexible. On the one hand, this result is confirmed 
also by Root Mean Square Fluctuation (RMSF) plots where the residues located at N- and C-termini 
present higher values of RMSF (Figure 4B). Instead, the gyration radii decreased during the simulations 
(Figure 4C) reaching a value of 0.5 nm. This suggests an increasing compactness of the two peptides, 
which result as if they were stabilized by a certain number of H-bonds of main chain–main chain 
(MM), main chain–side chain (MS) and side chain–side chain (SS) types (Figure 4D). For this reason, 
the two peptides tended to become more compact and the radius of gyration decreased. According to 
the data obtained by CD and NMR measurements in aqueous solution, the analysis of the secondary 
structure evolution clearly showed the high flexibility of both peptides during the simulations, which 
makes difficult the formation of stable regular secondary structure elements, i.e., helix and β-strand. 
Very flexible peptide structure are normally characterized by several conformers at equilibrium, hence 
they could be well described by a conformational ensemble. Having taken this property into proper 
account, we have firstly performed a cluster analysis to determine the groups of structures that share 
similar conformational features according to their RMSD values. 
 
Figure 4. Analysis of the molecular dynamics simulations performed on PepE (in black) 
and PepK (in grey) at physiological pH in explicit solvent in terms of: (A) root mean 
square deviation (RMSD) plot; (B) root mean square fluctuation (RMSF); (C) gyration 
radius plot; and (D) H-bonds plot. 
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The number of the most populated clusters resulted as equal to 8 for PepE and 9 for PepK. These 
clusters are mainly stabilized by MM H-bonds (Figure 5) that involved the atomic groups of the 
peptide backbone. This structural organization was observed by Pappu et al. [26] for charged peptides: 
it closely resembles the organization of collapsed and slightly soluble globules. 
Since CD spectra of PepK pointed out the presence of PII, we verified its possible occurrence in the 
most populated clusters by using the angular ranges following reference parameters for the angles: 
−110° ≤ φ ≤ −40° and 130° ≤ ψ ≤ 180° in the Ramachandran map [27]. No residues in PII were present 
in eight clusters of PepE whereas in 5 out of 9 clusters of PepK we identified residues in PII (Figure S2), 
according to CD analysis. 
It is well known that the peptide dynamics depend on the surrounding solvent, which mediates 
interactions among residues. Therefore, we have analyzed the total number of water molecules in the 
system and their possible role [28]: the simulation box for PepE and PepK contained 2956 and 2611 
water molecules, respectively. The total average number of water molecules that formed H-bonds 
resulted slightly higher for PepE if compared to PepK: 33 and 30 in PepE and PepK, respectively. This 
trend could be due to the different amino acid sequence of the two peptides; in fact PepK has got two 
oppositely charged residues in 3 and 7 positions, hence it may assume a more compact structure. The 
majority of H-bonds (indicatively 60%) for both peptides resulted to involve the peptide backbone, 
being of main chain—water oxygen type (MH) or of the water oxygen and main chain type (HM).  
A detailed analysis of the residues involved in H-bonds with water molecules pointed out that the 
residues in positions 1, 3 and 7 (Y, E and E in PepE and Y, E and K in PepK) have developed a higher 
number of H-bonds with water molecules than the residues located in the other four positions (Table S5). 
Furthermore, the average number of H-bonds developed by E and K with water molecules was lower 
than the average number of the H-bonds developed by E and E with water molecules in PepE. Hence, 
these results confirmed that PepE tended to assume more extended conformations being that it contains 
two negatively charged residues that could allow large interactions with water molecules. 
Generally, the data evidence that the structure of both peptides is very flexible, and can be 
dynamically stabilized by a network of MM H-bonds. Hence, their structures can be adequately 
represented as conformational ensembles characterized by fluctuating irregular secondary structures. In 
fact, the peptides do not assume stable and fixed conformations: they go continuously from one cluster 
to another. As the high flexibility of peptides did not allow us to calculate a 3D model based on NMR 
parameters, the MD was very useful to understand how these peptides can move as well as to 
understand that the best conformers needed to be put together to have a clear representation. In 
particular, the two peptides do not explore the full space, but rather, the rapid interchange among the 
flexible conformers induce quick changes between clusters. This is in line with the data shown in 
Figure 4B where it is visible that the more flexible residues are located in the terminal ends. 
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(A) 
 
(B) 
Figure 5. The map of MM H-bonds in the 8 and 9 clusters calculated for the PepE (A) and 
PepK (B), respectively, during MD simulations. We reported with the same colors the 
residues involved in the same MM H-bonds. 
2.4. Functional Characterization on CXCR4 Receptor 
We have designed a short disordered peptide the containing CPC motif and we have analyzed  
its binding capability on the CXCR4 receptor finding a behavior as ligand [15]. Hence, we performed 
PepK and PepE functional characterization on the same chemokine receptor. In order to assess the 
inhibitory capability of PepK and PepE on CXCR4 function, we have evaluated peptides binding to  
the receptor through an indirect binding assay; then, in addition we have assessed the inhibition of 
CXCL12-induced migration and evaluated the activity of the adenylate cyclase function. The results 
were compared to Plerixafor (known as AMD3100) that is used as a clinical antagonist of CXCR4. 
The treatment with plerixafor plus Granulocyte-colony stimulating factor (G-CSF) induced the 
mobilization of hematopoietic precursors from bone marrow, allowing a more efficient recovery of the 
CD34 stem cells necessary for autologous stem cell transplantation [29]. 
The binding of the two peptides to CXCR4 was evaluated in CCRF-CEM cells using a CXCR4 
12G5 monoclonal antibody as previously described [30]. PepK and PepE were evaluated at concentrations 
similar to the peptidic antagonists recently developed [16,30]. Indeed, we have tested only two peptide 
concentrations (1 and 10 µM), which are matching the ones previously used in CXCR4 binding assays. 
As shown in Figure S3, PepK and PepE did not displace the 12G5 antibody compared to AMD3100, 
which strongly reduced antibody binding to CXCR4 (Figure S3). These results may be explained 
considering the different binding sites on AMD3100/12G5 antibody and the high flexibility of the two 
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disordered peptides. Moreover, cAMP and migration assays were carried out as well in order to 
evaluate the peptide ability to inhibit the activation of CXCR4 mediated intracellular pathways. 
CXCR4 is a G-Protein coupled receptor, which, as result of the binding to CXCL12, inhibits 
through the G-protein the adenylate cyclase activity and the inhibition of cAMP production as “second 
messenger” [31]. In Figure S4, preliminary biological results are summarized. The results underline 
that in the presence of CXCL12 (100 ng/mL) and Forskolin (1 µM): (i) PepE determines a dose 
dependent increase of the cAMP level of 20% at the lower dose (1 μM) and 65% at the higher dose  
(10 μM); (ii) PepK increases cAMP but the effect is not dose-dependent; and (iii) AMD3100 has 
activities comparable or even less efficient than PepE. Hence, PepK and PepE result to modulate the 
adenylate cyclase at equal or higher levels as AMD3100. 
Finally, the migration was performed (Figure S5) and, both PepK and PepE reduced CCRF-CEM 
cells migration towards CXCL12 although less effectively than AMD3100. In particular, PepE reduces 
the migration index from 1.75- to 1.35-fold and PepK from 1.75- to 1.55-fold, whereas AMD3100 
from 1.75- to 1.15-fold. 
3. Experimental Section 
Protected fluorenylmethoxycarbonyl (Fmoc)Nα-Fmoc-amino acid derivatives, 2-chlorotrityl chloride 
resin pre-loaded with Fmoc-Glu-OAllyl and Fmoc-Lys-OAllyl and coupling reagents were purchased 
from Novabiochem (Schwalbach, Germany) and Iris Biotech GMBH (Marktredwitz, Germany). All 
other chemicals were commercially available by Sigma–Aldrich (Milwaukee, WI, USA) and Acros 
(Geel, Belgium). The purity of products was determined by analytic reverse-phase HPLC using a 
VWR Hitachi instrument (Radnor, PA, USA) equipped with a L-2450 auto sampler, two L-2130 
pumps, a Satisfaction RP18-AE column (5 μm, 250 × 4.6 mm) and a L-2450 diode array detector, at  
a flow rate of 0.8 mL/min. 
The compounds were purified by preparative reverse-phase HPLC using a VWR LaPrep system 
consisted of a P202 injector, two P110 pumps, a Satisfaction RP18-AB C18 column (5 μm, 250 × 20 mm) 
and a P314 UV detector, at a flow rate of 10 mL/min. 
The following eluents were used in a gradient mode: (A) 0.1% trifluoroacetic acid (TFA) in 
H2O/CH3CN (95/5) and (B) 0.1% TFA in CH3CN/H2O (95/5). Water was of Milli-Q quality and was 
obtained after filtration of distilled water through a Milli-Q® cartridge system (Millipore Co., Billerica, 
MA, USA). CH3CN and TFA were of HPLC use quality. Degassing of solvents was performed using 
argon bubbling. Gradient used for the analytic and preparative RP-HPLC was respectively from  
0% B to 100% B in 15 min and from 0% to 70% B in 70 min; UV detection at 214 nm. CH3CN was 
evaporated and the aqueous solution was freeze-dried to give purified PepK and PepE as white solids 
(68% and 54% yield, respectively). 
Peptide identity was confirmed by mass spectrometry analyses performed on an Ultraflex III 
TOF/TOF system (Bruker Daltonics, Bremen, Germany), equipped with 200 Hz smart beam laser  
(355 nm) and operating in reflectron positive ion mode. Mass spectra were acquired over the m/z range 
450–5000 by accumulating data from 1000 laser shots for each spectrum. The instrumental conditions 
employed to analyze molecular species were the following: ion source 1: 25.08 kV; ion source 2: 21.98 kV, 
lens: 11.03 kV, pulsed ion extraction: 30 ns, reflector: 26.39 kV, reflector 2: 13.79 kV. Matrix 
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suppression was activated by deflection mode: suppression up to 450 Da. Mass calibration was 
performed for each samples in range of ~700–3200 Da with a peptide calibration mixture (8206195, 
Peptide Calibration Standard, Bruker Daltonics). The instrument was controlled using Bruker’s 
flexControl 3.4 software and mass spectra were analyzed in Bruker’s FlexAnalysis 3.4 software. 
3.1. Synthesis 
PepK (sequence: YGECPCK-OAllyl) and PepE (sequence: YGECPCK-OAllyl) were synthesized 
by Fmoc standard chemistry protocol on 2-chlorotrityl chloride resin pre-loaded with the side chain of 
a Fmoc-Lys-OAllyl and a Fmoc-Glu-OAllyl, respectively (0.24 mmol scale). 
Swelling and Fmoc-deprotection: Swelling and Fmoc-deprotection steps were performed by treating 
the resin for 30 min in dichlorometane (DCM) and in dimethylformamide (DMF)/Piperidine (Pip) 
(80/20, v/v) solution, respectively. 
Washing: Washing steps after coupling and deprotection steps were performed by treating resin in 
DMF (3 × 1 min), MeOH (1 × 1 min), and DCM (3 × 1 min), successively. 
Amino acid coupling: The resin was immersed and mixed in a DMF solution containing the  
Fmoc-protected amino acid (3 eq), O-benzotriazole-tetramethyl-uronium-hexafluoro-phosphate (HBTU) 
(3 eq), and diisopropylethylamine (DIEA) (6 eq) for 2 h at room temperature. 
Peptide cleavage: The peptide was cleaved by immersing the resin in TFA/H2O/triisopropylsilane 
(TIS) (30 mL, 95/2.5/2.5, v/v/v) for 3 h. The cleavage cocktail was filtered from the resin, peptides 
were precipitated with ice-cold diethyl ether, centrifuged, and decanted. Precipitation, centrifugation, 
and decantation operations were repeated twice. The resulting white solid was dissolved in water  
(10 mL) and freeze-dried to give a white powder that was analyzed for purity and purified by 
preparative RP-HPLC, using the specified conditions. 
3.2. Circular Dichroism Measurement 
Far-UV CD spectra were recorded from 190 to 260 nm on a Jasco J-810 spectropolarimeter 
(JASCO Inc., Easton, MD, USA) equipped with a NesLab RTE111 thermal controller unit using  
a 1 mm quartz cell at 25 °C. Circular dichroism measurements were carried out on lyophilized  
peptides dissolved in 10 mM phosphate buffer at pH 7.4 M at a peptide concentration of 5 × 10−6 M. 
Other experimental settings were: scan speed, 10 nm·min−1; sensitivity, 50 mdeg; time constant,  
16 s; bandwidth, 1 nm. Each spectrum was obtained averaging three scans, and by subtracting 
contributions from other species in solution and converting the signal to mean residue ellipticity in 
units of deg·cm2·dmol−1·res−1. 
3.3. NMR Analysis 
NMR spectra were recorded at 25 °C on a Varian Unity Inova 600 MHz spectrometer (Varian Inc., 
Palo Alto, CA, USA) provided with a cold probe. The process of proton resonance assignments was 
carried out with a canonical protocol [25] based on analysis of the following two dimensional [1H, 1H] 
spectra: TOCSY (Total Correlation Spectroscopy) (70 ms mixing time) [22], DQFCOSY (Double 
Quantum Filter Correlation Spectroscopy) [32], NOESY (Nuclear Overhauser Enhancement 
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Spectroscopy) [21] (300 ms mixing time) and ROESY (Rotating frame Overhauser Enhancement 
Spectroscopy) [23] (200 ms mixing time). Chemical shifts were referenced with respect to the TSP 
(trimethylsilyl-3-propionic acid sodium salt-d4, 99% d, (Armar Scientific, Döttingen, Switzerland) 
signal at 0.0 ppm. 
1D spectra were acquired with a relaxation delay of 1 s and 32–128 scans. 2D experiments were 
generally acquired with 32–64 scans, 128–256 FIDs in t1, 1024 or 2048 data points in t2. The DPFGSE 
(Double Pulsed Field Gradient Selective Echo) sequence [33] was used to suppress water signal. 
Spectra were processed with the Varian software VNMRJ 1.1D (Varian by Agilent Technologies, 
Milan, Italy) and analyzed with the NEASY [34] program that is included in the CARA (Computer 
Aided Resonance Assignment) software package (http://www.nmr.ch/). 
3.4. Molecular Modeling and Dynamics Simulations 
PepK and PepE have been built by using the Builder module in InsightII and then subjected to 
molecular dynamics (MD) simulations performed with the GROMACS software package (v3.3.1) [35]. 
In detail, each peptide was put in a cubic box filled with SPC216 water molecules, and GROMOS43a1 
was selected as force field because it is commonly used as force field for MD simulations on peptides 
and our group has already used it in other previous papers in which we reported some conformational 
studies on different peptides where the results obtained from MD simulations proved to be in excellent 
agreement with CD and/or NMR studies [13,15,16]. In order to optimize the systems, the peptides 
were previously subjected to energy minimization and position restraints cycles. The simulations were 
carried out with periodic boundary conditions by adding chloride ions so that the net electrostatic 
charge of the system was zero. The bond lengths were constrained by the linear constraint solver 
algorithm. Particle mesh Ewald algorithm was used for the electrostatic interactions with a cutoff of 
0.9 nm, according to our recent papers [13,15,36]. All simulations were run for 20 ns at neutral pH and 
room temperature (300 K) coupling to the system an external bath. GROMACS routines RMSD and 
RMSF, gyration radius, number of H-bonds and secondary structure evolution were utilized to check 
the trajectories and the quality of the simulations. Additionally, on the basis of the distances between 
structures, like RMSD values, we founded a set of clusters that reflects the range of conformations 
accessible and the relative weight of each of these by using a clustering algorithm implemented in 
GROMACS as reported also in our recent papers [13,16]. The presence of putative H-bonds between 
the residues and with water molecules was evaluated by Hbplus [37]. 
3.5. Migration Assay 
CCRF-CEM cells migration was assayed in 24-well Transwell chambers (Corning Inc., Corning, 
NY, USA) using inserts with an 8-μm pore membrane. Membranes were precoated with collagen 
(human collagen type I/III) and fibronectin (20 mg/mL each). CCRF-CEM cells were placed in the 
upper chamber (1 × 105 cells/well) in RPMI containing 1% BSA (migration media). Cells were  
pre-incubated for 45 min with CXCR4 antagonist and allowed to migrate toward 100 ng/mL CXCL12 
in the lower chamber. After 16 h incubation, migrated cells were collected from the lower chamber and 
counted. The migration index was defined as the ratio between migrating cells in the experimental 
group and migrated cells in the control group. 
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3.6. Binding Assay 
PepK and PepE binding to CXCR4 was evaluatedas previously described [30]. Briefly 2.5 × 105 
CCRF–CEM cells were pre-incubated with 10 μM antagonist peptides in binding buffer (PBS 1× plus 
0.2% BSA and 0.1% NaN3) for 1 h at 37 °C, 5% CO2 and then labeled for 45 min with anti-CXCR4 
PE-antibody (FAB170P, clone 12G5, R&D Systems, Minneapolis, MN, USA). Cells were washed in 
PBS and analyzed by FACS Canto II cytofluorimeter (Becton Dickinson Immunocytometry Systems, 
Mountain View, CA, USA). 
3.7. cAMP Assay 
CCRF-CEM cells (1 × 106) were incubated in presence of PepK, PepE or Plerixafor (known as 
AMD3100) being a CXCR4 antagonist that has provided proof of concept for inhibition of the 
pathway [31] at different concentrations (1 and 10 μM) in combination with forskolin (F) (1 μM) for 
20 min, followed by stimulation with CXCL12 (100 ng/mL) for 10 min. Controls include cells 
stimulated with CXCL12 and forskolin or forskolin alone in absence of anti-CXCR4 inhibitors. Cells are 
harvested and lysed with 0.1 M HCl and cAMP levels was assayed using a direct competitive enzyme 
immunoassay (BioVision Incorporated, Milpitas, CA, USA) according to manufacture instructions. 
4. Conclusions 
As CXCR4 is overexpressed in several human cancers, the blockade of CXCR4–CXCL12 
interaction represents from many years an interesting drug-target [15]. Moreover, the plerixafor 
(previously known as AMD3100) is the most clinically advanced compound even if it showed 
cardiotoxicity, as reported in its clinical trial against HIV [38]. Therefore, this suggests the need to 
develop new antagonists able to block, without any other compliance, the binding between CXCL12 
and CXCR4. In this work we have described the structural preferences in solution of two synthetic 
linear peptides containing a few amino acids with disorder propensity, and an allylic ester group at the 
C-terminal end. NMR and CD solution studies, revealed the absence of regular secondary structure 
elements thus confirming the natively disordered nature of these peptides. MD simulations evidenced 
that, even if they are flexible, they are stabilized by a network of transient and dynamic intra-molecular 
H-bonds of MM type and by interactions with water molecules. In details, NMR and computational 
studies showed the flexibility of PepE and PepK, their inability to adopt a single ordered conformation 
and, hence, the need to represent them by conformational ensembles characterized by the presence of 
transient and dynamic MM H-bonds. 
Moreover, we have performed a functional characterization of the two peptides by investigating  
(a) their ability to interact with the CXCR4 receptor; (b) the inhibition of CXCL12-induced migration 
and (c) the reduction of cAMP levels. Generally, we pointed out that PepK and PepE result to modulate 
the adenylate cyclase as much or more as AMD3100, i.e., the best characterized CXCR4 inhibitor. 
These results indicate that the short flexible peptides could efficiently target the CXCR4 receptor. 
This preliminary evidence suggests that the PepK and PepE interact with CXCR4 and they 
represent a potential starting system able to be converted to more efficient in vitro and in vivo 
antagonists of CXCR4. 
 
Int. J. Mol. Sci. 2015, 16 12171 
 
Supplementary Materials 
Supplementary materials are available at http://www.mdpi.com/1422-0067/16/06/12159/s1. 
Acknowledgments 
Marian Vincenzi thanks the Università Italo Francese (UIF) for financial support, project C2-1, 
2014/38723, cap. 6.01.1810 UIF. Luisa Ronga and Jean Guillon thank the “Plateforme Protéome” of 
the University of Bordeaux for the access to the Ultraflex III TOF/TOF mass spectrometer and the precious 
advice in using it. The authors thank Leopoldo Zona and Luca De Luca for technical assistance. 
Author Contributions 
Marian Vincenzi and Marilisa Leone carried out NMR experiments and participated in writing the 
manuscript. Luisa Ronga and Jean Guillon performed peptide synthesis, purification and chemical 
physical characterization of linear peptides. Diego Tesauro and Antonella Accardo recorded and 
analyzed CD spectra. Susan Costantini and Giovanni Colonna performed MD analysis and contributed 
to write the paper. Stefania Scala, Luigi Portella and Anna Maria Trotta performed the biological test. 
Filomena Rossi and Luisa Ronga designed the research and wrote the paper. All authors have read and 
approved the final manuscript. 
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Habchi, J.; Tompa, P.; Longhi, S.; Uversky, V.N. Introducing protein intrinsic disorder. Chem. Rev. 
2014, 114, 6561–6588. 
2. He, B.; Wang, K.; Liu, Y.; Xue, B.; Uversky, V.N.; Dunker, A.K. Predicting intrinsic disorder in 
proteins: An overview. Cell Res. 2009, 19, 929–949. 
3. Motlagh, H.N.; Wrabl, J.O.; Li, J.; Hilsen, V.J. The ensemble nature of allostery. Nature 2014, 
508, 331–338. 
4. Wright, P.E.; Dyson, H.J. Intrinsically unstructured proteins: Re-assessing the protein  
structure-function paradigm. J. Mol. Biol. 1999, 293, 321–331. 
5. Iakoucheva, L.M.; Brown, C.J.; Lawson, J.D.; Obradovic, Z.; Dunker, A.K. Intrinsicdisorder in 
cell-signaling and cancer-associated proteins. J. Mol. Biol. 2002, 323, 573–584. 
6. Schweitzer-Stenner, R. Conformational propensities and residual structures in unfolded peptides 
and proteins. Mol. BioSyst. 2012, 8, 122–133. 
7. Uversky, V.N. Intrinsically disordered protein from A to Z. Int. J. Biochem. Cell Biol. 2011, 43, 
1090–1103. 
8. Leone, M.; Mercurio, F.A.; Vincenzi, M.; Accardo, A.; Ringhieri, P.; Tesauro, D.; Carrière, F.; 
Rossi, F. Conformational disorder in phosphopeptides: Solution studies by CD and NMR 
techniques. Peptidomics 2014, 1, 14–21. 
 
Int. J. Mol. Sci. 2015, 16 12172 
 
9. Miller, M. The importance of being flexible: The case of basic region leucine zipper transcriptional 
regulators. Curr. Protein Pept. Sci. 2009, 10, 244–269. 
10. Sigalov, A.B.; Uversky, V.N. Differential occurrence of protein intrinsic disorder in the 
cytoplasmic signaling domains of cell receptors. Self Nonself 2011, 2, 55–72. 
11. Costantini, S.; Sharma, A.; Raucci, R.; Costantini, M.; Autiero, I.; Colonna, G. Genealogy of an 
ancient protein family: The Sirtuins, a family of disordered members. BMC Evol. Biol. 2013, 13, 
60–80. 
12. Raucci, R.; Colonna, G.; Giovane, A.; Castello, G.; Costantini, S. N-terminal region of human 
chemokine receptor CXCR3: Structural analysis of CXCR3(1–48) by experimental and computational 
studies. Biochim. Biophys. Acta 2014, 1844, 1868–1880. 
13. Mittal, J.; HyeonYoo, T.; Georgiou, G.; Truskett, T.T. Structural ensemble of an intrinsically 
disordered polypeptide. J. Phys. Chem. B 2013, 117, 118–124. 
14. Chen, S.; Gao, S.; Cheng, D.; Huang, J. The characterization and comparison of amyloidogenic 
segments and non-amyloidogenic segments shed light on amyloid formation. Biochem. Biophys. 
Res. Commun. 2014, 447, 255–262. 
15. Costantini, S.; Raucci. R.; Colonna, G.; Mercurio, F.A.; Trotta, A.M.; Ringhieri, P.; Leone, M.; 
Rossi, F.; Pellegrino, C.; Castello, G.; et al. Peptides targeting chemokine receptor CXCR4: 
Structural behavior and biological binding studies. J. Pept. Sci. 2014, 20, 270–278. 
16. Palladino, P.; Portella, L.; Colonna, G.; Raucci, R.; Saviano, G.; Rossi, F.; Napolitano, M.;  
Scala, S.; Castello, G.; Costantini, S. The N-terminal region of CXCL11 as structural template  
for CXCR3 molecular recognition: Synthesis, conformational analysis, and binding studies.  
Chem. Biol. Drug Des. 2012, 80, 254–265. 
17. Underfriend, S.; Meienhofer, J. In The Peptides; Hruby, V.J., Ed.; Academic Press: New York, 
NY, USA, 1985; Volume 7. 
18. Wiedemann, C.I.; Bellstedt, P.; Görlach, M. CAPITO-a web server-based analysis and plotting 
tool for circular dichroism data. Bioinformatics 2013, 29, 1750–1757. 
19. Sreerama, N.; Woody, R.W. Poly(Pro)II helices in globular proteins: Identification and circular 
dichroic analysis. Biochemistry 1994, 33, 10022–10025. 
20. Bhatnagar, R.S.; Gough, C.A. Circular Dichroism and the Conformational Analysis of Biomolecules; 
Plenum Press: New York, NY, USA, 1996. 
21. Kumar, A.; Ernst, R.R.; Wuthrich, K. A two-dimensional nuclear Overhauser enhancement (2D NOE) 
experiment for the elucidation of complete proton-proton cross-relaxation networks in biological 
macromolecules. Biochem. Biophys. Res. Commun. 1980, 95, 1–6. 
22. Griesinger, C.; Otting, G.; Wüthrich, K.; Ernst, R.R. Clean TOCSY for proton spin system 
identification in macromolecules. J. Am. Chem. Soc. 1988, 110, 7870–7872. 
23. Bax, A.; Davis, D.G. Practical aspects of two-dimensional transverse NOE spectroscopy.  
J. Magn. Reson. 1985, 63, 207–213. 
24. Wishart, D.S.; Sykes, B.D.; Richards, F.M. Relationship between nuclear magnetic resonance 
chemical shift and protein secondary structure. J. Mol. Biol. 1991, 222, 311–333. 
25. Wüthrich, K. NMR of Proteins and Nucleic Acids; John Wiley & Sons: New York, NY, USA, 1986. 
 
Int. J. Mol. Sci. 2015, 16 12173 
 
26. Das, R.K.; Pappu, R.V. Conformations of intrinsically disordered proteins areinfluenced by linear 
sequence distributions of oppositely charged residues. Proc. Natl. Acad. Sci. USA 2013, 110, 
13392–13397. 
27. Vila, J.A.; Baldoni, H.A.; Ripoll, D.R.; Ghosh, A.; Scheraga, H.A. PII helix conformation in a 
proline-rich environment: A theoretical study. Biophys. J. 2004, 86, 731–742. 
28. Tarek, M.; Tobias, D.J. Role of protein–water hydrogen bond dynamics in the protein dynamical 
transition. Phys. Rev. Lett. 2002, 88, 138101. 
29. De Clercq, E. AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil). 
Biochem. Pharmacol. 2009, 77, 1655–1664. 
30. Portella, L.; Vitale, R.; de Luca, S.; D’Alterio, C.; Ieranò, C.; Napolitano, M.; Riccio, A.; 
Polimeno, M.N.; Monfregola, L.; Barbieri, A.; et al. Preclinical development of a novel class of 
CXCR4 antagonist impairing solid tumors growth and metastases. PLoS ONE 2013, 8, e74548. 
31. Teicher, B.A.; Fricker, S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res. 
2010, 16, 2927–2931. 
32. Piantini, U.; Sorensen, O.W.; Ernst, R.R. Multiple quantum filters for elucidating NMR coupling 
networks. J. Am. Chem. Soc. 1982, 104, 6800–6801. 
33. Dalvit, C. Efficient multiple-solvent suppression for the study of the interactions of organic 
solvents with biomolecules. J. Biomol. NMR 1998, 11, 437–444. 
34. Bartels, C.; Xia, T.H.; Billeter, M.; Guntert, P.; Wuthrich, K. The program XEASY for  
computer-supported NMR spectral analysis of biological macromolecules. J. Biomol. NMR 1995, 
6, 1–10. 
35. Van Der Spoel, D.; Lindahl, E.; Hess, B.; Groenhof, G.; Mark, A.E.; Berendsen, H.J. 
GROMACS: Fast, flexible, and free. J. Comput. Chem. 2005, 26, 1701–1718. 
36. Guariniello, S.; Colonna, G.; Raucci, R.; Costantini, M.; di Bernardo, G.; Bergantino, F.; Castello, G.; 
Costantini, S. Structure-function relationship and evolutionary history of the human selenoprotein 
M (SelM) found over-expressed in hepatocellular carcinoma. Biochim. Biophys. Acta 2014, 1844, 
447–456. 
37. McDonald, I.K.; Thornton, J.M. Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 
1994, 238, 777–793. 
38. Crump, M.P.; Gong, J.H.; Loetscher, P.; Rajarathnam, K.; Amara, A.; Arenzana-Seisdedos, F.; 
Virelizier, J.L.; Baggiolini, M.; Sykes, B.D.; Clark-Lewis, I. Solution structure and basis for 
functional activity of stromal cell derived factor-1; dissociation of CXCR4 activation from 
binding and inhibition of HIV-1. EMBO J. 1997, 16, 6996–7007. 
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
 
This journal is©The Royal Society of Chemistry 2015 Mol. BioSyst., 2015, 11, 2925--2932 | 2925
Cite this: Mol. BioSyst., 2015,
11, 2925
Intrinsically disordered amphiphilic peptides as
potential targets in drug delivery vehicles
Marian Vincenzi,†abc Antonella Accardo,†ab Susan Costantini,d Stefania Scala,e
Luigi Portella,e Annamaria Trotta,e Luisa Ronga,c Jean Guillon,c Marilisa Leone,b
Giovanni Colonna,f Filomena Rossia and Diego Tesauro*ab
Intrinsically disordered proteins/peptides play a crucial role in many physiological and pathological
events and may assume a precise conformation upon binding to a specific target. Recently, we have
described the conformational and functional properties of two linear ester peptides provided with the
following sequences: Y-G-E-C-P-C-K-OAllyl (PepK) and Y-G-E-C-P-C-E-OAllyl (PepE). Both peptides
are characterized by the presence of the ‘‘CPC’’ motif together with a few amino acids able to promote
disorder. The CPC sequence is a binding motif for the CXCR4 receptor that represents a well-known
target for cancer therapies. In this paper, we report on synthetic amphiphilic peptides that consist of
lipophilic derivatives of PepE and PepK bearing two stearic alkyl chains and/or an ethoxylic spacer.
These peptide amphiphiles form stable supramolecular aggregates; they present conformational features
that are typical of intrinsically disordered molecules as shown by CD spectroscopy. Solution
fluorescence and DLS studies have been performed to evaluate Critical Micellar Concentrations and the
dimension of supramolecular aggregates. Moreover, preliminary in vitro cell-based assays have been
conducted to investigate the molecular recognition processes involving the CXCR4 receptor. In the
end, the results obtained have been compared with the previous data generated by the corresponding
non-amphiphilic peptides (PepE and PepK).
1. Introduction
Peptides may carry out a broad range of biological functions
while acting as growth factors, neurotransmitters, and hormones.1–5
The regulatory role that they may play in physiological tasks has
pushed pharmacologists to exploit peptides as therapeutic6,7 or
diagnostic tools.8,9 Peptide drugs can offer many advantages:
they have specific features but they have a broad spectrum of
activity; they have less side effects than organic molecules; they
allow an infinite array of sequences which could be designed in
order to regulate physiological processes.10 Peptides can act as
agonists or antagonists of biomolecular processes by interacting
with cell surface receptor systems that show over-expression
in several neoplastic and non-neoplastic cells.11 As the CXCR4
receptor is overexpressed in several human cancers, it is con-
sidered one of the most relevant targets in drug discovery. The
blockade of the CXCR4–CXCL12 interaction has been extensively
investigated as a potential research path for new cancer thera-
pies.12 Recently, we have designed and synthesized a CPC motif
containing peptides by using the N-terminal region of CXCL12 as
a template.13
Afterwards, we generated two novel linear ester peptides
containing the following sequences: Y-G-E-C-P-C-K-OAllyl (PepK)
and Y-G-E-C-P-C-E-OAllyl (PepE). Both these peptides are charac-
terized by the presence of the same CPCmotif together with a few
amino acids able to foster disorder.14 For PepE and PepK, NMR
and circular dichroism (CD) spectra have revealed the lack of
well-defined secondary structure elements, thus confirming their
high conformational flexibility. Moreover, molecular dynamics
(MD) simulations have pointed out that PepE and PepK could
dynamically explore conformational ensembles, thanks to the
absence of a regular secondary structure. We have also preliminary
tested the biological properties of these peptides: they have
targeted CXCR4 and they have modulated the adenylate cyclase
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production with remarkable performances, better than the ones
obtained so far by AMD3100 i.e., a known CXCR4 antagonist.
The application of an intrinsically disordered peptide as a
biosensor (or even in molecular recognition) could rely on its
own capability to control the transition between diﬀerent
structural states.15 One opportunity to induce conformational
peptide rearrangement could be achieved by modifying the
bioactive peptide sequence with a hydrophobic moiety. This
modification led to the design of peptide amphiphiles (PAs), a
class of emergent molecules, that, by combining the structural
features of amphiphilic surfactants with the functions of bioactive
peptides,16–18 are useful for biotechnological applications in drug
delivery of pharmacological molecules.19–21 Furthermore, PAs are
able to self-assemble into a wide variety of nanostructures, such as
spherical entities with a cylindrical geometry or rod like micelles,
monolayers, bilayers, vesicles and nanofibers. Supramolecular
aggregation of PAs is driven by the presence of both hydrophilic
and hydrophobic moieties. In detail, the hydrophilic moiety is
composed of a bioactive peptide sequence enriched with hydro-
philic amino acids. In addition, the sequence can be improved by
an ethoxylic linker. The hydrophobic moiety is made of hydro-
carbon groups such as one or two long alkyl chains containing
more than ten carbon atoms.
Taking into account these elements, we have designed
lipophilic derivatives of PepE and PepK bearing two stearic
alkyl chains and/or an ethoxylic spacer. The structural charac-
terization of self-assembled PAs in aqueous solution was assessed
by fluorescence spectroscopy and Dynamic Light Scattering (DLS),
while the conformational preferences were evaluated by CD.
To test the binding properties and the biological behaviour of
peptides, biological assays were also carried out in cells over-
expressing the CXCR4 receptor. Finally, the structural features
revealed by this study were compared with the ones previously
found for disordered linear peptides.
2. Materials and Methods
2.1. Reagents
All Na-Fmoc-amino acid derivatives, 2-chlorotrityl chloride
resin pre-loaded with Fmoc-Glu-OAllyl and Fmoc-Lys-OAllyl
and coupling reagents were purchased from Calbiochem-
Novabiochem (Laufelfingen, Switzerland), Iris Biotech GMBH
(Marktredwitz, Germany) or from Inbios (Napoli, Italy). Fmoc-21-
amino-4,7,10,13,16,19-hexaoxaheneicosanoic acid (Fmoc-Ahoh-OH)
was purchased from Neosystem (Strasbourg, France). N,N-Diocta-
decylsuccinamic acid was synthesized according to the published
methods.22 All other chemicals were commercially available by
Sigma-Aldrich (Milano, Italy) and were used as received unless
otherwise stated.
Preparative RP-HPLC was carried out on a LC8 Shimadzu
HPLC system (Shimadzu Corporation, Kyoto, Japan) equipped
with a UV lambda-Max Model 481 detector using a Phenomenex
(Torrance, CA) C4 (300 Å, 250  21.20 mm, 5 m) column. Elution
solvents are H2O/0.1% TFA (A) and CH3CN/0.1% TFA (B), from
20% to 95% over 20 minutes at 20 mLmin1 flow rate. The purity
and identity of the products were assessed by analytical LC–MS
analyses by using Finnigan Surveyor MSQ single quadrupole
electrospray ionization (Finnigan/Thermo Electron Corporation
San Jose, CA), column C4-Phenomenex eluted with an H2O/0.1%
TFA (A) and CH3CN/0.1% TFA (B) from 20% to 95% over
20 minutes at 0.8 mL min1 flow rate.
2.2. Amphiphilic peptide synthesis
All amphiphilic peptides were synthesized following a solid
phase peptide standard protocol using Fmoc chemistry on
2-chlorotrityl chloride resin pre-loaded (0.24 scale mmol) with
the side chain of a Fmoc-Lys-OAllyl and a Fmoc-Glu-OAllyl,
respectively. The sequence H-YGECPC was built on both resins.
In particular the resins were allowed to swell in dichloro-
methane (DCM) and Fmoc-deprotection steps were performed
by treating the resin for 30 min in a dimethylformamide (DMF)/
Piperidine (Pip) (80/20, v/v) solution.
For coupling steps the resin was suspended in DMF containing
three equivalents of the Fmoc-protected amino acid, O-benzo-
triazole-tetramethyl-uronium-hexafluoro-phosphate (HBTU), and
diisopropylethylamine (DIEA) (6 eq.), and the reaction mixture
was shaken for 2 h at room temperature. The Fmoc ethoxylic
spacer and lipophilic N,N-dioctadecylsuccinic acid were coupled,
as previously described.23
Peptides were cleaved by soaking the resin in TFA/H2O/
triisopropylsilane (TIS) (3.0 mL, 95/2.5/2.5, v/v/v) for 3 h.
Cleavage mixtures were filtered from the resin and crude
products were precipitated by adding cold water, centrifuged,
and decanted. The resulting white solids were dissolved in a
water and acetonitrile 4 : 1 v : v (10 mL) mixture and freeze-dried
to obtain a white powder that was analyzed for purity and
purified by preparative RP-HPLC. Purified peptides were charac-
terized by LC-ESI-MS.Mass values found: 1443 a.m.u. [(C18)2-PepE];
1442 a.m.u. [(C18)2-PepK];1776 a.m.u. [(C18)2-L-PepK]; 1777 a.m.u.
[(C18)2-L-PepE].
2.3. Preparation of aggregate solutions
Samples were prepared by dissolving the lyophilized PAs in
aqueous solutions. In detail, (C18)2-PepK and (C18)2-L-PepK
were dissolved in 10 mM TRIS buﬀer at pH 8.0, whereas
(C18)2-PepE and (C18)2-L-PepE in 10 mM phosphate buﬀer
(PBS) at pH 7.4. The pH-meter was calibrated with three
standards at pH 4.00, pH 7.00 and pH 10.00. In most cases
the samples to be measured were prepared from stock solutions.
The concentrations of all solutions were determined by UV-Vis
absorbance measurements carried out on a Thermo Fisher
Scientific Inc (Wilmington, Delaware USA) Nanodrop 2000c
spectrophotometer equipped with a 1.0 cm quartz cuvette
(Hellma) using a molar absorptivity (e) of 1390 M1 cm1 at
l = 275 nm, which corresponds to the wavelength of the
tyrosine residue.
2.4. Fluorescence measurements
Values of critical micellar concentration (CMC) of peptide
amphiphiles were obtained by fluorescence measurements.
Fluorescence spectra were recorded at room temperature on a
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Jasco Model FP-750 spectrofluorophotometer (Jasco Int. Co.
Ltd, Tokio, Japan) in a 1.0 cm path length quartz cell. Equal
excitation and emission bandwidths were used throughout
the experiments, with a recording speed of 125 nm min1
and automatic selection of the time constant. CMC values were
measured by using 8-anilino-1-naphthalene sulfonic acid ammo-
nium salt (ANS) as the fluorescent probe.24 Small aliquots of
peptide aqueous solution were added to a fixed volume (1.00 mL)
of 2.0  105 M ANS fluorophore directly in the quartz cell. CMC
values were determined by linear least-squares fitting of the
fluorescence emission at 480 nm, upon excitation at 350 nm
versus the amphiphile concentration. Fluorescence emission
spectra of the tyrosine residue in the PAs were recorded at
5  105 M concentration and 25 1C exciting the peptide
solution at 275 nm.
2.5. Dynamic light scattering characterization
Dynamic light scattering (DLS) measurements were carried out
using a Zetasizer Nano ZS (Malvern Instruments, Westborough, MA)
that employs a 1731 backscatter detector. Other instrumental
settings are measurement position (mm): 4.65; attenuator: 8;
temperature 25 1C; cell: disposable sizing cuvette. DLS samples
were prepared at a final concentration of 2.0 104 M and
centrifuged at room temperature at 13000 rpm for 5 min.
2.6. CD measurements
Far-UV CD spectra were recorded from 260 to 190 nm on a Jasco
J-810 spectropolarimeter equipped with a NesLab RTE111
thermal controller unit using a 1 mm quartz cell at 25 1C. CD
spectroscopy of alkylated derivatives of PepE and PepK was
carried out at 2.0  104 M concentration in 2.0 mM phosphate
buﬀer and 10 mM TRIS, respectively. Other experimental set-
tings were: scan speed, 10 nm min1; sensitivity, 50 mdeg; time
constant, 16 s; bandwidth, 1 nm. Each spectrum was obtained
averaging three scans, and by subtracting contributions from
other species in solution and converting the signal to mean
residue ellipticity in units of deg cm2 dmol1 res1.
2.7. Biological test
The binding between CXCR4 and the four peptides was evaluated
as previously described.25 Briefly 2.5  105 CCRF–CEM cells were
pre-incubated with 10 mM antagonist peptides in binding buffer
(PBS 1 plus 0.2% BSA and 0.1% NaN3) for 1h at 37 1C, 5% CO2
and then labeled for 45 minutes with an anti-CXCR4 PE-antibody
(FAB170P, clone 12G5, R&D Systems, Minneapolis, MN, USA).
Cells were washed in PBS and analyzed using an FACS Canto II
cytofluorimeter (Becton Dickinson Immunocytometry Systems,
Mountain View, CA, USA). CCRF-CEM cell migration was assayed
in 24-well Transwell chambers (Corning Inc., Corning, NY) using
inserts with an 8 mm pore membrane. Membranes were pre-
coated with collagen (human collagen type I/III) and fibronectin
(20 mg mL1 each). CCRF-CEM cells were placed in the upper
chamber (1  105 cells per well) in RPMI containing 1% BSA
(migration media). Cells were pre-incubated for 45 min with the
CXCR4 antagonist and allowed to migrate toward 100 ng mL1
CXCL12 in the lower chamber. After 16 h incubation, migrated
cells were collected from the lower chamber and counted. The
migration index was defined as the ratio between migrating
cells in the experimental group and migrated cells in the
control group.
We have conducted c-AMP–assay by using CCRF-CEM cells
(1  106) that were incubated in the presence of four peptides
or Plerixafor (known as AMD3100: a CXCR4 antagonist) that
has provided proof of concept for inhibition of the CXCR4
pathway26 at two different concentrations (1 and 10 mM) in
combination with forskolin (F) (1 mM) for 20 min, followed by
stimulation with CXCL12 (100 ng mL1) for 10 min. Controls
include cells stimulated with CXCL12 and forskolin or forskolin
alone in the absence of anti-CXCR4 inhibitors. Cells have been
harvested and lysed with 0.1 M HCl and cAMP levels have been
assayed by a direct competitive enzyme immunoassay (BioVision
Incorporated) according to manufacture instructions.
3. Results and discussion
3.1. Design and synthesis
Recently we synthesized two linear intrinsically disordered
peptides, PepK and PepE, based on the same sequence (YGECPC).
This sequence was designed choosing amino acids with disorder
propensity.14 Subsequently, PepK and PepE were obtained by
adding one charged residue at the C-terminus. In the case of
PepK the charged residue was lysine, whilst PepE was provided
with glutamic acid. The charged amino acids, namely Lys and
Glu, were introduced in order to evaluate the influence of
negative and positive charges on the aggregation of short
sequence structures. Peptide amphiphiles, (C18)2-PepK and
(C18)2-PepE, reported in Fig. 1 were obtained by conjugating
two aliphatic chains of eighteen carbon atoms at the N-terminus
of both sequences. Two other PA derivatives, indicated in Fig. 1
as (C18)2-L-PepK and (C18)2-L-PepE, were obtained by inserting
the AhOh exoethylene linker between the peptide sequence
and the hydrophobic double-tail. This linker, the same for both
peptides, allows us to increase the hydrophilicity of PAs without
modifying their final charge, in this way avoiding intra- and
inter-electrostatic interactions. Indeed, the insertion of the
Fig. 1 Schematic representation of (C18)2-PepK, (C18)2-PepE and
(C18)2-L-PepK and (C18)2-L-PepE. The peptide sequences are reported
using the one-letter amino acid code.
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linker leads to the distancing between the bioactive peptide and
the hydrophobic shell of the aggregates. The relatively short
length of this moiety was chosen in order to avoid possible
formation of a hydrophilic pocket, able to hide the amino acid
sequences. Finally, as is well-known from the literature,27 the
presence of PEG chains can increase the in vivo blood circula-
tion of self-assembled PA aggregates. PAs were synthesized
according to standard solid phase peptide synthesis protocols
using 2-Cl-(Trt)-Cl preloaded resin as a polymeric support. The
ethoxylic moiety and the two alkyl chains at the N-terminus of
both peptide sequences were added as previously reported.23
After RP-HPLC purification, the products were identified by
ESI-MS spectrometry.
3.2. Aggregate preparation and structural characterization
Supramolecular aggregates of pure PA derivatives were obtained
by dissolving the lipophilic derivatives in 10 mM phosphate
buﬀer (pH 7.4) for PepE and in 10 mM TRIS buﬀer (pH 8.0) for
PepK. The choice of buﬀers to be used for solubilizing monomers
was imposed by their diﬀerent propensities to aggregate. In fact,
according to the pKa values of glutamic acid and lysine residues,
all PAs have shown a net charge in a neutral or slightly basic water
solution: negative in PepE and positive in PepK. Self-aggregation
properties of the amphiphilic peptides were investigated by
fluorescence spectroscopy and DLS.
Critical micellar concentration (CMC) values were estimated
by fluorescence spectroscopy by using ANS as a fluorescent
probe. The fluorescence intensity of ANS depends on the
surrounding environment. The ANS fluorophore emits only in
a hydrophobic environment such as the hydrophobic core of a
micellar aggregate, whereas it does not emit in water solution.
CMC values can be estimated according to the data provided by
the graphical break-point, reported in Fig. 2. These data have
been obtained by plotting the fluorescence intensity of ANS in
the emission maximum at 470 nm, as a function of the PA
derivative concentration. Table 1 displays CMC values: 7.0 
106 mol kg1 for (C18)2-PepK and 1.9  105 mol kg1 for
(C18)2-L-PepK. These values indicate that the introduction of
the ethoxylic linker slightly aﬀects the formation of aggregates
capable of capturing the ANS, but they also confirm the high
stability of both the resulting aggregates. Furthermore, these
values comply with those previously found for peptide amphi-
philes containing the same hydrophobic moiety.28,29 Nonetheless,
the CMC values of both the amphiphilic derivatives of PepE are
higher than the corresponding ones for PepK. This behaviour
indicates that PepE owns a lower propensity to aggregate if
compared to PepK; this may depend on the diﬀerent inter-
action of the charges with the buﬀer salts. Data obtained by the
DLS for all compounds are summarized in Table 1: the hydro-
dynamic radii, RH; the diﬀusion coeﬃcients, D; and the poly-
dispersity indices, PDI. Measurements were performed at
y = 1731 on self-assembled PAs at a concentration of 2 
104 mol kg1 in the previously reported buﬀer solution. All
aggregate solutions show a monomodal distribution, which
indicates the presence of just one population of aggregates.
At infinite dilution, RH values can be examined by using
translational diﬀusion coeﬃcients in the Stokes–Einstein equation.
An increase of the radius of 20% was observed for (C18)2-PepE
(100 nm) with respect to (C18)2-PepK (80 nm) (see Fig. 3). Whereas
only a slight difference in radii can be detected for the derivatives
containing the spacer. Fluorescence measurements were carried
out by exciting buffer solutions at 275 nm aiming to evaluate shifts
of tyrosine fluorophore emission as a consequence of aromatic
quenching on the surface of the aggregates. In Fig. 4 (upper panel)
Fig. 2 Fluorescence intensity of the ANS fluorophore at 470 nm as a
function of PAs [(C18)2-L-PepK (A) and (C18)2-PepK (B)] concentration;
data are multiplied by a scale factor for a better comparison. CMC values
are established from graphical break points.
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emission spectra for different PepE derivatives are reported. The
behaviour of tyrosine does not show significant differences in
intensity or in the wavelength shift. These results seem to exclude
interaction among peptide side chains on the surfaces of aggre-
gates. Similar results have been obtained for PepK derivatives
(Fig. 4 lower panel).
3.3. Circular dichroism measurement
Conformational behaviours of PepE and PepK amphiphiles
were investigated by CD spectroscopy. Lyophilized peptides
were dissolved in the suitable weakly basic buﬀer (TRIS or PBS,
see experimental section) at 2  104 M concentration. Under
these experimental conditions, PAs are well above the CMC
concentrations that have been determined by fluorescence and
the presence of supramolecular aggregates in aqueous solution is
fostered. In Fig. 5 the CD spectra of PepE (panel A) and PepK
(panel B) derivatives are reported. The corresponding conforma-
tional preferences for all peptides were also analyzed by the
CAPITO web-server.30 The CD spectrum of (C18)2-PepE does not
show any propensity to fold as indicated by CD spectra, present-
ing a negative minimum at around 198 nm, typical for unordered
structures. Moreover, the presence of the ethoxylic spacer does
not influence significantly the dichroic bent of the PA. This trend
was also confirmed by CAPITO analysis30 (data not shown).
Furthermore, two weak maxima at 208 and 232 nm are also
detectable in the CD spectra of PepK derivatives (see Fig. 5B), in
addition to the minimum at 196 nm. These spectra suggest that
the replacement of the glutamic acid with the lysine at the
C-terminus induces a rearrangement of the secondary structure
with a partial folding of the IDP.
Further attempts to validate the CD results with more precise
comparative conformational studies by NMR spectroscopy were
Table 1 Structural parameters for the aggregates obtained from fluores-
cence measurements (critical micellar concentration values) and dynamic
light scattering measurements (diﬀusion coeﬃcients, D, hydrodynamic
radii, RH, and polydispersity indices)
Systems CMC (mol kg1) RH (nm) D  1012 (m2 s1) PDI
(C18)2-PepK 7.0  106 80  27 3.1  1.0 0.270
(C18)2-L-PepK 1.9  105 82  34 3.1  1.5 0.182
(C18)2-PepE 3.9  105 112  44 1.9  0.7 0.264
(C18)2-L-PepE 3.2  105 101  39 2.4  0.5 0.226
Fig. 3 DLS profiles of (C18)2-PepK (A) and (C18)2-PepE (B) peptide
amphiphiles at a concentration of 2  104 M.
Fig. 4 Fluorescence emission spectra recorded by exciting buﬀer solutions
at 275 nm for PepE derivatives (up) and PepK derivatives (down).
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hampered by the high aggregation levels of PepE and PepK
derivatives. Indeed, this aggregation produced sample precipita-
tion and/or complete disappearance of signals in 1D [1H] and 2D
[1H, 1H] NMR spectra; this made impossible the process of
resonance assignments.
3.4. Functional characterization: peptide eﬀects on the
CXCR4 receptor pathway
Then, the peptides (C18)2-PepK, (C18)2-L-PepK, (C18)2-PepE,
and (C18)2-L-PepE, have been tested in order to determine:
Fig. 5 CD spectra of: (A) (C18)2-PepE and (C18)2-L-PepE; and (B) (C18)2-PepK and (C18)2-L-PepK.
Fig. 6 Comparison of cAMP modulation by PepE, PepK, (C18)2-PepE, (C18)2-L-PepE, (C18)2-PepK and (C18)2-L-PepK and AMD3100 at 1 mM
and 10 mM.
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(i) peptide binding to the receptor through an indirect binding
assay; (ii) the inhibition of CXCL12-induced migration;
(iii) cAMP levels. The results were compared to the ones for
AMD3100 that is the lead CXCR4 antagonist.26 The binding of
the four peptides to CXCR4 was evaluated in CCRF-CEM using a
CXCR4 12G5 monoclonal antibody as previously described,31
and two concentrations (1 mM and 10 mM) which are matching
the ones previously used in CXCR4 binding assays.
The four peptides did not displace 12G5 antibody compared
to AMD3100, which strongly reduced antibody binding to
CXCR4. These behaviours agree with those previously obtained
for the free PepE and PepK peptides.14 This could be explained
considering the diﬀerent binding sites on AMD3100/12G5 anti-
body and the four highly flexible and disordered peptides. Also,
a migration assay was performed and the four peptides resulted
to reduce the migration of CCRF-CEM cells towards CXCL12 even
if they showed less activity than AMD3100 (data not shown).
Taking into account that CXCR4 is a G-Protein coupled
receptor, it inhibits through the G-protein the adenylate cyclase
activity and fosters the cAMP production as ‘‘second messen-
ger’’.25 As a result of the binding to CXCL12, we also evaluated
the cAMP levels after treatment with the four peptides. The
results indicate that in the presence of CXCL12 (100 ng mL1)
and Forskolin (1 mM): (i) (C18)2-PepK, (C18)2-L-PepK, (C18)2-PepE,
and (C18)2-L-PepE show a dose dependent increase of the cAMP
level of about 66% at the lower dose (1 mM) and of 84% at the
higher dose (10 mM); (ii) at 10 mM, (C18)2-L-PepK increases cAMP
levels up to 93% and (C18)2-PepE increases the cAMP level to 95%;
(iii) AMD3100 exhibits less eﬃcient activities on the adenylate
cyclase when compared to the four peptides (Fig. 6).
4. Conclusions
We have explored the possibility that intrinsically disordered
peptides could be used as polar heads connected to alkyl chains
to generate new molecular buildings for drug delivery vehicles
in cells over-expressing the CXCR4 receptor. In our previous
investigations, two peptides were synthesized and studied by
NMR and CD spectroscopy.32 These compounds were indicated
as PepE and PepK due to the presence of a glutamic acid or a
lysine residue at the C-terminus. The absence of regular secondary
structure elements confirmed the natively disordered nature of
these peptides.
In the present study, we have investigated the opportunity
to induce conformational rearrangement by modifying these
peptide sequences with two alkyl chains of eighteen carbon
atoms each and with an ethoxylic linker. In fact, the insertion
on peptides of aliphatic moieties pushes the resulting amphi-
philic molecules to self-assemble in supramolecular aggregates.
Once confined on the external surface of the aggregates, peptides
could undergo a disorder-to-order transition.32 As demonstrated
by fluorescence and DLS studies, all the designed PAs are able to
self-assemble in large aggregates with an average diameter ranging
between 80 and 110 nm, independently from their charge and from
the presence of the PEG spacer.
All four PAs are strongly aggregated and poorly soluble
at high concentrations (0.50–1.0 mM). These characteristics
made them unsuitable for characterization performed by
means of solution NMR techniques; even after changing the
experimental conditions such as implementing buffers at
different pH and temperatures.
CMC values comply with those previously found for peptide
amphiphiles containing the same hydrophobic moiety and they
point out the high stability of the aggregates.28,29 The higher
CMC values of (C18)2-PepE and (C18)2-L-PepE indicate a lower
propensity to aggregate if compared with the corresponding
PepK derivatives. Also after the insertion of the hydrophobic
portion, PepE keeps its tendency towards the disordered/
unfolded state from the conformational point of view. Whereas
both the PepK derivatives show a partial folding, with respect to
the free peptide sequence. To the best of our knowledge, these
compounds are the first CPC motif containing amphiphilic
peptides which are able to aggregate. Comparing the four
peptide derivatives with previously studied PepE and PepK
sequences14, we can point out that (i) all peptides did not show
an evident binding aﬃnity for CXCR4; (ii) the best result about
the migration assay was obtained for PepE sequences; and
(iii) the highest cAMP percentages were obtained for (C18)2-L-
PepE- (93%) and (C18)2-L-PepK (95%) at 10 mM (Fig. 6).
According to these preliminary results, these PA systems
could be further modified to realize new supramolecular
peptide-based compounds, able to be encapsulated by living
cells for biomedical industrial application.
Abbreviations
AhOh 21-Amino-4,7,10,13,16,19-hexaoxaheneicosanoic
acid
ANS 8-Anilino-1-naphthalene sulfonic acid ammonium
salt
CMC Critical micellar concentration
cAMP Cyclic adenosine monophosphate
CD Circular dichroism
DCM Dichloromethane
DIEA N,N-Diisopropylethylamine
DLS Dynamic light scattering
DMF N,N-Dimethylformamide
DPC n-Dodecyl phosphatidylcholine
EDTA Ethylenediaminetetraacetic acid
Fmoc 9-Fluorenylmethoxycarbonyl
G-CSF Granulocyte-colony stimulating factor
GTP Guanine nucleotide triphosphate
HBTU O-benzotriazole-tetramethyl-uronium-hexafluoro-
phosphate
IDP Intrinsically disordered protein or peptide
MD Molecular dynamics
PAs Peptide amphiphiles
PBS Phosphate buﬀer
RP-HPLC Reverse-phase high-pressure liquid chromatography
SPPS Solid phase peptide synthesis
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TFA Trifluoroacetic acid
TIS Triisopropylsilane
TRIS buﬀer Tris(hydroxymethyl)aminomethane
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ABSTRACT:
The design and synthesis of novel peptides that inhibit
angiogenesis is an important area for anti-angiogenic
drug development. Cyclic and small peptides present sev-
eral advantages for therapeutic application, including
stability, solubility, increased bio-availability and lack of
immune response in the host cell. We describe here the
synthesis and biological evaluations of a new cyclic pep-
tide analog of CBO-P11: cyclo(RIKPHE), designated
herein as CBO-P23M, a hexamer peptide encompassing
residues 82 to 86 of VEGF which are involved in the
interaction with VEGF receptor-2. CBO-P23M was pre-
pared using in solution cyclization, therefore reducing the
peptide cyclodimerization occurred during solid-phase
cyclization. The cyclic dimer of CBO-P23M, which was
obtained as the main side product during synthesis of the
corresponding monomer, was also isolated and investi-
gated. Both peptides markedly reduce VEGF-A-induced
phosphorylation of VEGFR-2 and Erk1/2. Moreover, they
exhibit anti-angiogenic activity in an in vitro morphogene-
sis study. Therefore CBO-P23M and CBO-P23M dimer
appear as attractive candidates for the development of
novel angiogenesis inhibitors for the treatment of cancer
and other angiogenesis-related diseases.VC 2016 Wiley Peri-
odicals, Inc. Biopolymers (Pept Sci) 00: 000–000, 2016.
Keywords: cyclic peptide; angiogenesis; CBO-P23M;
CBO-P11; solid-supported cyclization; in solution cycli-
zation; dimerization
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INTRODUCTION
C
ancer is an angiogenesis-dependent disease1,2 and
blocking such angiogenesis is a well-established
strategy to markedly reduce tumor growth and
metastasis.3
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Among the numerous factors involved in angiogenesis, vascu-
lar endothelial growth factor (VEGF) is a potent mitogen for
endothelial cells that plays a central role in angiogenesis by inter-
action with its specific receptors (VEGFR-1 or VEGFR-2) and
subsequent activation of intracellular MAPK signaling pathways
(e.g. Erk1/2).4 Therefore, VEGF and its receptors VEGFR-1 and
VEGFR-2 are prime targets for anti-angiogenic intervention
which is thought to be one of the most promising strategies in
cancer therapy. Several approaches have been employed to inhibit
VEGF function. These include monoclonal neutralizing antibod-
ies directed against VEGF and VEGF receptors, recombinant
fusion proteins, recombinant soluble VEGF receptors, peptides
that interfere with VEGF/VEGFR interactions and small organic
molecules targeting the intracellular receptor kinase domain.5
A wide number of agents targeting both VEGF and its
receptors have recently become standard treatments for differ-
ent tumor types.6 However, as tumor resistance to these agents
may arise after a few months of treatment, new alternatives
need to be investigated.
Within this context, our group has synthesized, character-
ized and evaluated as angiogenesis inhibitor several novel pep-
tides derived from 79 to 93 VEGF sequence which is involved
in the interaction with VEGFR-2.7
Among these analogs, the CBO-P11, a 17-amino acids cyclo
peptide: cyclo(fPQIMRIKPHQGQHIGE), exhibits anti-angio-
genic activity in ovo on the chicken chorioallantoic membrane
(CAM) assay. Moreover, this peptide inhibits the growth of both
established human intracranial and syngeneic glioma in mice.8
These results prompted us to investigate the anti-
angiogenetic activity of a new, smaller CBO-P11 analog:
cyclo(RIKPHE), designated herein CBO-P23M, which encom-
passes the shorter 82-86 VEGF sequence with the key residues
Arg82, Lys84, and His86.9 A glutamic acid was added to the C-
terminal end of CBO-P23M in order to envisage a solid sup-
ported head to tail cyclization strategy and also for further
functionalization. The extensive polymerization observed dur-
ing the solid-supported cyclization led us to develop an alter-
native synthetic protocol employing cyclization in solution.
This synthetic strategy allowed the preparation of CBO-P23M
and its dimer as the main products which were isolated and
tested in vitro as novel anti-angiogenesis agents.
Both our peptides markedly reduce VEGF-A-induced phos-
phorylation of VEGFR-2 and Erk1/2 and exhibit anti-
angiogenic activity in an in vitro morphogenesis assay.
RESULTS AND DISCUSSION
Chemistry
In order to obtain CBO-P23M peptide, we decided to follow
the synthetic pathway depicted in SchemeS1 1. This synthesis is
based on the three-dimensional protection strategy Fmoc/tBu/
OAllyl and the Glu side chain anchoring to the resin (Scheme
1, step i). This synthetic approach allows the orthogonal
deprotection of the C- and N-termini for the subsequent on-
resin head-to-tail cyclization (Scheme 1, step iv) 10.
While the solid-phase cyclization usually takes advantage of
the pseudo-dilution phenomenon, in our synthesis, the on-
resin cyclization favors the formation of the cyclodimerization
product and only traces of the desired monomer are produced
(Figure F11). Further polymerization by-products are also
observed: the cyclic trimer and tetramer. The attempts to iso-
late these products by RP-HPLC failed due to the small quan-
tity of CBO-P23M formed and the co-elution of dimer, trimer
and tetramer under the same HPLC peak at tR5 5.7 min (Fig-
ure 1).
In order to avoid the formation of these side-products, the
solid supported cyclization was investigated by modifying dif-
ferent parameters. Firstly, we reduced the cyclization time from
18 h to 1.5 h. Under these conditions only the monomeric,
dimeric and trimeric linear peptides were obtained. Then, we
tried the PyBOP/HOBt/DIEA coupling system. In this case,
cyclo-dimerization and trimerization were mainly observed as
for DIC/HOBt activation. Finally, we employed a low loaded
resin (0.09 mmol/g) which was unfortunately not able to avoid
the formation of cyclic polymers.
Under these circumstances, we next envisioned the synthesis
of CBO-P23M peptide using the “in solution” cyclization of
side-chain protected peptide (Scheme S22). For this purpose, we
started the elongation of our linear peptide from the proline
residue in order to avoid epimerization of the C-terminal resi-
due during peptide cyclization.11 Then we performed the head
to tail cyclization in solution under high diluted conditions
and we obtained the expected CBO-P23M by reducing the
cyclodimerization and the formation of the other polymeriza-
tion side-products (Figure F22). The crude product was purified
and the CBO-P23M (Figure F33) and its dimer (Figure F44) iso-
lated with (6% and 4% yield), respectively.
Biological Evaluation
Because MAPK signaling pathway is one of the main target of
VEGF-A, we analyzed, by Western Blotting, VEGF receptor 2
(VEGFR-2) and Erk1/2 phosphorylation by VEGF-A in
absence or presence of CBO-P11,8 CBO-P23M or CBO-P23M
dimer. As shown in Figure F55, treatment of HUVECs with 20
ng/mL of VEGF-A for 10 min strongly stimulates VEGFR-2
and Erk1/2 phosphorylation. Interestingly, 15 min of treatment
(5 min of pretreatment and 10 min of co-treatment) with 20
mM of CBO-P11, CBO-P23M, or CBO-P23M dimer markedly
reduces VEGF-A-induced phosphorylation of VEGFR-2 and
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SCHEME 1 Synthesis of CBO-P23M by on resin cyclization; Reagents and conditions: (i) DIEA,
DCM, 3 h; (ii) PhSiH3, Pd(PPh3)4, 3 h; (iii) 20% piperidine in DMF, 2 3 20 min; (iv) Method a)
DIC/HOBt, DIEA in DMF, 18 h; Method b) DIC/HOBt, DIEA in DMF, 1.5 h; Method c) PyBOP/
HOBt, DIEA in DMF, 18 h (v) TFA/H2O/TIS, 90/5/5, v/v/v, 3 h.
FIGURE 1 MALDI spectrum and HPLC profile of crude CBO-P23M obtained by on solid sup-
port cyclization (18 h reaction, DIC/HOBt as coupling system).
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Erk1/2. CBO-P23M and CBO-P23M dimer display almost the
same inhibitor effect on VEGFR-2 phosphorylation (69.6%
and 79.3%, respectively); higher than that observed with CBO-
P11 (46.7%). On the other side, VEGF-induced phosphoryla-
tion of Erk1/2 is uniformly inhibited by CBO-P23M, its dimer
and CBO-P11.
SCHEME 2 Synthesis of CBO-P23M by in solution cyclization; reagents and conditions: (i)
DIEA, DCM, 3 h, (ii) 1% TFA in DCM, 5 3 1 min, (iii) DIC/HOBt, DIEA in DCM, 18 h, (iv) TFA/
H2O/TIS, 90/5/5, v/v/v, 3 h.
FIGURE 2 MALDI spectrum and HPLC profile of crude CBO-P23M obtained by in solution
cyclization.
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Then, we investigated the capacity of HUVECs to form
capillary-like structure by in vitro morphogenesis assay (Figure
F6 6). This experiment is considered as the closest to in vivo
angiogenesis12 as it recapitulates several cellular events leading
to vessel formation when HUVECs are cultured on extracellu-
lar matrix such as MatrigelVR . Typical capillary-like structures
were observed in basal condition (EGM-2 containing less than
2.5 ng/mL of VEGF-A) whereas, when cultured in presence of
additional 20 ng/mL VEGF-A, the formation of the structures
is stimulated by 44%. In contrast, treatments with 10 mM of
CBO-P11, CBO-P23M, or CBO-P23M dimer drastically
reduced this network. Taken together, these in vitro morpho-
genesis results highlight an anti-angiogenic capacity of CBO-
P23M and CBO-P23M dimer comparable to that of CBO-P11.
MATERIALS AND METHODS
Chemicals
2-Chlorotrityl chloride resin, Fmoc-protected amino acids (Fmoc-
Arg(Pbf)-OH, Fmoc-Ile-OH, Fmoc-Lys(Boc)-OH, Fmoc-Pro-OH,
Fmoc-Hys(Trt)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Glu-OAllyl),
N,N,N0,N0-tetramethyl-O-(1H-benzotriazol-1-yl)uranium hexafluoro-
phosphate (HBTU), benzotriazol-1-yl-oxytripyrrolidinophosphonium
hexafluorophosphate (PyBOP), Hydroxybenzotriazole (HOBt) and
FIGURE 3 MALDI spectrum and HPLC profile of pure CBO-P23M.
FIGURE 4 MALDI spectrum and HPLC profile of pure CBO-P23M dimer.
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N,N0-diisopropylcarbodiimide (DIC) were obtained from Iris Biotech
GMBH. All other chemicals were commercially available by Sigma-
Aldrich and Acros.
Solid-Phase Peptide Synthesis General Experimental
Procedures. The syntheses were performed manually at 0.25 to 0.5
mmol scale using Fmoc/tBu chemistry on 2-chlorotrityl chloride resin
(1.6 mmol/g).
Resin Swelling. Swelling was performed by treating the resin for 20
min in dichloromethane (DCM).
First Amino Acid Coupling. After swelling of the resin, Fmoc-
Pro-OH or Fmoc-Glu-OAllyl (2.3 eq) in DCM at 0.25M concentra-
tion and DIEA (6.9 eq) were added. The reaction mixture was left
under mechanic stirring for 3 h at room temperature. The resin was
left under vacuum overnight. Then the resin loading was determined
from the Fmoc-release monitored by UV absorption at 301 nm.
FIGURE 5 Inhibition of VEGF-A induced VEGFR-2 (A) and Erk1/2 (B) activation.
C
O
L
O
R
FIGURE 6 Inhibition of capillary-like network.
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Fmoc-Deprotection. Fmoc-deprotection steps were performed by
treating the resin 2 3 20 min in Piperidine (Pip)/DMF (80/20, v/v)
solution.
Washing. Washing steps after coupling and deprotection steps were
performed by treating the resin in dimethylformamide (DMF) (3 3 1
min), methanol (MeOH) (1 3 1 min), and DCM (3 3 1 min),
successively.
Amino Acid Coupling. The resin was immersed in a DMF solution
containing: Fmoc-protected amino acids (5 eq), HBTU (5 eq), and
DIEA (10 eq) and left under mechanic stirring for 2 h.
Peptide Cyclization
On Resin. After peptide elongation, the Allyl-protection was
removed from the peptide C-terminal carboxylate by treating the resin
with Pd(PPh3)4 (0.35 eq) and PhSiH3 (20 eq) in DCM, 3 h. The pep-
tide was then cyclized on solid support by using DIC (5 eq) and
HOBt (5 eq) in DMF overnight. Then the peptide was cleaved by
immersing the resin in a trifluoroacetic acid (TFA)/H2O/triisopropyl-
silane (TIS) (90/5/5, v/v/v) solution for 3 h. The cleavage cocktail was
filtered from the resin and concentrated. The peptide was precipitated
with ice-cold diethyl ether, centrifuged and decanted. Precipitation,
centrifugation, and decantation operations were repeated twice. The
resulting white solid was solubilized with H2O/CH3CN solution (50/
50, v/v) and freeze-dried.
In Solution. After swelling of the resin, side-chain protected peptide
was removed from the solid support by reacting the resin with a TFA/
DCM (1/99, v/v) solution for 1 min, five times. Then the resin was
washed with DCM (2 3 1 min). The cleavage and washing solutions
were collected and evaporated. The product was solubilized with
H2O/CH3CN solution (50/50, v/v) and freeze-dried.
The peptide was solubilized in DCM at 0.24 mM concentration
and added dropwise (over 2 h) to a DCM solution containing HOBt
(5 eq), DIC (5 eq), and DIEA (10 eq). This reaction mixture was left
under magnetic stirring overnight and then evaporated.
Side-chains deprotection was performed by treating the peptide
with a TFA/H2O/TIS (90/5/5, v/v/v) solution for 3 h under magnetic
stirring. Then the cleavage cocktail was concentrated and the peptide
was precipitated with ice-cold diethyl ether, centrifuged and decanted.
Precipitation, centrifugation, and decantation operations were
repeated twice. The resulting white solid was solubilized with H2O/
CH3CN solution (50/50, v/v) and freeze-dried.
For analysis, peptides were dissolved in a H2O/CH3CN/TFA solu-
tion (50:50:0.1, v/v/v) at 1 mg/mL concentration and analyzed by
HPLC and Maldi.
RP-HPLC Analysis and Purification of Peptides
The HPLC characterization of products was performed by analytic
reverse-phase HPLC using a VWR Hitachi instrument equipped with
an L-2450 auto sampler, two L-2130 pumps, a Satisfaction RP18-AE
column (5 lm, 250 3 4.6 mm) and a L-2450 diode array detector, at
a flow rate of 0.8 mL/min. The compounds were purified by prepara-
tive reverse-phase HPLC using a VWR LaPrep system consisted of a
P202 injector, two P110 pumps, a Satisfaction RP18-AB C18 column
(5 lm, 250 3 20 mm) and a P314 UV detector, at a flow rate of
10 mL/min. The following eluents were used in a gradient mode: (A)
0.1% TFA in H2O/CH3CN (95/5) and (B) 0.1% TFA in CH3CN/H2O
(95/5). Water was of Milli-Q quality and was obtained after filtration
of distilled water through a Milli-QVR cartridge system. CH3CN and
TFA were of HPLC use quality. Degassing of solvents was performed
using argon bubbling. Gradient used for the analytic and preparative
RP-HPLC was respectively from 0% B to 100% B in 15 min and from
0% to 50% B in 50 min; UV detection at 214 nm. CH3CN was evapo-
rated and the aqueous solution was freeze-dried to give purified pep-
tides as white solids.
Peptide Mass Analysis
Peptide identity was confirmed by mass spectrometry analyses per-
formed on an Ultraflex III TOF/TOF system (Bruker Daltonics, Bre-
men, Germany), equipped with 200 Hz smartbeam laser (355 nm)
and operating in reflectron positive ion mode. Mass spectra were
acquired over the m/z range 300 to 5000 by accumulating data from
1000 laser shots for each spectrum. The instrumental conditions
employed to analyze molecular species were the following: ion source
1: 25.08 kV; ion source 2: 21.98 kV, lens: 11.03 kV, pulsed ion extrac-
tion: 30 ns, reflector: 26.39 kV, reflector 2: 13.79 kV. Matrix suppres-
sion was activated by deflection mode: suppression up to 450 Da.
Mass calibration was performed for each sample in range of 400 to
2000 Da with a peptide calibration mixture (8206195, Peptide Cali-
bration Standard, Bruker Daltonics). The instrument was controlled
using Bruker’s flexControl 3.4 software and mass spectra were ana-
lyzed in Bruker’s FlexAnalysis 3.4 software.
Cell Culture
Human umbilical vein endothelial cells (HUVECs, Lonza) were cul-
tured in EGM-2 composed by endothelial cell basal medium-2 (EBM-
2) and EGM-2 SingleQuot Kit Suppl. & Growth Factors (FBS, hydro-
cortisone, hFGF, VEGF, R3-IGF-1, ascorbic acid, hEGF, GA-1000 and
heparin). HUVECs were used at early passages (1 to 8). Cells were
kept at 378C in a 5% CO2 humidified incubator.
Western Blotting
HUVECs were plated in 12-well plates at a density of 5 3 104 cells/
well in EGM-2 medium. After 3 days, cells were switched 16 h in basal
medium EBM-2 before exposition to VEGF and peptides at the indi-
cated concentrations and for the specified durations. Cells were col-
lected by scraping and then lysed with Laemmli reducing buffer.
Equivalent amounts of protein for each sample were analyzed by SDS-
PAGE, transferred onto nitrocellulose membrane and probed with the
following primary antibodies: anti-VEGFR2, anti-phospho-VEGFR
Tyr1175, anti-Erk1/2 and anti-phospho-Erk1/2 Thr202/Tyr204 (Cell
Signaling). Primary antibodies were detected using HRP-conjugated
goat anti-mouse antibody (Dako) and Luminata HRP Substrate
(Millipore). Densitometric analyses were performed in duplicate by 2
independent observers using ImageJ software. Statistical significance
was determined by ANOVA test and Dunnet post-test. *P< 0.05,
**P< 0.01, ***P< 0.001, ns: no statistical difference. Experiments
were done three times.
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Tube Formation Assay
Forty-eight-well plates were coated with 10 mg/mL MatrigelVR (BD
Biosciences) and kept at 378C for 4 h to allow gel formation. HUVECs
(5 3 104 cells/well) were then plated onto the MatrigelVR in EGM-2
supplemented by VEGF-A (20 ng/mL) and investigated peptides (10
mM). Sixteen hours later, networks were stained with calcein-AM (25
mM, 30 min at 378C) and fixed in PBS-2% formaldehyde (1 h at room
temperature). The three-dimensional cell organization was photo-
graphed using MVX10 macroscope (Olympus). Capillary-like struc-
tures were quantified by automatic counting using the AngioQuant
software. Images are representative of three independents experi-
ments. Statistical significance was determined by ANOVA test and
Dunnet post-test. *P< 0.05, **P< 0.01, ***P< 0.001, ns: no statistical
difference. Scale bar: 1 mm.
CONCLUSIONS
In summary, we designed the CBO-P23M as a novel cyclic
peptide with potential anti-angiogenic activity. CBO-P23M is
a cyclic hexamer peptide encompassing the 82 to 86 VEGF
sequence with the key residues Arg82, Lys84, and His86
involved in the interaction with VEGFR-2. We demonstrated
that CBO-P23M can be prepared using in solution cyclization,
therefore overcoming the peptide cyclodimerization recorded
during solid-phase cyclization
The anti-angiogenic activity of CBO-P23M was investigated
together with that of its cyclic dimer (CBO-P23M dimer),
obtained as the main side product during the synthesis of
monomer. Our biological evaluations highlight an anti-
angiogenic capacity of CBO-P23M and CBO-P23M dimer
comparable to that of CBO-P11 peptide which was previously
described by our group as promising anti-angiogenesis inhibi-
tor. However, as CBO-P23M includes exclusively six amino
acid residues, its synthesis appears much simpler than that of
the 17-mer CBO-P11. Overall, these results make CBO-P23M
an ideal candidate for the further development of new anti-
angiogenic compounds.
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a b s t r a c t
Leukemia is the most common blood cancer, and its development starts at diverse points, leading to
distinct subtypes that respond differently to therapy. This heterogeneity is rarely taken into account in
therapies, so it is still essential to look for new speciﬁc drugs for leukemia subtypes or even for therapy-
resistant cases. Among heterocyclic compounds that attracted a lot of attention because of its wide
spread biological activities, the pyrrolo[1,2-a]quinoxaline heterocyclic framework has been identiﬁed as
interesting scaffolds for antiproliferative activity against various human cancer cell lines. In the present
study, novel ethyl 4-[4-(4-substitutedpiperidin-1-yl)]benzyl-phenylpyrrolo[1,2-a]quinoxaline-carbox-
ylate derivatives 1a-l have been designed and synthesized. Their cytotoxicities were evaluated against
ﬁve different leukemia cell lines, including Jurkat and U266 (lymphoid cell lines), and K562, U937, HL60
(myeloid cell lines), as well as normal human peripheral blood mononuclear cells (PBMNCs). Then,
apoptosis study was performed with the more interesting compounds. The new pyrrolo[1,2-a]qui-
noxaline series showed promising cytotoxic potential against all leukemia cell lines tested, and some
compounds showed better results than the reference compound A6730. Some compounds, such as 1a,
1e, 1g and 1h are promising because of their high activity against leukemia and their low activity against
normal hematopoietic cells. Structure-activity relationships of these new synthetic compounds 1a-l are
here also discussed.
© 2016 Published by Elsevier Masson SAS.
1. Introduction
Acute leukemia is one of the most aggressive hematopoietic
malignancies and is characterized by the abnormal proliferation of
the immature cells and a premature block in lymphoid or myeloid
differentiation. Adult acute leukemia have a poor prognosis due to a
* Corresponding author. INSERM U1212, UMR CNRS 5320, ARNA Laboratory, F-
33000 Bordeaux, France.Q1,2
E-mail address: jean.guillon@u-bordeaux.fr (J. Guillon).
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large number of relapses. Thus, identifying and understanding the
treatment-related resistance mechanisms is of major interest to
improve the therapeutic strategy [1]. Therefore, there is an urgent
need to ﬁnd new therapeutics, which could led to the development
of novel treatment strategies with less or minimal side effects.
Heterocyclic compounds attracted a lot of attention because of
its wide spread biological activities. Among them, the pyrrolo[1,2-
a]quinoxaline heterocyclic framework constitutes the basis of an
important class of compounds possessing interesting biological
activities. These compounds have been reported to serve as key
intermediates for the assembly of several heterocycles including
antipsychotic agents [2], anti-HIV agents [3], adenosine A3 receptor
modulators [4], antiparasitic agents [5e10], and antitumor agents
[11e13]. In this last ﬁeld, the discovery and development of novel
therapeutic agents are one of themost important goals inmedicinal
chemistry. In this context, we have recently published three series
(Series A-C) of new interesting substituted pyrrolo[1,2-a]quinoxa-
lines (Fig. 1) endowed with good activity towards the human leu-
kemia cells [14e16]. These antiproliferative pyrrolo[1,2-a]
quinoxaline derivatives have been previously designed as novel
structural analogues of compound A6730, a well-described Akt
inhibitor that presents antiproliferative activity against different
human leukemia cell lines [14e17]. Continuing our efforts in this
ﬁeld and considering the pharmacological activities of pyrroloqui-
noxalines on human leukemic cells, a new series (Series D) was
designed and synthesized. Thus, by taking into accounts the best
results obtained in series B (Fig. 1), we decided to use the JG576 and
JG572 pyrrolo[1,2-a]quinoxaline moieties as a template for the
design of new derivatives 1a-l in which the pyrrole nucleus is
substituted in different positions by a phenyl and an ester function
(Series D, Fig. 1). In relation to our previous works, further phar-
macomodulations on the piperidine core have been considered,
such as the introduction of new substituted heterocyclic systems
[14e16]. The antiproliferative proﬁle of the obtained derivatives 1a-
lwas then evaluated in vitro against a panel of myeloid (U937, HL60,
K562) or lymphoid (Jurkat, U266) leukemic cell lines. Moreover, to
determine their respective cytotoxicity, the new ethyl 4-[4-(4-
substitutedpiperidin-1-yl)]benzyl-phenylpyrrolo[1,2-a]quinoxa-
line-carboxylate derivatives 1a-l were tested on activated human
peripheral blood mononuclear cells, and assessment of apoptosis
was performed with the more interesting compounds. Structure-
activity relationships of these new synthetic compounds 1a-l are
here discussed. Finally, we used simple computational programs to
predict the drug-like characteristics through the calculated
Fig. 1. Structure of bioactive compounds of previously described series A-C, and general structure of new synthesized substituted pyrrolo[1,2-a]quinoxaline derivatives 1a-l (series
D).
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physicochemical and toxicological properties of these new ethyl 4-
[4-(4-substitutedpiperidin-1-yl)]benzyl-phenylpyrrolo[1,2-a]qui-
noxaline-carboxylate derivatives to determine their potential anti-
leukemia activity.
2. Chemistry
All reported pyrrolo[1,2-a]quinoxaline derivatives 1a-l were
synthesized from various substituted phenyl-1H-pyrrole-dicar-
boxylic acid ethyl ester 2a-d (Schemes 1 and 2). Different strategies
using classical or microwaves heating were considered for the
synthesis of the phenyl-1H-pyrrole-diesters 2a-d in order to
introduce the phenyl and ester functions on the pyrrole ring
(Table 1). The synthesis of the diethyl 4-phenyl-1H-pyrrole-2,3-
dicarboxylate 2a has been accomplished by treatment of ethyl
isocyanide on ethyl phenylpropiolate under 1,3-
bis(diphenylphosphino)propane (dppp) catalysis via a formal
[3 þ 2] cyclo-addition (Scheme 1, Table 1) [18,19]. Various attempts
were investigated for the preparation of the diethyl 3-phenyl-1H-
pyrrole-2,4-dicarboxylate 2b. At ﬁrst, this pyrrole 2bwas prepared
by silver-catalyzed cycloaddition of commercially available ethyl
phenylpropiolate with ethyl isocyanoacetate in 1,4-dioxane or DMF
at 80 C (Scheme 1, Methods A-C, Table 1) [20,21]. The very low
yield obtained (12%, Table 1) using microwaves heating led us to
investigate other methodologies. The copper-catalyzed reaction of
ethyl isocyanide with the electron-deﬁcient alkyne, ethyl phenyl-
propiolate, gave the diethyl 3-phenyl-1H-pyrrole-2,4-dicarboxylate
2bwith 62% in dioxane at 100 C usingmicrowave heating (Table 1)
[1,2]. Pyrrole 2b could be also synthesized by reaction of ethyl
isocyanoacetate with benzaldehyde in the presence of 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) in THF [22,23]. The synthe-
sis of the diethyl 5-phenyl-1H-pyrrole-2,3-dicarboxylate 2c has
been accomplished in two steps starting from commercially avail-
able acetophenone via its oxime 3 (Scheme 1). The acetophenone
oxime 3, synthesized by the reaction of hydroxylamine on aceto-
phenone [7], was then reacted with diethyl acetylene in the pres-
ence of 1,4-diazabicyclo[2.2.2]octane (DABCO) to form pyrrole 2c
via a thermal rearrangement by Troﬁmov reaction [24,25]. Diethyl
5-phenyl-1H-pyrrole-2,4-dicarboxylate 2d was prepared by
manganese(III)-catalyzed formal [3 þ 2] annulation of ethyl 2-
azidoacrylate 4 and ethyl 3-oxo-3-phenylpropanoate [26]. The 2-
azidoacrylate 4 was previously synthesized by treatment of ethyl
2,3-dibromopropanoate with three equivalents of sodium azide
(NaN3) in aprotic polar solvent such as dimethylformamide (DMF)
[10,11]. A X-ray single crystal analysis was also performed on
phenyl-1H-pyrrole-diesters 2b-d in order to conﬁrm the structures
(Fig. 2). The preparation of N-aryl pyrroles 5a-d were obtained by
nucleophilic substitution of the various pyrrole-2-carboxylates 2a-
dwith 2-ﬂuoro-nitrobenzene using cesium carbonate as the base in
reﬂuxing DMF solution (Scheme 2) [15,16]. The preparation of 5a-
d was also performed under microwave irradiation. Reduction of
the nitro moiety with iron in hot glacial acetic acid produced the
spontaneous ring closure onto the ester in position 2 of the pyrrole
moiety to afford the desired tricyclic pyrrolo[1,2-a]quinoxalines 6a-
d through a one-pot reduction-cyclization step [15,16]. The lac-
tames 6a-d were subsequently chlorodehydroxylated with phos-
phorous oxychloride, leading to the 4-chloroquinoxalines 7a-d. 4-
(Pyrrolo[1,2-a]quinoxalin-4-yl)benzaldehydes 8a-d were easily
prepared by a direct Suzuki-Miyaura cross-coupling reaction of 4-
chloropyrroloquinoxalines 7a-d with 4-formylphenylboronic acid
performed in the presence of Pd(PPh3)4 as a catalyst, and in the
presence of potassium carbonate used as the base [14e16]. The
aldehydes 8a-d were then engaged in a reductive amination with
NaBH3CN and 4-(2-ketobenzimidazolin-1-yl)piperidine or 4-(5-
ﬂuorobenzimidazolin-2-yl)piperidine or 2-(3-piperidin-4-yl-1H-
1,2,4-triazol-5-yl)pyridine to give the pyrrolo[1,2-a]quinoxalines
1a-l [14e16]. The 3D spatial determinations of 1a, 1d, 1g and 1j
were established by X-ray crystallography (Fig. 3), and conﬁrmed
the structures in the solid state as anticipated on the basis of IR and
1H and 13C NMR data.
3. Biological activity
3.1. Cytotoxicity in leukemia cell lines
The twelve new compounds 1a-l were tested in MTS assay for
their in vitro antiproliferative activity against ﬁve human leukemic
cell lines (U937, K562, Jurkat, U266 and HL60). Compound A6730
(Fig. 1) was used in these tests as the reference standard drug. The
results are summarized in Table 2. In addition, compound LY-
294002, which showed antiproliferative activity against the HL60,
U937 and K562 cell lines [27e30], was also applied as a referential
cytotoxic agent.
The pyrrolo[1,2-a]quinoxalines 1c, 1f, 1g, 1h, 1i, 1k and 1l were
found the most antiproliferative compounds on the growth of hu-
man myeloid U937 cell line with IC50 of 3e11 mM. The two de-
rivatives 1h and 1k with IC50 of 4 and 3 mM respectively, showed a
better activity in comparison with the reference compound A6730
(IC50¼ 8 mM). These two compounds 1h and 1kwere substituted in
position 4 by a benzylpiperidinyl ﬂuorobenzimidazole group and in
position 1 by a phenyl. In general, the substitution by a phenyl on
position 1 of the pyrrole moiety led to active derivatives (1g-l
excepted 1j). Interestingly, 1c, 1f, 1i and 1l were substituted by a
Scheme 1. Synthesis of phenyl-1H-pyrrole-diesters 2a-d; Reagents and conditions: (i)
dppp, dioxane, 100 C; (ii) Method A: Ag2CO3, dioxane, 80 C; Method B: 1) Ag2CO3,
dioxane, 25 C; 2) 80 C; Method C: 1) Ag2CO3, NMP, 25 C; 2) 80 C; (iii) Method D:
Cu2O, phenanthroline, dioxane, 100 C; (iv) Method E: DBU, THF, 50 C; (v) H2NOH,
HCl, Pyridine, EtOH, reﬂux; (vi) 1) H5C2OOCeC^CeCOOC2H5, DABCO, toluene, 80 C;
2) 170 C, P; (vii) NaN3, DMF, 65 C; (viii) C6H5eCOeCH2eCOOC2H5, Mn(OAc)3 2H2O,
40 C.
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benzylpiperidinyl triazolylpyridine moiety in position 4 of the
pyrrolo[1,2-a]quinoxaline core, All other compounds derived from
the incorporation of the benzylpiperidinyl benzimidazolonemoiety
(compounds 1a, 1d and 1j), which was present in the reference
compound A6730, into the 4-position of the heterocyclic pyrrolo-
quinoxaline ring were found inactive on the U937 cell line in
comparison with their benzylpiperidinyl ﬂuorobenzimidazole or
benzylpiperidinyl triazolylpyridine analogues, excepted 1g that
was found active (IC50 ¼ 9 mM). From a SAR point of view, these
preliminary biological results on U937 cell line enlightened the
importance of the substitution at C-4 position of the pyrroloqui-
noxaline scaffold by a benzylpiperidinyl ﬂuorobenzimidazole
group, and also the need of a phenyl functionalisation in position 1
of the pyrrole ring (compounds 1h and 1k).
The antiproliferative potencies of these new derivatives 1a-l
were also examined towards the human myeloid leukaemia cell
lines K562 and HL60.
Among the twelve compounds tested for antiproliferative ac-
tivities on K562 cell line, the ﬁve pyrrolo[1,2-a]quinoxalines 1a, 1b,
1e,1k and 1lwere found themost active compoundswith an IC50 of
3e4 mM. All the other pyrroloquinoxalines 1 also showed signiﬁ-
cant antiproliferative activity with IC50 ranging from 7 to 14 mM,
better than the one found for the reference compound A6730
(IC50 ¼ 17 mM). Moreover, in terms of structure-activity relation-
ships discussion, it could be also noticed that the four quinoxalines
1b, 1e, 1h and 1k, bearing the benzylpiperidinyl ﬂuo-
robenzimidazole moiety in their 4-position, were always found the
most active compounds with IC50 of 3e7 mM in each subseries
diversely substituted by a phenyl and an ester on the pyrrole ring.
Against the HL60 human acute promyeloid leukemia cell line,
Scheme 2. Synthesis of pyrrolo[1,2-a]quinoxalines 1a-l; Reagents and conditions: (i) 2-ﬂuoro-nitrobenzene, Cs2CO3, DMF, D; (ii) Fe, CH3COOH, D; (iii) POCl3, D; (iv)
OHCeC6H4eB(OH)2, Pd[P(C6H5)3]4, K2CO3, toluene, EtOH, D; (v) 4-(2-ketobenzimidazolin-1-yl)piperidine or 4-(5-ﬂuorobenzimidazolin-2-yl)piperidine or 2-(3-piperidin-4-yl-1H-
1,2,4-triazol-5-yl]pyridine, NaBH3CN, MeOH, D.
Table 1
Synthesis of phenyl-1H-pyrrole-diester 2a-d under standard reaction conditions.
Reagents and conditions Time Yield (%)
2a (i) dppp, dioxane, 100 C 2 h 87a
2b (ii) Method A: Ag2CO3, dioxane, 80 C 1 h 9a
(ii) Method B: 1) Ag2CO3, dioxane, 25 C; 2) 80 C 1) 5 min
2) 30 min
10a
(ii) Method C: 1) Ag2CO3, NMP, 25 C; 2) 80 C 1) 5 min
2) 30 min
12b
(iii) Method D: Cu2O, phenanthroline, dioxane, 100 C 40 min 62b
(iv) Method E: DBU, THF, 50 C 1 h 35b
2c (vi) 1) H5C2OOCeC^CeCOOC2H5, DABCO, toluene, 80 C;
2) 170 C, P
1) 6 min
2) 45 min
28b
2d (viii) C6H5eCOeCH2eCOOC2H5, Mn(OAc)3 2H2O, 40 C 2 h 42a
a Conventional heating.
b Microwaves heating (200 W).
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most of the tested compounds showed antiproliferative activity
with IC50 values from 3 to 24 mM, excepted 1a and 1j that were
found inactive (IC50 > 50 mM). The two pyrroloquinoxalines 1d and
1f having an ester function and a phenyl respectively in position 2
and 3 exhibited better activities than their other homologues.
Compounds 1d and 1k showed a better activity that the one
noticed for the reference compound A6730: i.e. IC50¼ 3.5 and 3 mM
for 1d and 1k, respectively in comparison with 5.5 mM for A6730.
The antiproliferative activities of compounds 1a-l against the T-
acute lymphoblastic leukemia Jurkat cell line were also investi-
gated, and the results exhibited potent cytotoxicity for pyrrolo-
quinoxalines 1b-l (IC50 from 2 to 6.5 mM) as potent as the one
observed for A6730 (IC50 ¼ 3.5 mM). Nevertheless, the pyrrolo[1,2-
a]quinoxaline 1a showed low antiproliferative activity
(IC50 ¼ 41 mM). Hence in the subseries functionalized by a phenyl
and an ester at C2 and C3 respectively, the IC50 of 1b and 1c (5 mM)
was 8.2 times lower than those of compound 1a (IC50 ¼ 41 mM).
Against the human myeloma cell line U266, the same pyrrolo
[1,2-a]quinoxalines 1b, 1f, 1h, 1k and 1l, bearing a benzylpiper-
idinyl ﬂuorobenzimidazole or a benzylpiperidinyl triazolylpyridine
moiety in position 4 and substituted on the pyrrole ring, exhibited
potent cytotoxicity (IC50 from 3 to 5 mM). All the other tested pyr-
roloquinoxalines 1 (compounds 1d-e,1g and 1i) were also found to
be active on U266 cell line with IC50 ranging from 8 to 18 mM, with
the exception of 1a, 1c and 1j that presented an IC50 superior to
50 mM.
Against each human cancer cell lines, the antiproliferative ac-
tivities of compounds 1a-l were generally found superior to those
of the other reference drug LY-294002.
3.2. Cytotoxicity activity in activated normal peripheral blood
mononuclear cells
The compounds 1a-l were tested on activated (PBMNC þ PHA)
human peripheral blood mononuclear cells to evaluate their
respective cytotoxicity on normal cells (Table 2). As expected, most
of the pyrrolo[1,2-a]quinoxalines 1a-l showed signiﬁcant level of
cytotoxicity against lymphocytes with IC50 ranging from 8 to over
50 mM. These preliminary results were used to determine their
respective range of toxic concentration.
Indexes of selectivity (IS) were deﬁned as the ratio of the IC50
value on the human mononuclear cells to the IC50 value on the
K562, U937, HL60, Jurkat and U266 lines. Compounds that
demonstrated high selectivity (high index of selectivity) should
offer a potential of safer therapy. This led to identify compounds
with index of selectivity >16.7 and >12.5 for compounds 1e and 1a,
respectively, on the human myeloid leukemic cell lines K562; and
>12.5 for compound 1g against the human leukemic cell lines
Jurkat. We could notice that the more interesting new pyrroloqui-
noxaline structure (compound 1e) could be considered as a direct
combination of our previously bioactive described derivatives
JG572 and JG576. Moreover, we could notice that the compound 1a
showed interesting selectivity towards K562 CML cell lines. The
potential inhibitor 1h also showed interesting IS on U937 and U266
leukemic cell lines with value of 12.5. These four compounds could
now constitute suitable candidates for further pharmacological
studies. The reference compound A6730 showed interesting
selectivity with index of selectivity value noticed at 14.3 on the
Jurkat cell line.
Fig. 2. The ORTEP drawing of phenyl-1H-pyrrole-diesters 2b-d with thermal ellipsoids at 30% level.
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3.3. Determination of the action mode
The reference compound A6730, which showed interesting
selectivity on the Jurkat cell line, is additionally described as an Akt
inhibitor (Akt1 IC50 ¼ 58 nM, Akt2 IC50 ¼ 10 nM and IC50
Akt3 ¼ 2.2 mM) [31]. To determine the possible mechanism of ac-
tion of our compounds, we ﬁrst evaluated their potency on isolated
enzymes such as Akt 1, 2 and 3 as well as onmTOR. These tests have
been performed by DiscoverX at 1 and 10 mM [32]. Nevertheless,
only low effects have been detected. Akt2 activity was reduced of
38% and 35% with derivatives 1e and 1j at 10 mM, respectively. Such
of enzymatic interaction could not explain the cell effects. Next
assessment of apoptosis in K562 cell line was examined. Apoptosis
induces loss of membrane asymmetry resulting in phosphatidyl
Fig. 3. The ORTEP drawing of pyrrolo[1,2-a]quinoxalines 1a, 1d, 1g and 1j with thermal ellipsoids at 30% level.
Table 2
In vitro activity of compounds 1a-l on U937, K562, HL60, Jurkat and U266 cells, and cytotoxicity on human peripheral blood mononuclear cells PBMNC þ PHA.
IC50 values (mM)a
Compound K562 U937 HL60 Jurkat U266 Cytotoxicity on activated human peripheral blood mononuclear cells (PBMNC) PBMNC þ PHA
A6730 17 ± 0.3 8 ± 0.2 5.5 ± 0.2 3.5 ± 0.2 n.d.b >50
LY-294002 38 ± 1 14 ± 0.3 14 ± 0.3 22 ± 1 46 ± 2 >50
1a 4 ± 0.1 >50 >50 41 ± 1.2 >50 >50
1b 3 ± 0.1 21 ± 2.2 19 ± 2.8 5 ± 0.2 3.5 ± 0.1 14 ± 1
1c 14 ± 0.3 7 ± 0.3 12 ± 2.3 5 ± 0.1 >50 16 ± 2
1d 9 ± 0.3 >50 3.5 ± 0.1 4 ± 0.1 10 ± 0.8 41.3 ± 5
1e 3 ± 0.1 n.d. 10 ± 0.9 5 ± 0.2 18 ± 1.1 >50
1f 7 ± 0.2 7 ± 0.1 5 ± 0.1 2 ± 0.1 5 ± 0.1 8 ± 0.5
1g 8 ± 0.2 9 ± 0.4 6 ± 0.1 4 ± 0.1 9 ± 0.8 >50
1h 7 ± 0.3 4 ± 0.1 8 ± 0.2 6 ± 0.15 4 ± 0.1 50 ± 4
1i 12 ± 0.4 11 ± 0.9 24 ± 3 5 ± 0.1 8 ± 0.5 50 ± 6
1j 8.5 ± 0.3 >50 >50 6.5 ± 0.1 >50 >50
1k 3 ± 0.1 3 ± 0.1 3 ± 0.1 3.5 ± 0.1 3 ± 0.1 13 ± 1
1l 3.5 ± 0.1 8 ± 0.2 7 ± 0.3 3 ± 0.1 3 ± 0.1 12 ± 1
a The IC50 (mM) values correspond to the mean ± standard deviation from 3 independent experiments.
b n.d. ¼ not determined.
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serine (PS) exposure and alterations in mitochondrial membrane
potential. Cells were incubated with or without increasing doses 1e
for 3 days. Compound 1e, which showed themost interesting index
of selectivity on the human myeloid leukemic cell lines K562, in-
duces a signiﬁcantly increase in Annexin V positive cells from the
second and third days (92% ± 2.8) (Fig. 4). These results could
explain the inhibition of cell proliferation observed with this
compound 1e.
3.4. Predicted toxicity and other drug relevant properties
To speculate on any toxicity risks and drug-like characteristics of
these novel synthesized compounds, we computed a set of drug
relevant properties from their 2D chemical structures (Table 3). The
calculated properties indicated that our molecules 1 present the
same toxicological proﬁle as the anticancer reference compound
A6730. These parameters were calculated by the molinspiration
web services [33]. All compounds 1a-l were found lipophilic with
Clog P values between 6.44 and 7.70. The Clog P of the reference
compound A6730 was noticed at 5.55 slightly lower than those of
our compounds. To predict intestinal absorption, we estimated the
molecular polar surface areas (PSA) of these new pyrroloquinoxa-
line compounds 1a-l from the calculated TPSA. PSA has been
extensively used in medicinal chemistry for modeling absorption
phenomena and to optimize a drug's ability to permeate cells. The
PSA of a molecule is deﬁned as the surface sum over all polar atoms,
which primarily consist of oxygen and nitrogen as well as their
attached hydrogens. Molecules with a polar surface area greater
than 140 Å2 tend to be poor at permeating cell membranes, while a
PSA of less than 60 Å2 is usually needed for molecules to penetrate
the blood-brain barrier and thus act on the brain and other central
nervous system tissues [34,35]. The PSA of our compounds could
suggest an intestinal absorption (PSA < 140 Å2). On the other hand,
these pyrroloquinoxalines seem to be unlikely to cross the blood-
brain barrier (PSA > 60 Å2). Thus, based on these predicted data,
the calculated PSA values for these derivatives 1 could indicate a
possible better oral bioavailability with a smaller chance of CNS
toxicity.
4. Conclusion
In the present work, we synthesized a series of twelve new ethyl
4-[4-(4-substitutedpiperidin-1-yl)]benzyl-phenylpyrrolo[1,2-a]
quinoxaline-carboxylate derivatives 1a-l and investigated their
antileukemic activity on the human leukemic cell lines U937, K562,
Jurkat, U266 and HL60. These results have been discussed in a
preliminary SAR study. The ﬁrst biological evaluation of our new
substituted pyrrolo[1,2-a]quinoxalines showed cytotoxic activity in
these myeloid and lymphoid leukemia cell lines. Consequently,
compounds 1e, 1a, 1g and 1h are promising due to their high
cytotoxic activity against some leukemia cells (IC50 ranging from 3
to 9 mM) and their lower toxicity against normal hematopoietic
cells (estimated IC50 > 50 mM). These compounds showing inter-
esting index of selectivity may constitute suitable candidates for
further pharmacological studies. Moreover, it would be also inter-
esting to enlarge the biological evaluation of these new bioactive
pyrrolo[1,2-a]quinoxaline derivatives in order to precise now their
mechanism of action.
5. Experimental
5.1. Chemistry
Commercially reagents were used as received without addi-
tional puriﬁcation. Melting points were determined with an SM-
LUX-POL Leitz hot-stage microscope and are uncorrected. IR
spectra were recorded on an NICOLET 380FT-IR spectrophotometer.
NMR spectra were recorded with tetramethylsilane as an internal
standard using a BRUKER AVANCE 300 spectrometer. Splitting
patterns have been designated as follows: s ¼ singlet; bs ¼ broad
singlet; d ¼ doublet; t ¼ triplet; q ¼ quartet; dd ¼ double doublet;
ddd ¼ double double doublet; dt ¼ double triplet; m ¼ multiplet.
Analytical TLC were carried out on 0.25 precoated silica gel plates
(POLYGRAM SIL G/UV254) and visualization of compounds after UV
light irradiation. Silica gel 60 (70e230 mesh) was used for column
chromatography. Microwave experiments were carried out using a
focused microwave reactor (CEM Discover). High resolution mass
spectra (electrospray in positive mode, ESIþ) were recorded on a
Waters Q-TOF Ultima apparatus. Elemental analyses were found
within ±0.4% of the theoretical values.
5.1.1. Ethyl 2-azidoacrylate (4)
To a solution of sodium azide (3.75 g, 57.68 mmol) in DMF
(120 mL) at 65 C was added ethyl 2,3-dibromopropionate (5.00 g,
19.26 mmol). After 10 min, the reaction mixture was cooled and
poured into water (300 mL) and extracted with ether (3  120 mL).
The combined organic extracts were washed with water
(3 120 mL), dried over MgSO4, ﬁltered and evaporated in vacuo to
afford ethyl 2-azidoacrylate as a yellow oil (79%). Rf ¼ 0.38 (cyclo-
hexane/Et2O-98/2) [36,37].
Fig. 4. Effect of 1e on apoptosis of K562 cells. Cells were cultured with or without
increasing doses of 1e for 3 days in culture medium then stained with APC-Annexin V,
and analyzed by ﬂow cytometry. Results are expressed as Mean ± Standard Error (SEM)
of three independent experiments. ***p < 0.001 compared with control (t-test).
Table 3
Predicted drug-relevant properties of compounds 1a-l.
Compound Clog P TPSA nON nOH/NH N violationsa
A6730 5.55 95.50 8 2 2
1a 7.19 84.65 8 1 2
1b 7.70 75.53 7 1 2
1c 6.49 101.32 9 1 2
1d 7.19 84.65 8 1 2
1e 7.70 75.53 7 1 2
1f 6.49 101.32 9 1 2
1g 7.13 84.65 8 1 2
1h 7.65 75.53 7 1 2
1i 6.44 101.32 9 1 2
1j 7.13 84.65 8 1 2
1k 7.65 75.53 7 1 2
1l 6.44 101.32 9 1 2
a Number of violations to the Lipinski's “rule of ﬁve”: log P  5, molecular weight
500, number of hydrogen bond acceptors 10, and number of hydrogen bond
donors 5.
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5.1.2. Diethyl 4-phenyl-1H-pyrrole-2,3-dicarboxylate (2a)
To a 1,4-dioxane solution (10 mL) of 1,3-bis(diphenylphosphino)
propane (dppp) (0.32 g, 0.78 mmol) were added ethyl iso-
cyanoacetate (0.70 g, 6.19 mmol) and ethyl phenylpropiolate
(0.90 g, 5.17 mmol). The solution was stirred at 100 C for 2 h. After
the consumption of ethyl isocyanoacetate, the reactionmixturewas
cooled to room temperature, ﬁltered and evaporated in vacuo. The
crude was puriﬁed on silica gel (eluent: cyclohexane/AcOEt-90/10
then cyclohexane/AcOEt-70/30, Rf ¼ 0.33) to afford 2a as a color-
less oil (87%) [18,19].
5.1.3. Diethyl 3-phenyl-1H-pyrrole-2,4-dicarboxylate (2b)
Method A: To a mixture of ethyl phenylpropiolate (2.5 g,
14.3 mmol) and Ag2CO3 (0.264 g, 0.96 mmol) in 1,4-dioxane
(40 mL) at 80 C, ethyl isocyanoacetate (1.08 g, 9.55 mmol) was
slowly added. The solution was stirred at 100 C for 30 min. After
the consumption of ethyl isocyanoacetate, the reactionmixturewas
cooled to room temperature, ﬁltered and evaporated in vacuo. The
crude was puriﬁed on silica gel (eluent: cyclohexane/AcOEt-90/10
then cyclohexane/AcOEt-70/30, Rf ¼ 0.33) to afford 2b as white
crystals (9%).Method B: A mixture of ethyl phenylpropiolate (2.5 g,
14.3 mmol) and Ag2CO3 (0.264 g, 0.96 mmol) in 1,4-dioxane
(40 mL) was heated at 80 C for 5 min, then mixture was cooled
with an ice bath. To this resulting solution cooled at room tem-
perature, ethyl isocyanoacetate (1.08 g, 9.55 mmol) was added
dropwise. The reaction mixture was stirred for 5 min at 25 C, then
heated for 30 min at 80 C. The resulting slurry was concentrated
under reduced pressure and taken up with dichloromethane. The
organic layer was washed with brine, dried with Na2SO4, ﬁltered
and evaporated under vacuum. The crude was puriﬁed on silica gel
as above leading to 2b (10%). Method C: To a N-methyl-2-
pyrrolidone (NMP) solution (40 mL) of Ag2CO3 (0.264 g,
0.96 mmol) was added ethyl phenylpropiolate (2.5 g, 14.3 mmol).
After a prestirring of 30 s, the solution was irradiated during 1 min.
The irradiation was programmed to maintain a constant tempera-
ture (80 C) with a power of 200W. To the resulting solution cooled
at room temperature, ethyl isocyanoacetate (1.08 g, 9.55mmol) was
added dropwise. After a pre-stirring of 30 s, the solution was irra-
diated during 6 min with a ﬁrst step of irradiation of 1 min at 25 C
followed by a second one of 5 min at 80 C. The power was set at
200 W in both steps. The resulting slurry was concentrated under
reduced pressure and taken up with dichloromethane. The organic
layer was washed with brine, dried with Na2SO4, ﬁltered and
evaporated under vacuum. The crude was puriﬁed on silica gel as
above to afford 2b (12%). Method D: To a 1,4-dioxane solution
(25 mL) of Cu2O (0.085 g, 0.59 mmol) and 1,10-phenanthroline
(0.215 g, 1.19 mmol) were added ethyl isocyanoacetate (1.35 g,
11.9 mmol) and ethyl phenylpropiolate (2.5 g, 14.3 mmol). After a
prestirring of 30 s, the solution was irradiated during 40 min. The
irradiation was programmed to maintain a constant temperature
(100 C) with a power of 200W. The reactionmixturewas cooled to
room temperature, ﬁltered and concentrated in vacuo. The crude
was puriﬁed on silica gel as above to give 2b (62%).Method E: To a
THF solution (30 mL) of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)
(3.00 g, 19.7 mmol) was added ethyl isocyanoacetate (1.98 g,
17.5 mmol). After a prestirring of 30 s, the solution was irradiated
during 2 min. The irradiation was programmed to maintain a
constant temperature (50 C) with a power of 200 W. To the
resulting solution at the same temperature, ethyl isocyanoacetate
(1.08 g, 9.55 mmol) was added dropwise. After a prestirring of 30 s,
the solution was irradiated during 1 h. The irradiation was pro-
grammed to maintain a constant temperature (50 C) with a power
of 200 W. The reaction mixture was neutralized with acetic acid
and then the solvent was removed under reduced pressure. The
resulting residue was extracted with ethyl acetate and the extract
was washed with hydrochloric acid and water, dried with Na2SO4,
and then evaporated in vacuo. The crudewas puriﬁed on silica gel as
above to give 2b (35%) [20e22].
5.1.4. Diethyl 5-phenyl-1H-pyrrole-2,3-dicarboxylate (2c)
To 1,4-diazabicyclo[2.2.2]octane (0.083 g, 0.74mmol) and oxime
3 (1.00 g, 7.40 mmol) in dry toluene (20 mL) was added diethyl
acetylenedicarboxylate (1.26 g, 7.40 mmol), and the resultant
mixture was subjected to the two-stage microwave irradiation
sequence (stage 1: 80 C, 6 min; stage 2: 170 C, 45min). The power
was set at 200 W in both steps. The reaction mixture was cooled to
room temperature, ﬁltered and concentrated in vacuo. The crude
was puriﬁed on silica gel as above to give 2c (28%) [24,25].
5.1.5. Diethyl 5-phenyl-1H-pyrrole-2,4-dicarboxylate (2d)
To a solution of ethyl 2-azidoacrylate 4 (1.70 g, 12.1 mmol) and
ethyl phenylacetoacetate (3.47 g, 18.0 mmol) in MeOH (30 mL) was
added AcOH (1.45 g, 24.1 mmol) and manganese(III) acetate dihy-
drate (1.29 g, 4.81 mmol), and the solution was stirred at 40 C for
2 h. The reaction mixture was quenched with pH 9 ammonium
buffer (AcONH4 þ NH4OH), and then extracted twice with AcOEt.
The combined organic extracts were washed with brine, dried with
Na2SO4, ﬁltered and concentrated in vacuo. The resulting residue
was cooled, triturated in Et2O and ﬁltered. The crystals formedwere
ﬁltered, and dried under reduced pressure to give 2d as white
crystals (42%) [26].
5.1.6. General procedure for diethyl 1-(2-nitrophenyl)-phenyl-
pyrrole-dicarboxylate (5a-d)
Conventional heating: To a solution of diethyl phenyl-1H-pyr-
role-dicarboxylate 2a-d (2.75 mmol) in 11 mL of DMF was added
cesium carbonate (3.3 mmol). The mixture was stirred at room
temperature for 10 min, then 2-ﬂuoro-nitrobenzene (4.12 mmol)
was added. The reaction mixture was reﬂuxed for 1 h 30 (15 h for
5d), then was diluted in AcOEt (35 mL). The organic layer was
washed with water (2  30 mL), then brine (30 mL) and dried over
sodium sulfate. The organic layer was concentrated under vacuo to
give a brown oil. After triturating in Et2O a solid was obtained and
ﬁltered off, washed with Et2O and dried to give the desired product
5. Microwave heating: A suspension of diethyl phenyl-1H-pyrrole-
dicarboxylate 2a-d (3.4mmol),1-ﬂuoro-2-nitrobenzene (5.1mmol)
and cesium carbonate (4.06 mmol) in 12 mL of DMF was irradiated
during 10 min. The irradiation was programmed to maintain a
constant temperature (150 C) with a maximal power output of
200 W. The reaction mixture was then diluted in AcOEt (60 mL),
washed with water (2  50 mL), then brine (50 mL) and dried over
sodium sulphate. The organic layer was concentrated under vacuo
to give products 5a-d as an oil.
5.1.6.1. Ethyl 1-(2-nitrophenyl)-4-phenyl-pyrrole-2,3-dicarboxylate
(5a). Orange oil (85%/89%). 1H NMR (CDCl3) d: 8.13 (dd, 1H,
J ¼ 7.90 and 1.35 Hz, H-30), 7.74 (ddd, 1H, J ¼ 7.90, 7.90 and 1.35 Hz,
H-40), 7.63 (ddd, 1H, J ¼ 7.90, 7.90 and 1.35 Hz, H-50), 7.55e7.43 (m,
3H, H-60, H-2 phenyl and H-6 phenyl), 7.40e7.28 (m, 3H, H-3
phenyl, H-4 phenyl and H-5 phenyl), 7.02 (s, 1H, H-5), 4.39e4.30
(m, 2H, OCH2), 4.12 (q, 2H, J¼ 7.20 Hz, OCH2),1.31 (t, 3H, J¼ 7.20 Hz,
CH3), 1.15 (t, 3H, J ¼ 7.20 Hz, CH3). HRMS-ESI m/z [M þ Na]þ Calcd
for C22H20N2O6Na: 431.1219, Found: 431.1224.
5.1.6.2. Ethyl 1-(2-nitrophenyl)-3-phenyl-pyrrole-2,4-dicarboxylate
(5b). Yellow oil (89%/95%). 1H NMR (CDCl3) d: 8.19 (dd, 1H,
J ¼ 7.80 and 1.50 Hz, H-30), 7.77 (ddd, 1H, J ¼ 7.80, 7.80 and 1.50 Hz,
H-40), 7.67 (ddd, 1H, J ¼ 7.80, 7.80 and 1.50 Hz, H-50), 7.59 (s, 1H, H-
5), 7.51 (dd, 1H, J ¼ 7.80 and 1.50 Hz, H-60), 7.39e7.35 (m, 5H, 5H
phenyl), 4.14 (q, 2H, J ¼ 7.20 Hz, OCH2), 3.89e3.80 (m, 2H, OCH2),
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1.13 (t, 3H, J¼ 7.20 Hz, CH3), 0.77 (t, 3H, J¼ 7.20 Hz, CH3). HRMS-ESI
m/z [M þ Na]þ Calcd for C22H20N2O6Na: 431.1219, Found: 431.1236.
5.1.6.3. Ethyl 1-(2-nitrophenyl)-5-phenyl-pyrrole-2,3-dicarboxylate
(5c). Yellow oil (65%/76%). 1H NMR (CDCl3) d: 8.05e8.01 (m, 2H,
H-30 and H-60), 7.62e7.56 (m, 2H, H-2 phenyl and H-6 phenyl), 7.31
(t, 1H, J ¼ 7.50 Hz, H-40), 7.25e7.04 (m, 4H, H-50, H-3 phenyl, H-4
phenyl and H-5 phenyl), 6.77 (s, 1H, H-4), 4.34 (q, 2H, J ¼ 6.90 Hz,
OCH2), 4.12 (q, 2H, J ¼ 6.90 Hz, OCH2), 1.38e1.14 (m, 6H, 2CH3).
HRMS-ESIm/z [MþNa]þ Calcd for C22H20N2O6Na: 431.1219, Found:
431.1248.
5.1.6.4. Ethyl 1-(2-nitrophenyl)-5-phenyl-pyrrole-2,4-dicarboxylate
(5d). Yellow oil (28%/). 1H NMR (CDCl3) d: 8.04 (dd, 1H, J ¼ 7.50
and 1.80 Hz, H-30), 7.66 (s, 1H, H-3), 7.52 (ddd, 1H, J ¼ 7.50, 7.50 and
1.80 Hz, H-40), 7.46 (ddd, 1H, J ¼ 7.50, 7.50 and 1.80 Hz, H-50),
7.26e7.16 (m, 6H, H-60 and 5H phenyl), 4.17 (q, 2H, J ¼ 6.90 Hz,
OCH2), 4.15 (q, 2H, J ¼ 6.90 Hz, OCH2), 1.27 (t, 3H, J ¼ 6.90 Hz, CH3),
1.18 (t, 3H, J ¼ 6.90 Hz, CH3). HRMS-ESI m/z [MþNa]þ Calcd for
C22H20N2O6Na: 431.1219, Found: 431.1240.
5.1.7. General procedure for ethyl 4,5-dihydro-4-oxo-5H-
phenylpyrrolo[1,2-a]quinoxaline-carboxylate (6a-d)
A suspension of 5 (2.6 mmol) and iron powder (9.5 mmol) in
11 mL of acetic acid was heated under reﬂux for 2 h. The reaction
mixture was cooled, suspended in 20 mL of a 1 M aqueous solution
of HCl, agitated, then ﬁltered off, washed with HCl 1 M (8 mL),
water, Et2O and dried to give 6 as a ﬂuffy white solid.
5.1.7.1. Ethyl 4,5-dihydro-4-oxo-5H-2-phenylpyrrolo[1,2-a]quinoxa-
line-3-carboxylate (6a). Beige crystals (69%), mp 239e241 C. IR
(KBr) 3200, 2750 (NH),1720 (COO),1660 (CON). 1H NMR (DMSO-d6)
d: 11.49 (s, 1H, NH), 8.58 (s, 1H, H-1), 8.17 (d, 1H, J ¼ 8.10 Hz, H-9),
7.55 (d, 2H, J ¼ 7.50 Hz, H-2 phenyl and H-6 phenyl), 7.45 (t, 2H,
J ¼ 7.50 Hz, H-3 phenyl and H-5 phenyl), 7.34e7.27 (m, 4H, H-4
phenyl, H-6, H-7 and H-8), 4.30 (q, 2H, J ¼ 7.20 Hz, OCH2), 1.25 (t,
3H, J¼ 7.20 Hz, CH3). 13C NMR (DMSO-d6) d: 157.0 (C-4), 155.2 (C-7),
129.7 (C-9a), 122.6 (C-5a), 117.7 (C-1), 116.8 (C-3a), 116.0 (C-6), 112.3
(C-3), 111.0 (C-2), 108.9 (C-9), 100.8 (C-8), 55.4 (CH3O). Anal. Calcd.
for C12H10N2O2: C, 67.28; H, 4.71; N, 13.08. Found: C, 67.40; H, 4.81;
N, 12.94.
5.1.7.2. Ethyl 4,5-dihydro-4-oxo-5H-3-phenylpyrrolo[1,2-a]quinoxa-
line-2-carboxylate (6b). Beige crystals (88%), mp > 310 C. IR (KBr)
3200, 2800 (NH), 1720 (COO), 1665 (CON). 1H NMR (DMSO-d6) d:
11.25 (s, 1H, NH), 8.80 (s, 1H, H-1), 8.28 (d, 1H, J ¼ 7.80 Hz, H-9),
7.34e7.27 (m, 7H, H-6, H-8 and 5H phenyl), 7.21 (t, 1H, J ¼ 7.80 Hz,
H-7), 4.09 (q, 2H, J ¼ 6.90 Hz, OCH2), 1.09 (t, 3H, J ¼ 6.90 Hz, CH3).
13C NMR (DMSO-d6) d: 157.0 (C-4), 155.2 (C-7), 129.7 (C-9a), 122.6
(C-5a), 117.7 (C-1), 116.8 (C-3a), 116.0 (C-6), 112.3 (C-3), 111.0 (C-2),
108.9 (C-9), 100.8 (C-8), 55.4 (CH3O). Anal. Calcd. for C12H10N2O2: C,
67.35; H, 4.78; N, 13.15. Found: C, 67.47; H, 4.92; N, 13.30.
5.1.7.3. Ethyl 4,5-dihydro-4-oxo-5H-1-phenylpyrrolo[1,2-a]quinoxa-
line-3-carboxylate (6c). White crystals (58%), mp ¼ 218e220 C. IR
(KBr) 3200, 2700 (NH),1700 (COO),1670 (CON). 1H NMR (DMSO-d6)
d: 11.50 (s, 1H, NH), 7.56e7.53 (m, 5H, 5H phenyl), 7.32 (d, 1H,
J ¼ 7.70 Hz, H-9), 7.24 (t, 1H, J ¼ 7.70 Hz, H-8), 6.97 (d, 1H,
J¼ 7.70 Hz, H-6), 6.84 (t, 1H, J¼ 7.70 Hz, H-7), 6.81 (s, 1H, H-2), 4.27
(q, 2H, J ¼ 6.90 Hz, OCH2), 1.30 (t, 3H, J ¼ 6.90 Hz, CH3). Anal. Calcd.
for C12H10N2O2: C, 67.21; H, 4.64; N, 13.01. Found: C, 67.33; H, 4.74;
N, 12.76.
5.1.7.4. Ethyl 4,5-dihydro-4-oxo-5H-1-phenylpyrrolo[1,2-a]quinoxa-
line-2-carboxylate (6d). White crystals (84%), mp ¼ 229e231 C. IR
(KBr) 3200, 2700 (NH),1695 (COO),1665 (CON). 1H NMR (DMSO-d6)
d: 11.53 (s, 1H, NH), 7.61e7.53 (m, 3H, 3H phenyl), 7.50e7.47 (m, 2H,
2H phenyl), 7.44 (s, 1H, H-3), 7.29 (d, 1H, J ¼ 7.90 Hz, H-6), 7.20 (t,
1H, J ¼ 7.90 Hz, H-8), 6.75 (t, 1H, J ¼ 7.90 Hz, H-7), 6.64 (d, 1H,
J ¼ 7.90 Hz, H-9), 4.02 (q, 2H, J ¼ 6.90 Hz, OCH2), 1.30 (t, 3H,
J ¼ 6.90 Hz, CH3). Anal. Calcd. for C12H10N2O2: C, 67.31; H, 4.74; N,
13.11. Found: C, 67.43; H, 4.95; N, 12.86.
5.1.8. General procedure for ethyl 4-chloro-phenylpyrrolo[1,2-a]
quinoxaline-carboxylate (7a-d)
A solution of 5H-pyrrolo[1,2-a]quinoxalin-4-one 6 (4 mmol) in
POCl3 (8 mL) was reﬂuxed for 2 h. After removing excess of reactive
under vacuum, the residue was carefully dissolved in water at 0 C
and the resulting solution was made basic with sodium carbonate.
The precipitate was ﬁltered, dried and recrystallized from ethyl
acetate to give 7.
5.1.8.1. Ethyl 4-chloro-2-phenylpyrrolo[1,2-a]quinoxaline-3-
carboxylate (7a). White crystals (77%), mp ¼ 109e111 C. IR (KBr)
1715 (COO). 1H NMR (CDCl3) d: 7.97 (s,1H, H-1), 7.87 (dd,1H, J¼ 8.10
and 1.20 Hz, H-9), 7.80 (dd, 1H, J¼ 8.10 and 1.20 Hz, H-6), 7.58e7.32
(m, 7H, H-7, H-8 and 5H phenyl), 4.41 (q, 2H, J¼ 7.20 Hz, OCH2),1.34
(t, 3H, J ¼ 7.20 Hz, CH3). HRMS-ESI m/z [MþH]þ Calcd for
C20H15N2O2ClNa: 351.0900, Found: 351.0918.
5.1.8.2. Ethyl 4-chloro-3-phenylpyrrolo[1,2-a]quinoxaline-2-
carboxylate (7b). Beige crystals (96%), mp ¼ 144e146 C. IR (KBr)
1715 (COO). 1H NMR (CDCl3) d: 8.56 (s, 1H, H-1), 7.93 (dd, 1H,
J ¼ 8.10 and 1.50 Hz, H-9), 7.88 (dd, 1H, J ¼ 8.10 and 1.50 Hz, H-6),
7.59 (ddd,1H, J¼ 8.10, 7.90 and 1.50 Hz, H-8), 7.52 (ddd,1H, J¼ 8.10,
7.90 and 1.50 Hz, H-7), 7.44e7.37 (m, 5H, 5H phenyl), 4.19 (q, 2H,
J ¼ 7.20 Hz, OCH2), 1.14 (t, 3H, J ¼ 7.20 Hz, CH3). HRMS-ESI m/z
[MþH]þ Calcd for C20H15N2O2ClNa: 351.0900, Found: 351.0933.
5.1.8.3. Ethyl 4-chloro-1-phenylpyrrolo[1,2-a]quinoxaline-3-
carboxylate (7c). Beige crystals (94%), mp ¼ 108e110 C. IR (KBr)
1720 (COO). 1H NMR (CDCl3) d: 7.91 (d, 1H, J ¼ 8.10 Hz, H-9),
7.55e7.48 (m, 5H, 5H phenyl), 7.41 (t, 1H, J ¼ 8.10 Hz, H-8), 7.33 (d,
1H, J ¼ 8.10 Hz, H-6), 7.17 (t, 1H, J ¼ 8.10 Hz, H-7), 7.09 (s, 1H, H-2),
4.44 (q, 2H, J ¼ 7.20 Hz, OCH2), 1.44 (t, 3H, J ¼ 7.20 Hz, CH3). HRMS-
ESI m/z [MþH]þ Calcd for C20H15N2O2ClNa: 351.0900, Found:
351.0903.
5.1.8.4. Ethyl 4-chloro-1-phenylpyrrolo[1,2-a]quinoxaline-2-
carboxylate (7d). Orange crystals (90%), mp ¼ 178 C. IR (KBr)
1710 (COO). 1H NMR (CDCl3) d: 7.86 (dd, 1H, J ¼ 8.10 and 1.30 Hz, H-
6), 7.63e7.55 (m, 4H, 3H phenyl and H-3), 7.50e7.46 (m, 2H, 2H
phenyl), 7.37 (ddd,1H, J¼ 8.10, 7.85 and 1.30 Hz, H-8), 7.10 (ddd,1H,
J¼ 8.10, 7.85 and 1.30 Hz, H-7), 7.01 (dd, 1H, J¼ 8.10 and 1.30 Hz, H-
9), 4.19 (q, 2H, J ¼ 7.20 Hz, OCH2), 1.18 (t, 3H, J ¼ 7.20 Hz, CH3).
HRMS-ESI m/z [M þ H]þ Calcd for C20H15N2O2ClNa: 351.0900,
Found: 351.0925.
5.1.9. General procedure for ethyl 4-(4-formylphenyl)-
phenylpyrrolo[1,2-a]quinoxaline-carboxylate (8a-d)
To suspension of compound 7a-d (4.64 mmol), and Pd(PPh3)4
(0.232 mmol) in a mixture of toluene/EtOH (75/4.1 mL) under ni-
trogen were added K2CO3 (5.1 mmol) and 4-formylphenylboronic
acid (5.1 mmol). The reaction mixture was reﬂuxed for 24 h, and
the cooled suspension was extracted with CH2Cl2 (3  80 mL). The
organic layer was washedwith a saturated solution of NaCl (95mL),
and the combined organic extracts were dried over sodium sulfate,
ﬁltered, and evaporated under reduced pressure. The crude residue
was triturated in ethanol. The resulting precipitate was ﬁltered,
washed with ethanol, and puriﬁed by column chromatography on
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silica gel using dichloromethane as eluent gave the pure product 8.
5.1.9.1. Ethyl 4-(4-formylphenyl)-2-phenylpyrrolo[1,2-a]quinoxaline-
3-carboxylate (8a). Yellow crystals (83%), mp ¼ 76e78 C. IR (KBr)
1720 (COO), 1700 (CHO). 1H NMR (CDCl3) d: 10.13 (s, 1H, CHO), 8.12
(dd, 1H, J ¼ 8.10 and 1.30 Hz, H-9), 8.10 (s, 1H, H-1), 8.04 (d, 2H,
J ¼ 7.80 Hz, H-30 and H-50), 8.00 (dd, 1H, J ¼ 8.10 and 1.30 Hz, H-6),
7.96 (d, 2H, J ¼ 7.80 Hz, H-20 and H-60), 7.67 (ddd, 1H, J ¼ 8.10, 7.85
and 1.30 Hz, H-8), 7.64e7.52 (m, 3H, H-7 and 2H phenyl), 7.48e7.39
(m, 3H, 3H phenyl), 3.63 (q, 2H, J ¼ 6.90 Hz, OCH2), 0.89 (t, 3H,
J ¼ 6.90 Hz, CH3). HRMS-ESIm/z [M þ H]þ Calcd for C27H20N2O3Na:
421.1552, Found: 421.1552.
5.1.9.2. Ethyl 4-(4-formylphenyl)-3-phenylpyrrolo[1,2-a]quinoxaline-
2-carboxylate (8b). Yellow crystals (60%), mp ¼ 160e162 C. IR
(KBr) 1715 (COO), 1700 (CHO). 1H NMR (CDCl3) d: 9.93 (s, 1H, CHO),
8.69 (s, 1H, H-1), 8.09 (d, 1H, J ¼ 7.80 Hz, H-9), 8.05 (d, 1H,
J¼ 7.80 Hz, H-6), 7.66 (t, 1H, J¼ 7.80 Hz, H-8), 7.58 (t,1H, J¼ 7.80 Hz,
H-7), 7.53 (d, 2H, J¼ 7.20 Hz, H-30 and H-50), 7.38 (d, 2H, J¼ 7.20 Hz,
H-20 and H-60), 7.03e6.95 (m, 5H, 5H phenyl), 4.23 (q, 2H,
J ¼ 6.90 Hz, OCH2), 1.20 (t, 3H, J ¼ 6.90 Hz, CH3). HRMS-ESI m/z
[MþH]þ Calcd for C27H20N2O3Na: 421.1552, Found: 421.1532.
5.1.9.3. Ethyl 4-(4-formylphenyl)-1-phenylpyrrolo[1,2-a]quinoxaline-
3-carboxylate (8c). Pale yellow crystals (79%), mp ¼ 178e180 C. IR
(KBr) 1720 (COO),1695 (CHO). 1H NMR (CDCl3) d: 10.14 (s, 1H, CHO),
8.09e8.06 (m,1H, H-9), 8.04 (d, 2H, J ¼ 8.10 Hz, H-30 and H-50), 7.97
(d, 2H, J ¼ 8.10 Hz, H-20 and H-60), 7.58e7.56 (m, 5H, 5H phenyl),
7.48e7.44 (m, 2H, H-6 and H-8), 7.25e7.20 (m, 1H, H-7), 7.21 (s, 1H,
H-2), 3.80 (q, 2H, J ¼ 7.20 Hz, OCH2), 0.99 (t, 3H, J ¼ 7.20 Hz, CH3).
HRMS-ESIm/z [M þ H]þ Calcd for C27H20N2O3Na: 421.1552, Found:
421.1573.
5.1.9.4. Ethyl 4-(4-formylphenyl)-1-phenylpyrrolo[1,2-a]quinoxaline-
2-carboxylate (8d). Yellow crystals (89%), mp ¼ 182e184 C. IR
(KBr) 1700 (COO and CHO). 1H NMR (CDCl3) d: 10.18 (s, 1H, CHO),
8.20 (d, 2H, J ¼ 7.95 Hz, H-30 and H-50), 8.12 (d, 2H, J ¼ 7.95 Hz, H-20
and H-60), 8.02 (d, 1H, J ¼ 7.80 Hz, H-6), 7.62e7.48 (m, 6H, 5H
phenyl and H-3), 7.42 (t, 1H, J¼ 7.80 Hz, H-8), 7.13e7.09 (m, 2H, H-7
and H-9), 4.16 (q, 2H, J¼ 7.20 Hz, OCH2),1.13 (t, 3H, J¼ 7.20 Hz, CH3).
HRMS-ESIm/z [M þ H]þ Calcd for C27H20N2O3Na: 421.1552, Found:
421.1566.
5.1.10. General procedure for ethyl 4-{4-[(4-(2-oxo-2,3-dihydro-
1H-benzimidazol-1-yl)piperidin-1-yl)benzyl]}-phenylpyrrolo[1,2-a]
quinoxaline-carboxylate, ethyl 4-{4-[(4-(5-ﬂuoro-1H-benzimidazol-
2-yl)piperidin-1-yl)benzyl]}-phenylpyrrolo[1,2-a]quinoxaline-
carboxylate and ethyl 4-{4-[4-(3-(pyridin-2-yl)-1,2,4-triazol-5-yl)
piperidin-1-yl)benzyl]}-phenylpyrrolo[1,2-a]quinoxaline-
carboxylate (1a-l)
The pH of a solution of the aldehyde 8a-d (0.784 mmol) and 4-
(2-ketobenzimidazolin-1-yl)piperidine or 4-(5-chloro-2-
ketobenzimidazolin-1-yl)piperidine or 2-(3-piperidin-4-yl-1H-
1,2,4-triazol-5-yl)pyridine (0.941 mmol) in 15 mL methanol was
adjusted to 6 by the dropwise addition of acetic acid. Powered
sodium cyanoborohydride (2.15 mmol) was then added, and the
resultant mixture was reﬂuxed for 5 h. After removal of the
methanol by rotary evaporation, the residue was triturated inwater
and extractedwith dichloromethane. The organic layer waswashed
with water, dried over magnesium sulfate and evaporated to dry-
ness. Column chromatography of the residue on silica gel using
ethyl acetate - cyclohexane (1/1) then methanol-chloroform (1/9)
as eluents gave the crude product. This solid was then triturated
with diethyl ether, ﬁltered, washed with diethyl ether and dried
under reduced pressure to give the compounds 1a-l.
5.1.10.1. Ethyl 4-{4-[(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)
piperidin-1-yl)benzyl]}-2-phenylpyrrolo[1,2-a]quinoxaline-3-
carboxylate (1a). White crystals (53%), mp 185e187 C. 1H NMR
(CDCl3) d: 9.68 (s,1H, NH), 8.10 (d, J¼ 7.8 Hz,1H, H-9), 8.08 (s,1H, H-
1), 7.96 (d, J¼ 7.5 Hz,1H, H-6), 7.78 (d, J¼ 7.8 Hz, 2H, H-20 and H-60),
7.64e7.53 (m, 6H, H-7, H-8, H-30, H-50, H-4 benzimid. and H-7
benzimid.), 7.45e7.30 (m, 4H, H-2 phenyl, H-3 phenyl, H-5 phenyl
and H-6 phenyl), 7.10e7.07 (m, 3H, H-4 phenyl, H-5 benzimid. and
H-6 benzimid.), 4.46e4.37 (m, 1H, CH pip.), 3.67 (q, J ¼ 6.9 Hz, 2H,
CH2), 3.66 (s, 2H, CH2N), 3.13e3.08 (m, 2H, NCH2 pip.), 2.58e2.44
(m, 2H, NCH2 pip.), 2.28e2.20 (m, 2H, CH2 pip.), 1.88e1.84 (m, 2H,
CH2 pip.), 0.92 (t, J ¼ 6.9 Hz, 3H, CH3). 13C NMR (CDCl3) d: 166.94
(C]O), 156.52 (C-4), 155.69 (C]O benzimid.), 141.51 (C-3a and C-
5a), 139.74 (C-40 and C-1 phenyl), 137.42 (C-7a benzimid.), 134.64
(C-10), 131.82 (C-6), 130.59 (C-3 and C-5 phenyl), 130.37 (C-30 and C-
50), 129.86 (C-20 and C-60), 129.71 (C-4 phenyl), 129.33 (C-2 and C-6
phenyl), 129.04 (C-7), 127.57 (C-8), 127.19 (C-2 and C-3a benzimid.),
125.08 (C-9a), 122.49 (C-5 benzimid. and C-6 benzimid.), 115.18 (C-
9), 114.61 (C-3), 114.37 (C-1), 111.15 (C-4 benzimid. and C-7 benzi-
mid.), 64.05 (NCH2), 62.47 (CH2), 54.56 (NCH2 pip.), 52.12 (CH pip.),
30.65 (CH2 pip.), 15.08 (CH3). HRMS-ESI m/z [MþNa]þ Calcd for
C39H35N5O3Na: 644.2637, Found: 644.2634.
5.1.10.2. Ethyl 4-{4-[(4-(5-ﬂuoro-1H-benzimidazol-2-yl)piperidin-1-
yl)benzyl]}-2-phenylpyrrolo[1,2-a]quinoxaline-3-carboxylate (1b).
Cream crystals (61%), mp 162e164 C. 1H NMR (CDCl3) d: 8.08 (s,1H,
H-1), 8.04 (d, J ¼ 7.8 Hz, 1H, H-9), 7.96 (d, J ¼ 7.8 Hz, 1H, H-6), 7.70
(d, J ¼ 7.2 Hz, 2H, H-20 and H-60), 7.59 (t, J ¼ 7.2 Hz, 1H, H-7),
7.55e7.47 (m, 3H, H-30, H-50 and H-8), 7.44e7.33 (m, 7H, H-2
phenyl, H-3 phenyl, H-5 phenyl, H-6 phenyl, H-4 benzimid., H-6
benzimid. and H-7 benzimid.), 6.93 (t, J ¼ 7.2 Hz, 1H, H-4 phenyl),
3.61 (q, J ¼ 7.0 Hz, 2H, CH2), 3.54 (s, 2H, CH2N), 2.91 (d, 2H,
J ¼ 10.2 Hz, NCH2 pip.), 2.84 (t, J ¼ 11.4 Hz, 1H, CH pip.), 2.05 (t,
J ¼ 10.8 Hz, 2H, CH2 pip.), 1.99 (d, J ¼ 11.4 Hz, 2H, NCH2 pip.),
1.94e1.85 (m, 2H, CH2 pip.), 0.87 (t, J ¼ 7.0 Hz, 3H, CH3). 13C NMR
(CDCl3) d: 165.68 (C]O), 160.05 (d, J ¼ 234 Hz, C-5 benzimid.),
158.46 (C-4), 139.78 (C-40), 138.14 (C-1 phenyl, C-10, C-2 benzimid.,
C-5a and C-3a benzimid.), 135.91 (C-3a and C-5a), 133.21 (C-6 and
C-7a benzimid.), 130.55 (C-20 and C-60), 129.99 (C-30 and C-50),
129.23 (C-7), 128.91 (C-8), 128.51 (C-4 phenyl), 127.95 (C-2 phenyl,
C-3 phenyl, C-5 phenyl and C-6 phenyl), 127.73 (C-9a), 125.85 (C-2),
123.62 (C-3), 113.95 (C-9), 113.48 (C-1 and C-7 benzimid.), 113.24
(C-4 benzimid. and C-6 benzimid.), 62.71 (NCH2), 61.16 (CH2), 53.17
(NCH2 pip.), 36.50 (CH pip.), 30.74 (CH2 pip.), 13.63 (CH3). HRMS-ESI
m/z [MþH]þ Calcd for C39H35N5O2F: 624.2775, Found: 624.2751.
5.1.10.3. Ethyl 4-{4-[4-(3-(pyridin-2-yl)-1,2,4-triazol-5-yl)piperidin-
1-yl)benzyl]}-2-phenylpyrrolo[1,2-a]quinoxaline-3-carboxylate (1c).
White crystals (56%), mp 142e144 C. 1H NMR (CDCl3) d: 8.73 (d,
J ¼ 3.0 Hz, 1H, H-6 pyr.), 8.22 (d, J ¼ 7.8 Hz, 1H, H-5 pyr.), 8.08 (d,
J ¼ 8.4 Hz, 1H, H-6), 8.06 (s, 1H, H-1), 7.94 (d, J ¼ 8.4 Hz, 1H, H-9),
7.84 (t, J ¼ 7.8 Hz, 1H, H-4 pyr.), 7.74 (d, J ¼ 7.8 Hz, 2H, H-20 and H-
60), 7.58 (t, J ¼ 7.8 Hz, 1H, H-7), 7.56e7.49 (m, 4H, H-30, H-50, H-2
phenyl and H-6 phenyl), 7.44e7.40 (m, 2H, H-3 phenyl and H-5
phenyl), 7.38e7.34 (m, 2H, H-4 phenyl and H-3 pyr.), 7.28 (m,1H, H-
8), 3.65 (s, 2H, CH2N), 3.64 (q, J ¼ 7.2 Hz, 2H, CH2), 3.06 (d, 2H,
J ¼ 10.8 Hz, NCH2 pip.), 2.97e2.89 (m, 1H, CH pip.), 2.23 (t,
J ¼ 10.2 Hz, 2H, CH2 pip.), 2.12 (d, J ¼ 12.0 Hz, 2H, NCH2 pip.),
2.10e2.00 (m, 2H, CH2 pip.), 0.91 (t, J ¼ 7.2 Hz, 3H, CH3). 13C NMR
(CDCl3) d: 165.56 (C]O), 154.36 (C-4, C-3 Triazole and C-2 pyr.),
149.50 (C-6 pyr.), 147.15 (C-5 Triazole), 138.36 (C-40 and C-4 pyr.),
137.48 (C-1 phenyl, C-10 and C-5a), 136.04 (C-3a), 133.31 (C-6),
130.40 (C-20 and C-60), 129.41 (C-30, C-50 and C-7), 128.97 (C-8),
128.47 (C-4 phenyl), 128.31 (C-2 phenyl and C-6 phenyl), 127.95 (C-
3 phenyl and C-5 phenyl), 127.62 (C-9a), 125.83 (C-2), 124.60 (C-3
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pyr.), 123.69 (C-3), 121.79 (C-5 pyr.), 113.78 (C-9), 113.32 (C-1), 63.02
(CH2N), 61.19 (CH2), 53.39 (CH pip. and NCH2), 30.74 (CH2 pip.),
13.68 (CH3). HRMS-ESI m/z [MþNa]þ Calcd for C39H35N7O2Na:
656.2750, Found: 656.2768.
5.1.10.4. Ethyl 4-{4-[(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)
piperidin-1-yl)benzyl]}-3-phenylpyrrolo[1,2-a]quinoxaline-2-
carboxylate (1d). White crystals (60%), mp 259e262 C. 1H NMR
(CDCl3) d: 9.95 (s, 1H, NH), 8.67 (s, 1H, H-1), 8.07 (d, J ¼ 8.0 Hz, 1H,
H-6), 8.03 (d, J¼ 8.0 Hz,1H, H-9), 7.61 (t, J¼ 8.0 Hz,1H, H-7), 7.55 (t,
J ¼ 8.0 Hz, 1H, H-8), 7.34 (d, J ¼ 7.2 Hz, 1H, H-4 benzimid.), 7.23 (d,
J ¼ 7.8 Hz, 2H, H-20 and H-60), 7.15e7.07 (m, 3H, H-5 benzimid., H-6
benzimid., H-7 benzimid.), 7.06e6.96 (m, 7H, H-30, C-50, H-2
phenyl, H-3 phenyl, H-4 phenyl, H-5 phenyl and H-6 phenyl), 4.45
(t, 1H, CH pip.), 4.23 (q, 2H, CH2), 3.46 (s, 2H, CH2N), 3.00 (d,
J ¼ 10.2 Hz, 2H, NCH2 pip.), 2.52 (q, J ¼ 7.2 Hz, 2H, CH2 pip.), 2.15 (t,
J ¼ 11.4 Hz, 2H, NCH2 pip.), 1.88 (d, J ¼ 10.8 Hz, 2H, CH2 pip.), 1.19 (t,
J ¼ 7.2 Hz, 3H, CH3). 13C NMR (CDCl3) d: 165.54 (C]O), 158.05 (C-4),
156.58 (C]O benzimid.), 140.33 (C-40), 137.93 (C-10), 137.56 (C-3a
and C-5a), 135.22 (C-1 phenyl), 132.62 (C-3a benzimid., C-3 phenyl,
C-4 phenyl and C-5 phenyl), 131.80 (C-6), 130.70 (C-7a benzimid.),
130.06 (20 and C-60), 129.54 (C-7, C-30 and C-50), 128.20 (C-2 phenyl
and C-6 phenyl), 127.80 (C-8), 126.81 (C-9a),124.41 (C-2), 122.61 (C-
5 benzimid.), 122.52 (C-6 benzimid.), 120.66 (C-3), 119.65 (C-1),
115.21 (C-9) 111.25 (C-7 benzimid.), 111.17 (C-4 benzimid.), 64.03
(CH2N), 61.79 (CH2), 54.50 (NCH2 pip.), 52.37 (CH pip.), 30.81 (CH2
pip.), 15.53 (CH3). HRMS-ESI m/z [MþH]þ Calcd for C39H36N5O3:
622.2818, Found: 622.2795.
5.1.10.5. Ethyl 4-{4-[(4-(5-ﬂuoro-1H-benzimidazol-2-yl)piperidin-1-
yl)benzyl]}-3-phenylpyrrolo[1,2-a]quinoxaline-2-carboxylate (1e).
White crystals (78%), mp 244e247 C. 1H NMR (CDCl3) d: 9.87 (s,1H,
NH), 8.67 (s, 1H, H-1), 8.04 (d, J¼ 7.0 Hz, 1H, H-9), 8.03 (t, J¼ 7.0 Hz,
1H, H-6), 7.61 (t, J¼ 7.0 Hz,1H, H-7), 7.54 (t, J¼ 7.0 Hz,1H, H-8), 7.18
(d, J ¼ 8.0 Hz, 2H, H-20 and H-60), 7.06e6.96 (m, 7H, H-30, H-50, H-2
phenyl, H-3 phenyl, H-4 phenyl, H-5 phenyl, H-6 phenyl, H-4
benzimid., H-6 benzimid. and H-7 benzimid.), 4.23 (q, J ¼ 7.2 Hz,
2H, CH2), 3.41 (s, 2H, CH2N), 2.97e2.86 (m, 3H, NCH2 pip. and CH
pip.), 2.11 (d, J ¼ 11.6 Hz, 2H, CH2 pip.), 2.08 (t, J ¼ 11.6 Hz, 2H, NCH2
pip.), 1.93 (m, 2H, CH2 pip.), 1.20 (t, J ¼ 7.2 Hz, 3H, CH3). 13C NMR
(CDCl3) d: 165.56 (C]O), 161.10 (d, J ¼ 236 Hz, C-5 benzimid.),
158.21 (C-4), 140.16 (C-40), 138.00 (C-1 phenyl, C-10, C-2 benzimid.
and C-3a benzimid.), 137.57 (C-3a and C-5a), 135.19 (C-7a benzi-
mid.), 131.62 (C-6), 130.11 (C-20 and C-60), 129.64 (30 and C-50),
129.54 (C-7), 128.19 (C-8), 128.04 (C-2 phenyl, C-3 phenyl, C-4
phenyl, C-5 phenyl and C-6 phenyl), 127.77 (9a), 124.44 (C-2),
120.69 (C-3), 119.69 (C-1), 115.31 (C-9 and C-7 benzimid.), 111.90 (C-
4 benzimid. and C-6 benzimid.), 64.24 (CH2N), 61.92 (CH2), 54.66
(NCH2 pip.), 38.34 (CH pip.), 32.34 (CH2 pip.),15.60 (CH3). HRMS-ESI
m/z [M þ H]þ Calcd for C39H35N5O2F: 624.2775, Found: 624.2783.
5.1.10.6. Ethyl 4-{4-[4-(3-(pyridin-2-yl)-1,2,4-triazol-5-yl)piperidin-
1-yl)benzyl]}-3-phenylpyrrolo[1,2-a]quinoxaline-2-carboxylate (1f).
Pale yellow crystals (53%), mp 138e140 C. 1H NMR (CDCl3) d: 8.73
(d, J ¼ 3.0 Hz, 1H, H-6 pyr.), 8.64 (s, 1H, H-1), 8.23 (d, J ¼ 7.8 Hz, 1H,
H-5 pyr.), 8.02 (d, J ¼ 8.4 Hz, 1H, H-9), 7.99 (d, J ¼ 8.4 Hz, 1H, H-6),
7.84 (t, J ¼ 7.8 Hz, 1H, H-4 pyr.), 7.56 (t, J ¼ 7.8 Hz, 1H, H-7), 7.50 (t,
J ¼ 7.2 Hz, 1H, H-8), 7.36 (t, J ¼ 6.0 Hz, 1H, H-3 pyr.), 7.17 (d,
J ¼ 7.2 Hz, 2H, H-20 and H-60), 7.06e7.02 (m, 1H, H-4 phe-
nyl),7.01e6.94 (m, 6H, H-30, H-50, H-2 phenyl, H-3 phenyl, H-5
phenyl, and H-6 phenyl), 4.20 (q, J ¼ 7.2 Hz, 2H, CH2), 3.49 (s, 2H,
CH2N), 3.01e2.93 (m, 3H, NCH2 pip. and CH pip.), 2.23e2.13 (m, 4H,
NCH2 pip. and CH2 pip.), 2.12e2.03 (m, 2H, CH2 pip.), 1.17 (t,
J ¼ 7.2 Hz, 3H, CH3). 13C NMR (CDCl3) d: 164.07 (C]O), 156.45 (C-4,
C-3 Triazole and C-2 pyr.), 149.47 (C-6 pyr.), 147.36 (C-5 Triazole),
138.47 (C-40 and C-4 pyr.), 136.63 (C-1 phenyl and C-10), 135.97 (C-
5a), 133.63 (C-3a), 130.21 (C-6), 128.64 (C-20 and C-60), 128.48 (C-30
and C-50), 128.09 (C-7), 126.77 (C-8), 126.49 (C-3 phenyl, C-4 phenyl
and C-5 phenyl), 126.42 (C-2 phenyl and C-6 phenyl), 126.31 (9a),
125.41 (C-3 pyr.), 122.87 (C-2), 121.87 (C-5 pyr.), 119.12 (C-3), 118.26
(C-9), 113.76 (C-1), 62.64 (CH2N), 60.34 (CH2), 53.03 (NCH2 pip.),
35.14 (CH pip.), 30.41 (CH2 pip.), 14.07 (CH3). HRMS-ESI m/z
[M þ H]þ Calcd for C39H36N7O2: 634.2930, Found: 634.2952.
5.1.10.7. Ethyl 4-{4-[(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)
piperidin-1-yl)benzyl]}-1-phenylpyrrolo[1,2-a]quinoxaline-3-
carboxylate (1g). Pale yellow crystals (66%), mp 167e169 C. 1H
NMR (CDCl3) d: 10.52 (s, 1H, NH), 8.10 (d, J ¼ 8.0 Hz, 1H, H-6), 7.82
(d, J ¼ 7.6 Hz, 2H, H-20 and H-60), 7.62e7.53 (m, 8H, H-4 benzimid.,
H-2 phenyl, H-3 phenyl, H-4 phenyl, H-5 phenyl, H-6 phenyl, H-30
and H-50), 7.44 (d, J ¼ 8.0 Hz, 1H, H-9), 7.43 (t, J ¼ 8.0 Hz, 1H, H-7),
7.33 (d, J ¼ 8.0 Hz, 1H, H-5 benzimid.), 7.21e7.02 (m, 4H, H-2, H-8,
H-6 benzimid. and C-7 benzimid.), 4.52e4.36 (m, 1H, CH pip.), 3.79
(q, J ¼ 7.2 Hz, 2H, CH2), 3.69 (s, 2H, CH2N), 3.13 (d, J ¼ 10.8 Hz, 2H,
NCH2 pip.), 2.62e2.48 (m, 2H, CH2 pip.), 2.27 (t, J ¼ 10.8 Hz, 2H,
NCH2 pip.), 1.86 (d, J ¼ 14.8 Hz, 2H, CH2 pip.), 0.98 (t, J ¼ 7.2 Hz, 3H,
CH3). 13C NMR (CDCl3) d: 166.54 (C]O), 156.74 (C]O benzimid.),
155.97 (C-4), 141.21 (C-3a and C-40), 140.77 (C-5a), 134.78 (C-10),
133.44 (C-1 phenyl and C-3a benzimid.), 131.68 (C-6), 131.12 (C-30
and C-50), 130.56 (C-7a benzimid.), 130.37 (C-2 phenyl, C-3 phenyl,
C-4 phenyl, C-5 phenyl and C-6 phenyl), 129.64 (C-20 and C-60),
129.46 (C-7), 128.66 (C-8), 127.22 (C-9a), 122.56 (C-1, C-3 and C-5
benzimid.), 120.22 (C-2 and C-6 benzimid.), 118.10 (C-9), 111.22 (C-7
benzimid.), 111.19 (C-4 benzimid.), 64.09 (CH2N), 62.27 (CH2), 54.60
(NCH2 pip.), 52.18 (CH pip.), 30.69 (CH2 pip.), 15.27 (CH3). HRMS-ESI
m/z [M þ H]þ Calcd for C39H36N5O3: 622.2818, Found: 622.2802.
5.1.10.8. Ethyl 4-{4-[(4-(5-ﬂuoro-1H-benzimidazol-2-yl)piperidin-1-
yl)benzyl]}-1-phenylpyrrolo[1,2-a]quinoxaline-3-carboxylate (1h).
Pale yellow crystals (60%), mp 156e158 C. 1H NMR (CDCl3) d: 11.40
(s, 1H, NH), 8.02 (d, J ¼ 7.6 Hz, 1H, H-6), 7.74 (d, J ¼ 8.0 Hz, 2H, H-20
and H-60), 7.61e7.52 (m, 5H, H-2 phenyl, H-3 phenyl, H-4 phenyl, H-
5 phenyl and H-6 phenyl), 7.46 (d, J¼ 8.0 Hz,1H, H-9), 7.44e7.37 (m,
3H, H-7, H-30 and H-50), 7.21e7.15 (m, 4H, H-2, H-8, H-4 benzimid.
and H-7 benzimid.), 6.96 (td, J ¼ 9.2 Hz and 1.6 Hz, 1H, H-6 ben-
zimid.), 3.72 (q, J ¼ 7.2, 2H, CH2), 3.55 (s, 2H, CH2N), 2.98e2.84 (m,
3H, NCH2 pip. and CH pip.), 2.13e1.98 (m, 4H, NCH2 pip. and CH2
pip.), 1.96e1.81 (m, 2H, CH2 pip.), 0.92 (t, J ¼ 7.2 Hz, 3H, CH3). 13C
NMR (CDCl3) d: 166.61 (C]O), 160.7 (d, J ¼ 235 Hz, C-5 benzimid.),
156.16 (C-4), 141.49 (C-40), 140.40 (C-3a and C-5a), 138.66 (C-2
benzimid. and C-3a benzimid.), 134.65 (C-1 phenyl), 133.67 (C-7a
benzimid.), 131.22 (C-30 and C-50), 131.11 (C-3 phenyl, C-4 phenyl
and C-5 phenyl),130.63 (C-6, C-2 phenyl and C-6 phenyl),130.39 (C-
7), 129.35 (C-20 and C-60), 128.72 (C-8), 128.54 (C-9a), 127.38 (C-1, C-
3 and C-7 benzimid.), 120.33 (C-6 benzimid.), 118.21 (C-9), 111.50
(C-4 benzimid.), 64.19 (CH2N), 62.32 (CH2), 54.70 (NCH2 pip.), 38.34
(CH pip.), 32.34 (CH2 pip.), 15.21 (CH3). HRMS-ESI m/z [MþH]þ
Calcd for C39H35N5O2F: 624.2775, Found: 624.2800.
5.1.10.9. Ethyl 4-{4-[4-(3-(pyridin-2-yl)-1,2,4-triazol-5-yl)piperidin-
1-yl)benzyl]}-1-phenylpyrrolo[1,2-a]quinoxaline-3-carboxylate (1i).
Pale yellow crystals (69%), mp 145e147 C. 1H NMR (CDCl3) d: 9.12
(s, 1H, NH), 8.68 (d, J ¼ 4.0 Hz, 1H, H-6 pyr.), 8.20 (d, J ¼ 8.0 Hz, 1H,
H-5 pyr.), 8.06 (dd, J ¼ 8.2 and 1.6 Hz, 1H, H-6), 7.86 (td, J ¼ 7.6 and
1.6 Hz, 1H, H-4 pyr.), 7.78 (d, J ¼ 7.4 Hz, 2H, H-20 and H-60),
7.57e7.54 (m, 5H, H-2 phenyl, H-3 phenyl, H-4 phenyl, H-5 phenyl
and H-6 phenyl), 7.52 (d, J ¼ 7.4 Hz, 2H, H-30 and H-50), 7.43 (d,
J ¼ 8.2 Hz, 1H, H-9), 7.41 (t, J ¼ 7.2 Hz, 1H, H-7), 7.38 (dd, J ¼ 6.4 and
1.2 Hz, 1H, H-9), 7.37 (d, J ¼ 7.2 Hz, 1H, H-3 pyr.), 7.18 (td, J ¼ 7.2 Hz
and 1.6 Hz, 1H, H-8), 7.17 (s, 1H, H-2), 3.78 (q, J ¼ 7.2, 2H, CH2), 3.73
V. Desplat et al. / European Journal of Medicinal Chemistry xxx (2016) 1e14 11
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
EJMECH8398_proof ■ 23 February 2016 ■ 11/14
Please cite this article in press as: V. Desplat, et al., Synthesis and evaluation of the cytotoxic activity of novel ethyl 4-[4-(4-substitutedpiperidin-
1-yl)]benzyl-phenylpyrrolo[1,2-a]quinoxaline-carboxylate derivatives in myeloid and lymphoid leukemia cell lines, European Journal of
Medicinal Chemistry (2016), http://dx.doi.org/10.1016/j.ejmech.2016.02.047
(s, 2H, CH2N), 3.14e3.12 (m, 2H, NCH2 pip.), 3.00e2.88 (m, 1H, CH
pip.), 2.37e2.30 (m, 2H, CH2 pip.), 2.19e2.05 (m, 4H, 2 CH2 pip.),
0.97 (t, J ¼ 7.2 Hz, 3H, CH3). 13C NMR (CDCl3) d: 166.40 (C]O),
157.58 (C-2 pyr.), 155.85 (C-4), 148.75 (C-3 triazole), 150.77 (C-6
pyr.), 140.93 (C-5 triazole), 139.77 (C-3a), 138.84 (C-4 pyr.), 138.70
(C-5a), 134.70 (C-40), 133.41 (C-10 and C-1 phenyl), 131.59 (C-7),
131.06 (C-30 and C-50), 130.91 (C-3 phenyl and C-5 phenyl), 130.49
(C-8), 130.32 (C-20 and C-60), 129.46 (C-2 phenyl and C-6 phenyl),
128.61 (C-9a), 128.37 (C-6), 127.16 (C-9), 125.92 (C-4 phenyl), 125.77
(C-3), 123.23 (C-3 pyr.), 120.22 (C-5 pyr.), 118.04 (C-2), 115.92 (C-1),
64.02 (NCH2), 62.24 (CH2), 54.44 (NCH2 pip.), 36.29 (CH pip.), 31.67
(CH2 pip.), 15.22 (CH3). HRMS-ESI m/z [M þ H]þ Calcd for
C39H36N7O2: 634.2930, Found: 634.2959.
5.1.10.10. Ethyl 4-{4-[(4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)
piperidin-1-yl)benzyl]}-1-phenylpyrrolo[1,2-a]quinoxaline-2-
carboxylate (1j). White crystals (70%), mp 165e167 C. 1H NMR
(CDCl3) d: 10.19 (s, 1H, NH), 8.03 (d, J ¼ 7.8 Hz, 1H, H-6), 8.02 (d,
J¼ 7.8 Hz, 2H, H-20 and H-60), 7.67e7.57 (m, 6H, H-7, H-3 phenyl, H-
4 phenyl, H-5 phenyl, H-30 and H-50), 7.55 (s,1H, H-3), 7.54e7.51 (m,
2H, H-2 phenyl and H-6 phenyl), 7.41e7.33 (m, 2H, H-9 and H-4
benzimid.), 7.14e7.05 (m, 4H, H-8, H-5 benzimid., H-6 benzimid., H-
7 benzimid.), 4.47 (t, J ¼ 12.0 Hz, 1H, CH pip.), 4.17 (q, J ¼ 7.2 Hz, 2H,
CH2), 3.73 (s, 2H, CH2N), 3.23e3.08 (m, 2H, NCH2 pip.), 2.65e2.50
(m, 2H, CH2 pip.), 2.37e2.23 (m, 2H, NCH2 pip.), 1.89 (d, J ¼ 10.2 Hz,
2H, CH2 pip.), 1.13 (t, J ¼ 7.2 Hz, 3H, CH3). 13C NMR (CDCl3) d: 165.59
(C]O), 156.75 (C-4), 156.60 (C]O benzimid.), 139.29 (C-5a and C-
3a benzimid.), 138.22 (C-10), 136.20 (C-3a and C-1 phenyl), 131.88
(C-6), 131.85 (C-2 phenyl and C-6 phenyl), 130.85 (C-7a benzimid.),
130.80 (C-4 phenyl), 130.51 (C-30 and C-50), 130.24 (C-7), 130.12 (C-3
phenyl and C-5 phenyl), 129.67 (C-20 and C-60), 128.19 (C-8), 127.34
(C-9), 126.61 (C-2), 120.81 (C-1), 118.12 (C-5 benzimid. and C-6
benzimid.), 111.94 (C-3 and C-4 benzimid.), 111.20 (C-7 benzimid.),
64.01 (CH2N), 61.61 (CH2), 54.61 (NCH2 pip.), 52.15 (CH pip.), 30.67
(CH2 pip.), 15.42 (CH3). HRMS-ESI m/z [MþH]þ Calcd for
C39H36N5O3: 622.2818, Found: 622.2846.
5.1.10.11. Ethyl 4-{4-[(4-(5-ﬂuoro-1H-benzimidazol-2-yl)piperidin-1-
yl)benzyl]}-1-phenylpyrrolo[1,2-a]quinoxaline-2-carboxylate (1k).
White crystals (46%), mp 195e197 C. 1H NMR (CDCl3) d: 7.97 (d,
J¼ 7.8 Hz, 1H, H-6), 7.93 (d, J¼ 7.2 Hz, 2H, H-20 and H-60), 7.64e7.56
(m, 3H, H-7, H-9 and H-4 phenyl), 7.55e7.47 (m, 6H, H-3, H-3
phenyl, H-5 phenyl, H-30, H-50 and H-4 benzimid.), 7.36 (t,
J¼ 6.6 Hz, 2H, H-2 phenyl and H-6 phenyl), 7.09 (d, J¼ 7.8 Hz,1H, H-
8), 7.08 (d, J ¼ 7.8 Hz, 1H, H-7 benzimid.), 6.98 (t, J ¼ 7.8 Hz, 1H, H-6
benzimid.), 4.16 (q, J ¼ 7.2 Hz, 2H, CH2), 3.62 (s, 2H, CH2N), 2.99 (d,
J ¼ 11.4 Hz, 2H, NCH2 pip.), 2.94 (t, J ¼ 12 Hz, 1H, CH pip.), 2.15 (t,
J ¼ 11.4 Hz, 2H, NCH2 pip.), 2.06 (d, J ¼ 11.4 Hz, 2H, CH2 pip.),
1.98e1.89 (m, 2H, CH2 pip.), 1.11 (t, J ¼ 7.2 Hz, 3H, CH3). 13C NMR
(CDCl3) d: 165.75 (C]O), 160.57 (d, J ¼ 235 Hz, C-5 benzimid.),
156.90 (C-4), 142.10 (C-40), 139.21 (C-5a), 137.97 (C-10), 136.42 (C-2
benzimid. and C-3a benzimid.), 134.60 (C-1 phenyl), 132.51(C-9a),
131.90 (C-30 and C-50), 131.52 (C-3a), 130.91 (C-6), 130.84 (C-3
phenyl and C-5 phenyl), 130.32 (C-7a benzimid.), 130.05 (C-7, C-9
and C-4 phenyl.), 129.58 (C-20 and C-60), 128.37 (C-8), 127.52 (C-2
phenyl and C-6 phenyl), 120.93 (C-1 and C-2), 118.28 (C-7 benzi-
mid.), 111.82 (C-3 and C-6 benzimid.), 111.64 (C-4 benzimid.), 64.24
(CH2N), 61.79 (CH2), 54.74 (NCH2 pip.), 38.31 (CH pip.), 32.35 (CH2
pip.), 15.41 (CH3). HRMS-ESI m/z [MþH]þ Calcd for C39H35N5O2F:
624.2775, Found: 624.2747.
5.1.10.12. Ethyl 4-{4-[4-(3-(pyridin-2-yl)-1,2,4-triazol-5-yl)piper-
idin-1-yl)benzyl]}-1-phenylpyrrolo[1,2-a]quinoxaline-2-carboxylate
(1l). White crystals (42%), mp 144e146 C. 1H NMR (CDCl3) d: 8.69
(d, J ¼ 4.6 Hz, 1H, H-6 pyr.), 8.19 (d, J ¼ 7.8 Hz, 1H, H-5 pyr.), 7.99 (d,
J ¼ 7.0 Hz, 1H, H-6), 7.94 (d, J ¼ 7.0 Hz, 2H, H-20 and H-60), 7.83 (td,
J¼ 7.6 and 1.6 Hz,1H, H-4 pyr.), 7.62e7.45 (m, 8H, H-3, H-7, H-9, H-3
phenyl, H-4 phenyl, H-5 phenyl, H-30 and H-50), 7.40e7.29 (m, 3H,
H-2 phenyl, H-6 phenyl and H-3 pyr.), 7.04 (d, J ¼ 7.0 Hz, 1H, H-8),
4.14 (q, J ¼ 7.1 Hz, 2H, CH2), 3.67 (s, 2H, CH2N), 3.07 (d, J ¼ 11.0 Hz,
2H, NCH2 pip.), 2.99e2.79 (m, 1H, CH pip.), 2.34e1.90 (m, 6H, NCH2
pip. and 2 CH2 pip.),1.10 (t, J¼ 7.1 Hz, 3H, CH3). 13C NMR (CDCl3) d:
165.65 (C]O),156.79 (C-4 and C-2 pyr.), 150.99 (C-3 Triazole and C-
6 pyr.), 148.41 (C-5 Triazole), 139.39 (C-40), 138.86 (C-5a and C-4
pyr.), 138.18 (C-10), 134.72 (C-1 phenyl), 131.94 (C-3a, C-30 and C-50),
130.98 (C-6), 130.86 (C-3 phenyl and C-5 phenyl), 130.11 (C-7, C-9
and C-4 phenyl), 129.56 (C-20 and C-60), 128.22 (C-8), 127.37 (C-3
pyr., C-2 phenyl and C-6 phenyl), 123.11 (C-2, C-9a and C-5 pyr.),
120.84 (C-1), 112.01 (C-3), 64.51 (CH2N), 61.68 (CH2), 55.03 (NCH2
pip.), 32.32 (CH2 pip. and CH pip.), 15.49 (CH3). HRMS-ESI m/z
[M þ H]þ Calcd for C39H36N7O2: 634.2930, Found: 634.2962.
5.2. X-ray data
The structure of compounds 2b-d, 1a, 1d, 1g, 1j and 1k has been
established by X-ray crystallography (Figs. 3 and 4). Colorless single
crystal of 2b was obtained by slow evaporation from chloroform:
monoclinic, space group P21/c, a ¼ 11.9390(11) Å, b ¼ 13.8893(9) Å,
c ¼ 18.5001(19) Å, a ¼ 90, b ¼ 100.959(7), g ¼ 90, V ¼ 3011.8(5)
Å3, Z ¼ 8, d(calcd) ¼ 1.267 Mg m3, FW ¼ 287.31 for C16H17NO4,
F(000) ¼ 1216. Colorless single crystal of 2c was obtained by slow
evaporation from methanol/dichloromethane (20/80) solution:
monoclinic, space group P21/n, a ¼ 14.653(3) Å, b ¼ 5.1458(12) Å,
c ¼ 18.842(4) Å, a ¼ 90, b ¼ 94.447(14), g ¼ 90, V ¼ 1416.4(5) Å3,
Z ¼ 4, d(calcd) ¼ 1.347 Mg m3, FW ¼ 287.31 for C16H17NO4,
F(000) ¼ 608. Colorless single crystal of 2d was obtained by slow
evaporation from methanol/dichloromethane (20/80) solution:
triclinic, space group P-1, a ¼ 8.628(9) Å, b ¼ 9.798(2) Å,
c ¼ 10.095(3) Å, a ¼ 73.02(2), b ¼ 71.00(3), g ¼ 73.95(5),
V ¼ 756.1(8) Å3, Z ¼ 1, d(calcd) ¼ 1.262 Mg m3, FW ¼ 574.61 for
C32H34N2O8, F(000) ¼ 304. Colorless single crystal of 1a was ob-
tained by slow evaporation from methanol/dichloromethane (30/
70) solution: triclinic, space group P-1, a ¼ 10.0140(10) Å,
b ¼ 10.877(2) Å, c ¼ 17.580(2) Å, a ¼ 79.642(9), b ¼ 86.041(8),
g ¼ 65.016(8), V ¼ 1707.3(4) Å3, Z ¼ 2, d(calcd) ¼ 1.311 Mg m3,
FW ¼ 673.96 for C39H35N5O3,0.48(CH2Cl2O2),0.19(O), F(000) ¼ 710.
Colorless single crystal of 1d was obtained by slow evaporation
from methanol/dichloromethane (30/70) solution: triclinic, space
group P-1, a ¼ 8.3759(10) Å, b ¼ 12.6418(13) Å, c ¼ 16.6718(18) Å,
a ¼ 109.502(7), b ¼ 96.482(8), g ¼ 103.928(7), V ¼ 1578.7(3) Å3,
Z ¼ 2, d(calcd) ¼ 1.308 Mg m3, FW ¼ 621.72 for C39H35N5O3,
F(000) ¼ 656. Colorless single crystal of 1g was obtained by slow
evaporation from methanol/dichloromethane (20/80) solution:
triclinic, space group P-1, a ¼ 9.6882(14) Å, b ¼ 11.2689(13) Å,
c ¼ 19.639(2) Å, a ¼ 77.504(8), b ¼ 83.067(11), g ¼ 72.264(11),
V ¼ 1990.4(4) Å3, Z ¼ 2, d(calcd) ¼ 1.347 Mg m3, FW ¼ 807.16 for
C39H35N5O3,1.56(CHCl3), F(000) ¼ 836. Colorless single crystal of 1j
was obtained by slow evaporation from methanol/dichloro-
methane (30/70) solution: triclinic, space group P-1, a ¼ 9.7518(8)
Å, b ¼ 11.1004(8) Å, c ¼ 17.9247(12) Å, a ¼ 86.622(5),
b ¼ 82.713(5), g ¼ 66.141(5), V ¼ 1760.1(2) Å3, Z ¼ 2,
d(calcd) ¼ 1.398 Mg m3, FW ¼ 741.09 for C39H35N5O3,CHCl3,
F(000) ¼ 772. Pale-yellow single crystal of 1kwas obtained by slow
evaporation from methanol/dichloromethane (30/70) solution:
monoclinic, space group C2/c, a ¼ 18.0617(14) Å, b ¼ 9.4210(8) Å,
c¼ 43.021(3) Å, a¼ 90, b¼ 93.345(5), g¼ 90, V¼ 7307.9(10) Å3,
Z ¼ 8, d(calcd) ¼ 1.296 Mg m3, FW ¼ 712.78 for
C39H34FN5O2,5(H2O) F(000) ¼ 3016. Full crystallographic results
have been deposited at the Cambridge Crystallographic Data Centre
(CCDC-1014944, CCDC-891817, CCDC-891816, CCDC-891812, CCDC-
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891811, CCDC-891813, CCDC-891814, CCDC-891815, respectively),
UK, as Supplementary Material [38]. The data were corrected for
Lorentz and polarization effects and for empirical absorption
correction [39]. The structure was solved by direct methods Shelx
2013 [40] and reﬁned using Shelx 2013 [40] suite of programs.
5.3. Biology
5.3.1. Cell culture
The human leukemic cell lines U937, K562, HL60, U266 and
Jurkat were grown in RPMI 1640 medium (Life Technology, France)
supplemented with 10% fetal calf serum (FCS), antibiotics (100 U/
mL penicillin, 100 mg/mL streptomycin) and L-glutamin, (Eurobio,
France) at 37 C, 5% CO2 in air. The toxicity of various molecules was
also evaluated on non-activated, freshly isolated normal human
peripheral blood mononuclear cells (PBMNC), as well as phytohe-
magglutinin (T lymphoproliferative agent) (PHA)-induced cells.
PBMNC from blood of healthy volunteers were obtained following
centrifugation on Ficoll gradient. Cells were then incubated in
medium alone or induced to enter cell cycle by the addition of PHA
(5 mg/mL, Murex Biotech Limited, Dartford, UK).
5.3.2. Cytotoxicity test
The MTS cell proliferation assay (Promega, France) is a colori-
metric assay system, which measures the reduction of a tetrazo-
lium component (MTS) into formazan produced by the
mitochondria of viable cells. Cells were washed twice in PBS
(Phosphate Buffer Saline) and plated in quadruplicate into
microtiter-plate wells in 100 mL culture media with or without our
various compounds at increasing concentrations (0, 1, 5, 10, 20 and
50 mM) during 1, 2 and 3 days. After 3 h of incubation at 37 C with
20 mL MTS/well, the plates were read by using an ELISA microplate
reader (Thermo, Electrocorporation) at 490 nm wavelength. The
amount of colour produced was directly proportional to the num-
ber of viable cells. The results are expressed as the concentrations
inhibiting cell growth by 50% after a 3 days incubation period. The
50% cytotoxic concentrations (CC50) were determined by linear
regression analysis, expressed in mM ± SD (Microsoft Excel).
5.3.3. Annexin V staining by ﬂow cytometry
Cells (2  105) were incubated for 3 days with increasing doses
of 1e (0, 1, 5, and 10). Experiments were performed with APC-
Annexin V (Biolegend, CA) according to the manufacturer's in-
structions. Brieﬂy, cells (2  104) were incubated with 5 mL of APC-
Annexin V resuspended in 295 mL of 1X binding buffer for 10 min
at room temperature in the dark. Then, cells were analyzed by ﬂow
cytometry. The APC-Annexin V-positive cells were considered as
apoptotic. Flow cytometry analysis was performed with a BD FACS
Canto II ﬂow cytometer (Becton-Dickinson, France) and experi-
ments were analyzed using the Diva software.
5.3.4. Computational prediction of toxicity and drug relevant
properties
Calculations of Clog P and calculations of Topological Polar
Surface Area (TPSA), number of hydrogen bond acceptor (nON) and
donor (nNH/OH) atoms, and any violations to the Lipinski's “rule of
ﬁve” (logP  5, molecular weight 500, number of hydrogen bond
acceptors 10, and number of hydrogen bond donors 5) [34];
were performed using the MIPC server at http://www.
molinspiration.com/cgi-bin/properties [33].
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